

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 July 2003 (03.07.2003)

PCT

(10) International Publication Number
WO 03/054162 A2

(51) International Patent Classification: C12N

(21) International Application Number: PCT/US02/41014

(22) International Filing Date:
19 December 2002 (19.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/029,397 20 December 2001 (20.12.2001) US

(71) Applicant (for all designated States except US): AM-
BION, INC. [US/US]; 2130 Woodward St., Suite 200,
Austin, TX 78744-1832 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MURPHY, George,
L. [US/US]; 8825 Escabosa Dr., Austin, TX 78748 (US).
WHITLEY, J. Penn [US/US]; 5203 Avenue F, Austin, TX
78751 (US).

(74) Agent: SHISHIMA, Gina, N.; Fulbright & Jaworski
L.L.P., Suite 2400, 600 Congress Avenue, Austin, TX
78701 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW).
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM).
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IT, LT, LU, MC, NL, PT, SE, SI, SK,
TR). OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: METHOD AND SYSTEM FOR DEPLETING rRNA POPULATIONS

(57) Abstract: The present invention concerns a system for isolating, depleting, or separating a targeted nucleic acid, such as rRNA, from a sample comprising targeted and nontargeted nucleic acids. It effects a way of enriching for nontargeted nucleic acids, such as mRNAs. The invention further concerns methods of implementing the system and kits for implementing the system, which involves at least one bridging nucleic acid comprising 1) a targeting region complementary to a region on the targeted nucleic acid and 2) a bridging region complementary to the capture region of a capture nucleic acid that comprises a nonreactant structure. The nonreactant structure can be used to isolate the hybridizing molecules after incubation under conditions that allows hybridization.

DESCRIPTION

METHOD AND SYSTEM FOR DEPLETING rRNA POPULATIONS

BACKGROUND OF THE INVENTION

5 1. **Field of the Invention**

The present invention relates generally to the fields of molecular biology and microbial pathogenesis. More particularly, it concerns methods, compositions, and kits for isolating, depleting, separating a targeted nucleic acid population from other nucleic acid populations as a means for enriching those other nucleic acid population(s). More particularly, it concerns
10 methods, compositions, and kits for enriching mRNA populations by depleting eukaryotic and/or prokaryotic rRNA from a sample using engineered bridging and capture nucleic acid molecules.

2. **Description of Related Art**

The ongoing efforts in microbial genome sequencing will enable unprecedented advances in our understanding of microbes and host-microbe interactions. Dozens of prokaryotic
15 genomes, including those of numerous human pathogens, have been completely sequenced, and many others are in progress. Consequently, a renewal of focus and energy has emerged in the fields of microbial evolution, microbial pathogenesis, and infectious diseases. The potential impact of genomics on these disciplines is the subject of several recent reviews (Cummings *et al.*, 2000; Cornelis *et al.*, 2001; Fox *et al.*, 2001; *Current Opinion in Microbiology*). For host-
20 microbe interactions, the ability to measure the expression of every single gene in a microorganism will make possible studies of such complex interactions as the global regulation of virulence factors and the mechanisms of response to host cells and their microenvironment. Scientists will also be able to evaluate the complete repertoire of host cell gene expression in response to the pathogen. Undoubtedly, novel interactions and responses between microbes and
25 their hosts will be discovered, leading to a more complete picture of infectious diseases and how to control them.

In the past decade, researchers studying bacteria developed several novel approaches to evaluate global gene transcription in response to environmental stimuli, including host-microbe interactions. Prior to the era of genome sequencing, Chuang *et al.* (Chuang *et al.*, 1993) used an
30 ordered set of *E. coli* lambda library clones to evaluate global transcription responses of *E. coli*. Other groups employed subtractive hybridization and differential screening to evaluate induction

of gene expression in *Mycobacterium avium* after phagocytosis by macrophages (Plum *et al.*, 1994) or in *Pyrococcus* grown under specific environmental conditions (Robinson *et al.*, 1994). Researchers further developed this approach with an elegant procedure for the selective capture of transcribed sequences (SCOTS) (Graham *et al.*, 1999). At the same time, many scientists
5 bypassed library construction altogether and used using differential display (Liang *et al.*, 1995) to discover genes that are transcribed differently under various growth conditions. Although useful in certain circumstances, differential display is frequently a hit-or-miss prospect and gives no information on global transcription. More recently, serial analysis of gene expression (SAGE) (Velculescu *et al.*, 1995) emerged as a method for analyzing the complete transcriptome
10 of a cell. SAGE, like differential display, can be useful but requires large amounts of nucleic acid sequencing. Not unexpectedly, for organisms whose genomes have been sequenced, array analysis is emerging as the method of choice for global gene expression studies with bacteria. Macroarrays (filter-based arrays) and microarrays (slide-based arrays) of complete genomes have made possible the simultaneous expression analysis of thousands of genes. The advent of
15 microarray technology has already enabled analyses of the host response to interactions with pathogenic organisms (Cummings *et al.*, 2000). Similarly, microarray analysis and other methods have been used to evaluate gene expression in bacteria grown under different environmental conditions *in vitro*.

The application of array analysis to gene expression profiling in prokaryotes was an
20 immediate outgrowth of similar studies with eukaryotic organisms, occurring only within the past two to three years. Infectious disease researchers have already begun applying microarray analysis to the study of complex host-microbe interactions. To date, such analyses of host-microbe interactions have been limited to the evaluation of host cell responses to bacteria or viruses. *Bordetella pertussis*, *Listeria monocytogenes*, *Neisseria meningitidis*, *Pseudomonas*
25 *aeruginosa*, *Legionella pneumophila*, *Salmonella dublin*, and *Staphylococcus aureus* are among the bacterial pathogens whose effects on host cell gene expression have been evaluated with microarrays. Array analyses of eukaryotic host cell transcription are feasible because of the ability to isolate polyadenylated mRNAs from eukaryotic cells and to specifically label mRNAs by oligo dT-primed cDNA synthesis.

30 Although it has been alluded to in the literature (Cummings *et al.*, 2000; Rappuoli, 2000), complete genome array expression analyses of bacteria in response to interactions with host cells

have not been widely published, if at all. Studies that examine the global bacterial gene response in the presence of host cells will require the development of tools to enable the efficient isolation, enrichment, and labeling of bacterial mRNAs (Cummings *et al.*, 2000; Graham *et al.*, 1999; Gingeras *et al.*, 2000; Graham *et al.*, 2001).

- 5 However, technical limitations of current methods available for purification and evaluation of bacterial mRNAs preclude these types of whole genome analysis. To realize the full potential of the genomics revolution, methods for purifying mRNAs from total bacterial RNA populations and particularly from mixtures of host cell and bacterial RNA need to be developed.
- 10 Isolating sufficient quantities of high quality bacterial mRNA is perhaps the most demanding technical requirement impeding analyses of bacterial gene expression in the presence of host cells. A small percentage of bacterial mRNAs may be A-tailed, but these are targeted for degradation and tend to be unstable. As a result, the commonly used method for mRNA purification with eukaryotic cells, oligo-dT capture, is ineffective.
- 15 Only a few studies have described methods for enriching or purifying bacterial mRNAs. Several groups (Plum *et al.*, 1994; Robinson *et al.*, 1994; Su *et al.*, 1998) have used rRNA subtraction to enrich for bacterial mRNAs. These procedures involved hybridization of rRNAs to biotinylated plasmid containing rRNA genes or to biotinylated antisense rRNAs followed by streptavidin capture and removal. This yields some benefits, but it requires fairly large amounts
- 20 of plasmids or antisense RNA. Biotinylation of large amounts of DNA or RNA is often tricky and can be prohibitively expensive if biotin-modified nucleotides are incorporated during antisense RNA synthesis. In general, these methods have not seen widespread use. As mentioned above, Graham and Clarke-Curtiss (Graham *et al.*, 1999) went further in enriching for mycobacterial mRNAs with SCOTS. The SCOTS procedure is effective for detecting genes
- 25 specifically expressed in the presence of host cells but is hampered by being a multi-step procedure that requires production of normalized double-stranded cDNA, PCR, differential hybridization, and cDNA capture. In addition to these methods, researchers have developed methods to polyadenylate bacterial mRNAs, thereby allowing for their purification by oligo dT-capture. Amara and Vijaya (Amara *et al.*, 1997) demonstrated that mRNAs in purified
- 30 polysomes can be specifically polyadenylated and purified by oligo-dT capture. Wendisch *et al.* (Wendisch *et al.*, 2001) showed that the same process can be carried out with crude cell extracts.

Several shortcomings are associated with the polyadenylation approach. Different mRNAs may be polyadenylated to different extents or not at all depending on the structure of their 5' and 3' ends (Feng *et al.*, 2000). Polyadenylation in a cell lysate, followed by purification of RNA, will require inactivation of cellular RNases so that transcripts are not degraded during the polyadenylation reaction. Optimizing the reaction to work reproducibly in many different bacterial cell lysates would likely be very difficult. Despite many worthy attempts, simple and universal procedures for bacterial mRNA enrichment, especially in the presence of host cell RNA, remain elusive. Thus, there remains a continued need for improvements in mRNA enrichment and/or the depletion of other RNA populations.

SUMMARY OF THE INVENTION

The present invention involves a system that allows for the isolation, separation, and depletion of a population of nucleic acid molecules. The system involves components that may be used to implement methods for isolating, separating, or depleting a targeted nucleic acid. Such components may also be included in kits of the invention.

In embodiments of the invention, a population of nucleic acids may be targeted for isolation, separation, or depletion. Such a nucleic acid is referred to as "targeted nucleic acid" or "targeted nucleic acid molecule." Alternatively, it may be referred to as a "nucleic acid target." In particular embodiments of the invention, the targeted nucleic acid is rRNA. In alternative embodiments, the targeted nucleic acid is mRNA, tRNA, or DNA including, cDNA and genomic DNA. The targeted nucleic acid may be in a sample, which is a composition that is suspected of containing the targeted nucleic acid. In some embodiments, the sample is obtained from or includes prokaryotes or eukaryotes or both. The sample may be cells, tissues, organs, and lysates, fractionations, or portions thereof. Furthermore, the targeted nucleic acid is targeted via a "targeting region" in the targeted nucleic acid. A "targeted region" refers to a region of the targeted nucleic acid that is complementary with the targeting region of a bridging nucleic acid and that allows the targeted nucleic acid to be separated from other non-targeted nucleic acid populations.

In embodiments in which the targeted nucleic acid is rRNA, the rRNA may be the 5S, 16S, or 23S rRNA from prokaryotes, though it may be any rRNA species from a prokaryotes. It is specifically contemplated that nucleic acids may be targeted in Gram positive bacteria and Gram negative bacteria. In further embodiments, the targeted rRNA is 5.8S, 17S or 18S, or 28S

rRNA (referred to as "types of rRNA") from a eukaryote. It is further contemplated that tRNA may be a targeted nucleic acid population either by itself or in combination with any of the targeted nucleic acids described herein. A non-limiting list of targeted rRNAs from various organisms is provided in a later section and is contemplated to be part of the invention.

5 In embodiments of the invention, the system involves a bridging nucleic acid, a capture nucleic acid, and a targeted nucleic acid, as shown, for example, in FIG. 1. While in many embodiments of the invention it is contemplated that the bridging nucleic acid and the capture nucleic acid are oligonucleotides, it is specifically contemplated that they may be polynucleotides as well. Thus, any embodiment involving an oligonucleotide may be
10 implemented with a polynucleotide. Bridging nucleic acids, capture nucleic acids, and targeted nucleic acids of the invention may include, be at least or be at most 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91,
15 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980,
20 990, 1000 or more residues in length.

Furthermore, a "bridging nucleic acid" is a nucleic acid molecule that comprises a bridging region and a targeting region, while a "capture nucleic acid" is a nucleic acid molecule that comprises a capture region. It is contemplated that bridging, targeting, and capture regions of the invention may be, be at least or be at most 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
25 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450,
30 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830,

840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000 residues in length.

A "bridging nucleic acid" refers to a molecule that includes nucleic acid residues or analogs and that includes at least one targeting region and at least one bridging region. A

5 "targeting region" refers to a region of the molecule that is involved in targeting a particular nucleic acid or nucleic acid population and is thus complementary to all or part of the sequence of the targeted nucleic acid. It is further contemplated that more than one targeting region may be included in a bridging nucleic acid. The bridging nucleic acid may include or have up to 2, 3,

10 4, 5, 6, 7, 8, 9, 10, or more targeting regions. When there are multiple targeting regions, it is contemplated that the regions may be complementary to different, nonoverlapping sequences from the same targeted nucleic acid or they may be complementary to similar or overlapping sequences from the same targeted nucleic acid, or they may be complementary to sequences in different targeted nucleic acids. While mRNA may be targeted, it is specifically contemplated that mRNA is not targeted and thus the targeting region does not have a stretch of

15 polypyrimidine residues, such as poly-T or poly-U to hybridize to the poly-A tail of eukaryotic mRNA. Also considered part of the invention is using single or multiple bridging nucleic acids to deplete an rRNA population. In some embodiments, a single bridging nucleic acid may contain one or more targeting regions that are complementary to different types of rRNA ("types" refer to sizes based on intact lengths). Thus, in some embodiments, the largest type of

20 rRNA may be targeted ("largest" refers to longest nucleic acid molecule when intact, even though molecules that are no longer intact may also be targeted if they retain the sequence that is complementary to all or part of a targeting region). In still further embodiments, the second largest rRNA or the first and second largest rRNA types may be targeted by a single bridging nucleic acid with targeting regions to each or to more than one nucleic acid, each with a targeting

25 region to a different type of rRNA. In still further embodiments, a bridging nucleic acid has a targeting region complementary to one or more of the following prokaryotic and eukaryotic rRNA types: 5S, 16S, 23S, 5.8S, 17S, 18S, and/or 28S. A bridging nucleic acid may target 1, 2, 3, 4, 5, 6, 7, or more types of rRNA, as well as any and all tRNA types, both eukaryotic and prokaryotic.

30 A "bridging region" in a bridging nucleic acid refers to a region that mediates an interaction with a capture nucleic acid. In further embodiments, the bridging region is a

polypurine or polypyrimidine stretch of residues. A bridging region can include a stretch of adenine or guanine residues or cytosine, uracil, or thymidine residues. In some embodiments, it is contemplated that more than one bridging region is included in a bridging nucleic acid, such as 2, 3, 4, 5, or more bridging regions.

5 A "capture nucleic acid" refers to a molecule that includes nucleotides or nucleotide analogs, a capture region, and a nonreacting structure. A "capture region" refers to a region that interacts with the bridging region of a bridging nucleic acid. In embodiments of the invention, the bridging region and the capture region are complementary to each other and hybridize to one another under conditions that allow for hybridization of complementary regions. In some
10 embodiments of the invention, the capture region and bridging region are a stretch of complementary repeated nucleotides (complementary homopolymeric regions). For example, they may be homopolymeric A, T, G, C, or U. In other embodiments of the invention, however, the bridging and capture regions are any sequence, so long as they are complementary. In some embodiments of the invention, the capture region has a sequence that includes at least 5, 6, 7, 8,
15 9, 10 or more contiguous nucleotides of SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, and SEQ ID NO:92 (collectively referred to as "SEQ ID NOs: 87-92"). In some embodiments, the capture regions comprises any of of SEQ ID NOs 87-92.

There may be more than one nonreacting structure attached, covalently or noncovalently, to a capture nucleic acid. There may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more nonreacting structures
20 as part of a capture nucleic acid.

A capture nucleic acid also includes a "nonreacting structure," which refers to a compound that does not chemically react with a nucleic acid. In some embodiments, a nonreacting structure is a magnetic bead or rod, which allows the capture nucleic acid, a bridging nucleic acid and a target nucleic acid to be isolated from a sample with a magnetic field, such as
25 a magnetic stand. In still further embodiments, the nonreacting structure is a bead or other structure that can be physically captured, such as by using a basket, filter, or by centrifugation. It is contemplated that a bead may include plastic, glass, teflon, silica, a magnet or be magnetizeable, a metal such as a ferrous metal or gold, carbon, cellulose, latex, polystyrene, and other synthetic polymers, nylon, cellulose, nitrocellulose, polymethacrylate, polyvinylchloride,
30 styrene-divinylbenzene, or any chemically-modified plastic or any other nonreacting structure. In still further embodiments, the nonreacting structure is biotin or iminobiotin. Biotin or

iminobiotin binds to avidin or streptavidin, which can be used to isolate the capture nucleic acid and any hybridizing molecules. Furthermore, in some embodiments of the invention, the nonreacting structure is cellulose or an analog thereof.

It is contemplated that the location of the targeting and bridging regions in the bridging
5 nucleic acid may be at a variety of positions. The location of targeted regions in a targeted
nucleic acid or a capture region in a capture nucleic acid may also vary. The location of any of
these regions or nonreacting structure may be or be within 10, 20, 30, 40, 50, 60, 70, 80, 90, 100,
110, 12, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290,
300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480,
10 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670,
680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860,
870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000, 1100, 1200, 1300, 1400,
1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900,
3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900, 4000, 4100, 4200, 4300, 4400,
15 4500, 4600, 4700, 4800, 4900, 5000 or more nucleotides from the 3' and/or 5' end of the
relevant nucleic acid ("relevant nucleic acid" refers to the nucleic acid in which the region is
located). Moreover, it is contemplated that a region, such as a bridging, capture, targeted, or
targeting region—as well as a nonreacting structure—may be at or within 100-5000 residues,
150-4000 residues, 200-3000 residues, 250-2000 residues, 300-1500 residues, 350-1000
20 residues, 400-900 residues, 450-800 residues, or 500-700 residues of the 5' or 3' end of the
relevant nucleic acid.

Furthermore, it is also contemplated that the spacing between regions may vary. Regions
in the same nucleic acid or a region and a nonreacting structure may be adjacent to one another
or there may be residues between them or between each of them. The number of intervening
25 residues may be the following or may be at least or at most of the following: 5, 6, 7, 8, 9, 10, 11,
12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37,
38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63,
64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,
90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210,
30 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400,
410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590,

600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, or more nucleotides between them or each of them.

- 5 As for the location of the sequence to which the targeting region is complementary, termed "targeted region," this may be 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99,
- 10 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900, 4000, 4100, 4200, 4300, 4400, 4500, 4600, 4700, 4800, 4900, 5000 nucleotides or more from the 3' and/or 5' end of the targeted nucleic acid. It is specifically contemplated that the targeting
- 15 region hybridizes to a sequence located between 100 and 5000, 150 and 4000, 200 and 3000, 250 and 2000, and 300 and 1000 residues of the 5' and/or 3' end of the targeted nucleic acid. It is also contemplated that the targeted region is at the 3' or 5' end of the targeted nucleic acid. Alternatively, the targeted region may not be within 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700,
- 20 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900, 4000, 4100, 4200, 4300, 4400, 4500, 4600, 4700, 4800, 4900, 5000 or more nucleotides from the termini of a targeted nucleic acid.

- In some embodiments, the targeting region comprises or is complementary to all or 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33,
- 25 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560,
- 30 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940,

950, 960, 970, 980, 990, 1000 or more contiguous nucleotides of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, or SEQ ID NO:73 (collectively referred to as "SEQ ID NOS:1-73"), as well as SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, and SEQ ID NO:92 (collectively referred to as "SEQ ID NOS:1-92"). It is specifically contemplated that targeting regions of the invention comprise, in some embodiments, at least 5 contiguous nucleotides of SEQ ID NO:1-22; it is also contemplated that targeting regions of the invention are complementary to a sequence ("sequence" in the context of complementary regions refers to a sequence of at least 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, or more nucleotides in length) of SEQ ID NOS:23-86, which are sequences of rRNA molecules.

It will be understood that any embodiment discussed with respect to nucleotides applies also when nucleotide analogs are used. It is specifically contemplated that nucleotide analogs may be employed with respect to bridging and capture nucleic acids of the invention.

It is contemplated that nucleic acids of the invention include RNA, DNA, locked nucleic acid™ (LNA), iso-bases, and/or peptide mimetics. It is contemplated that all or part of nucleic acids of the invention may include such nucleic acid components.

The present invention further concerns methods of isolating and/or depleting nucleic acids from a sample. In some embodiments, methods include a) incubating a sample with a first

bridging nucleic acid comprising (1) at least one bridging region comprising at least 5 nucleic acid residues, under conditions allowing hybridization between the first targeting region and the targeted nucleic acid; b) incubating the first bridging nucleic acid with a capture nucleic acid comprising a nonreacting structure and a capture region comprising at least 5 nucleic acid residues, under conditions that allowing hybridization between the first bridging region and the capture region. In additional embodiments, one or more other steps may be included in combination with the method discussed above. Other steps involve isolating the targeted nucleic acid from the remainder of the sample; discarding the portion of the sample that hybridizes directly or indirectly to the capture nucleic acid (indirect hybridization refers to specific association of compounds that occurs through hybridization with a mediating compound, for example, indirect hybridization of a capture nucleic acid and a targeted nucleic acid via hybridization to a bridging nucleic acid); incubating the sample with additional bridging nucleic acids, under conditions allowing hybridization between the targeting region of the additional bridging nucleic acid and the targeted nucleic acid; implementing the method with respect to other targeted nucleic acids; washing the capture nucleic acid after incubation with the sample and the bridging nucleic acid; incubating the capture nucleic acid, bridging nucleic acid, and sample with elution buffer after isolating the targeted nucleic acid from the rest of the sample; eluting the targeted nucleic acid from the nonreactant structure; using the capture nucleic acid in a subsequent method involving a new sample; discarding the targeted nucleic acid after separating it from the sample; performing hybridizations between the bridging nucleic acid and the sample and the capture nucleic acid and the sample at the same temperatures or at different temperatures; performing the above hybridization steps at the same time, sequentially (one after the other or the other after the one); exposing the sample to a magnetic field or magnet, particularly when a magnetic bead or other object comprises all or part of the non-reacting structure of the capture nucleic acid; and incubating the sample with streptavidin or avidin, particularly if biotin or iminobiotin is used as a non-reacting structure.

In some embodiments of the invention, the sample, a bridging nucleic acid and/or a capture nucleic acid are incubated in a buffer, which, in some embodiments, includes TEAC or TMAC.

In methods of the invention involving more than one bridging nucleic acid, it is contemplated that the targeting region of the first bridging nucleic acid may be complementary to

a different sequence of a different targeted nucleic acid than a targeting region of another bridging nucleic acid. Alternatively, different bridging nucleic acids may have targeting regions that are complementary to the same targeted nucleic acid. In the latter case, it is further contemplated that the targeting regions be complementary to sequences that overlap one another or may be complementary to sequences in non-overlapping locations.

In cases in which targeting regions are complementary to different targeted nucleic acids, embodiments may involve targeting the largest rRNA molecule in a sample with one bridging nucleic acid and the second largest rRNA molecule in a sample with another bridging nucleic acid. In still further embodiments, another or third bridging nucleic acid will target the third largest rRNA molecule in a sample, while another or a fourth bridging nucleic acid will target the fourth largest rRNA molecule in a sample.

In another embodiment of the invention, there is a method for depleting rRNA from a sample comprising incubating the sample with (1) at least a first bridging oligonucleotide comprising a bridging region comprising a polypurine region of at least 5 residues in length and a targeting region comprising at least 5 contiguous residues complementary to an rRNA molecule in the sample and (2) a capture oligonucleotide comprising a magnetic bead and a capture region comprising a polypyrimidine region of at least 5 residues in length, under conditions allowing hybridization between the bridging oligonucleotide and the capture oligonucleotide and between the bridging oligonucleotide and the rRNA; b) incubating the sample with a magnetic bead; and c) isolating the magnetic bead. In still further embodiments, the first bridging oligonucleotide comprises a targeting region complementary to prokaryotic 23S rRNA. In still further embodiments, there is a second bridging oligonucleotide with a targeting region complementary to a different region of a prokaryotic 23S RNA than the first bridging oligonucleotide. In even further embodiments, there is a third and fourth bridging oligonucleotide each with a targeting region complementary to different sequences of a prokaryotic 16S rRNA.

As discussed earlier, a sample may be depleted or isolated as a way of enriching for the nontargeted nucleic acid, such as mRNA. In further embodiments of the invention, enriched mRNA can be used to prepare cDNA according to methods known to those of ordinary skill in the art, and as described herein. Thus, in cases in which mRNA is enriched as a result of methods of the invention, embodiments may further include discarding the portion of the sample

- that hybridizes to the capture oligonucleotide. More specifically targeted rRNA may be discarded and the mRNA remaining in the sample may be used to produce cDNA molecules. cDNA molecules may be used in a variety of methods, including, but not limited to, library production, production of proteins, and for creating and screening arrays. Therefore, in some
- 5 embodiments of the invention, cDNA made from mRNA enriched according to methods of the invention are attached to a solid support or surface so as to create a nucleic acid array. The term "nucleic acid array" refers to a plurality of target elements, wherein each target element comprising one or more nucleic acid molecules immobilized on one or more solid surfaces at discrete locations to which sample nucleic acids can be hybridized. The nonreacting solid
- 10 surface or support may be any of a number of materials, including plastic, glass, or nylon. In some embodiments, the solid support is a plate. The plate may have wells that contain the target elements. Plates may have 2, 3, 4, 5, 6, 7, 8, 9, 10 or more wells ("multi-well"), and up to at least 96 or 192 wells. In some embodiments of the invention, the sample nucleic acids comprise cDNAs made by depleting a sample of rRNA, according to methods of the invention. Those
- 15 embodiments may further involve contacting a nucleic acid array with the cDNA. Alternatively, cDNA made according to the invention may be used as target elements on an array. In any of these embodiments of the invention, it is specifically contemplated that enriched mRNA may be amplified into RNA or DNA by techniques known to those of skill in the art and then used in methods of the invention, such as to probe or screen an array.
- 20 The present invention also concerns kits that include compositions of the invention to implement the methods discussed herein. These kits can be used for the depletion, isolation, or purification of nucleic acids. Kits contain these compositions in a suitable container means.

- In some embodiments, a kit includes 1) at least one capture oligonucleotide comprising a capture region and a magnetic bead; and 2) at least a first bridging oligonucleotide comprising i)
- 25 at least one bridging region complementary to all or part of the capture region of the capture oligonucleotide and ii) at least one targeting region comprising 10 contiguous nucleic acids complementary to an rRNA.

- In additional embodiments, there is a second bridging oligonucleotide comprising i) at least one bridging region complementary to all or part of the capture region of the capture
- 30 oligonucleotide and ii) at least one targeting region comprising 10 contiguous nucleic acids complementary to an rRNA. In some kits, the targeting region of the second bridging

oligonucleotide is complementary to the same rRNA as the targeting region of the first bridging oligonucleotide, while in other embodiments, these are complementary to different rRNAs. Further embodiments involve kits in which the targeting region of the first bridging oligonucleotide is complementary to the largest rRNA of a prokaryote or eukaryote. In other
5 embodiments, the second bridging oligonucleotide has a targeting region that is complementary to either the largest rRNA of a prokaryote or eukaryote or the second largest rRNA of a prokaryote or eukaryote. It is specifically contemplated that kits may include one or more bridging oligonucleotides targeting prokaryotic rRNA (16S, 23S, or both) *and* one or more bridging oligonucleotides targeting eukaryotic rRNA (18S, 28S, or both); thus, a kit may be used
10 for depleting both eukaryotic and prokaryotic rRNA, in some embodiments.

Kits may also include a third, fourth, fifth, sixth, seventh, eighth, ninth, tenth or more bridging oligonucleotides with targeting region complementary to the same or different rRNAs as the targeting regions of the first and second bridging oligonucleotides. It is contemplated that the targeting regions of the bridging oligonucleotides in kits of the invention may be
15 complementary to prokaryote 16S rRNA, prokaryote 23S rRNA, prokaryote 5S rRNA, eukaryote 17S or 18S rRNA, eukaryote 28SrRNA, and/or eukaryote 5.8S rRNA. It is further contemplated that targeting regions of bridging oligonucleotides in kits may have all or part of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ
20 ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, or SEQ ID NO:22 (collectively referred to as "SEQ ID NOS:1-22"). Alternatively, kits may include targeting regions as discussed above with respect to SEQ ID NOS:23-86, *i.e.* targeting regions complementary to a sequence from SEQ ID NOS:23-86. Kits of the invention may also include one or more of the following: binding buffer with TMAC,
25 binding buffer with TEAC, magnetic stand, wash solution, nuclease-free water; RNase inhibitors, glycogen, control RNA, sodium acetate, ammonium acetate, streptavidin beads, avidin beads, magnetic beads, beads of any nonreacting structure—including those discussed above—capture basket; capture filters, RNA markers, nuclease-free containers such as tubes and tips, and any other composition described herein.

It is contemplated that kits of the invention may be used to implement methods of the invention, that methods of the invention may be implemented with compositions of the invention, and that kits may include any composition of the invention.

It is further contemplated that kits, methods, and compositions of the invention may
5 effect a depletion of a targeted nucleic acid in a sample by reducing its amount in the sample by
at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, 99.1,
99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9 or more percent.

Kits of the invention also include materials for creating a nucleic acid array and probing a
nucleic acid array. Any of the kits discussed above may also include a solid support for
10 preparing a nucleic acid array.

The use of the word "a" or "an" when used in conjunction with the term "comprising" in
the claims and/or the specification may mean "one," but it is also consistent with the meaning of
"one or more," "at least one," and "one or more than one." When the term "at least" is used in
the context of bridging, targeting, or capture regions, as well as for capture and bridging
15 oligonucleotides, it is contemplated that there is an upper limit of 20 for practical purposes, even
though more such regions or oligonucleotides could be implemented with the invention.
Furthermore, it should be understood that a number (cardinal or ordinal) used in the context of
compositions of the invention refers to a "kind" of that composition; thus, "a first
oligonucleotide" in the context of a "second oligonucleotide" refers to "one of that kind of
20 oligonucleotide," and not one single oligonucleotide molecule.

Other objects, features and advantages of the present invention will become apparent
from the following detailed description. It should be understood, however, that the detailed
description and the specific examples, while indicating specific embodiments of the invention,
are given by way of illustration only, since various changes and modifications within the spirit
25 and scope of the invention will become apparent to those skilled in the art from this detailed
description.

BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

FIG. 1. Depiction of molecules in system. A bridging oligonucleotide is shown with a targeting region and a bridging region. The targeting region is complementary to a targeted region in the targeted nucleic acid, which is an rRNA molecule. The bridging region is complementary to the capture region in the capture oligonucleotide, which is attached, by way of example, to a magnetic bead as a nonreacting structure.

FIG. 2A-1 to A-14 and FIG. 2B-1 to B-27. Sequence comparison of different rRNAs from different bacteria to *E. coli* rRNA with MegAlign sequence analysis software version 4.05 from DNA Star, Incorporated. A. The 5' end of the sequence is shown on the first page of the figure in FIG. 2A-1 and continues until the last page of the figure, FIG. 2A-14, in which the 3' end of the same sequence is shown. Shown is a sequence comparison of 16S rRNA of listed prokaryotic organisms to 16S rRNA from *E. coli* (SEQ ID NO:34). The sequences are the 16S rRNA from the following organisms: *B. subtilis* (SEQ ID NO:23); *B. anthracis* (SEQ ID NO. 24); *E. faecalis* (SEQ ID NO. 25); *L. lactis* (SEQ ID NO. 26); *L. monocyt* (SEQ ID NO. 27); *S. aureus* (SEQ ID NO. 28); *S. mutans* (SEQ ID NO. 29); *S. pneumon* (SEQ ID NO. 30); *S. pyogenes* (SEQ ID NO. 31); *M. avian* (SEQ ID NO. 32); *M. tuberculosis* (SEQ ID NO. 33); *K. pneumoniae* (SEQ ID NO. 35); *A. actino* (SEQ ID NO. 36); *H. influenzae* (SEQ ID NO. 37); *E. bronchiseptica* (SEQ ID NO. 38); *B. paraptussis* (SEQ ID NO. 39); *B. pertussis* (SEQ ID NO. 40); *B. cepacia* (SEQ ID NO. 41); *B. mallei* (SEQ ID NO. 42); *B. pseudomallei* (SEQ ID NO. 43); *N. gonorrhoeae* (SEQ ID NO. 44); *N. mening* (SEQ ID NO. 45); *P. aeruginosa* (SEQ ID NO. 46); *V. cholerae* (SEQ ID NO. 47); and *Y. enterocolitica* (SEQ ID NO. 48). B. The 5' end of the sequence is shown on the first page of the figure in FIG. 2B-1 and continues until the last page of the figure, FIG. 2B-27, in which the 3' end of the same sequence is shown. Shown is a sequence comparison of 23S rRNA of listed prokaryotic organisms to 23S rRNA from *E. coli* (SEQ ID NO:60). The sequences are the 23S rRNA from the following organisms: *B. subtilis* (SEQ ID NO:49); *B. anthracis* (SEQ ID NO. 50); *E. faecalis* (SEQ ID NO. 51); *L. lactis* (SEQ ID

NO. 52); *L. monocytogenes* (SEQ ID NO. 53); *S. aureus* (SEQ ID NO. 54); *S. mutans* (SEQ ID NO. 55); *S. pneumoniae* (SEQ ID NO. 56); *S. pyogenes* (SEQ ID NO. 57); *M. avium* (SEQ ID NO. 58); *M. tuberculosis* (SEQ ID NO. 59); *K. pneumoniae* (SEQ ID NO. 61); *H. influenzae* (SEQ ID NO. 62); *B. bronchiseptica* (SEQ ID NO. 63); *B. parapertussis* (SEQ ID NO. 64); *B.*
5 *pertussis* (SEQ ID NO. 65); *B. cepacia* (SEQ ID NO. 66); *E. mallei* (SEQ ID NO. 67); *E. pseudomallei* (SEQ ID NO. 68); *N. gonorrhoeae* (SEQ ID NO. 69); *N. meningitidis* (SEQ ID NO. 70); *P. aeruginosa* (SEQ ID NO. 71); *V. cholerae* (SEQ ID NO. 72); *Y. enterocolitica* (SEQ ID NO. 73).

FIG. 3. Electropherograms of RNA from a control reaction. *E. coli* total RNA
10 was purified with RNAwiz™ (Ambion) and carried through the rRNA depletion procedure as described in Example 2, except that bridging nucleic acids were left out of the reaction. A sample of the RNA was analyzed with the RNA 6000 Lab Chip Kit® (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01).

FIG. 4. Electropherograms of RNA from an experimental reaction after ribosomal
RNA depletion. *E. coli* total RNA was purified with RNAwiz™ (Ambion) and carried through the rRNA depletion procedure as described in Example 2. A sample of the RNA was analyzed as described in the legend to FIG. 3.

FIG. 5A-B. Electropherograms of RNA from experiments. **A.** Agilent 2100
20 Bioanalyzer electropherogram of a sample from a control reaction performed as described in Example 5, but with no bridging oligonucleotides. The sample contains *E. coli* and rat liver total RNA. The RNA sample was analyzed with the RNA 6000 Lab Chip Kit® (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01). **B.**
25 Agilent 2100 Bioanalyzer electropherogram of a sample from an experimental reaction performed as described in Example 5 with bridging oligonucleotides. The sample is depleted of *E. coli* 16S and 23S rRNA and rat liver 18S and 28S rRNA. The RNA sample was analyzed with the RNA 6000 Lab Chip Kit® (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent
30 2100 Bioanalyzer Bio Sizing software (Version A.02.01).

FIG. 6A-B. Electropherograms of RNA from experiments. **A.** Agilent 2100 Bioanalyzer electropherogram of a sample from a control reaction performed as described in Example 6, but with no bridging oligonucleotides. The sample contains human liver total RNA. The RNA sample was analyzed with the RNA 6000 Lab Chip Kit® (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01). **B.** Agilent 2100 Bioanalyzer electropherogram of a sample from an experimental reaction performed as described in Example 6 with bridging oligonucleotides. The sample is depleted of human 18S and 28S rRNA. The RNA sample was analyzed with the RNA 6000 Lab Chip Kit® (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01).

FIG. 7A-B. Electropherograms of RNA from experiments. **A.** Agilent 2100 Bioanalyzer electropherogram of a sample from a control reaction performed as described in Example 7, but with no bridging oligonucleotides. The sample contains rat liver total RNA. The RNA sample was analyzed with the RNA 6000 Lab Chip Kit® (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01). **B.** Agilent 2100 Bioanalyzer electropherogram of a sample from an experimental reaction performed as described in Example 6 with bridging oligonucleotides. The sample is depleted of rat 18S and 28S rRNA. The RNA sample was analyzed with the RNA 6000 Lab Chip Kit® (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01).

FIG. 8A-B. Electropherograms of RNA from experiments. **A.** Agilent 2100 Bioanalyzer electropherogram of a sample from a control reaction performed as described in Example 6, but with no bridging oligonucleotides. The sample contains mouse liver total RNA. The RNA sample was analyzed with the RNA 6000 Lab Chip Kit® (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01). **B.** Agilent 2100 Bioanalyzer electropherogram of a sample from an experimental reaction performed as described in Example 8 with bridging oligonucleotides. The sample is depleted of mouse 18S and 28S

rRNA. The RNA sample was analyzed with the RNA 6000 Lab Chip Kit[®] (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01).

- 5 **FIG. 9A-B.** Electropherograms of RNA from experiments. **A.** Agilent 2100 Bioanalyzer electropherogram of a sample from a control reaction performed as described in Example 11 with no bridging oligonucleotides. The sample contains human total RNA (50 µg) and *E. coli* total RNA (500 ng). The RNA sample was analyzed with the RNA 6000 Lab Chip Kit[®] (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The
10 electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01). **B.** Agilent 2100 Bioanalyzer electropherogram of a sample from an experimental reaction performed as described in Example 11 with bridging oligonucleotides. The sample is depleted of human 18S and 28S rRNA, but *E. coli* total RNA remains in the sample. The RNA sample was analyzed with the RNA 6000 Lab Chip Kit[®] (Caliper
15 Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01).

- FIG. 10A-C.** Electropherograms of RNA from experiments. **A.** Agilent 2100 Bioanalyzer
20 electropherogram of a sample from a control reaction with no bridging oligonucleotides performed as described in Example 12. The sample contains rat liver total RNA (25 µg) and *E. coli* total RNA (2 µg). The RNA sample was analyzed with the RNA 6000 Lab Chip Kit[®] (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software
25 (Version A.02.01). **B.** Agilent 2100 Bioanalyzer electropherogram of a sample from an experimental reaction performed as described in Example 12 with bridging oligonucleotides. The sample is depleted of rat 18S and 28S rRNA, but *E. coli* total RNA remains in the sample. The RNA sample was analyzed with the RNA 6000 Lab Chip Kit[®] (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was
30 generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01). **C.** Agilent

2100 Bioanalyzer electropherogram of a sample from an experimental reaction performed as described in Example 12 with bridging oligonucleotides. The sample is depleted of rat 18S and 28S rRNA and *E. coli* 16S and 23S rRNA. The RNA sample was analyzed with the RNA 6000 Lab Chip Kit[®] (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01).

FIG. 11A-B. *E. coli* gene arrays probed with cDNA from experiments. Experimental reactions were performed as described in Example 13. RNA samples were used to generate radiolabeled cDNA for use as probes with replicate portions of Sigma-Genosys Panorama[™] *E. coli* gene arrays. A. *E. coli* gene array probed with a sample from a control reaction. The sample contains human total RNA (25 µg) and *E. coli* total RNA (2 µg). B. *E. coli* gene array probed with an RNA sample that was depleted of human 18S and 28S rRNA and *E. coli* 16S and 23S rRNA.

FIG. 12A-B. Electropherograms of RNA from experiments. A. Agilent 2100 Bioanalyzer electropherogram of a sample from a control reaction performed as described in Examples 1 and 2 with no bridging oligonucleotides. The sample contains *Campylobacter fetus* total RNA (10 µg). The RNA sample was analyzed with the RNA 6000 Lab Chip Kit[®] (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01). B. Agilent 2100 Bioanalyzer electropherogram of a sample from an experimental reaction with 10 µg of *Campylobacter fetus* total RNA that employed the bridging oligonucleotides d16S-807, d16S-1092, d23S-479CH, and d23S-2511. The sample is depleted of 16S rRNA, 23S rRNA fragment (1260 nt), and 23S rRNA fragment (1667 nt). The RNA sample was analyzed with the RNA 6000 Lab Chip Kit[®] (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01).

FIG. 13A-B. Electropherograms of RNA from experiments. A. Agilent 2100 Bioanalyzer electropherogram of a sample from a control reaction performed as described in Examples 1 and 2 with no bridging oligonucleotides. The sample contains *Rhodobacter sphaeroides* total RNA (10 µg). The RNA sample was analyzed with the RNA 6000 Lab Chip Kit[®] (Caliper

Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01). B. Agilent 2100 Bioanalyzer electropherogram of a sample from an experimental reaction with 10 µg of *Rhodobacter sphaeroides* total RNA that employed the bridging oligonucleotides d16S-537 (16 pmol), d16S-1114R(16 pmol), d23S-479CH (16 pmol), d23S-1954 (16 pmol), and d23S-2511 (16 pmol). The sample is depleted of the 16S rRNA and the 23S rRNA fragment that co-migrates with the 16S rRNA. The sample is also depleted of the 23S rRNA fragment (1260 nt). The RNA sample was analyzed with the RNA 6000 Lab Chip Kit® (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01).

FIG. 14A-B. Electropherograms of RNA from experiments. A. Agilent 2100 Bioanalyzer electropherogram of a sample from a control reaction performed as described in Examples 1 and 2 with no bridging oligonucleotides. The sample contains *Anabaena sp.* total RNA (10 µg). The RNA sample was analyzed with the RNA 6000 Lab Chip Kit® (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01). B. Agilent 2100 Bioanalyzer electropherogram of a sample from an experimental reaction with 10 µg of *Anabaena sp.* total RNA that employed the bridging oligonucleotides d16S-364 (12.5 pmol), d16S-1087CY (12.5 pmol), d23S-485 (20 pmol), and d23S-1954 (35 pmol). The sample is depleted of 16S rRNA and the 23S rRNA fragments at 520 nt, 2090 nt, and 2470 nt. The RNA sample was analyzed with the RNA 6000 Lab Chip Kit® (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01).

DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

The present invention concerns a system for isolating, depleting, or identifying specific, targeted nucleic acid populations, such as rRNA in a sample, in some cases for the purpose of enriching for other nucleic acid populations. The targeted nucleic acid, components of the system, and the methods for implementing the system, as well as variations thereof, are provided below.

I. Targeted Nucleic Acid

The present invention concerns targeting a particular nucleic acid population (*i.e.*, mRNA, rRNA, tRNA, genomic DNA) or targeting types of a nucleic acid population, such as individual tRNAs, rRNAs (5S, 16S, or 23S rRNA from prokaryotes; 5.8S, 17S or 18S, or 28S from eukaryotes), or specific mRNAs. A nucleic acid is targeted by using a bridging nucleic acid that has a targeting region—a region complementary to all or part of the targeted nucleic acid.

In some embodiments, the invention is specifically concerned with depleting or isolating rRNA from other nucleic acids (“non-targeted nucleic acids” or “enriched population”). The 5S, 16S, and/or 23S rRNA from a prokaryote may be the targeted nucleic acid. Also, the 5.8S, 17S (observed in yeast) or 18S, and/or 28S from a eukaryote may be the targeted nucleic acid. Alternatively, rRNAs from both prokaryotes and eukaryotes may be targeted, such as with a sample that has eukaryotic host cells infected with a prokaryotic organism. The sequences for ribosomal RNAs are well known to those of ordinary skill in the art and can be readily found in sequence databases such as GenBank (www.ncbi.nlm.nih.gov/) or are published. Nucleic acids may be targeted by targeting regions that are complementary to all or part of the targeted nucleic acid. Targeted nucleic acids may be, be at least, or be at most 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900, 4000, 4100, 4200, 4300, 4400, 4500, 4600, 4700, 4800, 4900, 5000, 5100, 5200, 5300, 5400, 5500, 5600, 5700, 5800, 5900, 6000, 6100, 6200, 6300, 6400, 6500, 6600, 6700, 6800, 6900, 7000, 7100, 7200, 7300, 7400, 7500, 7600, 7700, 7800, 7900, 8000, 8100, 8200, 8300, 8400, 8500, 8600, 8700, 8800, 8900, 9000, 9100, 9200, 9300, 9400, 9500, 9600, 9700, 9800, 9900, 10000, or more nucleotides in length. Furthermore, any region of at least five contiguous nucleotides in the targeted nucleic acid may be used as the targeted region—that is, the region that is complementary to the targeting region of a bridging nucleic acid. Also, there may be more than one targeted region in a targeted nucleic acid. There may be, be at least, or be at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or

more targeted regions in a targeted nucleic acid. A targeted region may be a region in a targeted nucleic acid that has greater than 70%, 80%, or 90% homology with a sequence from a different targeted nucleic acid. In some embodiments, the targeted region from a targeted nucleic acid is identical to a sequence in a different targeted nucleic acid. For example, 23S rRNA of various prokaryotes may be targeted using a targeted region common to a group of organisms, such as Gram negative bacteria or a subset of such bacteria. Alternatively, a targeted region may be a sequence unique to a particular targeted nucleic acid. However, for purposes of this application, a "targeted region" is not a poly-A region, such as a poly-A tail of an eukaryotic mRNA. Additional information regarding targeted rRNAs is provided below. This information is provided as an example of targeted nucleic acids. However, it is contemplated that there may be sequence variations from individual organism to organism and these sequences provided as simply an example of one sequenced nucleic acid, even though such variations exist in nature. It is contemplated that these variations may also be targeted, and this may or may not require changes to a targeting nucleic acid or to the hybridization conditions, depending on the variation, which one of ordinary skill in the art could evaluate and determine.

A number of patents concern a targeted nucleic acid, for example, U.S. Patent Nos. 4,486,539; 4,563,419; 4,751,177; 4,868,105; 5,200,314; 5,273,882; 5,288,609; 5,457,025; 5,500,356; 5,589,335; 5,702,896; 5,714,324; 5,723,597; 5,759,777; 5,897,783; 6,013,440; 6,060,246; 6,090,548; 6,110,678; 6,203,978; 6,221,581; 6,228,580; and WO 01/32672, all of which are specifically incorporated herein by reference.

A. Prokaryotic rRNA

Prokaryotic rRNA can be a targeted nucleic acid of the invention. The following examples are provided, but the invention is not limited solely to these organisms and sequences (GenBank accession number provided and/or region within sequence that corresponds to the targeted rRNA):

1. Superkingdom Archaea (archaeobacteria)

<i>Aeropyrum pernix</i>	D83259
16S	
<i>Aeropyrum pernix</i> NC_000854	
APErRNA05 (16S)	1218763-1220185
APErRNA03 (23S)	1213627-1218039
<i>Methanococcus jannaschii</i>	
16S	M59126

	<i>Methanococcus jannaschii</i> NC_000909	
	MJrtnA16S	157985-159459
	MJrtnA23S	154759-157648
5	<i>Halobacterium marismortui</i>	
	23S	X13738
	<i>Halobacterium sp. NRC-1</i> NC_002607	
	rrs (16S)	1875505-1876977
	rrlA (23S)	1877506-1880411
10	<i>Thermoplasma acidophilum</i>	
	23S	M32298
	<i>Thermoplasma acidophilum</i> NC_002578	
	16S	1475300-1475770
2.	Superkingdom <u>Eubacteria</u> (eubacteria)	
	a. Firmicutes (Gram-positive bacteria)	
15	i) <u>Bacillus/Clostridium</u> group (low G+C gram-positive bacteria)	
	<i>Listeria innocua</i> Clip 11262 NC_003212	
	16S	260527-262081
20	23S	262327-265257
	<i>Listeria monocytogenes</i> strain EGD NC_003210	
	16S	237466-239020
	23S	239265-242195
25	<i>Bacillus subtilis</i> NC000964	
	RmO 16S	9809-11361
	RmA 23S	11707-14634
	<i>Bacillus anthracis</i>	
30	16S (1508nt)	AF155950
	23S (2922nt)	AF267877
	<i>Bacillus thuringiensis</i>	
35	16S (1486nt)	D16281
	23S (2923nt)	AF267880
	<i>Staphylococcus aureus</i> strain Mu50 NC_002758	
	16S	530479-532033
40	23S	532398-535231
	<i>Staphylococcus aureus</i> N315 NC_002745	
	SarRNA01 16S	506138-507692
	SarRNA02 23S	508166-510999
45	<i>Clostridium acetobutylicum</i> ATCC824 NC_003030	
	16SarRNA	9710-11219
	23SarRNA	11398-14303
	<i>Clostridium difficile</i>	
50	16S (1470nt)	X73450

	<i>Clostridium perfringens</i>	
	16S	M69264 (499-2294)
	<i>Mycoplasma genitalium</i> G37	L43967
5	MgrrnA16S	170009-171527
	MgrrnA23S	171730-174463
	<i>Mycoplasma pneumoniae</i> NC_000912	
10	16S	118312-119824
	23S	120057-122961
	<i>Mycoplasma pulmonis</i> NC_002771	
15	16S	813583-815113
	23S	810563-813297
	<i>Streptococcus pneumoniae</i> R6 NC_003098	
	RRNA16S-1	15161-16674
	RRNA23S-1	16945-19846
20	<i>Streptococcus pneumoniae</i> TIGR4 AE005672	
	SprmaA16S	15394-16806
	SprmaA23S	17142-20043
25	<i>Streptococcus pyogenes</i> AE004092	
	16S	17170-18504
	23S	19037-21937
	<i>Streptococcus mutans</i>	
30	16S (1334nt)	X58303
	23S	AF139599 (1940-4840)
	<i>Lactococcus lactis</i>	
35	16S	X64887 (508-2055)
	23S	X64887 (2360-5257)
	<i>Enterococcus faecalis</i>	
	16S (1449nt)	Y18293
	23S (2912nt)	AJ295306
40	ii) Actinobacteria (high G+C gram-positive bacteria)	
	<i>Mycobacterium leprae</i> strain TN NC_002677	
	Rrs16S	1341144-1342692
	Rrl23S	1342976-1346100
45	<i>Mycobacterium tuberculosis</i> CDC 1551 NC_002755	
	MtrmaA16S	1471388-1472923
	MtrmaA23S	1473199-1476336
50	<i>Mycobacterium avium</i>	
	16S (1372nt)	M61673
	23S	X74494 (295-3401)

		<i>Corynebacterium glutamicum</i>	
		16S (1479nt)	Z46753
		<i>Rhodococcus equi</i>	
5		16S (1478nt)	X80614
	b. Spirochaetales (spirochetes)		
	<i>Borrelia burgdorferi</i>	AE000783	
	RriB 16S	444581-446118	
10	RriB 23S	438590-441508	
	<i>Treponema pallidum</i>	AE000520	
	TprmaA16S	230162-231656	
15	TprmaA23S	231950-234850	
	<i>Borrelia burgdorferi</i>		
	16S	AE001147 (9459-10996)	
	23S	AE001147 (212-3145)	
20	c. Thermotogales		
	<i>Thermotoga maritima</i>	AE000512	
	TmrnaA16S	188968-190526	
	TmrnaA23S	190766-193787	
25	d. Thermus/Deinococcus group		
	<i>Deinococcus radiodurans</i>	R1 NC_001263	
	DrrnaA16S	2285518-2287019	
	DrrnaA23S	2245319-2246194	
30	<i>Deinococcus radiodurans</i>		
	16S	AE002076 (7275-8776)	
	23S	AE001886 (8829-10771)	
	e. Chlamydiales (chlamydias)		
35	<i>Chlamydia trachomatis</i>	AE001273	
	16SrRNA1	854128-855677	
	23SrRNA1	855993-858862	
	<i>Chlamydomonas pneumoniae</i>	AR39 NC_002179	
40	CprnA16S	1069329-1070785	
	CprnA23S	1066159-1069022	
	<i>Chlamydomonas psittaci</i>		
45	16S	U68447 (1-1553)	
	23S	U68447 (1778-4721)	
	f. Proteobacteria (purple bacteria)		
	i) Alpha subdivision		
	<i>Rickettsia conorii</i>	Malish 7 NC_003103	

27

	Rrs16S	884601-886108
	Rrl23S	281797-284557
5	<i>Rickettsia prowazekii</i> strain Madrid E	AJ235269
	Rrs16S	772263-773769
	Rrl23S	257853-260613
	<i>Rickettsia typhi</i>	
10	16S (1444nt)	M20499
	23S	Y13133 (956-3716)
	<i>Ehrlichia bovis</i>	
	16S (1488nt)	U03775
15	<i>Agrobacterium tumefaciens</i> C58	AE007870
	16S	768991-770427
	23S	765313-767565
20	<i>Brucella melitensis</i>	
	16S	AF220148 (645-2129)
	23S	AF220148 (2896-3024..3204-5807)
	<i>Rhizobium rhizogenes</i>	
25	16S (1369nt)	D13945
	ii) Beta subdivision	
	<i>Neisseria meningitidis</i> strain MC58	AE002098
30	NmrnaA16S	60971-62514
	NmrnaA23S	63178-66068
	<i>Bordetella bronchiseptica</i>	
	16S (1532nt)	X57026
	23S (2865nt)	X70371
35	<i>Bordetella parapertussis</i>	
	16S (1464nt)	U04949
	23S (2865nt)	X68368
40	<i>Bordetella pertussis</i>	
	16S (1464nt)	U04950
	<i>Burkholderia mallei</i>	
45	16S (1488nt)	AF110188
	23S (2882nt)	Y17183
	<i>Burkholderia pseudomallei</i>	
	16S (1488nt)	U91839
	23S (2882nt)	Y17184
50	<i>Neisseria gonorrhoeae</i>	
	16S (1544nt)	X07714
	23S (2890nt)	X67293

iii)	Gamma group		
	<i>Buchnera</i> sp. APS NC_002528		
5	Rrs 16S	274065-275524	
	Rrl 23S	539539-542451	
	<i>Escherichia coli</i> K12 U00096		
	RrsH 16S	223771-225312	
10	RrlH 23S	225759-228662	
	<i>Escherichia coli</i> 0157:H7 NC_002695		
	RrsH 16S	227102-228643	
	RrlH 23S	229090-231992	
15	<i>Salmonella enterica</i> serovar Typhi NC_003198		
	16S	287479-289020	
	23S	289375-292380	
	<i>Salmonella typhimurium</i> LT2 NC_003197		
20	RrsH16S	289189-290732	
	RrlH23S	291244-294336	
	<i>Yersinia pestis</i> NC_003143		
25	16S	12292-13763	
	23S	14272-17178	
	<i>Klebsiella pneumoniae</i>		
	16S (1534nt)	X87276	
30	23S (2903nt)	X87284	
	<i>Yersinia enterocolitica</i>		
	16S (1484nt)	Z49830	
	23S (2906nt)	U77925	
35	<i>Proteus vulgaris</i>		
	16S (2067nt)	X07652	
	<i>Shigella flexneri</i>		
40	16S (1468nt)	X80679	
	<i>Shigella sonnei</i>		
	16S (1467nt)	X80726	
	<i>Shigella dysenterica</i>		
45	16S (1487nt)	X96966	
	<i>Haemophilus influenzae</i> Rd L42023		
	HirmE16S	1511137-1512634	
50	HirmE23S	123801-126697	
	<i>Pasteurella multocida</i>		
	16S (1543nt)	M35018	

	<i>Actinobacillus actinomycetemcomitans</i>	
	16S (1485nt)	M75037
5	<i>Actinobacillus pleuropneumoniae</i>	
	16S	D30032 (83-1625)
	<i>Haemophilus somnus</i>	
10	16S (1483nt)	M75046
	<i>Legionella pneumophila</i>	
	16S (1544nt)	M59157
	<i>Mannheimia haemolytica</i>	
15	16S (1472nt)	U57072
	<i>Vibrio cholerae</i> chromosomal	NC_002505
	16Sa rRNA	53823-55357
20	23Sa rRNA	55784-58670
	<i>Vibrio parahaemolyticus</i>	
	16S (1499nt)	M59161
	<i>Coxiella burnetii</i>	
25	16S (1484nt)	M21291
	23S	X79704 (1620-3350)
	<i>Aeromonas hydrophila</i>	
30	16S (1538nt)	X87271
	<i>Aeromonas salmonicida</i>	
	16S (1502nt)	X60405
	<i>Francisella tularensis</i>	
35	16S (1517nt)	Z21931
	<i>Moraxella catarrhalis</i>	
	16S (1511nt)	U10876
	<i>Pseudomonas aeruginosa</i>	AE004091
40	16S	722096-726631
	23S	724103-726993
	<i>Pseudomonas putida</i>	
45	16S (1527nt)	D84020
	iv) Delta/Epsilon subdivisions	
	<i>Campylobacter jejuni</i>	AL111168
50	16S	39249-40761
	23S	41568-44457

Helicobacter pylori 26695 NC_000915

HPrmB16S	1511137-1512634
HPrmB23S	1473918-1476893

g. **Cyanobacteria***Synechocystis* sp. PCC 6803 NC_000911

Rrm16Sa	2452187-2453675
Rrm23Sa	2448839-2451721

Synechococcus sp. (*Anacystis nidulans*)

16S	X03538 (1432-2918)
23S	X00512 (251-3126)

h. **CFB/Green sulfur bacteria group***Porphyromonas gingivalis*

16S (1474nt)	L16492
--------------	--------

B. Eukaryotic rRNA

Targeted nucleic acids of the invention may also be one or more types of eukaryotic rRNAs. Eukaryotes include, but are not limited to: mammals, fish, birds, amphibians, fungi, and plants. The following provides sequences for some of these targeted nucleic acids. It is contemplated that other eukaryotic rRNA sequences can be readily obtained by one of ordinary skill in the art, and thus, the invention includes, but is not limited to, the sequences shown below.

Superkingdom **Eukaryota** (eucaryotes)*Homo sapiens* (human)

18S	M10098
18S	K03432
18S	X03205
28S	M11167

Mus musculus

18S	X00686
28S	X00525

Rattus norvegicus

18S	M11188
18S	X01117

Rattus norvegicus V01270.1

18S	1-1874
28S	3862-8647

II. Isolation and/or Depletion System Nucleic Acids

The present invention concerns compositions comprising a nucleic acid or a nucleic acid analog in a system or kit to deplete, isolate, or separate a nucleic acid population from other nucleic acid populations, for which enrichment may be desirable. It concerns a bridging nucleic acid and a capture nucleic acid to deplete, isolate, or separate out a targeted nucleic acid, as discussed above.

A. Bridging Nucleic Acids

Bridging nucleic acids of the invention comprise a bridging region and a targeting region. As discussed in other sections, the location of these regions may be throughout the molecule, which may be of a variety of lengths. The bridging nucleic acid may comprise RNA, DNA, both, or analogs of either or both.

The bridging region comprises a sequence that is complementary to at least five contiguous nucleotides in the capture nucleic acid. It is contemplated that that this region may be a homogenous sequence, that is, have the same nucleotide repeated across its length, such as a repeat of A, C, G, T, or U residues. However, to avoid hybridizing with a poly-A tailed mRNA in a sample comprising eukaryotic nucleic acids, it is contemplated that most embodiments will not have a poly-U or poly-T bridging region when dealing with such samples having poly-A tailed RNA. In some embodiments, the bridging region is a poly-C region and the capture region is a poly-G region, or vice versa. In other embodiments, the bridging region will be a random sequence that is complementary to the capture region (or the capture region will be random and the bridging region will be complementary to it). In further embodiments, the bridging region will have a designed sequence that is not homopolymeric but that is complementary to the capture region or vice versa. Sequences may be determined empirically. In many embodiments, it is preferred that this will be a random sequence or a defined sequence that is not a homopolymer. Some sequences will be determined empirically during evaluation in the assay.

B. Capture Nucleic Acids

Capture nucleic acids of the invention comprise a capture region and a nonreacting structure that allows the capture nucleic acid, any molecules specifically binding or hybridizing to the capture nucleic acid—such as the bridging nucleic acid—and any molecules specifically binding or hybridizing to the bridging nucleic acid—such as the targeted nucleic acid—to be isolated away from other nucleic acid populations.

The capture nucleic acid may comprise RNA, DNA, both, or analogs of either or both. However, in some embodiments of the invention, it is specifically contemplated to be homopolymeric (only one type of nucleotide residue in molecule, such as poly-C), though in other embodiments, it is specifically contemplated not to be homopolymeric and be
5 heteropolymeric, as described for bridging regions.

1. Capture Regions

The main requirement for bridging and capture nucleic acid sequences is that they are complementary to one another. The capture region may be a poly-pyrimidine or poly-purine region comprising at least 5 nucleic acid residues. In addition, it may be heteropolymeric, either
10 a random sequence or a designed sequence that is complementary to the bridging region of the nucleic acid with which it should hybridize.

In addition to the capture oligos already described herein, the following are also considered for use with the present invention:

- 15 NRS-5'-TAACCTGGTCGTAAC-3' (SEQ ID NO:87)
- NRS-5'-CCCCCCCCCCCC-3' (SEQ ID NO:88)
- NRS-5'-GCCCCCTAACCTCGTCG (SEQ ID NO:89)
- 20 NRS-5'-CGGCCCTAGCCGGGTCGTACCTCCGG (SEQ ID NO:90)
- NRS-5'-CGGCCCTAACCTGGTCGTAACCTCCGG (SEQ ID NO:91)
- 25 NRS-5'-AGGCTTCGATCCCGGGATCCGCG (SEQ ID NO:92)

As discussed below, "NRS" refers to a non-reacting structure.

2. Nonreacting Structures (NRS)

- A nonreacting structure is a compound or structure that will not react chemically with nucleic acids, and in some embodiments, with any molecule that may be in a sample.
- 30 Nonreacting structures may comprise plastic, glass, teflon, silica, a magnet, a metal such as gold, carbon, cellulose, latex, polystyrene, and other synthetic polymers, nylon, cellulose, nitrocellulose, polymethacrylate, polyvinylchloride, styrene-divinylbenzene, or any chemically-

modified plastic. They may also be porous or non-porous materials. The structure may also be a particle of any shape that allows the targeted nucleic acid to be isolated, depleted, or separated. It may be a sphere, such as a bead, or a rod, or a flat-shaped structure, such as a plate with wells. Also, it is contemplated that the structure may be isolated by physical means or electromagnetic means. For example, a magnetic field may be used to attract a non-reacting structure that includes a magnet. The magnetic field may be in a stand or it may simply be placed on the side of a tube with the sample and a capture nucleic acid that is magnetized. Examples of physical ways to separate nucleic acids with their specifically hybridizing compounds are well known to those of skill in the art. A basket or other filter means may be employed to separate the capture nucleic acid and its hybridizing compounds (direct and indirect). The non-reacting structure and sample with nucleic acids of the invention may be centrifuged, filtered, dialyzed, or captured (with a magnet). When the structure is centrifuged it may be pelleted or passed through a centrifugible filter apparatus. The structure may also be filtered, including filtration using a pressure-driven system. Many such structures are available commercially and may be utilized herewith. Other examples can be found in WO 86/05815, WO90/06045, U.S. Patent 5,945,525, all of which are specifically incorporated by reference.

Cellulose is a structural polymer derived from vascular plants. Chemically, it is a linear polymer of the monosaccharide glucose, using β , 1-4 linkages. Cellulose can be provided commercially, including from the Whatman company, and can be chemically sheared or chemically modified to create preparations of a more fibrous or particulate nature. CF-1 cellulose from Whatman is an example that can be implemented in the present invention.

Synthetic plastic or glass beads may be employed in the context of the invention. The beads may be complexed with avidin or streptavidin and they may also be magnetized. The complexed streptavidin can be used to capture biotin linked to an oligo-dT or -U or poly (dT) or poly(U) moiety, either before or after hybridization to the poly(A) tails of mRNA. Alternatively, the oligo/poly(dT/U) moiety can be attached to the beads directly through chemical coupling. The beads may be collected using gravity- or pressure-based systems and/or filtration devices. If the beads are magnetized, a magnet can be used to separate the beads from the rest of the sample. The magnet may be employed with a stand or a stick or other type of physical structure to facilitate isolation.

Other components include isolation apparatuses such as filtration devices, including spin filters or spin columns.

C. Nucleic Acid Compositions

Embodiments of the present invention concern bridging, capture, and targeted nucleic acids. In particular aspects, a targeted nucleic acid encodes for or comprises a transcribed nucleic acid. In other aspects, a bridging nucleic acid comprises a targeting region that comprises a nucleic acid segment having the sequence of all or part of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:72, or SEQ ID NO:73 (collectively referred to as "SEQ ID NOS:1-73"), as well as SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, and SEQ ID NO:92 (collectively referred to as "SEQ ID NOS:1-92"). In particular aspects, a targeted nucleic acid encodes a protein, polypeptide, peptide. Nucleic acids of the invention comprise RNA, DNA, analogs of RNA, analogs of DNA, or a combination thereof.

The term "nucleic acid" is well known in the art. A "nucleic acid" as used herein will generally refer to a molecule (*i.e.*, a strand) of DNA, RNA or a derivative or analog thereof, comprising a nucleobase. A nucleobase includes, for example, a naturally occurring purine or pyrimidine base found in DNA (*e.g.*, an adenine "A," a guanine "G," a thymine "T" or a cytosine "C") or RNA (*e.g.*, an A, a G, an uracil "U" or a C). The term "nucleic acid" encompass the

terms "oligonucleotide" and "polynucleotide," each as a subgenus of the term "nucleic acid." The term "oligonucleotide" refers to a molecule of between about 3 and about 100 nucleobases in length. The term "polynucleotide" refers to at least one molecule of greater than about 100 nucleobases in length.

- 5 These definitions generally refer to a single-stranded molecule, but in specific embodiments will also encompass an additional strand that is partially, substantially or fully complementary to the single-stranded molecule. Thus, a nucleic acid may encompass a double-stranded molecule or a triple-stranded molecule that comprises one or more complementary strand(s) or "complement(s)" of a particular sequence comprising a molecule. As used herein, a
10 single stranded nucleic acid may be denoted by the prefix "ss," a double stranded nucleic acid by the prefix "ds," and a triple stranded nucleic acid by the prefix "ts."

1. Nucleobases

- As used herein a "nucleobase" refers to a heterocyclic base, such as for example a naturally occurring nucleobase (*i.e.*, an A, T, G, C or U) found in at least one naturally occurring
15 nucleic acid (*i.e.*, DNA and RNA), and naturally or non-naturally occurring derivative(s) and analogs of such a nucleobase. A nucleobase generally can form one or more hydrogen bonds ("anneal" or "hybridize") with at least one naturally occurring nucleobase in manner that may substitute for naturally occurring nucleobase pairing (*e.g.*, the hydrogen bonding between A and T, G and C, and A and U).
- 20 "Purine" and/or "pyrimidine" nucleobase(s) encompass naturally occurring purine and/or pyrimidine nucleobases and also derivative(s) and analog(s) thereof, including but not limited to, those of a purine or pyrimidine substituted by one or more of an alkyl, caboxyalkyl, amino, hydroxyl, halogen (*i.e.*, fluoro, chloro, bromo, or iodo), thiol or alkylthiol moiety. Preferred alkyl (*e.g.*, alkyl, caboxyalkyl, etc.) moieties comprise of from about 1, about 2, about 3, about 4,
25 about 5, to about 6 carbon atoms. Other non-limiting examples of a purine or pyrimidine include a deazapurine, a 2,6-diaminopurine, a 5-fluorouracil, a xanthine, a hypoxanthine, a 8-bromoguanine, a 8-chloroguanine, a bromothymine, a 8-aminoguanine, a 8-hydroxyguanine, a 8-methylguanine, a 8-thioguanine, an azaguanine, a 2-aminopurine, a 5-ethylcytosine, a 5-methylcytosine, a 5-bromouracil, a 5-ethyluracil, a 5-iodouracil, a 5-chlorouracil, a 5-propyluracil, a thiouracil, a 2-methyladenine, a methylthioadenine, a N,N-dimethyladenine, an
30 azaadenines, a 8-bromoadenine, a 8-hydroxyadenine, a 6-hydroxyaminopurine, a 6-thiopurine, a

4-(6-aminohexyl)cytosine), and the like. A table of non-limiting, purine and pyrimidine derivatives and analogs is also provided herein below.

Table 1-Purine and Pyrimidine Derivatives or Analogs			
Abbr.	Modified base description	Abbr.	Modified base description
ac4c	4-acetylcytidine	Mam5s2u	5-methoxyaminomethyl-2-thiouridine
Chm5u	5-(carboxyhydroxymethyl)uridine	Man q	Beta,D-mannosylqueosine
Cm	2'-O-methylcytidine	Mcm5s2u	5-methoxycarbonylmethyl-2-thiouridine
Cmm5s2u	5-carboxymethylamino-methyl-2-thioridine	Mcm5u	5-methoxycarbonylmethyluridine
Cmm5u	5-carboxymethylaminomethyluridine	Mo5u	5-methoxyuridine
D	Dihydrouridine	Ms2i6a	2-methylthio-N6-isopentenyladenosine
Fm	2'-O-methylpseudouridine	Ms2i6a	N-((9-beta-D-ribofuranosyl-2-methylthiopurine-6-yl)carbamoyl)threonine
Gal q	Beta,D-galactosylqueosine	Mt6a	N-((9-beta-D-ribofuranosylpurine-6-yl)N-methyl-carbamoyl)threonine
Gm	2'-O-methylguanosine	Mv	Uridine-5-oxyacetic acid methylester
I	Inosine	o5u	Uridine-5-oxyacetic acid (v)
I6a	N6-isopentenyladenosine	Osyw	Wybutoxosine
m1a	1-methyladenosine	P	Pseudouridine

Table 1-Purine and Pyrimidine Derivatives or Analogs

Abbr.	Modified base description	Abbr.	Modified base description
m1f	1-methylpseudouridine	Q	Queosine
m1g	1-methylguanosine	s2c	2-thiocytidine
m1I	1-methylinosine	s2t	5-methyl-2-thiouridine
m22g	2,2-dimethylguanosine	s2u	2-thiouridine
m2a	2-methyladenosine	s4u	4-thiouridine
m2g	2-methylguanosine	T	5-methyluridine
m3c	3-methylcytidine	t6a	N-((9-beta-D-ribofuranosylpurine-6-yl)carbamoyl)threonine
m5c	5-methylcytidine	Tm	2'-O-methyl-5-methyluridine
m6a	N6-methyladenosine	Um	2'-O-methyluridine
m7g	7-methylguanosine	Yw	Wybutosine
Mam5u	5-methylaminomethyluridine	X	3-(3-amino-3-carboxypropyl)uridine, (acp3)u

A nucleobase may be comprised of a nucleoside or nucleotide, using any chemical or natural synthesis method described herein or known to one of ordinary skill in the art.

2. Nucleosides

- 5 As used herein, a "nucleoside" refers to an individual chemical unit comprising a nucleobase covalently attached to a nucleobase linker moiety. A non-limiting example of a "nucleobase linker moiety" is a sugar comprising 5-carbon atoms (*i.e.*, a "5-carbon sugar"), including but not limited to a deoxyribose, a ribose, an arabinose, or a derivative or an analog of a 5-carbon sugar. Non-limiting examples of a derivative or an analog of a 5-carbon sugar
- 10 include a 2'-fluoro-2'-deoxyribose or a carbocyclic sugar where a carbon is substituted for an oxygen atom in the sugar ring.

Different types of covalent attachment(s) of a nucleobase to a nucleobase linker moiety are known in the art. By way of non-limiting example, a nucleoside comprising a purine (*i.e.*, A

or G) or a 7-deazapurine nucleobase typically covalently attaches the 9 position of a purine or a 7-deazapurine to the 1'-position of a 5-carbon sugar. In another non-limiting example, a nucleoside comprising a pyrimidine nucleobase (*i.e.*, C, T or U) typically covalently attaches a 1 position of a pyrimidine to a 1'-position of a 5-carbon sugar.

3. Nucleotides

As used herein, a "nucleotide" refers to a nucleoside further comprising a "backbone moiety". A backbone moiety generally covalently attaches a nucleotide to another molecule comprising a nucleotide, or to another nucleotide to form a nucleic acid. The "backbone moiety" in naturally occurring nucleotides typically comprises a phosphorus moiety, which is covalently attached to a 5-carbon sugar. The attachment of the backbone moiety typically occurs at either the 3'- or 5'-position of the 5-carbon sugar. However, other types of attachments are known in the art, particularly when a nucleotide comprises derivatives or analogs of a naturally occurring 5-carbon sugar or phosphorus moiety.

4. Nucleic Acid Analogs

A nucleic acid may comprise, or be composed entirely of, a derivative or analog of a nucleobase, a nucleobase linker moiety and/or backbone moiety that may be present in a naturally occurring nucleic acid. As used herein a "derivative" refers to a chemically modified or altered form of a naturally occurring molecule, while the terms "mimic" or "analog" refer to a molecule that may or may not structurally resemble a naturally occurring molecule or moiety, but possesses similar functions. As used herein, a "moiety" generally refers to a smaller chemical or molecular component of a larger chemical or molecular structure. Nucleobase, nucleoside and nucleotide analogs or derivatives are well known in the art, and have been described (see for example, Scheit, 1980, incorporated herein by reference).

Additional non-limiting examples of nucleosides, nucleotides or nucleic acids comprising 5-carbon sugar and/or backbone moiety derivatives or analogs, include those in U.S. Patent No. 5,681,947 which describes oligonucleotides comprising purine derivatives that form triple helixes with and/or prevent expression of dsDNA; U.S. Patents 5,652,099 and 5,763,167 which describe nucleic acids incorporating fluorescent analogs of nucleosides found in DNA or RNA, particularly for use as fluorescent nucleic acids probes; U.S. Patent 5,614,617 which describes oligonucleotide analogs with substitutions on pyrimidine rings that possess enhanced nuclease stability; U.S. Patents 5,670,663, 5,872,232 and 5,859,221 which describe oligonucleotide

analogs with modified 5-carbon sugars (*i.e.*, modified 2'-deoxyfuranosyl moieties) used in nucleic acid detection; U.S. Patent 5,446,137 which describes oligonucleotides comprising at least one 5-carbon sugar moiety substituted at the 4' position with a substituent other than hydrogen that can be used in hybridization assays; U.S. Patent 5,886,165 which describes oligonucleotides with both deoxyribonucleotides with 3'-5' internucleotide linkages and ribonucleotides with 2'-5' internucleotide linkages; U.S. Patent 5,714,606 which describes a modified internucleotide linkage wherein a 3'-position oxygen of the internucleotide linkage is replaced by a carbon to enhance the nuclease resistance of nucleic acids; U.S. Patent 5,672,697 which describes oligonucleotides containing one or more 5' methylene phosphonate internucleotide linkages that enhance nuclease resistance; U.S. Patents 5,466,786 and 5,792,847 which describe the linkage of a substituent moiety, which may comprise a drug or label to the 2' carbon of an oligonucleotide to provide enhanced nuclease stability and ability to deliver drugs or detection moieties; U.S. Patent 5,223,618 which describes oligonucleotide analogs with a 2 or 3 carbon backbone linkage attaching the 4' position and 3' position of adjacent 5-carbon sugar moiety to enhanced cellular uptake, resistance to nucleases and hybridization to target RNA; U.S. Patent 5,470,967 which describes oligonucleotides comprising at least one sulfamate or sulfamide internucleotide linkage that are useful as nucleic acid hybridization probe; U.S. Patents 5,378,825, 5,777,092, 5,623,070, 5,610,289 and 5,602,240 which describe oligonucleotides with three or four atom linker moiety replacing phosphodiester backbone moiety used for improved nuclease resistance, cellular uptake and regulating RNA expression; U.S. Patent 5,858,988 which describes hydrophobic carrier agent attached to the 2'-O position of oligonucleotides to enhance their membrane permeability and stability; U.S. Patent 5,214,136, which describes oligonucleotides conjugated to anthraquinone at the 5' terminus that possess enhanced hybridization to DNA or RNA; enhanced stability to nucleases; U.S. Patent 5,700,922 which describes PNA-DNA-PNA chimeras wherein the DNA comprises 2'-deoxy-erythro-pentofuranosyl nucleotides for enhanced nuclease resistance, binding affinity, and ability to activate RNase H; and U.S. Patent 5,708,154 which describes RNA linked to a DNA to form a DNA-RNA hybrid. Other analogs that may be used with compositions of the invention include U.S. Patent 5,216,141 (discussing oligonucleotide analogs containing sulfur linkages), U.S. Patent 5,432,272 (concerning oligonucleotides having nucleotides with heterocyclic bases), and U.S. Patents 6,001,983, 6,037,120, 6,140,496 (involving oligonucleotides with non-standard bases), all of which are incorporated by reference.

5. Polyether and Peptide Nucleic Acids and Locked Nucleic Acids

In certain embodiments, it is contemplated that a nucleic acid comprising a derivative or analog of a nucleoside or nucleotide may be used in the methods and compositions of the invention. A non-limiting example is a "polyether nucleic acid", described in U.S. Patent Serial No. 5,908,845, incorporated herein by reference. In a polyether nucleic acid, one or more nucleobases are linked to chiral carbon atoms in a polyether backbone.

Another non-limiting example is a "peptide nucleic acid", also known as a "PNA", "peptide-based nucleic acid analog" or "PENAM", described in U.S. Patent Serial Nos. 5,786,461, 5,891,625, 5,773,571, 5,766,855, 5,736,336, 5,719,262, 5,714,331, 5,539,082, and WO 92/20702, each of which is incorporated herein by reference. Peptide nucleic acids generally have enhanced sequence specificity, binding properties, and resistance to enzymatic degradation in comparison to molecules such as DNA and RNA (Egholm *et al.*, 1993; PCT/EP/01219). A peptide nucleic acid generally comprises one or more nucleotides or nucleosides that comprise a nucleobase moiety, a nucleobase linker moiety that is not a 5-carbon sugar, and/or a backbone moiety that is not a phosphate backbone moiety. Examples of nucleobase linker moieties described for PNAs include aza nitrogen atoms, amido and/or ureido tethers (see for example, U.S. Patent No. 5,539,082). Examples of backbone moieties described for PNAs include an aminoethylglycine, polyamide, polyethyl, polythioamide, polysulfonamide or polysulfonamide backbone moiety.

In certain embodiments, a nucleic acid analogue such as a peptide nucleic acid may be used to inhibit nucleic acid amplification, such as in PCR, to reduce false positives and discriminate between single base mutants, as described in U.S. Patent Serial No. 5,891,625. Other modifications and uses of nucleic acid analogs are known in the art, and are encompassed by the bridging and capture nucleic acids of the invention. In a non-limiting example, U.S. Patent 5,786,461 describes PNAs with amino acid side chains attached to the PNA backbone to enhance solubility of the molecule. In another example, the cellular uptake property of PNAs is increased by attachment of a lipophilic group. Several alkylamino moieties used to enhance cellular uptake of a PNA are described in U.S. Patent Nos. 5,766,855, 5,719,262, 5,714,331 and 5,736,336, which describe PNAs comprising naturally and non-naturally occurring nucleobases and alkylamine side chains that provide improvements in sequence specificity, solubility and/or binding affinity relative to a naturally occurring nucleic acid.

Another non-limiting example is a locked nucleic acid or "LNA." An LNA monomer is a bicyclic compound that is structurally similar to RNA nucleosides. LNAs have a furanose conformation that is restricted by a methylene linker that connects the 2'-O position to the 4'-C position, as described in Koshkin *et al.*, 1998a and 1998b and Wahlestedt *et al.*, 2000.

5 6. Preparation of Nucleic Acids

A nucleic acid may be made by any technique known to one of ordinary skill in the art, such as for example, chemical synthesis, enzymatic production or biological production. Non-limiting examples of a synthetic nucleic acid (e.g., a synthetic oligonucleotide), include a nucleic acid made by *in vitro* chemical synthesis using phosphotriester, phosphite or phosphoramidite chemistry and solid phase techniques such as described in EP 266,032, incorporated herein by reference, or via deoxynucleoside H-phosphonate intermediates as described by Froehler *et al.*, 1986 and U.S. Patent No. 5,705,629, each incorporated herein by reference. In the methods of the present invention, one or more oligonucleotide may be used. Various different mechanisms of oligonucleotide synthesis have been disclosed in for example, U.S. Patents. 4,659,774, 4,816,571, 5,141,813, 5,264,566, 4,959,463, 5,428,148, 5,554,744, 5,574,146, 5,602,244, each of which is incorporated herein by reference.

A non-limiting example of an enzymatically produced nucleic acid include one produced by enzymes in amplification reactions such as PCRTM (see for example, U.S. Patent 4,683,202 and U.S. Patent 4,682,195, each incorporated herein by reference), or the synthesis of an oligonucleotide described in U.S. Patent No. 5,645,897, incorporated herein by reference. A non-limiting example of a biologically produced nucleic acid includes a recombinant nucleic acid produced (*i.e.*, replicated) in a living cell, such as a recombinant DNA vector replicated in bacteria (see for example, Sambrook *et al.* 1989, incorporated herein by reference).

7. Purification of Nucleic Acids

25 A nucleic acid may be purified on polyacrylamide gels, cesium chloride centrifugation gradients, or by any other means known to one of ordinary skill in the art (see for example, Sambrook *et al.*, 1989, incorporated herein by reference).

In certain aspect, the present invention concerns a nucleic acid that is an isolated nucleic acid. As used herein, the term "isolated nucleic acid" refers to a nucleic acid molecule (e.g., an RNA or DNA molecule) that has been isolated free of, or is otherwise free of, the bulk of the

total genomic and transcribed nucleic acids of one or more cells. In certain embodiments, "isolated nucleic acid" refers to a nucleic acid that has been isolated free of, or is otherwise free of, bulk of cellular components or in vitro reaction components such as for example, macromolecules such as lipids or proteins, small biological molecules, and the like.

5 8. Nucleic Acid Segments

In certain embodiments, the nucleic acid comprises a nucleic acid segment. As used herein, the term "nucleic acid segment," are smaller fragments of a nucleic acid, such as for non-limiting example, those that correspond to targeted, targeting, bridging, and capture regions. Thus, a "nucleic acid segment" may comprise any part of a gene sequence, of from about 2 nucleotides to the full length of a targeted nucleic acid, capture nucleic acid, or bridging nucleic acid.

Various nucleic acid segments may be designed based on a particular nucleic acid sequence, and may be of any length. By assigning numeric values to a sequence, for example, the first residue is 1, the second residue is 2, etc., an algorithm defining all nucleic acid segments can be created:

15 n to n + y

where n is an integer from 1 to the last number of the sequence and y is the length of the nucleic acid segment minus one, where n + y does not exceed the last number of the sequence. Thus, for a 10-mer, the nucleic acid segments correspond to bases 1 to 10, 2 to 11, 3 to 12 ... and so on. For a 15-mer, the nucleic acid segments correspond to bases 1 to 15, 2 to 16, 3 to 17 ... and so on. For a 20-mer, the nucleic segments correspond to bases 1 to 20, 2 to 21, 3 to 22 ... and so on. In certain embodiments, the nucleic acid segment may be a probe or primer. As used herein, a "probe" generally refers to a nucleic acid used in a detection method or composition. As used herein, a "primer" generally refers to a nucleic acid used in an extension or amplification method or composition.

25 9. **Nucleic Acid Complements**

The present invention also encompasses a nucleic acid that is complementary to a other nucleic acids of the invention and targeted nucleic acids. More specifically, a targeting region in a bridging nucleic acid is complementary to the targeted region of the targeted nucleic acid and a bridging region of the bridging nucleic acid is complementary to a capture region of a capture nucleic acid. In particular embodiments the invention encompasses a nucleic acid or a nucleic

acid segment identical or complementary to all or part of the sequences set forth in SEQ ID NOS:1-92. A nucleic acid is "complement(s)" or is "complementary" to another nucleic acid when it is capable of base-pairing with another nucleic acid according to the standard Watson-Crick, Hoogsteen or reverse Hoogsteen binding complementarity rules. Unless otherwise
5 specified, a nucleic acid region is "complementary" to another nucleic acid region if there is at least 70, 80%, 90% or 100% Watson-Crick base-pairing (A:T or A:U, C:G) between or between at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430,
10 440, 450, 460, 470, 480, 490, 500 or more contiguous nucleic acid bases of the regions. As used herein "another nucleic acid" may refer to a separate molecule or a spatial separated sequence of the same molecule.

As used herein, the term "complementary" or "complement(s)" also refers to a nucleic acid comprising a sequence of consecutive nucleobases or semiconsecutive nucleobases
15 (e.g., one or more nucleobase moieties are not present in the molecule) capable of hybridizing to another nucleic acid strand or duplex even if less than all the nucleobases do not base pair with a counterpart nucleobase. In certain embodiments, a "complementary" nucleic acid comprises a sequence in which at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,
20 98%, 99% or 100%, and any range derivable therein, of the nucleobase sequence is capable of base-pairing with a single or double stranded nucleic acid molecule during hybridization, as described in the Examples. In certain embodiments, the term "complementary" refers to a nucleic acid that may hybridize to another nucleic acid strand or duplex under conditions described in the Examples, as would be understood by one of ordinary skill in the art.

25 In certain embodiments, a "partly complementary" nucleic acid comprises a sequence that may hybridize in low stringency conditions to a single or double stranded nucleic acid, or contains a sequence in which less than about 70% of the nucleobase sequence is capable of base-pairing with a single or double stranded nucleic acid molecule during hybridization.

10. Hybridization

30 As used herein, "hybridization", "hybridizes" or "capable of hybridizing" is understood to mean the forming of a double or triple stranded molecule or a molecule with partial double or

triple stranded nature. The term "anneal" as used herein is synonymous with "hybridize." The term "hybridization", "hybridize(s)" or "capable of hybridizing" encompasses the terms "stringent condition(s)" or "high stringency" and the terms "low stringency" or "low stringency condition(s)."

- 5 As used herein "stringent condition(s)" or "high stringency" are those conditions that allow hybridization between or within one or more nucleic acid strand(s) containing complementary sequence(s), but precludes hybridization of random sequences. Stringent conditions tolerate little, if any, mismatch between a nucleic acid and a target strand. Such conditions are well known to those of ordinary skill in the art, and are preferred for applications
- 10 requiring high selectivity. Non-limiting applications include isolating a nucleic acid, such as a gene or a nucleic acid segment thereof, or detecting at least one specific mRNA transcript or a nucleic acid segment thereof, and the like.

- Stringent conditions may comprise low salt and/or high temperature conditions, such as provided by about 0.02 M to about 0.15 M NaCl at temperatures of about 50°C to about 70°C.
- 15 Alternatively, stringent conditions may be determined largely by temperature in the presence of a TMAC solution with a defined molarity such as 3M TMAC. For example, in 3 M TMAC, stringent conditions include the following: for complementary nucleic acids with a length of 15 bp, a temperature of 45 °C to 55 °C; for complementary nucleotides with a length of 27 bases, a temperature of 65 °C to 75 °C; and, for complementary nucleotides with a length of >200
- 20 nucleotides, a temperature of 90 °C to 95°C. The publication of Wood *et al.*, 1985, which is specifically incorporated by reference, provides examples of these parameters. It is understood that the temperature and ionic strength of a desired stringency are determined in part by the length of the particular nucleic acid(s), the length and nucleobase content of the target sequence(s), the charge composition of the nucleic acid(s), and to the presence or concentration
- 25 of formamide, tetramethylammonium chloride or other solvent(s) in a hybridization mixture.

- It is also understood that these ranges, compositions and conditions for hybridization are mentioned by way of non-limiting examples only, and that the desired stringency for a particular hybridization reaction is often determined empirically by comparison to one or more positive or negative controls. Depending on the application envisioned it is preferred to employ varying
- 30 conditions of hybridization to achieve varying degrees of selectivity of a nucleic acid towards a target sequence. In a non-limiting example, identification or isolation of a related target nucleic

acid that does not hybridize to a nucleic acid under stringent conditions may be achieved by hybridization at low temperature and/or high ionic strength. Such conditions are termed "low stringency" or "low stringency conditions", and non-limiting examples of low stringency include hybridization performed at about 0.15 M to about 0.9 M NaCl at a temperature range of about 5 20°C to about 50°C. Of course, it is within the skill of one in the art to further modify the low or high stringency conditions to suite a particular application.

11. Oligonucleotide Synthesis

Oligonucleotide synthesis is performed according to standard methods. See, for example, Itakura and Riggs (1980). Additionally, U.S. Patent 4,704,362; U.S. Patent 5,221,619, U.S. 10 Patent 5,583,013 each describe various methods of preparing synthetic structural genes.

Oligonucleotide synthesis is well known to those of skill in the art. Various different mechanisms of oligonucleotide synthesis have been disclosed in for example, U.S. Patents. 4,659,774, 4,816,571, 5,141,813, 5,264,566, 4,959,463, 5,428,148, 5,554,744, 5,574,146, 5,602,244, each of which is incorporated herein by reference.

15 Basically, chemical synthesis can be achieved by the diester method, the triester method polynucleotides phosphorylase method and by solid-phase chemistry. These methods are discussed in further detail below.

Diester method. The diester method was the first to be developed to a usable state, primarily by Khorana and co-workers. (Khorana, 1979). The basic step is the joining of two 20 suitably protected deoxynucleotides to form a dideoxynucleotide containing a phosphodiester bond. The diester method is well established and has been used to synthesize DNA molecules (Khorana, 1979).

Triester method. The main difference between the diester and triester methods is the presence in the latter of an extra protecting group on the phosphate atoms of the reactants and 25 products (Itakura *et al.*, 1975). The phosphate protecting group is usually a chlorophenyl group, which renders the nucleotides and polynucleotide intermediates soluble in organic solvents. Therefore purification's are done in chloroform solutions. Other improvements in the method include (i) the block coupling of trimers and larger oligomers, (ii) the extensive use of high-

performance liquid chromatography for the purification of both intermediate and final products, and (iii) solid-phase synthesis.

5 **Polynucleotide phosphorylase method.** This is an enzymatic method of DNA synthesis that can be used to synthesize many useful oligodeoxynucleotides (Gillam *et al.*, 1978; Gillam *et al.*, 1979). Under controlled conditions, polynucleotide phosphorylase adds predominantly a single nucleotide to a short oligodeoxynucleotide. Chromatographic purification allows the desired single adduct to be obtained. At least a trimer is required to start the procedure, and this primer must be obtained by some other method. The polynucleotide phosphorylase method works and has the advantage that the procedures involved are familiar to most biochemists.

10 **Solid-phase methods.** Drawing on the technology developed for the solid-phase synthesis of polypeptides, it has been possible to attach the initial nucleotide to solid support material and proceed with the stepwise addition of nucleotides. All mixing and washing steps are simplified, and the procedure becomes amenable to automation. These syntheses are now routinely carried out using automatic DNA synthesizers.

15 **Phosphoramidite chemistry** (Beaucage, and Lyser, 1992) has become by far the most widely used coupling chemistry for the synthesis of oligonucleotides. As is well known to those skilled in the art, phosphoramidite synthesis of oligonucleotides involves activation of nucleoside phosphoramidite monomer precursors by reaction with an activating agent to form activated intermediates, followed by sequential addition of the activated intermediates to the
20 growing oligonucleotide chain (generally anchored at one end to a suitable solid support) to form the oligonucleotide product.

12. Expression Vectors

Other ways of creating nucleic acids of the invention include the use of a recombinant vector created through the application of recombinant nucleic acid technology known to those of
25 skill in the art or as described herein. A recombinant vector may comprise a bridging or capture nucleic acid, particularly one that is a polynucleotide, as opposed to an oligonucleotide. An expression vector can be used create nucleic acids that are lengthy, for example, containing multiple targeting regions or relatively lengthy targeting regions, such as those greater than 100 residues in length.

The term "vector" is used to refer to a carrier nucleic acid molecule into which a nucleic acid sequence can be inserted for introduction into a cell where it can be replicated. A nucleic acid sequence can be "exogenous," which means that it is foreign to the cell into which the vector is being introduced or that the sequence is homologous to a sequence in the cell but in a position within the host cell nucleic acid in which the sequence is ordinarily not found. Vectors include plasmids, cosmids, viruses (bacteriophage, animal viruses, and plant viruses), and artificial chromosomes (*e.g.*, YACs). One skill in the art would be well equipped to construct a vector through standard recombinant techniques (see, for example, Sambrook *et al.*, 2001 and Ausubel *et al.*, 1994, both incorporated herein by reference).

The term "expression vector" refers to any type of genetic construct comprising a nucleic acid coding for a RNA capable of being transcribed. Expression vectors can contain a variety of "control sequences," which refer to nucleic acid sequences necessary for the transcription and possibly translation of an operable linked coding sequence in a particular host cell. In addition to control sequences that govern transcription (promoters and enhancers) and translation, vectors and expression vectors may contain nucleic acid sequences that serve other functions as well that are well known to those of skill in the art, such as screenable and selectable markers, ribosome binding site, multiple cloning sites, splicing sites, poly A sequences, origins of replication, and other sequences that allow expression in different hosts.

Numerous expression systems exist that comprise at least a part or all of the compositions discussed above. Prokaryote- and/or eukaryote-based systems can be employed for use with the present invention to produce nucleic acid sequences, or their cognate polypeptides, proteins and peptides. Many such systems are commercially and widely available.

The nucleotide and protein, polypeptide and peptide sequences for various genes have been previously disclosed, and may be found at computerized databases known to those of ordinary skill in the art. For example, the nucleotide sequences of rRNAs of various organisms are readily available. One such database is the National Center for Biotechnology Information's Genbank and GenPept databases (<http://www.ncbi.nlm.nih.gov/>). The coding regions for all or part of these known genes may be amplified and/or expressed using the techniques disclosed herein or by any technique that would be known to those of ordinary skill in the art.

13. Nucleic Acid Arrays

Because the present invention provides efficient methods of enriching in mRNA, which can be used to make cDNA, the present invention extends to the use of cDNAs with arrays. The term "array" as used herein refers to a systematic arrangement of nucleic acid. For example, a cDNA population that is representative of a desired source (e.g., human adult brain) is divided up into the minimum number of pools in which a desired screening procedure can be utilized to detect a cDNA and which can be distributed into a single multi-well plate. Arrays may be of an aqueous suspension of a cDNA population obtainable from a desired mRNA source, comprising: a multi-well plate containing a plurality of individual wells, each individual well containing an aqueous suspension of a different content of a cDNA population. The cDNA population may include cDNA of a predetermined size. Furthermore, the cDNA population in all the wells of the plate may be representative of substantially all mRNAs of a predetermined size from a source. Examples of arrays, their uses, and implementation of them can be found in U.S. Patent Nos. 6,329,209, 6,329,140, 6,324,479, 6,322,971, 6,316,193, 6,309,823, 5,412,087, 5,445,934, and 5,744,305, which are herein incorporated by reference.

The number of cDNA clones array on a plate may vary. For example, a population of cDNA from a desired source can have about 200,000-6,000,000 cDNAs, about 200,000-2,000,000, 300,000-700,000, about 400,000-600,000, or about 500,000 cDNAs, and combinations thereof. Such a population can be distributed into a small set of multi-well plates, such as a single 96-well plate or a single 384-well plate. For instance, when about 1000-10,000 cDNAs, preferably about 3,500-7,000, more preferably about 5,000, from a population are present in a single well of a 96-well or 384-well plate, PCR can be utilized to clone a single, target gene using a set of primers.

The term a "nucleic acid array" refers to a plurality of target elements, each target element comprising one or more nucleic acid molecules immobilized on one or more solid surfaces to which sample nucleic acids can be hybridized. The nucleic acids of a target element can contain sequence(s) from specific genes or clones, e.g. from the regions identified here. Other target elements will contain, for instance, reference sequences. Target elements of various dimensions can be used in the arrays of the invention. Generally, smaller, target elements are preferred. Typically, a target element will be less than about 1 cm in diameter. Generally element sizes are from 1 μ m to about 3 mm, between about 5 μ m and about 1 mm. The target elements

of the arrays may be arranged on the solid surface at different densities. The target element densities will depend upon a number of factors, such as the nature of the label, the solid support, and the like. One of skill will recognize that each target element may comprise a mixture of nucleic acids of different lengths and sequences. Thus, for example, a target element may contain
5 more than one copy of a cloned piece of DNA, and each copy may be broken into fragments of different lengths. The length and complexity of the nucleic acid fixed onto the target element is not critical to the invention. One of skill can adjust these factors to provide optimum hybridization and signal production for a given hybridization procedure, and to provide the required resolution among different genes or genomic locations. In various embodiments, target
10 element sequences will have a complexity between about 1 kb and about 1 Mb, between about 10 kb to about 500 kb, between about 200 to about 500 kb, and from about 50 kb to about 150 kb.

Microarrays are known in the art and consist of a surface to which probes that correspond in sequence to gene products (e.g., cDNAs, mRNAs, cRNAs, polypeptides, and fragments thereof), can be specifically hybridized or bound at a known position. In one embodiment, the
15 microarray is an array (i.e., a matrix) in which each position represents a discrete binding site for a product encoded by a gene (e.g., a protein or RNA), and in which binding sites are present for products of most or almost all of the genes in the organism's genome. In a preferred embodiment, the "binding site" (hereinafter, "site") is a nucleic acid or nucleic acid analogue to which a
20 particular cognate cDNA can specifically hybridize. The nucleic acid or analogue of the binding site can be, e.g., a synthetic oligomer, a full-length cDNA, a less-than full length cDNA, or a gene fragment.

A microarray may contains binding sites for products of all or almost all genes in the target organism's genome, but such comprehensiveness is not necessarily required. Usually the
25 microarray will have binding sites corresponding to at least about 50% of the genes in the genome, often at least about 75%, more often at least about 85%, even more often more than about 90%, and most often at least about 99%. Preferably, the microarray has binding sites for genes relevant to the action of a drug of interest or in a biological pathway of interest. A "gene" is identified as an open reading frame (ORF) of preferably at least 50, 75, or 99 amino acids
30 from which a messenger RNA is transcribed in the organism (e.g., if a single cell) or in some cell in a multicellular organism. The number of genes in a genome can be estimated from the number

of mRNAs expressed by the organism, or by extrapolation from a well-characterized portion of the genome. When the genome of the organism of interest has been sequenced, the number of ORFs can be determined and mRNA coding regions identified by analysis of the DNA sequence.

5 The nucleic acid or analogue are attached to a solid support, which may be made from glass, plastic (e.g., polypropylene, nylon), polyacrylamide, nitrocellulose, or other materials. A preferred method for attaching the nucleic acids to a surface is by printing on glass plates, as is described generally by Schena *et al.*, 1995a. See also DeRisi *et al.*, 1996; Shalon *et al.*, 1996; Schena *et al.*, 1995b. Each of these articles is incorporated by reference in its entirety.

10 Other methods for making microarrays, e.g., by masking (Maskos *et al.*, 1992), may also be used. In principal, any type of array, for example, dot blots on a nylon hybridization membrane (see Sambrook *et al.*, 1989, which is incorporated in its entirety for all purposes), could be used, although, as will be recognized by those of skill in the art, very small arrays will be preferred because hybridization volumes will be smaller.

15 Labeled cDNA is prepared from mRNA by oligo dT-primed or random-primed reverse transcription, both of which are well known in the art (see e.g., Klug *et al.*, 1987). Reverse transcription may be carried out in the presence of a dNTP conjugated to a detectable label, most preferably a fluorescently labeled dNTP. Alternatively, isolated mRNA can be converted to labeled antisense RNA synthesized by in vitro transcription of double-stranded cDNA in the presence of labeled dNTPs (Lockhart *et al.*, 1996, which is incorporated by reference in its
20 entirety for all purposes). In alternative embodiments, the cDNA or RNA probe can be synthesized in the absence of detectable label and may be labeled subsequently, e.g., by incorporating biotinylated dNTPs or rNTP, or some similar means (e.g., photo-cross-linking a psoralen derivative of biotin to RNAs), followed by addition of labeled streptavidin (e.g., phycoerythrin-conjugated streptavidin) or the equivalent.

25 Fluorescently-labeled probes can be used, including suitable fluorophores such as fluorescein, lissamine, phycoerythrin, rhodamine (Perkin Elmer Cetus), Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7, FluorX (Amersham) and others (see, e.g., Kricka, 1992). It will be appreciated that pairs of fluorophores are chosen that have distinct emission spectra so that they can be easily distinguished. In another embodiment, a label other than a fluorescent label is used. For example,
30 a radioactive label, or a pair of radioactive labels with distinct emission spectra, can be used (see

Zhao et al., 1995; Pietu et al., 1996). However, because of scattering of radioactive particles, and the consequent requirement for widely spaced binding sites, use of radioisotopes is a less-preferred embodiment.

- In one embodiment, labeled cDNA is synthesized by incubating a mixture containing 0.5 mM dGTP, dATP and dCTP plus 0.1 mM dTTP plus fluorescent deoxyribonucleotides (e.g., 0.1 mM Rhodamine 110 UTP (Perkin Elmer Cetus) or 0.1 mM Cy3 dUTP (Amersham)) with reverse transcriptase (e.g., SuperScript™, Invitrogen Inc.) at 42°C for 60 min.

III. Methods for Isolating and Depleting Targeted Nucleic Acids

- Methods of the invention involve preparing a sample comprising a targeted nucleic acid, preparing a bridging nucleic acid, preparing a capture nucleic acid, incubating the sample with the bridging nucleic acid, incubating the sample with a capture nucleic acid, incubating the bridging nucleic acid with the capture nucleic acid, incubating compounds under conditions allowing for hybridization among complementary regions, washing the sample and/or the capture and/or bridging nucleic acids, and isolating the capture nucleic acids and any accompanying compounds (compounds that bind or hybridize directly or indirectly to the capture nucleic acids). Steps of the invention are not required to be in a particular order and thus, the invention covers methods in which the order of the steps varies.

- Hybridization conditions are discussed earlier. Wash conditions may involve temperatures between 20°C and 75°C, between 25°C and 70°C, between 30°C and 65°C, between 35°C and 60°C, between 40°C and 55°C, between 45°C and 50°C, or at temperatures within the ranges specified.

- Buffer conditions for hybridization of nucleic acid compositions are well known to those of skill in the art. It is specifically contemplated that isostabilizing agents may be employed in hybridization and wash buffers in methods of the invention. U.S. Ser. No. 09/854,412 describes the use of tetramethylammonium chloride (TMAC) and tetraethylammonium chloride (TEAC) in such buffers; this application is specifically incorporated by reference herein. The concentration of an isostabilizing agent in a hybridization (binding) buffer may be between about 1.0 M and about 5.0 M, is about 4.0 M, or is about 2.0 M. Also specifically contemplated is a wash solution with an isostabilizing agent concentration of between about 0.1 M and 3.0 M, including 0.1 M increments within the range. Wash buffers may or may not contain Tris. However, in

some embodiments of the invention, the wash solution consists of water and no other salts or buffers. In some embodiments of the invention, the hybridizing or wash buffer may include guanidinium isothiocyanate, though in some embodiments this chemical is specifically contemplated to be absent. The concentration of guanidinium may be between about 0.4 M and about 3.0 M

A solution or buffer to elute targeted nucleic acids from the hybridizing nucleic acids (indirect or direct) may be implemented in some kits and methods of the invention. The elution buffer or solution can be an aqueous solution lacking salt, such as TE or water. Elution may occur at room temperature or it may occur at temperatures between 15°C and 100°C, between 20°C and 95°C, between 25°C and 90°C, between 30°C and 85°C, between 35°C and 80°C, between 40°C and 75°C, between 45°C and 70°C, between 50°C and 65°C, between 55°C and 60°C, or at temperatures within the ranges specified.

A. Quantitation of RNA

1. Assessing RNA yield by UV absorbance

The concentration and purity of RNA can be determined by diluting an aliquot of the preparation (usually a 1:50 to 1:100 dilution) in TE (10 mM Tris-HCl pH 8, 1 mM EDTA) or water, and reading the absorbance in a spectrophotometer at 260 nm and 280 nm.

An A_{260} of 1 is equivalent to 40 μg RNA/ml. The concentration ($\mu\text{g}/\text{ml}$) of RNA is therefore calculated by multiplying the A_{260} X dilution factor X 40 $\mu\text{g}/\text{ml}$. The following is a typical example:

The typical yield from 10 μg total RNA is 3 - 5 μg . If the sample is re-suspended in 25 μl , this means that the concentration will vary between 120 $\text{ng}/\mu\text{l}$ and 200 $\text{ng}/\mu\text{l}$. One μl of the prep is diluted 1:50 into 49 μl of TE. The A_{260} = 0.1. RNA concentration = $0.1 \times 50 \times 40 \mu\text{g}/\text{ml} = 200 \mu\text{g}/\text{ml}$ or 0.2 $\mu\text{g}/\mu\text{l}$. Since there are 24 μl of the prep remaining after using 1 μl to measure the concentration, the total amount of remaining RNA is $24 \mu\text{l} \times 0.2 \mu\text{g}/\mu\text{l} = 4.8 \mu\text{g}$.

2. Assessing RNA yield with RiboGreen®

Molecular Probes' RiboGreen® fluorescence-based assay for RNA quantitation can be employed to measure RNA concentration.

B. Denaturing Agarose Gel Electrophoresis

Many mRNAs form extensive secondary structure. Ribosomal RNA depletion may be evaluated by agarose gel electrophoresis. Because of this, it is best to use a denaturing gel system to analyze RNA samples. A positive control should be included on the gel so that any
5 unusual results can be attributed to a problem with the gel or a problem with the RNA under analysis. RNA molecular weight markers, an RNA sample known to be intact, or both, can be used for this purpose. It is also a good idea to include a sample of the starting RNA that was used in the enrichment procedure.

Ambion's NorthernMax™ reagents for Northern Blotting include everything needed for
10 denaturing agarose gel electrophoresis. These products are optimized for ease of use, safety, and low background, and they include detailed instructions for use. An alternative to using the NorthernMax reagents is to use a procedure described in "Current Protocols in Molecular Biology", Section 4.9 (Ausubel et al., eds.), hereby incorporated by reference. It is more difficult and time-consuming than the Northern-Max method, but it gives similar results.

C. Agilent 2100 Bioanalyzer

1. Evaluating rRNA Removal with the RNA 6000 LabChip

An effective method for evaluating rRNA removal utilizes RNA analysis with the Caliper RNA 6000 LabChip Kit and the Agilent 2100 Bioanalyzer. Follow the instructions provided with the RNA 6000 LabChip Kit for RNA analysis. This system performs best with RNA
20 solutions at concentrations between 50 and 250 ng/μl. Loading 1 μl of a typical enriched RNA sample is usually adequate for good performance.

2. Expected Results

In enriched mRNA samples from prokaryotes, the 16S and 23S rRNA peaks will be absent or present in only very small amounts. The peak calling feature of the software may fail
25 to identify the peaks containing small quantities of leftover 16S and 23S rRNAs. A peak corresponding to 5S and tRNAs may be present depending on how the total RNA was initially purified. If RNA was purified by a glass fiber filter method prior to enrichment, this peak will be smaller. The size and shape of the 5S rRNA-tRNA peak is unchanged by some embodiments.

IV. KITS

Any of the compositions described herein may be comprised in a kit. In a non-limiting example, a bridging nucleic acid and a capture nucleic acid may be comprised in a kit. The kits will thus comprise, in suitable container means, a bridging nucleic acid and a capture nucleic acid of the present invention. It may also include one or more buffers, such as hybridization buffer or a wash buffer, compounds for preparing the sample, and components for isolating the capture nucleic acid via the nonreacting structure. Other kits of the invention may include components for making a nucleic acid array, and thus, may include, for example, a solid support.

The kits may comprise suitably aliquoted nucleic acid compositions of the present invention, whether labeled or unlabeled, as may be used to isolate, deplete, or separate a targeted nucleic acid. The components of the kits may be packaged either in aqueous media or in lyophilized form. The container means of the kits will generally include at least one vial, test tube, flask, bottle, syringe or other container means, into which a component may be placed, and preferably, suitably aliquoted. Where there are more than one component in the kit (bridging and capture nucleic acids may be packaged together), the kit also will generally contain a second, third or other additional container into which the additional components may be separately placed. However, various combinations of components may be comprised in a vial. The kits of the present invention also will typically include a means for containing the nucleic acids, and any other reagent containers in close confinement for commercial sale. Such containers may include injection or blow-molded plastic containers into which the desired vials are retained.

When the components of the kit are provided in one and/or more liquid solutions, the liquid solution is an aqueous solution, with a sterile aqueous solution being particularly preferred.

However, the components of the kit may be provided as dried powder(s). When reagents and/or components are provided as a dry powder, the powder can be reconstituted by the addition of a suitable solvent. It is envisioned that the solvent may also be provided in another container means.

The container means will generally include at least one vial, test tube, flask, bottle, syringe and/or other container means, into which the nucleic acid formulations are placed,

preferably, suitably allocated. The kits may also comprise a second container means for containing a sterile, pharmaceutically acceptable buffer and/or other diluent.

The kits of the present invention will also typically include a means for containing the vials in close confinement for commercial sale, such as, *e.g.*, injection and/or blow-molded plastic containers into which the desired vials are retained.

Such kits may also include components that facilitate isolation of the targeting molecule, such as filters, beads, or a magnetic stand. Such kits generally will comprise, in suitable means, distinct containers for each individual reagent or solution as well as for the targeting agent.

A kit will also include instructions for employing the kit components as well the use of any other reagent not included in the kit. Instructions may include variations that can be implemented.

Kits of the invention may also include one or more of the following, in addition to a capture nucleic acid and a bridging nucleic acid:

- 1) Control RNA (*E. coli* or other appropriate RNA);
- 2) Nuclease-free water;
- 3) RNase-free containers, such as 1.5 ml tubes;
- 4) RNase-free elution tubes;
- 5) glycogen;
- 6) ethanol;
- 7) sodium acetate;
- 8) ammonium acetate;
- 9) magnetic stand or other magnetic field;
- 10) agarose;
- 11) nucleic acid size marker;
- 12) RNase-free tube tips;
- 13) and RNase or DNase inhibitors.

IV. Examples

The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

Furthermore, these examples are provided as one of many ways of implementing the claimed method and using the compositions of the invention. It is contemplated that the invention is not limited to the specific conditions set forth below, but that the conditions below provide examples of how to implement the invention.

EXAMPLE 1:

Materials

The following materials were used in the methods described herein for the selective removal of 16S and 23S rRNA and/or 18S and 28S rRNA, and hence mRNA enrichment, from total RNA. All steps are performed at room temperature unless otherwise indicated.

1. Bridging Nucleic Acids

In the following examples, the bridging regions are the poly-A stretches in the respective oligonucleotides.

Targeting regions for prokaryotic 16S and 23S rRNAs were designed based on a sequence comparison of different rRNAs from different bacteria to *E. coli* rRNA with MegAlign sequence analysis software version 4.05 from DNA Star, Incorporated (FIG. 2). The targeting regions are shown, in the examples below, 3' of the bridging regions. Thus, the targeting region encompasses the remaining, non-bridging region of each molecule described below. SEQ ID NOs are provided for the targeting regions of the bridging nucleic acids provided below (*i.e.*, sequence of bridging regions not included in SEQ ID NO.).

16S prokaryotic rRNA bridging oligonucleotides

d16S-358 (SEQ ID NO:1)

5'-AAAAAAAAAAAAAAAAAACTGCTGCCTCCCGTAGGAGTCT-3'

d16S-537 (SEQ ID NO:2)

5'-AAAAAAAAAAAAAAAAAAACGTATTACCGCGGCTGCTGGCAC-3'

d16S-548 (SEQ ID NO:3)

5'-AAAAAAAAAAAAAAAAAAACGCCAGTAATTCCGATTAACGC-3'

d16S-807 (SEQ ID NO:4)

5'-AAAAAAAAAAAAAAAAAAATGGACTACCAGGTATCTAATCC-3'

d16S-1092 (SEQ ID NO:5)

5'-AAAAAAAAAAAAAAAAAAGGTTGCGCTCGTTGCGGGACTT-3'

d16S-3' (SEQ ID NO:6)

5'-AAAAAAAAAAAAAAAAAATAAGGAGGTGATCCAACCGCAGG-3'

23S prokaryotic rRNA bridging oligonucleotides

d23S-488 (SEQ ID NO:7)

5'-AAAAAAAAAAAAAAAAAAGGTTCTTTTCACTCCCTCGCC-3'

d23S-581 (SEQ ID NO:8)

5'-AAAAAAAAAAAAAAAAAAGACCCATTATACAAAAGGTACGC-3'

d23S-1118 (SEQ ID NO:9)

5'-AAAAAAAAAAAAAAAAAAGCCCCGTTACATCTTCCGCGCAG-3'

d23S-1926 (SEQ ID NO:10)

5'-AAAAAAAAAAAAAAAAAACGACAAGGAATTCGCTACCTTA-3'

d23S-1954 (SEQ ID NO:11)

5'-AAAAAAAAAAAAAAAAAACTTACCCGACAAGGAATTCGCG-3'

d23S-2511 (SEQ ID NO:12)

5'-AAAAAAAAAAAAAAAAAAGAGCCGACATCGAGGTGCCAAAC-3'

d23S-3' (SEQ ID NO:13)

5'-AAAAAAAAAAAAAAAAAAGGTTAAGCCTCACGGTTCATT-3'

d23S-1704 (SEQ ID NO:15)

5'-AAAAAAAAAAAAAAAAAAACCCCTTCTCCCGAAGTTACGGGG-3'

d23S-1105 (SEQ ID NO:16)

5'-AAAAAAAAAAAAAAAAAAGTGAGCTATTACGCTTCTTT-3'

RNA oligo bridging oligonucleotide

r23S-3' (SEQ ID NO:14)

5'-AAAAAAAAAAAAAAAAAGGUUAAGCGUCACGGUUCUU-(inverted (dT))-3'
(inverted refers to bases attached 3' to 3')

5

Eukaryotic 18S rRNA bridging oligonucleotides

d18S-3711 (SEQ ID NO:17)

AAA AAA AAA AAA AAA TAC CGG CCG TGC GTA CTT AGA CA

10 d18S-4238 (SEQ ID NO:18)

AAA AAA AAA AAA AAA TGC CCT CCA ATG GAT CCT CGT TA

d18S-5482 (SEQ ID NO:19)

AAA AAA AAA AAA AAA CTA CGG AAA CCT TGT TAC GAC TT

15

Eukaryotic 28S rRNA bridging oligonucleotides

d28S-11599 (SEQ ID NO:20)

AAA AAA AAA AAA AAA GAG CAC TGG GCA GAA ATC ACA TC

20

d28S-7979 (SEQ ID NO:21)

AAA AAA AAA AAA AAA GTT TCT TTT CCT CCG CTG ACT AA

d28S-12533 (SEQ ID NO:22)

25 AAA AAA AAA AAA AAA TCC TCA GCC AAG CAC ATA CAC CA

2. *Binding Buffer* (also referred to as hybridization buffer)

3 M TMAC, 10 mM Tris, (pH 7.0)

30 3. *Bridging Nucleic Acid Mixture*

Mixtures of 16S, 23S, 18S, and/or 28S bridging oligonucleotides were used. All oligonucleotides were purchased from IDT and purified from polyacrylamide gels.

4. *Capture Nucleic Acid (Oligo(dT) MagBeads)*

Seradyn MGOL #2815-2103.

35

5. *Wash Solution*

2 M TMAC, 6.67 mM Tris (pH 7.0) (this is a dilution of binding buffer).

EXAMPLE 2:
Methods for rRNA Depletion from Prokaryotic Total RNA

The following methods are provided by way of example for practicing methods of the invention. They have been performed and shown to effect methods of the invention. The invention is not intended to be limited to these protocols, and it is specifically contemplated that variations of the methods below may be employed that fall within the scope of the invention if they effect depletion, isolation, or separation of a targeted nucleic acid, particularly rRNA.

This example demonstrates the depletion of 16S and 23S rRNA from *E. coli* total RNA.

10 *RNA/Bridging Nucleic Acid Mixture Annealing*

RNA (10 µg/15 µl) was added to 200 µl of binding buffer. The bridging nucleic acid mixture consisted of d16S-807 (5 µM), d16S-1092 (5 µM), d23S-1954 (5 µM), d23S-2511 (5 µM). The bridging nucleic acid mixture (4 µl) was added to the RNA and the mixture was incubated at 70°C for 10 minutes and then shifted to 37°C for 30 minutes.

- 15 Thirty minutes was found to be an adequate time for the annealing step. Longer time periods can be used with no adverse effects. Between fifteen and 120 minutes have been used successfully in the methods of the invention.

Preparation of Capture Nucleic Acid

- 20 Capture nucleic acid (Oligo (dT) MagBeads, Seradyn) in storage buffer was mixed and 50 µl was removed to a separate tube. A magnetic stand was applied to the side of the tube to capture the magnetic beads and the supernatant was removed. The capture nucleic acid was equilibrated one time with distilled, deionized water (50 µl) and once with binding buffer (50 µl). The captured nucleic acid was captured again with a magnetic stand, and the binding buffer wash was removed. The magnetic beads were resuspended in 50 µl of binding buffer.

25 *rRNA Capture*

Following the 30 minute annealing of RNA with the bridging nucleic acid mixture, the capture nucleic acid was added and the mixture was incubated at room temperature for 15 minutes. A magnetic stand was then applied to the tube to capture the magnetic beads. The supernatant containing mRNA, 5S rRNA, and tRNAs was removed to another tube and saved.

- 30 An optional washing step was performed next. The magnetic beads were washed with Wash

Solution (100 μ l) and captured again. The wash supernatant was removed and added to the original supernatant.

Fifteen minutes was found to be an adequate time for rRNA capture. Longer time periods can be used with no adverse effects. rRNA capture likely occurs rapidly, and capture times of 5 minutes – 60 minutes have been used successfully in the methods of the invention.

Precipitating mRNA

mRNA, 5S rRNA, and tRNAs were precipitated by adding 1/10 volume of 3M NaOAc (pH 5.5) and 3 volumes of 100% EtOH and incubating at -20°C for 60 minutes. The precipitated RNA was pelleted in a microfuge, washed with 70% EtOH, and resuspended in TE (pH 8.0).

Analysis of Purified mRNA

Purified mRNA was analyzed with the Caliper RNA 6000 LabChip kit on an Agilent Bioanalyzer. Purified RNA was compared with a control *E. coli* total RNA sample that was carried through the reaction as described above, except that the Bridging Nucleic Acid Mixture was left out. This assay system uses electrophoretic and electrokinetic separation in a capillary electrophoresis type system. The rRNAs appear as peaks on an electropherogram (FIG. 3). The percentage of a rRNA present in the sample is calculated from the area under the peak.

Under the protocol conditions described above, the 5S + tRNA peak area is essentially the same in the control and in experimental samples. The % of 16S or 23S rRNA removed was calculated using the ratios of $16\text{S}_{\text{peak area}}/5\text{S}_{\text{peak area}}$ and $23\text{S}_{\text{peak area}}/5\text{S}_{\text{peak area}}$. Enriched and control RNAs with similar 5S + tRNA peak areas were compared.

% 16S rRNA removed =

$$\frac{(16\text{S}_{\text{peak area}}/5\text{S}_{\text{peak area}})_{\text{no oligos control}} - (16\text{S}_{\text{peak area}}/5\text{S}_{\text{peak area}})_{\text{experimental}}}{(16\text{S}_{\text{peak area}}/5\text{S}_{\text{peak area}})_{\text{no oligos control}}} \times 100$$

A corresponding formula was used to calculate % 23S rRNA removed.

Electropherograms of RNA from a control reaction and from an experimental reaction after ribosomal RNA depletion are shown in FIG. 3 and FIG. 4.

EXAMPLE 3:**Evaluations of Efficacy with Prokaryotic Targets**

The materials and methods of Examples 1 and 2 were employed to determine the efficiency of removal of 16S rRNA or 23S rRNA or both from *E. coli* total RNA. Changes in the parameters of the experiments are noted when appropriate. These experiments were performed to evaluate the efficacy of various bridging nucleic acids and reaction conditions.

The following results are from reactions that employed 10 μ g of *E. coli* total RNA, 40 pmol of total 16S rRNA bridging nucleic acid, 40 pmol of total 23S rRNA bridging nucleic acid, and 50 μ l of capture nucleic acid described in Example 1.

Bridging Nucleic Acid 16S/23S	% 16S Removed average of 2 reactions	% 23S Removed average of 2 reactions
d16S-358/d23S-2511	96.48285	89.86496
d16S-537/d23S-1954	97.47974	91.32074
d16S-537/d23S-2511	97.48704	91.216
d16S-807/d23S-1954	95.79126	89.85388
d16S-807/d23S-2511	95.25362	91.06399
d16S-1092/d23S-1118	97.91265	96.50658
d16S-1092/d23S-1954	96.7473	89.40605
d16S-1092/d23S-2511	97.61689	91.5964
d16S-358/d23S-1954	96.74434	88.07242
d16S1092/d23S-1954 (20 pmol) d23S-2511 (20 pmol)	97.19134	98.44728

The following results are from reactions that employed 10 μ g of *E. coli* total RNA, 26 pmol of 16S rRNA bridging nucleic acid, 26 pmol of 23S rRNA bridging nucleic acid, and 35 μ l of capture nucleic acid described in Example 1.

Bridging Nucleic Acid 16S/23S	% 16S Removed average of 2 reactions	% 23S Removed average of 2 reactions
d16S-1092/d23S-1118	97.38534	95.02083
d16S-1092/d23S-1957	97.8291	90.798

The following results are from reactions that employed 10 μ g of *E. coli* total RNA, 75 pmol of 16S rRNA bridging nucleic acid, 75 pmol of 23S rRNA bridging nucleic acid, and 100 μ l of capture nucleic acid described in Example 1.

Bridging Nucleic Acid 16S.....23S	% 16S Removed average of 2 reactions	% 23S Removed average of 2 reactions
d16S-1092.....d23S-1118	99.14812	99.11895
d16S-1092.....d23S-1954	98.79938	98.45245
d16S-1092.....d23S-2511	99.00567	98.84033

- 5 The following results are from reactions that employed 10 μ g of *E. coli* total RNA, 37.5 pmol of 16S rRNA bridging nucleic acid, 37.5 pmol of 23S rRNA bridging nucleic acid, and 50 μ l of capture nucleic acid described in Example 1.

Bridging Nucleic Acid 16S/23S	% 16S Removed average of 2 reactions	% 23S Removed average of 2 reactions
d16S-1092/d23S-1118	98.95563	98.28748
d16S-1092/d23S-1954	97.83593	94.84438

- 10 The following results are from reactions that employed 10 μ g of *E. coli* total RNA, 75 pmol of 16S rRNA bridging nucleic acid or 75 pmol of 23S rRNA bridging nucleic acid with 75 μ l of capture nucleic acid described in Example 1.

Bridging Nucleic Acid 16S/23S	% 16S Removed	% 23S Removed
n.a./d23S-581	-	98.98529
n.a./d23S-581	-	98.87251
n.a./d23S-1118	-	93.62175
n.a./d23S-1118	-	91.4927
n.a./d23S-1954	-	98.68262
n.a./d23S-1954	-	99.03237
n.a./d23S-2511	-	99.31982
n.a./d23S-2511	-	99.13291
d16S-358/n.a.	97.65586	-
d16S-358/n.a.	97.51393	-
d16S-537/n.a.	99.16427	-
d16S-537/n.a.	98.92345	-
d16S-807/n.a.	98.0661	-
d16S-807/n.a.	98.14292	-

n.a. = not applicable

- The following results are from reactions that employed 5 μ g of *E. coli* total RNA, 25 pmol of each 16S rRNA or 23S rRNA bridging nucleic acid, and 25 μ l of capture nucleic acid described in Example 1. The rRNA/bridging nucleic acid annealing reaction was for 60 minutes at 37°C.

Bridging Nucleic Acid 16S/23S	% 16S Removed	% 23S Removed
n.a./d23S-488	-	~100
n.a./d23S-1118	-	~100
d16S-3'/d23S-488	89.024	94.228
d16S-548/d23S-488	~100	93.718
d16S-1092/d23S-488	~100	92.652

- The following results are from reactions that employed 5 μ g of *E. coli* total RNA, 16S rRNA bridging nucleic acid as indicated, 23S rRNA bridging nucleic acid as indicated, and 25 μ l of capture nucleic acid described in Example 1. The rRNA/bridging nucleic acid annealing reaction was for 120 minutes at 37°C.

Bridging Nucleic Acid 16S/23S	% 16S Removed	% 23S Removed
d16S-3' (25 pmol)/n.a.	89.137	-
d16S-548 (25 pmol)/n.a.	~100	-
d16S-1092 (25 pmol)/n.a.	~100	-
d16S-3' (25 pmol)		
d16S-548 (25 pmol)/n.a.	~100	-
d16S-3' (25 pmol)		
d16S-1092 (25 pmol)/n.a.	~100	-
d16S-548 (25 pmol)		
d16S-1092 (25 pmol)/n.a.	~100	-
d16S-548 (25 pmol)/ d23S-3' (25 pmol)	~100	~100
d16S-1092 (25 pmol)/ d23S-3' (25 pmol)	~100	~100
d16S-3' (25 pmol)/ d23S-3' (25 pmol)	92	~100

EXAMPLE 4:**The Effect of Washing the Capture Nucleic Acid**

The purpose of this experiment was to determine if washing the capture nucleic acid and combining the wash with the purified mRNA had an effect on the presence of rRNA in the purified mRNA sample. Reactions employed 10 μ g of *E. coli* total RNA, 75 pmol d16S-1092, 75 pmol of d23S-d1118, and 100 μ l of capture nucleic acid described in Example 1. The rRNA/bridging nucleic acid annealing reaction proceeded for 60 min at 37°C. After the nucleic acid capture step, the capture nucleic acid (with bound rRNA) was resuspended and washed with 100 μ l of the indicated solution at room temperature for 5 minutes. The capture nucleic acid was re-captured with a magnetic stand and the supernatant was removed and combined with mRNA in the supernatant from the first capture. mRNA in the combined supernatants were precipitated with ethanol and evaluated with RNA 6000 Lab Chip assay for the presence of rRNAs. The percent of rRNA removal for the entire process is indicated in the table below.

Wash	% 16S Removed	% 23S Removed
0.4 M TMAC	66.061	66.175
1.0 M TMAC	95.810	96.708
1.5 M TMAC	~100	~100
2.0 M TMAC	~100	~100

These results demonstrate that lowering the molarity of the TMAC wash solution increases the stringency of the rRNA capture reaction when the temperature is held constant at room temperature. The results also demonstrate that washing the capture nucleic acid magnetic beads with 1.5 and 2.0 M TMAC does not remove rRNA from the capture nucleic acid.

EXAMPLE 5:**Evaluation of Efficacy with Prokaryotic and Eukaryotic rRNA Targets**

The purpose of this example was to evaluate efficacy of the methods of the invention for depleting 16S rRNA, 18S rRNA, 23S rRNA, and 28S rRNA from mixtures of prokaryotic and eukaryotic total RNA. Depletion methods were verified using various mammalian samples, including rat livers.

Equal amounts (2.5 μ g) of *E. coli* total RNA and rat liver total RNA were mixed prior to the mRNA enrichment procedure. The bridging oligonucleotides employed were:

5
10
15
20

d16S-1092	(10 pmol)
d16S- 807	(10 pmol)
d23S-1954	(10 pmol)
d23S-2511	(10 pmol)
d18S-3711	(20 pmol)
d28S-11599	(20 pmol)

The reaction used 50 μ l of capture nucleic acid as described in Example 1. No wash step was employed. Otherwise the reaction was performed according to methods in Example 2. The results are shown in FIG. 5A and 5B. Note that all rRNAs were depleted except the 5S and 5.8S rRNAs for which no bridging oligonucleotides were added.

EXAMPLE 6:

Evaluation of Efficacy with Human rRNA Targets

Additional experiments were done using human samples to evaluate the extent of human rRNA depletion using the bridging oligonucleotides shown below. Depletion of 18S rRNA and 28S rRNA was observed from human liver total RNA. rRNAs were depleted from human liver total RNA (5 μ g). The bridging oligonucleotides employed were:

20
25

d18S-3711	(40 pmol)
d28S-11599	(40 pmol)

The reaction used 50 μ l of capture nucleic acid as described in Example 1. No wash step was employed. Otherwise the reaction was performed according to Example 2.

The results are shown in FIG. 6A and 6B. Note that all rRNAs (18S, 28S) were depleted except the 5S and 5.8S rRNAs for which no bridging oligonucleotides were added.

25

EXAMPLE 7:

Evaluation of Efficacy with Rat rRNA Targets

Additional experiments were done using rat samples to evaluate the extent of rat rRNA depletion using the bridging oligonucleotides shown below. Depletion of 18S rRNA and 28S rRNA was observed from rat liver total RNA. rRNAs were depleted from rat liver total RNA (5 μ g). The bridging oligonucleotides employed were:

30

d18S-3711R-polyA	(40 pmol)
d28S-11599R-polyA	(40 pmol)

The reaction used 50 μ l of capture nucleic acid as described in Example 1. No wash step was employed. Otherwise the reaction was performed according to Example 2.

The results are shown in FIG. 7A and 7B. Note that all rRNAs (18S, 28S) were depleted except the 5S and 5.8S rRNAs for which no bridging oligonucleotides were added.

5

EXAMPLE 8:**Evaluation of Efficacy with Mouse rRNA Targets**

Additional experiments were done using mouse samples to evaluate the extent of rat rRNA depletion using the bridging oligonucleotides shown below. Depletion of 18S rRNA and 28S rRNA was observed from mouse liver total RNA (5 μ g). The bridging oligonucleotides employed were:

d18S-3711R-polyA (40 pmol)

d28S-11599R-polyA (40 pmol)

The reaction used 50 μ l of capture nucleic acid as described in Example 1. No wash step was employed. Otherwise the reaction was performed according to Example 2.

The results are shown in FIG. 8A and 8B. Note that all rRNAs (18S, 28S) were depleted except the 5S and 5.8S rRNAs for which no bridging oligonucleotides were added.

EXAMPLE 9:**Use of Purified *E. coli* mRNA in Gene Array Expression Analysis**

mRNA was purified from total *E. coli* RNA (10 μ g) using the methods of the invention as described in Example 2. A control reaction was also performed in which the bridging nucleic acid mixture was omitted from the reaction. Control total RNA and purified mRNA (1.5 μ g) were added to 70 pmol random hexamers in a final volume of 7.25 μ l. The mixture was heated at 70°C for 10 minutes, then transferred to ice for 3 minutes. The following components were added to each reaction:

5 μ l	cDNA 1 st strand synthesis buffer (Invitrogen)
2.5 μ l	0.1 M DTT
1.25 μ l	10 mM dATP

1.25 μ l	10 mM dGTP
1.25 μ l	10 mM dTTP
5 μ l	10 mCi/ml 33 P-dCTP (Perkin Elmer-NEN)
1 μ l	Superscript II reverse transcriptase (Invitrogen) 200 U/ μ l

5

The reactions were incubated at 42°C for 120 minutes. Unincorporated nucleotides were removed from the reactions with a Qiaquick PCR cleanup column (Qiagen). The labeled cDNAs (3×10^7 cpm/blot) were used to probe replicate portions of Panorama™ *E. coli* gene arrays, using hybridization buffers supplied by the array manufacturer (Sigma-Genosys). The arrays were washed and exposed to film. This example demonstrates a dramatic increase in hybridization signal (sensitivity) on gene arrays when labeled cDNA is prepared from bacterial mRNA, purified according to the methods of the invention, rather than from total RNA.

EXAMPLE 10:**Instructions for Use with Kit**

The following instructions have been followed with a kit of the invention described below for the successful depletion of 16S and 23S rRNA from a sample comprising prokaryotic RNA populations. Bridging oligonucleotides with targeting regions complementary to 18S and 28S rRNA may be employed according to the method below to effect a similar result (as in Examples 5-8).

Materials Provided with a Kit Embodiment

30 μ l	Control RNA
1.2 ml	Capture Nucleic Acid [as in Example 1]
7 ml	Binding Buffer [as in Example 1]
95 μ l	Bridging Oligonucleotide Mix [as in Example 2]
25 2.4 ml	Wash Solution [as in Example 1]
1.75 ml	Nuclease-free Water
50 ea	RNase-free 1.5 ml tubes
25 ea	RNase-free 2ml Elution tubes
200 μ l	Glycogen (5 mg/ml)
30 875 μ l	3 M NaOAc

Experimental Parameters

A. RNA Source

This mRNA enrichment procedure is designed to work with purified total RNA from many different bacteria, including both gram-positive and gram-negative species. The procedure was optimized with total *E. coli* RNA and has been found to remove 90-99% of the rRNA from *Bacillus subtilis*, *Staphylococcus aureus*, *Prochlorococcus* sp., *Neisseria meningitidis*, and *Pseudomonas aeruginosa*, for example. It is contemplated that any eubacterial species may be targeted using the methods and compositions of the invention.

This procedure is designed so that small RNAs (including tRNA and 5S rRNA) remain in the enriched mRNA population. However, if the loss of very small RNA species (<200 base) will not be an issue, the initial isolation of total RNA should be performed with Ambion's RNAQUEOUS KIT. The RNAQUEOUS KIT will remove most small RNA species and provide the highest possible level of mRNA enrichment. If small RNAs are of interest to the user, it is best to avoid glass fiber filter-based purification.

B. Precipitate RNA to remove salt and concentrate if necessary

Total RNA prepared from a solid-phase extraction method such as RNAQUEOUS can be used immediately after elution because such samples are unlikely to have high levels of salt. On the other hand, RNA isolated by methods that include organic extractions, for example using the products RNAWIZ, TRIZOL or ToTALLY RNA, may have a substantial amount of residual salt. If RNA from these types of procedures has been precipitated only a single time, we recommend doing a second alcohol precipitation and 70% EtOH wash to remove residual salt before starting the enrichment procedure.

The recommended maximum amount of RNA per reaction is 10 μ g and the recommended maximum volume for the RNA is 15 μ l. If the RNA sample is too dilute, it will be necessary to precipitate and concentrate the RNA to at least 10 μ g/15 μ l. Precipitate the RNA with:

- 0.1 volume 5 M Ammonium Acetate or 3 M sodium acetate
- 1 μ l Glycogen (The glycogen acts as a carrier to increase precipitation efficiency from dilute RNA solutions; it is unnecessary for solutions with 200 μ g RNA/ml)
- 2.5 volumes 100% ethanol

- a. Leave the precipitation mixture at -20°C overnight, or quick-freeze it in either ethanol and dry ice, or in a -70°C freezer for 30 minutes.
- b. Recover the RNA by centrifugation at 12,000 x g for 30 minutes at 4°C .
- 5 c. Carefully remove and discard the supernatant. The RNA pellet may not adhere tightly to the walls of the tubes, so we suggest removing the supernatant by gentle aspiration with a fine-tipped pipette.
- d. Centrifuge the tube briefly a second time, and aspirate any additional fluid that collects with a fine-tipped pipette.
- 10 e. Add 1 ml 70% ethanol, and vortex the tube a few times. Repellet the RNA by microcentrifuging, for 10 minutes at 4°C . Remove supernatant carefully as in steps c and d above.

RNA should be dissolved in TE or Ambion's THE RNA STORAGE SOLUTION. It is important to accurately quantitate RNA so as not to overload the system. Ambion recommends
15 using the RiboGreen RNA Quantitation Assay and Kit (Molecular Probes) or a high quality, calibrated spectrophotometer.

C. Save an aliquot of your total RNA

If possible, retain a small aliquot ($\sim 1\text{--}2\text{ }\mu\text{g}$) of the total RNA used for comparison with enriched mRNA by gel electrophoresis after the procedure is finished.

20 *Instructions*

A. Anneal RNA and Bridging Oligonucleotide Mix

1. Add RNA to Binding buffer

Add total RNA (up to 10 μg total RNA in a maximum volume of 15 μl) to 200 μl Binding Buffer in a 1.5 ml tube provided with the kit. Close the tube and tap or vortex gently to mix.

25 2. Add Bridging Oligonucleotide Mix to RNA

Add 4.0 μl of the Bridging Oligonucleotide Mix to the RNA in Binding Buffer. Close the tube and tap or vortex gently to mix. Pulse in a microcentrifuge very briefly to get mixture to bottom of tube.

3. Incubate reactions at 70°C for 10 minutes.

Incubating the mixture at 70°C for 10 minutes denatures secondary structures in RNA, including the 16S and 23S rRNAs, allowing for maximal hybridization of the bridging oligonucleotides to the rRNAs.

5 4. Incubate reactions at 37°C for 1 hour.

Incubating the mixture at 37°C for 1 hour allows for binding of the bridging oligonucleotides to the 16S and 23S rRNA. The Binding Buffer has been optimized to function specifically and efficiently at this temperature.

B. Prepare the Capture Nucleic Acid

- 10 During the 1 hour RNA^{Bridging} Oligonucleotide Mix annealing step, prepare the Capture Nucleic Acid. The Capture Nucleic Acid is in a 1% (10 mg/ml) suspension, vortex the tube briefly before pipetting to be sure they are well suspended.

1. Aliquot the Capture Nucleic Acid

- 15 For each 10 µg reaction remove 50 µl Capture Oligos to a 1.5 ml tube. Capture Nucleic Acid for up to 10 reactions can be processed in a single 1.5 ml tube.

2. Wash the Capture Nucleic Acid once with water and once with Binding Buffer

- 20 a. Capture the beads (Capture Nucleic Acid) by placing the tube on the Magnetic Stand. Leave the tube on the stand until all of the Capture Nucleic Acid is arranged inside the tube near the magnet. This will take ~3 minutes for microfuge tubes.

b. Carefully remove the supernatant by aspiration, leaving the beads in the tube, and discard the supernatant.

- c. Add Nuclease Free Water to the captured beads at a ratio of 50 µl/50 µl beads).

- 25 d. Remove the tube from the Magnetic Stand, resuspend the beads by gently vortexing briefly, recapture the beads with a Magnetic Stand, carefully aspirate the supernatant, leaving the beads in the tube, and discard the supernatant.

- e. Add Binding Buffer to the captured beads at a ratio of 50 µl/50 µl beads).

f. Repeat step d.

3. Resuspend the Capture Nucleic Acid in Binding Buffer

a. Add Binding Buffer to the captured beads at a ratio of 50 μ l/50 μ l beads).

b. Remove the tube from the Magnetic Stand, resuspend the beads by gently tapping
5 the tube or very gentle vortexing.

c. Pulse spin in a microcentrifuge to get liquid to the bottom of the tube.

C. Capture the rRNA with Capture Nucleic Acid and Recover the Enriched mRNA

10 **1. Add Capture Nucleic Acid (50 μ l/rxn) to RNA/Bridging Oligonucleotide Mix and incubate at RT for 15 minutes.**

a. After the 1 hour incubation at 37°C (Step A.4) remove tubes to room temperature (RT) and immediately add 50 μ l of the washed and equilibrated beads (Capture Nucleic Acid, from Step B.3c) to each purification reaction. Very gently vortex or tap tube to mix briefly and pulse spin in a microcentrifuge to get liquid to the bottom of the tube.

15 b. Incubate 15 minutes at RT. During this step the oligonucleotide sequence on the Capture Nucleic Acid anneals to the bridging oligonucleotides. The bridging oligonucleotides remain hybridized to the 16S and 23S rRNAs. The hybridization "sandwich" of bridging oligonucleotide and capture oligonucleotide (via the capture region on the capture oligo and the bridging region on the bridging oligo) is formed at this step.

20 **2. Recover the supernatant containing the enriched mRNA.**

a. Capture the beads by placing the tube on the Magnetic Stand. Leave the tube on the stand until all of the beads are arranged inside the tube near the magnet. This will take ~3 minutes for microfuge tubes. Allow the beads to be completely captured by the magnet for at least 3 minutes.

25 b. Remove the supernatant by aspiration, being careful not to dislodge the beads. Put the supernatant into a 2 ml nipple bottom tube on ice and save. Do not be overly concerned if there seems to be beads in the removed supernatant. The excess can be removed at the end of the procedure. The supernatant contains the enriched mRNA sample.

3. Wash the Oligo MagBeads with Wash Solution and recover the wash.

- a. Add Wash Solution to the captured beads at a ratio of 100 μ l Wash Solution/50 μ l beads.
 - b. Remove the tube from the Magnetic Stand, resuspend the beads by gently vortexing briefly.
 - c. Incubate at RT for 5 minutes.
 - d. Recapture the beads with the Magnetic Stand as in step C.2a. Allow the beads to be completely captured by the magnet for at least 3 minutes.
 - e. Remove the supernatant by aspiration, being careful not to dislodge the beads.
- 10 Put this supernatant in the 2 ml nipple bottom tube on ice with that from step C.2b.

D. Precipitate and resuspend the enriched mRNA in the supernatant.**1. Perform an EtOH precipitation on the collected supernatant.**

- a. Add 1/10 Volume 3M NaOAc (35 μ l) and 5 mg/ml glycogen to a final concentration of 100 μ g/ml (7 μ l) to the supernatant from step C.3.e. (the supernatant volume should be ~350 μ l).
 - b. Briefly vortex the sample to mix.
 - c. Add 3 Vol. ice cold 100% EtOH (1175 μ l) and mix well by vortexing the sample.
 - d. Precipitate the sample at -20°C for at least 1 hour.
- 20 e. Centrifuge the sample for 30 min. @ 13,000 rpm.
- f. Carefully decant the supernatant.
 - g. Add 750ml ice cold 70% EtOH, vortex briefly, and centrifuge for 5 min. @ 13,000 rpm. Decant the supernatant.
 - h. Repeat step D.1.g.

i. After decanting the supernatant spin briefly to collect. Remove the remaining supernatant with a pipettor, being careful not to dislodge the pellet. Air dry for 5 min.

2. Resuspend the enriched mRNA in an appropriate buffer.

- a. After the pellet has air dried for no more than 5 min. add 2 μ l TE pH 8.0 (RNA STORAGE SOLUTION, 1 mM EDTA or Nuclease-Free ddH₂O could be substituted).
- b. Allow the RNA to resuspend for 15 min. at room temperature. Vortex the sample vigorously to resuspend. Collect the sample by brief centrifugation. NOTE: If the pellet refuses to go into solution the sample can be incubated for 5 min. @ 70°C. This should help resuspend the pellet. NOTE: Often there will be beads remaining in the sample after the precipitation (This will cause the RNA solution to appear brownish in color). This can be remedied by applying the sample to the Magnetic stand for ~3 min. and removing the supernatant to a new tube.

E. Compatibility with respect to other microorganisms

- Based on experimental evidence and sequence information, the following organisms
- 15 should be compatible (removal of 16S rRNA and of 23S rRNA) with the oligos identified in Example 1 (non-control oligos): *Acidithiobacillus ferrooxidans*, *Acinetobacter calcoaceticus*, *Actinobacillus actinomycetemcomitans*, *Aeromonas hydrophila*, *Agrobacterium tumefaciens*, *Alcaligenes faecalis*, *Bacillus alcalophilus*, *Bacillus anthracis*, *Bacillus cereus*, *Bacillus halodurans*, *Bacillus licheniformis*, *Bacillus mycoides*, *Bacillus subtilis*, *Bacillus thuringiensis*,
 - 20 *Bartonella bacilliformis*, *Bordetella avium*, *Bordetella bronchiseptica*, *Bordetella parapertussis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Bradyrhizobium japonicum*, *Bradyrhizobium lupini*, *Brevundimonas diminuta*, *Brucella melitensis*, *Brucella melitensis biovar suis*, *Buchnera aphidicola*, *Buchnera sp.* APS, *Burkholderia cepacia*, *Burkholderia mallei*, *Burkholderia pseudomallei*, *Caulobacter crescentus*, *Chlamydia muridarum*, *Chlamydia suis*, *Chlamydia*
 - 25 *trachomatis*, *Chlamydomydia abortus*, *Chlamydomydia caviae*, *Chlamydomydia felis*, *Chlamydomydia pecorum*, *Chlamydomydia pneumoniae*, *Chlamydomydia psittaci*, *Chlorobium limicola*, *Chlorobium tepidum*, *Citrobacter freundii*, *Clostridium acetobutylicum*, *Clostridium difficile*, *Clostridium histolyticum*, *Corynebacterium diphtheriae*, *Corynebacterium glutamicum*, *Cytophaga hutchinsonii*, *Desulfovibrio vulgaris*, *Dichelobacter nodosus*, *Enterococcus asini*,
 - 30 *Enterococcus avium*, *Enterococcus casseliflavus*, *Enterococcus cecorum*, *Enterococcus*

- columbae*, *Enterococcus dispar*, *Enterococcus durans*, *Enterococcus faecalis*, *Enterococcus faecium*, *Enterococcus flavescens*, *Enterococcus gallinarum*, *Enterococcus hirae*, *Enterococcus malodoratus*, *Enterococcus mundtii*, *Enterococcus pseudoavium*, *Enterococcus raffinosus*, *Enterococcus saccharolyticus*, *Enterococcus sulfureus*, *Erwinia chrysanthemi*, *Escherichia coli*,
- 5 *Fibrobacter succinogenes*, *Frankia* sp., *Fusobacterium nucleatum*, *Geobacillus stearothermophilus*, *Geobacter sulfurreducens*, *Gluconacetobacter europaeus*, *Gluconacetobacter intermedius*, *Gluconacetobacter xylinus*, *Haemophilus ducreyi*, *Haemophilus influenzae*, *Klebsiella pneumoniae*, *Lactobacillus amylolyticus*, *Lactobacillus delbrueckii*, *Lactococcus lactis*, *Leuconostoc carnosum*, *Leuconostoc lactis*, *Leuconostoc mesenteroides*,
 - 10 *Listeria grayi*, *Listeria innocua*, *Listeria ivanovii*, *Listeria monocytogenes*, *Listeria seeligeri*, *Melissococcus plutonius*, *Micrococcus luteus*, *Mycobacterium avium*, *Mycobacterium avium* supsp., *Paratuberculosis*, *Mycobacterium bovis*, *Mycobacterium kansasii*, *Mycobacterium leprae*, *Mycobacterium phlei*, *Mycobacterium smegmatis*, *Mycobacterium tuberculosis*, *Myxococcus xanthus*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nitrosomonas europaea*, *Pasteurella*
 - 15 *multocida*, *Peptococcus niger*, *Plesiomonas shigelloides*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Ralstonia pickettii*, *Ralstonia solanacearum*, *Renibacterium salmoninarum*, *Rhizobium vitis*, *Rhodococcus erythropolis*, *Rhodococcus fascians*, *Rhodopseudomonas palustris*, *Rhodospirillum rubrum*, *Rickettsia akari*, *Rickettsia australis*, *Rickettsia bellii*, *Rickettsia canadensis*, *Rickettsia conorii*, *Rickettsia montanensis*,
 - 20 *Rickettsia parkeri*, *Rickettsia prowazekii*, *Rickettsia rhipicephali*, *Rickettsia rickettsii*, *Rickettsia sibirica*, *Rickettsia typhi*, *Salmonella bongori*, *Salmonella enterica*, *Salmonella enteritidis*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shewanella putrefaciens*, *Sinorhizobium meliloti*, *Sporosarcina globispora*, *Staphylococcus aureus*, *Staphylococcus carnosus*, *Staphylococcus condimentii*, *Staphylococcus epidermidis*, *Stigmatella aurantiaca*,
 - 25 *Streptococcus equi*, *Streptococcus gordonii*, *Streptococcus macedonicus*, *Streptococcus mitis*, *Streptococcus mutans*, *Streptococcus oralis*, *Streptococcus parauberis*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Streptococcus thermophilus*, *Streptococcus uberis*, *Streptomyces ambofaciens*, *Streptomyces coelicolor*, *Streptomyces griseus*, *Streptomyces lividans*, *Streptomyces nodosus*, *Streptomyces rimosus*, *Thermoanaerobacter tengcongensis*,
 - 30 *Thermobifida fusca*, *Thermomonospora chromogena*, *Thiobacillus ferrooxidans*, *Triteponema denticola*, *Treponema pallidum*, *Vibrio cholerae*, *Yersinia enterocolitica*, *Yersinia pestis*, *Xanthomonas campestris*, *Xanthomonas axonopodis* pv. *Citri*, and *Xylella fastidiosa*.

Based on experimental evidence and sequence information, the following organisms should be partially compatible (removal of 23S rRNA and of 50-100% 16S rRNA) with oligos identified in Example 1 (non-control): *Azotobacter vinelandii*, *Bacteroides fragilis*, *Carboxydotherrnus hydrogeniformans*, *Clostridium tyrobutyricum*, *Desulfovibrio vulgaris*,
 5 *Dictyoglomus thermophilum*, *Enterococcus solitarius*, *Erysipelothrix rhusiopathiae*, *Erysipelothrix tonsillarum*, *Flexibacter flexilis*, *Legionella pneumophila*, *Leptospira interrogans*, *Leucothrix mucor*, *Listeria welshimeri*, *Methylococcus capsulatus*, *Myroides odoratus*, *Oenococcus oeni*, *Paracoccus denitrificans*, *Pectinatus frisingensis*, *Porphyromonas gingivalis*, *Prevotella intermedia*, *Silicibacter pomeroyi*, *Tannerella forsythensis*, *Tetragenococcus*
 10 *halophilus*, *Thermobispora bispora*, *Thermus thermophilus* and, *Thiomonas cuprina*

Based on experimental evidence and sequence information, the following organisms should be partially compatible (removal of 16S rRNA and 50-100% of 23S rRNA) with oligos identified in Example 1 (non-control): *Burkholderia fungorum*, *Clostridium perfringens*, *Desulfitobacterium hafniense*, *Magnetospirillum magnetotacticum*, *Mesorhizobium loti*,
 15 *Nannocystis exedens*, *Novosphingobium aromaticivorans*, *Parachlamydia acanthamoebae*, *Ruminobacter amylophilus*, *Ruminococcus albus*, *Tropheryma whipplei*, and *Wolbachia endosymbiont* of *Drosophila melanogaster*.

Based on experimental data and sequence information, the following organisms are believed to be incompatible with the oligos in Example 1: *Archaeobacteria*, *Campylobacter spp.*,
 20 *Chloroflexus aurantiacus*, *Cyanobacteria*, *Dehalococcoides ethenogenes*, *Deinococcus radiodurans*, *Fervidobacterium islandicum*, *Helicobacter pylori*, *Mycoplasma spp.*, *Pirellula marina*, *Propionibacterium freundenreichii*, *Simkania negevensis*, *Thermotoga maritima*, and *Ureaplasma urealyticum*.

EXAMPLE 11:

25 Methods for Eukaryotic rRNA Depletion from Mixed Human/*E. coli* Total RNA

These experiments were performed to demonstrate the depletion of 18S and 28S rRNAs from a mixture of prokaryotic and eukaryotic total RNA. Materials from Example 1 were used in the following experiments, except where noted.

30 *RNA/Bridging Nucleic Acid Mixture Annealing*

RNA (50 µg human total / 0.5 µg *E. coli* total) in 30 µl TE pH8.0 was added to 300 µl of binding buffer (The binding buffer in this example contains 0.02% Triton-X 100 which has been shown to reduce non-specific interactions between nucleic acids target and the capture nucleic acid). The bridging nucleic acid mixture consisted of d18S-3711, d18S-4238, d18S-5482, d28S-7979, d28S-11599 and d28S-12533 (each of these bridging oligonucleotides is at a final concentration of 3.33 µM). The bridging nucleic acid mixture (20 µl) was added to the RNA and the mixture was incubated at 70°C for 10 minutes and then shifted to 37°C for 1 hour.

Preparation of Capture Nucleic Acid

Capture nucleic acid (Oligo (dT) MagBeads, Seradyn) in storage buffer was mixed and 250 µl was removed to a separate tube. A magnetic stand was applied to the side of the tube to capture the magnetic beads and the supernatant was removed. The capture nucleic acid was equilibrated one time with distilled, deionized water (250 µl) and once with binding buffer (250 µl). The captured nucleic acid was captured again with a magnetic stand, and the binding buffer wash was removed. The magnetic beads were stored on ice until used in the next step (rRNA Capture).

rRNA Capture

Following the 1 hour annealing of RNA with the bridging nucleic acid mixture, the RNA-bridging oligonucleotide mixture was added to the capture nucleic acid (see Preparation of Capture Nucleic Acid), and the mixture was incubated at 37°C for 15 minutes. A magnetic stand was applied to the tube to capture the magnetic beads. The supernatant containing *E. coli* total RNA was removed to another tube and saved. An optional washing step was performed. The magnetic beads were washed with Wash Solution (100 µl) and captured again. The wash supernatant was removed and added to the original supernatant.

Fifteen minutes was found to be an adequate length of time for rRNA capture. Longer time periods can be used with no adverse effects. rRNA capture occurs rapidly, and capture times of 5 – 60 minutes have been used successfully in the methods of the invention.

Precipitating RNA

E. coli total RNA was precipitated by adding 1/10 volume of 3 M NaOAc (pH 5.5) and 3 volumes of 100% EtOH and incubating at -20°C for 60 minutes. The precipitated RNA was pelleted in a microfuge, washed with 70% EtOH, and resuspended in TE (pH 8.0).

Analysis of Purified RNA

Purified RNA was analyzed with the Caliper RNA 6000 LabChip kit on an Agilent Bioanalyzer. Purified RNA was compared with a control total RNA sample that was carried through the reaction as described above, except that the Bridging Nucleic Acid Mixture was omitted (FIG. 9). The percentage of a rRNA present in the sample is calculated from the area under the peak. The percentage removal of the 18S and 28S rRNAs was calculated as described in Example 2 for removal of 16S and 23S rRNAs.

Electropherograms of RNA from a control reaction and from an experimental reaction after ribosomal RNA depletion are shown in FIG. 9.

10

EXAMPLE 12:**Evaluation of efficacy with Mixed Prokaryotic and Eukaryotic rRNA Targets**

The purpose of this experiment was to determine if one could, first remove the eukaryotic RNA and subsequently remove the prokaryotic rRNAs from a mixture of the two total RNAs. The materials and methods of Examples 1, 2 and 11 were used, except where noted. Depletion methods were verified using various mammalian samples, including rat liver total RNA, and both *E. coli* and *Bacillus subtilis* total RNA.

25 µg rat liver total RNA and 2 µg *E. coli* total RNA were mixed prior to the RNA enrichment procedure. The bridging oligonucleotides employed were: d16S-807, d16S-1092, d23S-1954, d23S-2511, d18S-3711, d18S-4238, d18S-5482, d28S-7979, d28S-11599, and d28S-12533.

The reactions began with procedures similar to Example 11, except for the following changes. 10 µl bridging nucleic acid mixture and 125 µl capture nucleic acid were used to remove the mammalian 18S and 28S rRNAs. Following the wash step, the wash solution and the unbound fraction containing the bacterial RNA were combined. The precipitation step was not performed. Instead the bacterial 16S and 23S rRNA was removed as in Example 2, with the following modifications. The bridging nucleic acid mixture (4 µl) containing d16S-807, d16S-1092, d23S-1954, and d23S-2511 was added directly to the combined wash and unbound

fractions containing the bacterial RNA. The remainder of the procedure for 16S and 23S rRNA followed the methods from Example 2.

- Electropherograms of RNA from a control reaction with no bridging nucleic acids (FIG. 10A), from a reaction following 18S and 28S rRNA removal (FIG. 10B), and from a reaction following subsequent removal of 16S and 23S rRNA (FIG. 10C) are shown in FIG. 10.

EXAMPLE 13:

Use of Purified *E. coli* mRNA from Mixed Eukaryotic/Prokaryotic Samples in Gene Array

Expression Analysis

- mRNA was purified from total *E. coli* RNA (2 µg) in a background of human total RNA (25 µg) using the methods of the invention as described in Example 12 (16S, 23S, 18S and 28S rRNAs were all depleted from the sample). A control reaction was also performed in which the bridging nucleic acid mixtures were omitted from the reaction. Control total RNA (8.4 µg) and purified mRNA (1.0 µg) were added to 160 pmol random decamers in a final volume of 24.5 µl. These RNA amounts represent equal fractions of the control and purified RNA samples after the procedure is complete. The mixture was heated at 70°C for 10 minutes, then transferred to ice for 3 minutes. The following components were added to each reaction:

- | | |
|-------|---|
| 12 µl | cDNA 1 st strand synthesis buffer (Invitrogen) |
| 6 µl | 0.1 M DTT |
| 3 µl | 10 mM dATP |
| 3 µl | 10 mM dGTP |
| 3 µl | 10 mM dTTP |
| 5 µl | 10 mCi/ml ³² P-dCTP (Perkin Elmer-NEN) |
| 1 µl | RNase Inhibitor (cloned) |

- The reaction was then incubated at room temperature for 10 minutes, and the following component was added:

- 2 µl Superscript II reverse transcriptase (Invitrogen) 200 U/µl

The reactions were incubated at 42°C for 120 minutes. Unincorporated nucleotides were removed from the reactions with a Qiaquick PCR™ cleanup column (Qiagen). RNA present in the cDNA probes was hydrolyzed by incubation at 65°C for 10 minutes in .05 N NaOH. The probes were subsequently neutralized with 0.05 M HCl. The labeled cDNAs (5 x 10⁷ cpm/blot) were used to probe replicate portions of Panorama™ *E. coli* gene arrays, using hybridization buffers supplied by the array manufacturer (Sigma-Genosys). The arrays were washed and exposed to film. This example demonstrates a dramatic increase in hybridization signal (sensitivity) on gene arrays when labeled cDNA is prepared from enriched bacterial mRNA, purified according to the methods of the invention, rather than from the mixed prokaryotic and eukaryotic total RNA.

Example 14:

Evaluations of Efficacy with non-*E.coli* Prokaryotic Targets

The materials and methods of Examples 1 and 2 were employed in the Examples below except where noted. These experiments were performed to evaluate the efficacy of various bridging nucleic acids with different bacterial species.

Additional targeting regions for prokaryotic 16S and 23S rRNAs were designed. The targeting regions are shown, in the examples below, 3' of the bridging regions. Thus, the targeting region encompasses the remaining, non-bridging region of each molecule described below. SEQ ID NOs are provided for the targeting regions of the bridging nucleic acids provided below (i.e., sequence of bridging regions not included in SEQ ID NO.). Furthermore, the oligos have been further designated with a suffix at the end of the oligo number. CY refers to cyanobacteria; P refers to pseudomonas; R refers to rhodobacter; and CH refers to campylobacter/helicobacter.

16S prokaryotic rRNA bridging oligonucleotides

d16S-1114P
5'-AAAAAAAAAAAAAAAAAGGGTTGCGCTCGTTACGGGACTT-3' (SEQ ID NO:74)

d16S-1114R
5'-AAAAAAAAAAAAAAAAAGGGTTGCGCTCGTTGCCGGACTT-3' (SEQ ID NO:75)

d16S-364
5'-AAAAAAAAAAAAAAAAATCCCCACTGCTGCCTCCCGTAGG-3' (SEQ ID NO:76)

d16S-1087

5'-AAAAAAAAAAAAAAAAAACAACATCTCACGACACGAGCTGA-3' (SEQ ID NO:77)

d16S-364CY

5'-AAAAAAAAAAAAAAAAAATCCCCACTGCTGCCTCCCGTAGG-3' (SEQ ID NO:78)

d16S-534CY

5'-AAAAAAAAAAAAAAAAAATTACCGCGGCTGCTGGCACGGA-3' (SEQ ID NO:79)

d16S-928CY

10 5'-AAAAAAAAAAAAAAAAAACCCCGTCAATTCTTTGAGTTTC-3' (SEQ ID NO:80)

d16S-1087CY

5'-AAAAAAAAAAAAAAAAAACAACATCTCACGACACGAGCTGA-3' (SEQ ID NO:81)

15

23S prokaryotic rRNA bridging oligonucleotides

d23S-479RCH

5'-AAAAAAAAAAAAAAAAAATTCACCTTCCCTCACGGTACT-3' (SEQ ID NO:82)

20 d23S-485

5'-AAAAAAAAAAAAAAAAAAGGTTCTTTTACCTTCCCTCGC-3' (SEQ ID NO:83)

d23S-518 CH

5'-AAAAAAAAAAAAAAAAAATGGTTTCAGGTTCTATTCACTC-3' (SEQ ID NO:84)

25

d23S-1954 CH

5'-AAAAAAAAAAAAAAAAAATTAACCGACAAGGAATTCGCG-3' (SEQ ID NO:85)

d23S-485CY

30 5'-AAAAAAAAAAAAAAAAAAGGTTCTTTTACCTTCCCTCGC-3' (SEQ ID NO:86)

The following results are from reactions that employed 10 µg of *Pseudomonas aeruginosa* total RNA, 40 pmol of 16S bridging nucleic acid and 40 pmol of 23S bridging nucleic acid, and 50 µl of capture nucleic acid described in Example 1.

35

Bridging Nucleic Acid 16S/23S	% 16S Removed average of 2 reactions	% 23S Removed average of 2 reactions
d16S-807 (20 pmol), d16S-1092 (20 pmol) d23S-1954 (20 pmol), d23S-2511 (20 pmol)	90.1%	99.5%
d16S-807 (20 pmol), d16S-1114P (20 pmol) d23S-1954 (20 pmol), d23S-2511 (20 pmol)	97.0%	99.4%

The following results are from reactions that employed 10 µg of *Bacillus subtilis* total RNA, 40 pmol of 16S bridging nucleic acid and 40 pmol of 23S bridging nucleic acid, and 50 µl of capture nucleic acid described in Example 1.

Bridging Nucleic Acid 16S/23S	% 16S Removed average of 2 reactions	% 23S Removed average of 2 reactions
d16S-807 (20 pmol), d16S-1092 (20 pmol) d23S-1954 (20 pmol), d23S-2511 (20 pmol)	98.2%	96.2%

5

The following results are from reactions that employed 10 µg of *Campylobacter fetus* total RNA, 40 pmol of 16S bridging nucleic acid and 40 pmol of 23S bridging nucleic acid, and 50 µl of capture nucleic acid described in Example 1. The *Campylobacter fetus* 23S rRNA is processed into two fragments (FIG. 12).

Bridging Nucleic Acid 16S/23S	% 16S Removed average of 2 reactions	% 23S (1260 nt fragment) Removed average of 2 reactions	% 23S (1667 nt fragment) Removed average of 2 reactions
d16S-807 (20 pmol), d16S-1092 (20 pmol) d23S-479CH (20 pmol), d23S-2511 (20 pmol)	97.3%	97.7%	89.3%
d16S-807 (20 pmol), d16S-1092 (20 pmol) d23S-518CH (20 pmol), d23S-2511 (20 pmol)	95.9%	96.7%	89.5%

10

The following results are from reactions that employed 10 µg of *Rhodobacter sphaeroides* total RNA, 40 pmol of 16S bridging nucleic acid and 40 pmol of 23S bridging nucleic acid, and 50 µl of capture nucleic acid, as described in Example 1 unless otherwise noted. The *Rhodobacter sphaeroides* 23S rRNA is processed into two fragments (FIG. 13). One
15 fragment migrates with the 16S rRNA.

Bridging Nucleic Acid 16S/23S	% 16S + 23S fragment (1600 nt) Removed average of 2 reactions	% 23S Removed average of 2 reactions
d16S-807 (20 pmol), d16S-1092 (20 pmol) d23S-479CH (20 pmol), d23S-2511 (20 pmol)	81.6%	96.8%
d16S-807 (20 pmol), d16S-1092 (20 pmol) d23S-518CH (20 pmol), d23S-2511 (20 pmol)	95.9%	96.7%
d16S-537 (20 pmol), d16S-1114R (20 pmol) d23S-479CH (20 pmol), d23S-2511 (20 pmol)	89.3%	96.1%
d16S-537 (20 pmol), d16S-1114R (20 pmol) d23S-479CH (20 pmol), d23S-1954 (20 pmol), d23S-2511 (20 pmol)	97.0%	96.4%
d16S-807 (20 pmol), d16S-1114R (20 pmol) d23S-479CH (20 pmol), d23S-2511 (20 pmol)	83.1%	96.5%
d16S-807 (20 pmol), d16S-1114R (20 pmol) d23S-479CH (20 pmol), d23S-1954 (20 pmol) d23S-2511 (20 pmol)	90.2%	95.9%
d16S-537 (20 pmol), d16S-807 (20 pmol), d16S-1114R (20 pmol) d23S-479CH (20 pmol), d23S-1954 (20 pmol) d23S-2511 (20 pmol)	96.7%	94.9%
d16S-537 (20 pmol), d16S-1114R (20 pmol) d23S-479CH (20 pmol), d23S-1954 (20 pmol) d23S-2511 (20 pmol)	95.0%	90.2%
d16S-537 (20 pmol), d16S-1114R (20 pmol) d23S-479CH (20 pmol), d23S-1954 (20 pmol) d23S-2511 (20 pmol)	95.2%	89.8%

The results demonstrate that bridging nucleic acids will function with various species. This example also demonstrates functionality based on sequence comparison, *i.e.*, that a bridging oligonucleotide will function with rRNAs in different organisms based on sequence identity between the oligonucleotide and the rRNA of the organism.

Evaluations of Efficacy with Cyanobacteria Targets

The materials and methods of Examples 1 and 2 were employed except where noted. These experiments were performed to evaluate the efficacy of various bridging nucleic acids with different bacterial species.

The following results are from reactions that employed 10 μ g of *Anabaena* spp. total RNA, the indicated amounts of the bridging nucleic acids, and 50 μ l of capture nucleic acid described in Example 1. The *Anabaena* sp. 23S rRNA and 23S rRNAs from other cyanobacteria may be processed into several fragments (FIG. 14).

Bridging Nucleic Acid 16S/23S	% 16S Removed average of 2 reactions	% 23S Removed average of 2 reactions		
		520 nt fragment	2090 nt fragment	2470 nt fragment
d16S-364CY (20 pmol), d16S-928CY (20 pmol)	94.3	NA	NA	NA
d16S-364CY (20 pmol), d16S-1087CY (20 pmol)	93.1	NA	NA	NA
d16S-928CY (20 pmol), d16S-1087CY (20 pmol)	93.7	NA	NA	NA
d23S-485 (20 pmol), d23S-1954 (20 pmol)	NA	98.6	94.1	99.5
d23S-485 (20 pmol), d23S-2511 (20 pmol)	NA	98.4	95.7	99.5
d16S-364CY (20 pmol), d16S-928CY (20 pmol) d23S-485, (20 pmol), d23S-1954 (20 pmol)	99.5	96.5	84.7	97.7
d16S-364CY (20 pmol), d16S-928CY (20 pmol) d23S-485, (20 pmol), d23S-2511 (20 pmol)	99.2	96.3	87.2	98.5
d16S-364CY (20 pmol), d16S-1087CY (20 pmol) d23S-485 (20 pmol), d23S-1954 (20 pmol)	99.7	98.6	88.3	98.3
d16S-364CY (20 pmol), d16S-1087CY (20 pmol) d23S-485 (20 pmol), d23S-2511 (20 pmol)	99.7	99.2	89.2	99.1
d16S-928CY (20 pmol), d16S-1087CY (20 pmol) d23S-485 (20 pmol), d23S-2511 (20 pmol)	96.9	97.6	86.8	98.9
d16S-364 (20 pmol), d16S-1087CY (20 pmol) d23S-485 (20 pmol), d23S-1954 (20 pmol)	99.2	98.2	88.1	97.7
d16S-364 (17.5 pmol), d16S-1087CY (17.5 pmol) d23S-485 (20 pmol), d23S-1954 (25 pmol)	99.8	98.8	88.4	98.5
d16S-364 (15 pmol), d16S-1087CY (15 pmol) d23S-485 (20 pmol), d23S-1954 (30 pmol)	99.8	99.1	90.6	98.3
d16S-364 (12.5 pmol), d16S-1087CY (12.5 pmol) d23S-485 (20 pmol), d23S-1954 (35 pmol)	99.9	98.7	92.5	98.9

Bridging Nucleic Acid 16S/23S	% 16S Removed average of 2 reactions	% 23S Removed average of 2 reactions		
		520 nt fragment	2090 nt fragment	2470 nt fragment
d16S-364 (10 pmol), d16S- 1087CY (10 pmol) d23S-485 (20 pmol), d23S- 1954 (40 pmol)	99.9	98.9	90.6	98.6

5 All of the compositions and methods disclosed and claimed herein can be made and
executed without undue experimentation in light of the present disclosure. While the
compositions and methods of this invention have been described in terms of preferred
embodiments, it will be apparent to those of skill in the art that variations may be applied to the
compositions and/or methods and in the steps or in the sequence of steps of the method described
herein without departing from the concept, spirit and scope of the invention. More specifically,
10 it will be apparent that certain agents that are both chemically and physiologically related may be
substituted for the agents described herein while the same or similar results would be achieved.
All such similar substitutes and modifications apparent to those skilled in the art are deemed to
be within the spirit, scope and concept of the invention as defined by the appended claims.

REFERENCES

The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.

5 U.S. Application No. 09/854,412

U.S. Patent No. 4,486,539

U.S. Patent No. 4,563,419

U.S. Patent No. 4,659,774

10 U.S. Patent No. 4,682,195

U.S. Patent No. 4,683,202

U.S. Patent No. 4,751,177

U.S. Patent No. 4,816,571

U.S. Patent No. 4,868,105

15 U.S. Patent No. 4,894,325

U.S. Patent No. 4,959,463

U.S. Patent No. 5,124,246

U.S. Patent No. 5,141,813

U.S. Patent No. 5,200,314

20 U.S. Patent No. 5,214,136

U.S. Patent No. 5,216,141

U.S. Patent No. 5,223,618

U.S. Patent No. 5,264,566

U.S. Patent No. 5,273,882

25 U.S. Patent No. 5,288,609

U.S. Patent No. 5,378,825

U.S. Patent No. 5,412,087

U.S. Patent No. 5,428,148

U.S. Patent No. 5,432,272

30 U.S. Patent No. 5,445,934

U.S. Patent No. 5,446,137

U.S. Patent No. 5,457,025

- U.S. Patent No. 5,466,786
U.S. Patent No. 5,470,967
U.S. Patent No. 5,500,356
U.S. Patent No. 5,539,082
5 U.S. Patent No. 5,554,744
U.S. Patent No. 5,574,146
U.S. Patent No. 5,589,335
U.S. Patent No. 5,602,240
U.S. Patent No. 5,602,244
10 U.S. Patent No. 5,610,289
U.S. Patent No. 5,614,617
U.S. Patent No. 5,623,070
U.S. Patent No. 5,645,897
U.S. Patent No. 5,652,099
15 U.S. Patent No. 5,670,663
U.S. Patent No. 5,672,697
U.S. Patent No. 5,681,947
U.S. Patent No. 5,700,922
U.S. Patent No. 5,702,896
20 U.S. Patent No. 5,708,154
U.S. Patent No. 5,709,629
U.S. Patent No. 5,714,324
U.S. Patent No. 5,714,331
U.S. Patent No. 5,714,606
25 U.S. Patent No. 5,719,262
U.S. Patent No. 5,723,597
U.S. Patent No. 5,736,336
U.S. Patent No. 5,744,305
U.S. Patent No. 5,759,777
30 U.S. Patent No. 5,763,167
U.S. Patent No. 5,766,855
U.S. Patent No. 5,773,571

- U.S. Patent No. 5,777,092
U.S. Patent No. 5,786,461
U.S. Patent No. 5,792,847
U.S. Patent No. 5,858,988
5 U.S. Patent No. 5,859,221
U.S. Patent No. 5,872,232
U.S. Patent No. 5,886,165
U.S. Patent No. 5,891,625
U.S. Patent No. 5,897,783
10 U.S. Patent No. 5,908,845
U.S. Patent No. 5,945,525
U.S. Patent No. 6,001,983
U.S. Patent No. 6,013,440
U.S. Patent No. 6,037,120
15 U.S. Patent No. 6,060,246
U.S. Patent No. 6,090,548
U.S. Patent No. 6,110,678
U.S. Patent No. 6,140,496
U.S. Patent No. 6,203,978
20 U.S. Patent No. 6,221,581
U.S. Patent No. 6,228,580
U.S. Patent No. 6,309,823
U.S. Patent No. 6,316,193
U.S. Patent No. 6,322,971
25 U.S. Patent No. 6,324,479
U.S. Patent No. 6,329,140
U.S. Patent No. 6,329,209
- 30 EP 266,032
PCT/EP/01219
PCT/US00/29865

WO 01/32672

WO 86/05815

WO90/06045

WO 92/20702

5

The entire issue of *Current Opinion in Microbiology*, Volume 4, February 2001.

Amara *et al.*, *Nucl. Acids Res.* 25:3465-3470, 1997.

Arfin *et al.*, *J. Biol. Chem.* 275:29672-29684.

- 10 Ausubel *et al.*, In: *Current Protocols in Molecular Biology*, John, Wiley & Sons, Inc, New York, 1994.

Beaucage, *Methods Mol. Biol.* 20:33-61, 1993.

Chuang *et al.*, *J. Bacteriol.* 175:2026-2036, 1993.

Coombes *et al.*, *Infect. Immun.* 69:1420-1427, 2001.

- 15 Cornelis *et al.*, *Curr. Opin. Microbiol.* 4:13-15, 2001.

Cummings *et al.*, *Emerg. Inf. Dis.* 6:513-524, 2000.

DeRisi *et al.*, *Nature Genetics* 14:457-460, 1996.

Detweller *et al.*, *Proc. Natl. Acad. Sci. USA* 98:5850-5855, 2001.

Egholm *et al.*, *Nature* 365(6446):566-568, 1993.

- 20 Feng *et al.*, *Proc. Natl. Acad. Sci. USA* 97:6415-6420, 2000.

Fox, J.L. *et al.*, *ASM News* 67:247-252, 2001.

Froehler *et al.*, *Nucleic Acids Res.*, 14(13):5399-5407, 1986.

Gillam *et al.*, *J. Biol. Chem.* 253(8):2532-9, 1978.

Gillam *et al.*, *Gene* 8(1):99-106, 1979.

- 25 Gingeras *et al.*, *ASM News* 66:463-469, 2000.

Graham *et al.*, *Curr. Opin. Microbiol.* 4:65-70, 2001.

Graham *et al.*, *Proc. Natl. Acad. Sci. USA* 96:11554-11559, 1999.

Ichikawa *et al.*, *Proc. Natl. Acad. Sci. USA* 97:9659-9664, 2000.

Itakura *et al.*, *J. Am. Chem. Soc.* 97(25):7327-32, 1975.

- 30 Kagnoff *et al.*, *Curr. Opin. Microbiol.* 4:246-250, 2001.

Khorana, *Science* 203(4381):614-25, 1979.

Klug *et al.*, *Methods Enzymol.* 152:316-325, 1987.

- Koshkin *et al.*, *Tetrahedron* 54:3607-3630, 1998.
- Koshkin *et al.*, *J. Am. Chem. Soc.* 120:13252-13253, 1998.
- Kricka, *Nonisotopic DNA Probe Techniques*, Academic Press, San Diego, California, 1992.
- Liang *et al.*, *Methods Enzymol.* 254:304-321, 1995.
- 5 Lockhart *et al.*, *Nature Biotech.* 14:1675, 1996.
- Maskos *et al.*, *Nuc. Acids. Res.* 20:1679-1684, 1992.
- Neidhardt *et al.*, in *Escherichia coli and Salmonella* (Neidhardt, FC, Ed.), Vol. 1, pp.13-16, ASM Press, Washington, DC, 1996.
- Newton *et al.*, *J Comput. Biol.* 8:37-52, 2001.
- 10 Pietu *et al.*, *Genome Res.* 6:492, 1996.
- Plum, *et al.*, *Infect. Immun.* 62:476-483, 1994.
- Rappuoli, R. *Proc. Natl. Acad. Sci. USA* 97:13467-13469, 2000.
- Robinson *et al.*, *Gene* 148:137-141, 1994.
- Rosenberger *et al.*, *J. Immunol.* 164:5894-5904, 2000.
- 15 Sambrook *et al.*, In: *Molecular Cloning: A Laboratory Manual*, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
- Sambrook *et al.*, In: *Molecular Cloning: A Laboratory Manual*, 3rd Ed., Cold Spring Harbor Press, Cold Spring Harbor, NY, 2001.
- Schena *et al.*, *Science* 270:467-470, 1995a.
- 20 Schena *et al.*, *Proc. Natl. Acad. Sci. USA* 93:10539-11286, 1995b.
- Shalon *et al.*, *Genome Res.* 6:639-645, 1996.
- Su *et al.*, *Molec. Biotechnol.* 10:83-85, 1998.
- Velculescu *et al.*, *Science* 270:484-487, 1995.
- Wahlestedt *et al.*, *PNAS* 97:5633-5638, 2000.
- 25 Wei *et al.*, *J. Bacteriol.* 183:545-556, 2001.
- Wendisch, *et al.*, *Anal. Biochem.* 290:205-213, 2001.
- Wood *et al.*, *Proc. Natl. Acad. Sci. USA.* 82:1585-1588, 1985.
- Yoshida *et al.*, *Nucl. Acids Res.* 29:683-692, 2001.
- Zhao *et al.*, *Gene* 156:207, 1995.

CLAIMS

1. A method for depleting or isolating a targeted nucleic acid from a sample comprising:
 - a) incubating the sample with a first bridging oligonucleotide comprising (1) at least
5 one bridging region comprising at least 5 nucleic acid residues and (2) at least one
targeting region comprising at least 5 nucleic acid residues, under conditions
allowing hybridization between the first targeting region and the targeted nucleic
acid;
 - b) incubating the first bridging oligonucleotide with a capture oligonucleotide
10 comprising a nonreacting structure and a capture region comprising at least 5
nucleic acid residues, under conditions allowing hybridization between the
bridging region and the capture region; and
 - c) isolating the targeted nucleic acid from the remainder of the sample.
- 15 2. The method of claim 1 wherein the targeted nucleic acid is rRNA.
3. The method of claim 2, wherein the rRNA is prokaryotic 16S, prokaryotic 23S,
eukaryotic 17S or 18S, or eukaryotic 28S rRNA.
- 20 4. The method of claim 3, wherein the rRNA comprises the sequence of SEQ ID NO:23,
SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID
NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ
ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40,
SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID
25 NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ
ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57,
SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID
NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ
ID NO:69, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75,
30 SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID
NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, or SEQ ID NO:86.

5. The method of claim 1, wherein the sample comprises eukaryotic nucleic acid.
6. The method of claim 1, wherein the sample comprises prokaryotic nucleic acid.
- 5 7. The method of claim 6, wherein the prokaryotic nucleic acid is from a gram positive bacterium.
8. The method of claim 6, wherein the prokaryotic nucleic acid is from a gram negative bacterium.
- 10 9. The method of claim 1, wherein the bridging region, targeting region, or capture region comprises at least 10 nucleic acid residues.
10. The method of claim 9, wherein the bridging region, targeting region, or capture region
15 comprises at least 15 nucleic acid residues.
11. The method of claim 10, wherein the bridging region, targeting region, or capture region comprises at least 20 nucleic acid residues.
- 20 12. The method of claim 1, wherein the bridging region or the capture region is polypurine or polypyrimidine.
13. The method of claim 12, wherein the bridging region is polypurine and the capture region is polypyrimidine.
- 25 14. The method of claim 1, further comprising incubating the sample with a second bridging oligonucleotide comprising (1) at least one bridging region comprising at least 5 nucleic acid residues and (2) at least one targeting region comprising at least 5 nucleic acid residues, under conditions allowing hybridization between the targeting region of the second bridging
30 oligonucleotide and the targeted nucleic acid.

15. The method of claim 14, wherein the targeting region of the first bridging oligonucleotide is complementary to the sequence of a targeted nucleic acid and the targeting region of the second bridging oligonucleotide is complementary to a different sequence of a targeted nucleic acid.
- 5 16. The method of claim 15, wherein the targeting region of the first bridging oligonucleotide and the targeting region of the second bridging oligonucleotide are complementary to the same targeted nucleic acid.
- 10 17. The method of claim 15, wherein the targeting region of the first bridging oligonucleotide and the targeting region of the second bridging oligonucleotide are complementary to different targeted nucleic acids.
- 15 18. The method of claim 17, wherein the targeting region of the first bridging oligonucleotide is complementary to a sequence of the largest rRNA molecule and the targeting region of the second bridging oligonucleotide is complementary to a sequence of the second largest rRNA molecule in the sample.
- 20 19. The method of claim 14, wherein the targeting region of the first or second bridging oligonucleotide hybridizes to a sequence located between 100 and 5000 residues of the 5' or 3' end of the targeted nucleic acid.
- 25 20. The method of claim 19, wherein the targeting region of the first or second bridging oligonucleotide hybridizes to a sequence located between 150 and 4000 residues of the 5' or 3' end of the targeted nucleic acid.
- 30 21. The method of claim 20, wherein the targeting region of the first or second bridging oligonucleotide hybridizes to a sequence located between 200 and 3000 residues of the 5' or 3' end of the targeted nucleic acid.

22. The method of claim 21, wherein the targeting region of the first or second bridging oligonucleotide hybridizes to a sequence located between 250 and 2000 residues of the 5' or 3' end of the targeted nucleic acid.
- 5 23. The method of claim 22, wherein the targeting region of the first or second bridging oligonucleotide hybridizes to a sequence located between 300 and 1500 residues of the 5' or 3' end of the targeted nucleic acid.
24. The method of claim 23, wherein the targeting region of the first or second bridging
10 oligonucleotide hybridizes to a sequence located between 350 and 1000 residues of the 5' or 3' end of the targeted nucleic acid.
25. The method of claim 24, wherein targeting region of the first or second bridging oligonucleotide hybridizes to a sequence located between 400 and 900 residues of the 5' or 3'
15 end of the targeted nucleic acid.
26. The method of claim 25, wherein the targeting region of the first or second bridging oligonucleotide hybridizes to a sequence located between 450 and 800 residues of the 5' or 3' end of the targeted nucleic acid.
20
27. The method of claim 26, wherein the targeting region of the first or second bridging oligonucleotide hybridizes to a sequence located between 500 and 700 residues of the 5' or 3' end of the targeted nucleic acid.
- 25 28. The method of claim 14, wherein the targeting region of the first or second bridging oligonucleotide hybridizes to a sequence at the 3' or 5' end of the targeted nucleic acid.
29. The method of claim 14, wherein the targeting region of the first or second bridging oligonucleotide hybridizes to a sequence not within 100 residues from the 3' or 5' end of the
30 targeted nucleic acid.

30. The method of claim 14, wherein targeting region of the first or second bridging oligonucleotide hybridizes to a sequence not within 200 residues from the 3' or 5' end of the targeted nucleic acid.
- 5 31. The method of claim 14, wherein the targeting region of the first or second bridging oligonucleotide hybridizes to a sequence not within 400 residues from the 3' or 5' ends of the targeted nucleic acid.
32. The method of claim 14, wherein the targeting region of the first or second bridging
10 oligonucleotide comprises SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID
15 NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, or SEQ ID NO:86.
33. The method of claim 1, wherein the bridging oligonucleotide comprises a second targeting region comprising at least 5 nucleic acid residues complementary to a different
20 sequence than the sequence to which the first targeting region is complementary.
34. The method of claim 33, wherein the first targeting region is complementary to a different targeting nucleic acid than the second targeting region is.
- 25 35. The method of claim 1, wherein the first bridging oligonucleotide comprises two bridging regions.
36. The method of claim 1, wherein the bridging oligonucleotide or the capture oligonucleotide is RNA, DNA, LNA, iso-bases, or a peptide nucleic acid.
- 30 37. The method of claim 1, further comprising washing the capture oligonucleotide after incubation with the sample and the bridging oligonucleotide.

38. The method of claim 1, wherein a) and b) are performed at the same temperature.
39. The method of claim 1, wherein a) and b) are performed at a different temperature.
- 5 40. The method of claim 38, wherein a) and b) are performed at the same time.
41. The method of claim 1, wherein the nonreacting structure comprises a bead comprising plastic, glass, teflon, silica, a magnet, cellulose, latex, polystyrene, nylon, cellulose, 10 nitrocellulose, polymethacrylate, polyvinylchloride, or styrene-divinylbenzene
42. The method of claim 41, wherein isolating the targeted nucleic acid away from the sample comprises exposing the sample with the capture oligonucleotide to a magnetic field.
- 15 43. The method of claim 1, wherein the nonreacting structure is cellulose.
44. The method of claim 1, wherein the nonreacting structure is biotin.
45. The method of claim 44, wherein isolating the targeted nucleic acid comprises incubating 20 the sample with streptavidin or avidin.
46. The method of claim 1, wherein the sample, capture oligonucleotide, and bridging oligonucleotide are incubated in a buffer comprising TMAC or TEAC.
- 25 47. The method of claim 1, further comprising:
- d) discarding the portion of the sample that hybridizes to the capture oligonucleotide.
48. The method of claim 2, further comprising:
- 30 d) discarding the targeted rRNA nucleic acid; and
- e) producing cDNA using mRNA in the remainder of the sample.

49. The method of claim 2, further comprising:
- d) amplifying nucleic acids in the remainder of the sample, wherein the remainder of the sample is enriched for mRNA.
- 5 50. The method of claim 49., further comprising:
- e) using the amplified nucleic acids to probe a nucleic acid array.
51. The method of claim 48, further comprising:
- f) attaching the cDNA to a solid support, wherein a nucleic acid array is created.
- 10 52. The method of claim 51, wherein the solid support is plastic, glass, or nylon.
53. The method of claim 52, wherein the solid support is a plate.
- 15 54. The method of claim 53, wherein the plate is a multiple-well plate.
55. The method of claim 48, further comprising:
- f) contacting a nucleic acid array with the cDNA.
- 20 56. The method of claim 1, further comprising incubating the sample with a second bridging oligonucleotide comprising (1) at least one bridging region comprising at least 5 nucleic acid residues and (2) at least one targeting region comprising at least 5 nucleic acid residues, under conditions allowing hybridization between the targeting region of the second bridging oligonucleotide and a second targeted nucleic acid.
- 25 57. The method of claim 56, further comprising incubating the sample with a third bridging oligonucleotide comprising (1) at least one bridging region comprising at least 5 nucleic acid residues and (2) at least one targeting region comprising at least 5 nucleic acid residues, under conditions allowing hybridization between the targeting region of the third bridging
- 30 oligonucleotide and a third targeted nucleic acid.

58. The method of claim 57, further comprising incubating the sample with a fourth bridging oligonucleotide comprising (1) at least one bridging region comprising at least 5 nucleic acid residues and (2) at least one targeting region comprising at least 5 nucleic acid residues, under conditions allowing hybridization between the targeting region of the fourth bridging
5 oligonucleotide and a fourth targeted nucleic acid.
59. The method of claim 56, wherein prokaryotic and eukaryotic rRNAs are targeted nucleic acids.
- 10 60. A method for depleting rRNA from a sample comprising:
- a) incubating the sample with at least a first (1) bridging oligonucleotide comprising a bridging region comprising a poly-purine region of at least 5 residues and a targeting region comprising at least 5 contiguous nucleic acid residues complementary to a sequence of an rRNA molecule and a (2) capture
15 oligonucleotide comprising a magnetic bead and a capture region comprising a poly-pyrimidine region of at least 5 residues, under conditions to allow hybridization between the bridging oligonucleotide and the capture oligonucleotide and the bridging oligonucleotide and the rRNA;
 - b) incubating the sample with a magnetic bead; and
 - 20 c) isolating the magnetic bead.
61. A kit, in a suitable container means, comprising:
- a) a capture oligonucleotide comprising a capture region and a magnetic bead; and
 - b) at least a first bridging oligonucleotide comprising (1) at least one bridging region
25 complementary to all or part of the capture region of the capture oligonucleotide and a (2) at least one targeting region comprising 10 contiguous nucleic acids complementary to a sequence of an rRNA.
62. The kit of claim 61, wherein the first bridging oligonucleotide comprises a second
30 targeting region.

63. The kit of claim 62, wherein the first and second targeting regions have the same nucleic acid sequence.
64. The kit of claim 62, wherein the first and second targeting regions have different nucleic acid sequences.
65. The kit of claim 64, wherein the first targeting region is complementary to a sequence of an eukaryotic rRNA and the second targeting region is complementary to a sequence of a prokaryotic rRNA.
66. The kit of claim 64, wherein the first targeting region is complementary to a sequence of an eukaryotic rRNA and the second targeting region is complementary to a sequence of a different eukaryotic rRNA than the first targeting region.
67. The kit of claim 64, wherein the first targeting region is complementary to a sequence of a prokaryotic rRNA and the second targeting region is complementary to a sequence of a different prokaryotic rRNA than the first targeting region.
68. The kit of claim 61, further comprising a second bridging oligonucleotide comprising (1) at least one bridging region complementary to all or part of the capture region of the capture oligonucleotide and a (2) at least one targeting region comprising 10 contiguous nucleic acids complementary to a sequence of an rRNA.
69. The kit of claim 68, wherein the targeting region of the second bridging oligonucleotide is complementary to a sequence of the same rRNA as the first targeting region.
70. The kit of claim 68, wherein the targeting region of the first bridging oligonucleotide is complementary to a sequence of the largest rRNA and the targeting region of the second bridging oligonucleotide is complementary to a sequence of the second largest rRNA in the sample.

71. The kit of claim 68, wherein the targeting region of the first bridging oligonucleotide is complementary to a sequence of an eukaryotic rRNA and the targeting region of the bridging oligonucleotide is complementary to a sequence of a prokaryotic rRNA.
- 5 72. The kit of claim 70, wherein the targeting region of the first bridging oligonucleotide is complementary to a sequence of an eukaryotic 28S rRNA and the targeting region of the second bridging oligonucleotide is complementary to a sequence of a eukaryotic 17S or 18S rRNA.
73. The kit of claim 70, wherein the targeting region of the first bridging oligonucleotide is
10 complementary to a sequence of a prokaryotic 23S rRNA and the targeting region of the second bridging oligonucleotide is complementary to a sequence of a prokaryotic 16S rRNA.
74. The kit of claim 70, wherein the targeting region of the first bridging oligonucleotide is complementary to a sequence of an eukaryotic 28S rRNA and the targeting region of the second
15 bridging oligonucleotide is complementary to a sequence of a prokaryotic 23S rRNA.
75. The kit of claim 68, further comprising a third bridging oligonucleotide comprising (1) at least one bridging region complementary to all or part of the capture region of the capture oligonucleotide and a (2) at least one targeting region comprising 10 contiguous nucleic acids
20 complementary to a sequence of an rRNA.
76. The kit of claim 75, wherein the targeting region of the third bridging oligonucleotide is complementary to a sequence of a prokaryotic 23S rRNA.
- 25 77. The kit of claim 75, wherein the targeting region of the third bridging oligonucleotide is complementary to a sequence of a eukaryotic 18S rRNA.
78. The kit of claim 75, further comprising a fourth bridging oligonucleotide comprising (1) at least one bridging region complementary to all or part of the capture region of the capture
30 oligonucleotide and a (2) at least one targeting region comprising 10 contiguous nucleic acids complementary to a sequence of an rRNA.

79. The kit of claim 78, wherein (i) the targeting region of the first bridging oligonucleotide is complementary to a sequence of a prokaryotic 16S rRNA, (ii) the targeting region of the second bridging oligonucleotide is complementary to a sequence of a prokaryotic 23S rRNA, (iii) the targeting region of the third bridging oligonucleotide is complementary to a sequence of a eukaryotic 18S rRNA, and (iv) the targeting region of the fourth bridging oligonucleotide is complementary to a sequence of a eukaryotic 28S rRNA,
80. The kit of claim 61, wherein the first targeting region of the bridging oligonucleotide comprises SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, or SEQ ID NO:86.
81. The kit of claim 61, further comprising a buffer comprising TMAC or TEAC.
82. The kit of claim 61, further comprising a magnetic stand.
83. The kit of claim 61, further comprising:
c) a solid support for preparing a nucleic acid array.
84. A bridging oligonucleotide comprising a (1) bridging region comprising a polypyrimidine or polypurine stretch and a (2) targeting region comprising at least 10 contiguous nucleic acid residues complementary to a sequence of an rRNA.
85. The oligonucleotide of claim 84, wherein the rRNA is eukaryotic.
86. The oligonucleotide of claim 85, wherein the rRNA is the 28S rRNA.
87. The oligonucleotide of claim 84, wherein the rRNA is prokaryotic.

88. The oligonucleotide of claim 87, wherein the rRNA is the 23S rRNA.
89. A method for depleting or isolating a targeted rRNA from a sample comprising:
- 5 a) obtaining the kit of claim 61;
- b) incubating the sample with the bridging oligonucleotide under conditions allowing hybridization between the targeting region and the targeted rRNA;
- c) incubating the bridging oligonucleotide with the capture oligonucleotide under conditions allowing hybridization between the bridging region and the capture
- 10 region; and
- d) isolating the targeted rRNA from the remainder of the sample by incubating the sample with a magnetic field.
90. The method of claim 89, further comprising:
- 15 e) obtaining the remainder of the sample enriched for mRNA;
- f) preparing cDNA from the mRNA.
91. The method of claim 90, further comprising:
- 20 g) constructing a nucleic acid array with the cDNA.
92. The method of claim 89, wherein the mRNA or prepared cDNA is amplified.
93. The method of claim 92, wherein the cDNA is used to probe a nucleic acid array.




FIG. 1

Alignment Report of Gram -48- 16S align.MEG, using Clustal method with Weighted residue weight table.
 Tuesday, November 27, 2001 4:14 PM

	290	300	310	320	330	340	350	360	370	380	390	400
Ambrill16S.BSQ	..C.AC.	..G.T.G.	..G.	..G.	..C.	..C.	..C.G.	..A.	..C.G.	..A.A.	..T.	..C.G..A.C.
Banckia16S.BSQ	..C.AC.	..G.T.G.	..G.	..G.	..C.	..C.	..C.G.	..A.	..C.G.	..A.A.	..T.	..C.G..A.C.
Elleceia16S.BSQ	..C.AC.	..G.T.G.	..G.	..G.	..C.	..C.	..C.G.	..A.	..C.G.	..A.A.	..T.	..C.G..A.C.
Lactia16S.BSQ	..C.AC.	..G.T.G.	..G.	..G.	..C.	..C.	..C.G.	..A.	..C.G.	..A.A.	..T.	..C.G..A.C.
Leuocyt16S.BSQ	..C.AC.	..G.T.G.	..G.	..G.	..C.	..C.	..C.G.	..A.	..C.G.	..A.A.	..T.	..C.G..A.C.
Saurau16S.BSQ	..C.AC.	..G.T.G.	..G.	..G.	..C.	..C.	..C.G.	..A.	..C.G.	..A.A.	..T.	..C.G..A.C.
Senanai16S.BSQ	..C.AC.	..G.T.G.	..G.	..G.	..C.	..C.	..C.G.	..A.	..C.G.	..A.A.	..T.	..C.G..A.C.
Spruam16S.BSQ	..C.AC.	..G.T.G.	..G.	..G.	..C.	..C.	..C.G.	..A.	..C.G.	..A.A.	..T.	..C.G..A.C.
Spygwe16S.BSQ	..C.AC.	..G.T.G.	..G.	..G.	..C.	..C.	..C.G.	..A.	..C.G.	..A.A.	..T.	..C.G..A.C.
Nervu16S.BSQ	..C.AC.	..G.T.G.	..G.	..G.	..C.	..C.	..C.G.	..A.	..C.G.	..A.A.	..T.	..C.G..A.C.
Modi16S.BSQ	..C.AC.	..G.T.G.	..G.	..G.	..C.	..C.	..C.G.	..A.	..C.G.	..A.A.	..T.	..C.G..A.C.
Ecoli 0157 16S.BSQ	..C.AC.	..G.T.G.	..G.	..G.	..C.	..C.	..C.G.	..A.	..C.G.	..A.A.	..T.	..C.G..A.C.
Nonum16S.BSQ	..C.AC.	..G.T.G.	..G.	..G.	..C.	..C.	..C.G.	..A.	..C.G.	..A.A.	..T.	..C.G..A.C.
Acetiv16S.BSQ	..C.AC.	..G.T.G.	..G.	..G.	..C.	..C.	..C.G.	..A.	..C.G.	..A.A.	..T.	..C.G..A.C.
Minflu16S.BSQ	..C.AC.	..G.T.G.	..G.	..G.	..C.	..C.	..C.G.	..A.	..C.G.	..A.A.	..T.	..C.G..A.C.
Burmodi16S.BSQ	..C.AC.	..G.T.G.	..G.	..G.	..C.	..C.	..C.G.	..A.	..C.G.	..A.A.	..T.	..C.G..A.C.
Sparticus16S.BSQ	..C.AC.	..G.T.G.	..G.	..G.	..C.	..C.	..C.G.	..A.	..C.G.	..A.A.	..T.	..C.G..A.C.
Spacis16S.BSQ	..C.AC.	..G.T.G.	..G.	..G.	..C.	..C.	..C.G.	..A.	..C.G.	..A.A.	..T.	..C.G..A.C.
Small16S.BSQ	..C.AC.	..G.T.G.	..G.	..G.	..C.	..C.	..C.G.	..A.	..C.G.	..A.A.	..T.	..C.G..A.C.
Spondul16S.BSQ	..C.AC.	..G.T.G.	..G.	..G.	..C.	..C.	..C.G.	..A.	..C.G.	..A.A.	..T.	..C.G..A.C.
Spornos16S.BSQ	..C.AC.	..G.T.G.	..G.	..G.	..C.	..C.	..C.G.	..A.	..C.G.	..A.A.	..T.	..C.G..A.C.
Naung16S.BSQ	..C.AC.	..G.T.G.	..G.	..G.	..C.	..C.	..C.G.	..A.	..C.G.	..A.A.	..T.	..C.G..A.C.
Phag16S.BSQ	..C.AC.	..G.T.G.	..G.	..G.	..C.	..C.	..C.G.	..A.	..C.G.	..A.A.	..T.	..C.G..A.C.
Voltera16S.BSQ	..C.AC.	..G.T.G.	..G.	..G.	..C.	..C.	..C.G.	..A.	..C.G.	..A.A.	..T.	..C.G..A.C.
Tantarob16S.BSQ	..C.AC.	..G.T.G.	..G.	..G.	..C.	..C.	..C.G.	..A.	..C.G.	..A.A.	..T.	..C.G..A.C.

FIG. 2A-4

Alignment Report of Gram +8- 16S align.MEG. using Clustal method with Weighted residue weight table.
Tuesday, November 27, 2001 4:14 PM




FIG. 2A-5

Alignment Report of Gram +&- 16S align.MEG, using Clustal method with Weighted residue weight table.
Tuesday, November 27, 2001 4:14 PM

[illegible]

FIG. 2A-11

Alignment Report of Gram +&- 16S align.MEG, using Clustal method with Weighted residue weight table.
Tuesday, November 27, 2001 4:14 PM

[illegible]

FIG. 2A-12

Alignment Report of Gram +&- 16S align.MEG, using Clustal method with Weighted residue weight table.
 Tuesday, November 27, 2001 4:14 PM

	1480	1490	1500	1510	1520	1530	1540	
Subtilisin16S.SSQ								1427
Banthracis16.SSQ								1544
Efsealis 16S.SSQ								1449
Lactis 16S.SSQ								1548
Lemoocytis.SSQ								1524
Saureus16S.SSQ								1355
Smutans16S.SSQ								1551
Syrmomonis.SSQ								1335
Syrmomonis16S.SSQ								1465
Navium16S.SSQ								1536
Mch16S.SSQ								1542
Ecoli 0157 16S.SSQ								1485
Kyrmomonis 16S.SSQ								1534
Actinob16S.SSQ								1467
Kiafiluense 16S.SSQ								1352
Bronchiolseptic 16S.SSQ								1465
Sparsperatus16S.SSQ								1485
Spertusis 16S.SSQ								1465
Deopacia 16S.SSQ								1485
Shallai 16S.SSQ								1485
Pseudomallei 16S.SSQ								1485
Hymonitrose 16S.SSQ								1485
Bamling 16S.SSQ								1485
Pteruginose 16S.SSQ								1485
Voluare 16S.SSQ								1485
Yenterocolitica 16S.SSQ								1485

Decoration 'Decoration P1': Hide (as ',') residues that match Ecoli 0157 16S.SSQ exactly.

FIG. 2A-14

Alignment Report of Gram +&- 23S align.MEG, using Clustal method with Weighted residue weight table.
Tuesday, November 27, 2001 4:14 PM




FIG. 2B-2

Alignment Report of Gram +8- 23S align.MEG, using Clustal method with Weighted residue weight table.
 Tuesday, November 27, 2001 4:14 PM

	940	950	960	970	980	990	1000	1010	1020	1030	1040	1050
Baebellia 235.82Q	TC.TT.....T..G.T..-A...A..GA..A..-CGA.A.....G.....ATAC.....A..G.....AGTT..TT.....	1094										
Bantheis 235.82Q	TC.TT.....T..G.T..-A...A..GA..A..-CGA.A.....G.....ATAC.....A..G.....AGTT..TT.....	1096										
Escherichia 235.82Q	TC.TT.....T..G.T..-A...A..GA..A..-CGA.A.....G.....ATAC.....A..G.....AGTT..TT.....	1098										
Lactia 235.82Q	TC.TT.....T..G.T..-A...A..GA..A..-CGA.A.....G.....ATAC.....A..G.....AGTT..TT.....	1099										
Leuconocypenes 235.82Q	TC.TT.....T..G.T..-A...A..GA..A..-CGA.A.....G.....ATAC.....A..G.....AGTT..TT.....	1094										
Saureus 235.82Q	TC.TT.....T..G.T..-A...A..GA..A..-CGA.A.....G.....ATAC.....A..G.....AGTT..TT.....	1094										
Smutsia 235.82Q	TC.TT.....T..G.T..-A...A..GA..A..-CGA.A.....G.....ATAC.....A..G.....AGTT..TT.....	1094										
Spauromia 235.82Q	TC.TT.....T..G.T..-A...A..GA..A..-CGA.A.....G.....ATAC.....A..G.....AGTT..TT.....	1094										
Spysopene 235.82Q	TC.TT.....T..G.T..-A...A..GA..A..-CGA.A.....G.....ATAC.....A..G.....AGTT..TT.....	1094										
Mavium 235.82Q	TC.TT.....T..G.T..-A...A..GA..A..-CGA.A.....G.....ATAC.....A..G.....AGTT..TT.....	1094										
Mtuberculois 235.82Q	TC.TT.....T..G.T..-A...A..GA..A..-CGA.A.....G.....ATAC.....A..G.....AGTT..TT.....	1094										
Zeeil 235.82Q	TC.TT.....T..G.T..-A...A..GA..A..-CGA.A.....G.....ATAC.....A..G.....AGTT..TT.....	1094										
Xpauromia 235.82Q	TC.TT.....T..G.T..-A...A..GA..A..-CGA.A.....G.....ATAC.....A..G.....AGTT..TT.....	1094										
Minifluensia 235.82Q	TC.TT.....T..G.T..-A...A..GA..A..-CGA.A.....G.....ATAC.....A..G.....AGTT..TT.....	1094										
Brecheisepia 235.82Q	TC.TT.....T..G.T..-A...A..GA..A..-CGA.A.....G.....ATAC.....A..G.....AGTT..TT.....	1094										
Spartusis 235.82Q	TC.TT.....T..G.T..-A...A..GA..A..-CGA.A.....G.....ATAC.....A..G.....AGTT..TT.....	1094										
Scapacia 235.82Q	TC.TT.....T..G.T..-A...A..GA..A..-CGA.A.....G.....ATAC.....A..G.....AGTT..TT.....	1094										
Smallei 235.82Q	TC.TT.....T..G.T..-A...A..GA..A..-CGA.A.....G.....ATAC.....A..G.....AGTT..TT.....	1094										
Spauromia 235.82Q	TC.TT.....T..G.T..-A...A..GA..A..-CGA.A.....G.....ATAC.....A..G.....AGTT..TT.....	1094										
Ngonorhoes 235.82Q	TC.TT.....T..G.T..-A...A..GA..A..-CGA.A.....G.....ATAC.....A..G.....AGTT..TT.....	1094										
Neminigitidis 235.82Q	TC.TT.....T..G.T..-A...A..GA..A..-CGA.A.....G.....ATAC.....A..G.....AGTT..TT.....	1094										
Psaruginea 235.82Q	TC.TT.....T..G.T..-A...A..GA..A..-CGA.A.....G.....ATAC.....A..G.....AGTT..TT.....	1094										
Vcholeris 235.82Q	TC.TT.....T..G.T..-A...A..GA..A..-CGA.A.....G.....ATAC.....A..G.....AGTT..TT.....	1094										
Venterocolitis 235.82Q	TC.TT.....T..G.T..-A...A..GA..A..-CGA.A.....G.....ATAC.....A..G.....AGTT..TT.....	1094										

FIG. 2B-10

Alignment Report of Gram +s: 23S align.MEG, using Clustal method with Weighted residue weight table.
Tuesday, November 27, 2001 4:14 PM

[illegible]

FIG. 2B-12

Alignment Report of Gram +&- 23S align.MEG, using Clustal method with Weighted residue weight table.
Tuesday, November 27, 2001 4:14 PM

[illegible]

FIG. 2B-16

Alignment Report of Gram +&- 23S align.MEG, using Clustal method with Weighted residue weight table,

Tuesday, November 27, 2001 4:14 PM

[illegible]

FIG. 2B-17

Alignment Report of Gram +&- 23S align.MEG, using Clustal method with Weighted residue weight table.
 Tuesday, November 27, 2001 4:14 PM

	1790	1790	1800	1810	1820	1830	1840	1850	1860	1870	1880	1890
Baebillia 218.85Q	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.
Baebillia 218.85Q	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.
Efcaella 218.85Q	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.
Lilactia 218.85Q	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.
Leuocococcus 218.85Q	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.
Saureus 218.85Q	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.
Smittia 218.85Q	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.
Sprengia 218.85Q	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.
Spyrogonia 218.85Q	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.
Navium 218.85Q	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.
Stubercolis 218.85Q	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.
Ecoli 218.85Q	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.
Neomonas 218.85Q	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.
Minifluencia 218.85Q	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.
Brochispecta 218.85Q	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.
Spartartus 218.85Q	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.
Beopelia 218.85Q	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.
Small 218.85Q	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.
Sprengia 218.85Q	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.
Neomonas 218.85Q	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.
Redingitidis 218.85Q	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.
Paragonia 218.85Q	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.
Volcania 218.85Q	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.
Enterococcus 218.85Q	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.	..C.

FIG. 2B-18

Alignment Report of Gram+&- 23S align.MEG, using Clustal method with Weighted residue weight table.
Tuesday, November 27, 2001 4:14 PM

	2020	2010	2000	1990	1980	1970	1960	1950	1940	1930	1920	1910	1900	1890	1880	1870	1860	1850	1840	1830	1820	1810	1800	1790	1780	1770	1760	1750	1740	1730	1720	1710	1700	1690	1680	1670	1660	1650	1640	1630	1620	1610	1600	1590	1580	1570	1560	1550	1540	1530	1520	1510	1500	1490	1480	1470	1460	1450	1440	1430	1420	1410	1400	1390	1380	1370	1360	1350	1340	1330	1320	1310	1300	1290	1280	1270	1260	1250	1240	1230	1220	1210	1200	1190	1180	1170	1160	1150	1140	1130	1120	1110	1100	1090	1080	1070	1060	1050	1040	1030	1020	1010	1000	990	980	970	960	950	940	930	920	910	900	890	880	870	860	850	840	830	820	810	800	790	780	770	760	750	740	730	720	710	700	690	680	670	660	650	640	630	620	610	600	590	580	570	560	550	540	530	520	510	500	490	480	470	460	450	440	430	420	410	400	390	380	370	360	350	340	330	320	310	300	290	280	270	260	250	240	230	220	210	200	190	180	170	160	150	140	130	120	110	100	90	80	70	60	50	40	30	20	10	0	-10	-20	-30	-40	-50	-60	-70	-80	-90	-100	-110	-120	-130	-140	-150	-160	-170	-180	-190	-200	-210	-220	-230	-240	-250	-260	-270	-280	-290	-300	-310	-320	-330	-340	-350	-360	-370	-380	-390	-400	-410	-420	-430	-440	-450	-460	-470	-480	-490	-500	-510	-520	-530	-540	-550	-560	-570	-580	-590	-600	-610	-620	-630	-640	-650	-660	-670	-680	-690	-700	-710	-720	-730	-740	-750	-760	-770	-780	-790	-800	-810	-820	-830	-840	-850	-860	-870	-880	-890	-900	-910	-920	-930	-940	-950	-960	-970	-980	-990	-1000	-1010	-1020	-1030	-1040	-1050	-1060	-1070	-1080	-1090	-1100	-1110	-1120	-1130	-1140	-1150	-1160	-1170	-1180	-1190	-1200	-1210	-1220	-1230	-1240	-1250	-1260	-1270	-1280	-1290	-1300	-1310	-1320	-1330	-1340	-1350	-1360	-1370	-1380	-1390	-1400	-1410	-1420	-1430	-1440	-1450	-1460	-1470	-1480	-1490	-1500	-1510	-1520	-1530	-1540	-1550	-1560	-1570	-1580	-1590	-1600	-1610	-1620	-1630	-1640	-1650	-1660	-1670	-1680	-1690	-1700	-1710	-1720	-1730	-1740	-1750	-1760	-1770	-1780	-1790	-1800	-1810	-1820	-1830	-1840	-1850	-1860	-1870	-1880	-1890	-1900	-1910	-1920	-1930	-1940	-1950	-1960	-1970	-1980	-1990	-2000	-2010	-2020	-2030	-2040	-2050	-2060	-2070	-2080	-2090	-2100	-2110	-2120	-2130	-2140	-2150	-2160	-2170	-2180	-2190	-2200	-2210	-2220	-2230	-2240	-2250	-2260	-2270	-2280	-2290	-2300	-2310	-2320	-2330	-2340	-2350	-2360	-2370	-2380	-2390	-2400	-2410	-2420	-2430	-2440	-2450	-2460	-2470	-2480	-2490	-2500	-2510	-2520	-2530	-2540	-2550	-2560	-2570	-2580	-2590	-2600	-2610	-2620	-2630	-2640	-2650	-2660	-2670	-2680	-2690	-2700	-2710	-2720	-2730	-2740	-2750
--	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	----	----	----	----	----	----	----	----	----	---	-----	-----	-----	-----	-----	-----	-----	-----	-----	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------

FIG. 2B-20

Alignment Report of Gram +&- 23S align.m.MEG, using Clustal method with Weighted residue weight table.
Tuesday, November 27, 2001 4:14 PM

[illegible]

FIG. 2B-21

Alignment Report of Gram +&- 23S align.MEG, using Clustal method with Weighted residue weight table.

Tuesday, November 27, 2001 4:15 PM

	2610	2620	2630	40	2650	2660	2670	2680	2690	2700	2710	2720
Bubtulis 23S.82QC.T.C.A.A.T.A.A.TC.T.	C.G.A.CA.TC.G.TC.TC.TC.TC.
Bacthacis 23S.82QC.T.C.TA.A.TT.A.A.TC.T.	C.G.A.CA.TC.G.TA.TC.TC.TC.
Macbacis 23S.82QC.T.C.TA.A.TT.A.A.TC.T.	C.G.A.CA.TC.G.TA.TC.TC.TC.
Lactis 23S.82QC.T.C.TA.A.TT.A.A.TC.T.	C.G.A.CA.TC.G.TA.TC.TC.TC.
Leucocytogen 23S.82QC.T.C.TA.A.TT.A.A.TC.T.	C.G.A.CA.TC.G.TA.TC.TC.TC.
Saurus 23S.82QC.T.C.TA.A.TT.A.A.TC.T.	C.G.A.CA.TC.G.TA.TC.TC.TC.
Smucis 23S.82QC.T.C.TA.A.TT.A.A.TC.T.	C.G.A.CA.TC.G.TA.TC.TC.TC.
Synumilis 23S.82QC.T.C.TA.A.TT.A.A.TC.T.	C.G.A.CA.TC.G.TA.TC.TC.TC.
Synumilis 23S.82QC.T.C.TA.A.TT.A.A.TC.T.	C.G.A.CA.TC.G.TA.TC.TC.TC.
Navium 23S.82QC.T.C.TA.A.TT.A.A.TC.T.	C.G.A.CA.TC.G.TA.TC.TC.TC.
Hubercolitis 23S.82QC.T.C.TA.A.TT.A.A.TC.T.	C.G.A.CA.TC.G.TA.TC.TC.TC.
Ecoli 23S.82QC.T.C.TA.A.TT.A.A.TC.T.	C.G.A.CA.TC.G.TA.TC.TC.TC.
Kennumilis 23S.82QC.T.C.TA.A.TT.A.A.TC.T.	C.G.A.CA.TC.G.TA.TC.TC.TC.
Kinflumilis 23S.82QC.T.C.TA.A.TT.A.A.TC.T.	C.G.A.CA.TC.G.TA.TC.TC.TC.
Burichleptis 23S.82QC.T.C.TA.A.TT.A.A.TC.T.	C.G.A.CA.TC.G.TA.TC.TC.TC.
Spertartusis 23S.82QC.T.C.TA.A.TT.A.A.TC.T.	C.G.A.CA.TC.G.TA.TC.TC.TC.
Spertusis 23S.82QC.T.C.TA.A.TT.A.A.TC.T.	C.G.A.CA.TC.G.TA.TC.TC.TC.
Bespais 23S.82QC.T.C.TA.A.TT.A.A.TC.T.	C.G.A.CA.TC.G.TA.TC.TC.TC.
Beslei 23S.82QC.T.C.TA.A.TT.A.A.TC.T.	C.G.A.CA.TC.G.TA.TC.TC.TC.
Pseudomilis 23S.82QC.T.C.TA.A.TT.A.A.TC.T.	C.G.A.CA.TC.G.TA.TC.TC.TC.
Ngonorheas 23S.82QC.T.C.TA.A.TT.A.A.TC.T.	C.G.A.CA.TC.G.TA.TC.TC.TC.
Nemigitidis 23S.82QC.T.C.TA.A.TT.A.A.TC.T.	C.G.A.CA.TC.G.TA.TC.TC.TC.
Pacuglines 23S.82QC.T.C.TA.A.TT.A.A.TC.T.	C.G.A.CA.TC.G.TA.TC.TC.TC.
Volcheras 23S.82QC.T.C.TA.A.TT.A.A.TC.T.	C.G.A.CA.TC.G.TA.TC.TC.TC.
Yentecolitis 23S.82QC.T.C.TA.A.TT.A.A.TC.T.	C.G.A.CA.TC.G.TA.TC.TC.TC.

FIG. 2B-25

Alignment Report of Gram +&- 23S align.MEG, using Clustal method with Weighted residue weight table.
 Tuesday, November 27, 2001 4:15 PM

	2730	2740	2750	2760	2770	2780	2790	2800	2810	2820	2830	2840
Bacillus 238.89QC.G.....T.G.OCC.T.A.....A.T.....ATG.CC-A.G.AAGT.....ATG.C.G.A.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....
Banthracis 238.89QG.....T.G.OCC.T.A.....A.T.....ATG.CC-A.G.AAGT.....ATG.C.G.A.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....
Efcalalis 238.89Q	Ad.....G.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....
Llactis 238.89QT.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....
Leuconyctogenes 238.89QT.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....
Saurina 238.89Q	Ad.....G.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....
Smittina 238.89Q	Ad.....G.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....
Spneumoniae 238.89Q	Ad.....G.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....
Spyrogenes 238.89Q	Ad.....G.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....	Ad.....C.....
Styrium 238.89QT.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....
Tuberculoles 238.89QT.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....
Ecoli 238.89QT.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....
Pneumoniae 238.89QT.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....
Histifluens 238.89QT.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....
Brochisepitica 238.89QT.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....
Spurpurtusis 238.89QT.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....
Scapacia 238.89QT.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....
Smalli 238.89QT.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....
Spseudomali 238.89QT.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....
Spneumoniae 238.89QT.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....
Neumigitidis 238.89QT.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....
Spneumoniae 238.89QT.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....
Yoshikawa 238.89QT.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....
Ventricolitis 238.89QT.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....T.G.C.G.....

FIG. 2B-26




FIG. 3




FIG. 4




FIG. 5A




FIG. 5B




FIG. 6A




FIG. 6B




FIG. 7A




FIG. 7B




FIG. 8A




FIG. 8B




FIG. 9A




FIG. 9B




FIG. 10A




FIG. 10B




FIG. 10C




FIG. 11A




FIG. 11B




FIG. 12A




FIG. 12B




FIG. 13A




FIG. 13B




FIG 14A.




FIG 14B.

SEQUENCE LISTING

- <110> MURPHY, GEORGE L.
WHITLEY, J. PENN
- 5 <120> METHOD AND SYSTEM FOR DEPLETING rRNA POPULATIONS
- <130> AMBI:076WO
- 10 <140> UNKNOWN
- <141> 2002-12-20
- <150> 10/029,397
- <151> 2001-12-20
- 15 <160> 92
- <170> PatentIn Ver. 2.1
- 20 <210> 1
- <211> 22
- <212> DNA
- <213> Artificial Sequence
- 25 <220>
- <223> Description of Artificial Sequence: Synthetic
Primer
- 30 <400> 1
- ctgctgcctc cgttaggagt ct 22
- <210> 2
- <211> 23
- 35 <212> DNA
- <213> Artificial Sequence
- <220>
- <223> Description of Artificial Sequence: Synthetic
Primer
- 40 <400> 2
- cgtattaccg cggtgctgg cac 23
- 45 <210> 3
- <211> 23
- <212> DNA
- <213> Artificial Sequence
- 50 <220>
- <223> Description of Artificial Sequence: Synthetic
Primer
- 55 <400> 3
- cgcccagtaa ttccgattaa cgc 23

5 <210> 4
<211> 23
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Description of Artificial Sequence: Synthetic
Primer

<400> 4
tggactacca gggatatctaa tcc 23

15 <210> 5
<211> 23
<212> DNA
<213> Artificial Sequence

20 <220>
<223> Description of Artificial Sequence: Synthetic
Primer

25 <400> 5
gggttgcgct cggtgcgga ctt 23

30 <210> 6
<211> 23
<212> DNA
<213> Artificial Sequence

35 <220>
<223> Description of Artificial Sequence: Synthetic
Primer

40 <400> 6
taaggagggtg atccaaccgc agg 23

45 <210> 7
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Primer

50 <400> 7
ggttcttttt cactccctc gcc 23

55 <210> 8
<211> 23

<212> DNA
<213> Artificial Sequence

5 <220>
<223> Description of Artificial Sequence: Synthetic
Primer

10 <400> 8
gaccattat acaaaaggta cgc 23

15 <210> 9
<211> 23
<212> DNA
<213> Artificial Sequence

20 <220>
<223> Description of Artificial Sequence: Synthetic
Primer

<400> 9
gccccgttac atcttcgcg, cag 23

25 <210> 10
<211> 23
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Description of Artificial Sequence: Synthetic
Primer

35 <400> 10
cgacaaggaa ttctgctacc tta 23

40 <210> 11
<211> 22
<212> DNA
<213> Artificial Sequence

45 <220>
<223> Description of Artificial Sequence: Synthetic
Primer

<400> 11
cttaccggac aaggaaatttc gc 22

50 <210> 12
<211> 23
<212> DNA
<213> Artificial Sequence

55 <220>

<223> Description of Artificial Sequence: Synthetic
Primer

5 <400> 12
gagcgcacat cgaggtgcc aac 23

10 <210> 13
<211> 21
<212> DNA
<213> Artificial Sequence

15 <220>
<223> Description of Artificial Sequence: Synthetic
Primer

20 <400> 13
ggttaagcct cacggttcac t 21

25 <210> 14
<211> 14
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Description of Artificial Sequence: Synthetic
Primer

35 <400> 14
ggaagcgac ggca 14

40 <210> 15
<211> 23
<212> DNA
<213> Artificial Sequence

45 <220>
<223> Description of Artificial Sequence: Synthetic
Primer

50 <400> 15
ccccttctcc cgaagttacg ggg 23

55 <210> 16
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Primer

<400> 16

gtgagctatt acgctttctt t 21

5 <210> 17
<211> 23
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Description of Artificial Sequence: Synthetic
Primer

<400> 17
taccggccgt gcgtacttag aca 23

15

<210> 18
<211> 23
<212> DNA
20 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Primer

25 <400> 18
tgccctccaa tggatcctcg tta 23

30

<210> 19
<211> 23
<212> DNA
<213> Artificial Sequence

35 <220>
<223> Description of Artificial Sequence: Synthetic
Primer

40 <400> 19
ctacggaac cttgttacga ctt 23

45

<210> 20
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Primer

50

<400> 20
gagcactggg cagaaatcac atc 23

55 <210> 21

<211> 23
 <212> DNA
 <213> Artificial Sequence

5 <220>
 <223> Description of Artificial Sequence: Synthetic
 Primer

10 <400> 21
 gtttcttttc ctccgctgac taa 23

15 <210> 22
 <211> 23
 <212> DNA
 <213> Artificial Sequence

20 <220>
 <223> Description of Artificial Sequence: Synthetic
 Primer

<400> 22
 tctctcagcca agcacatata cca 23

25 <210> 23
 <211> 1427
 <212> DNA
 <213> *Bacillus subtilis*

30 <220>
 <221> modified_base
 <222> (554)..(873)
 <223> N = A, C, G or T/U

35 <400> 23
 gagagtttga tcttggctca ggacgaacgc tggcggcgtg cctaatacat gcaagtcgag 60
 cggacagatg ggagcttgct ccttgatgtt agcggcggac gggtagtaaa cacgtgggta 120
 40 acctgcctgt aagactcggg taactccggg aaaccggggc taataccgga tgggtgtttg 180
 aaccgcctgt tacaacataa aaaggtggct tcggctacca cttacagatg gaccgcggcg 240
 gcattagcta gttggtgagg taacggctca ccaaggcaac gatcgtagc cgacctgaga 300
 gggtagtcgg ccacactggg actgagacac ggcccagact cctacgggag gcagcagtag 360
 ggaatcttcc gcaatggagc aaagtctgac ggagcaacgc cgcgtgagtg atgaaggttt 420
 tcggatcgta aagctctgtt gttagggaag aacaagtacc gttcgaatag ggcggtagct 480
 45 tgacggatcc taaccagaaa gccacgggta actacgtgcc agcagccgcg gtaatacgta 540
 ggtgccaagc gttntccgga attattgggc gtaaaaggct cgcaggcggg ttcttaagtc 600
 tgatgtgaaa gcccccggct caaccgggga gggctcattg aaactgggga acctgagtcg 660
 agaagaggag agtggaattc cactgtgtnc ggtgaaatgc gtatagatgt ggaggaacac 720
 cagtggcgaa ggcgactctc tggctctgta ctgacgtga ggagcgaaag cgtggggagc 780
 50 gaacaggatt agtaccctgt gtagtccacg ccgtaaacga tgagtgtctaa gtgttagggg 840
 gtttccgccct ctcttgctgt cagtaacgca tttagcactc cgccctgggga gtacggtcgc 900
 aagactgaaa ctcaaaaggaa ttgacggggg ccgcacaagc ggtggagcat gtggtttaat 960
 tcgaagcaac gcgaagaacc ttaccaggtc ttgacatcct gtgacaatcc tagagatagg 1020
 acgtctctgg gggcagagtg acagtggtgt catgggtgtc gtcagctcgt gtcgtgagat 1080
 55 gttgggttga gtcccgcac gagegcaacc ctggatctta gttgccagca ttcagttcgg 1140
 cactcttaag tgactgccgg tgacaaaccc gaggaagggt gggatgacgt caaatcatca 1200

	tgcccccttat	gacctgggct	acacacgtgc	tacaatggac	agaacaaaag	gcagcgaaac	1260
	cgcgagggtta	agcacaatccc	acaaatctgt	tctcagttcg	gatcgagtc	tgcacactcga	1320
	ctgcgtgaag	ctggaatcgc	tagtaatcgc	ggatcagcat	gccgcggtgc	atacgttccc	1380
	gggccttgta	cacaccgcc	gtcacaccac	gagagttgt	aacacc		1427
5							
	<210> 24						
	<211> 1544						
	<212> DNA						
10	<213> <i>Bacillus anthracis</i>						
	<400> 24						
	gtttgatcct	ggctcaggat	gaacgctggc	ggcgtgccta	atacatgcaa	gtcagcgcaa	60
	tggattaaga	gcttgctctt	atgaaagttag	cggcggaagg	gtgagtaaca	cgtgggtaac	120
15	ctgcccataa	gactgggata	actccgggaa	accggggcta	ataccggata	acattttgaa	180
	ccgcgtggtt	cgaaattgaa	aggcggcttc	ggctgtcact	tatggatgga	cccgcgtcgc	240
	attagctagt	tggtgaggta	acggctcacc	aaggcaacga	tgctgagcgc	acctgagagg	300
	gtgatcgccg	acactgggac	tgagacacgg	cccagactcc	tacgggaggc	agcagtaggg	360
	aattcttcgc	aatggacgaa	agtcctgacg	agcaacgcgc	cgtgagtgat	gaagcgcttc	420
20	gggtcgtaaa	actctgttgt	taggggaagaa	caagtgtcag	ttgataaagc	tggcaccttc	480
	acggtagacta	accagaaagc	cacggctaac	tacgtgccag	cagccgcggt	aatacgttagg	540
	tggcaagcgt	tatccggaat	tattggcgct	aaagcgcgcg	cagtggtgtt	cttaagtcctg	600
	atgtgaaagc	ccacggctca	accgtggagg	gtcattggaa	actgggagac	ttgagtcgag	660
	aagaggaaag	tgaatttcca	tgtgtagcgg	tgaatcgct	agagatatgg	aggaacacca	720
25	gtggcggaag	cgactttctg	gtctgtaact	gacactgagg	cgcgaaagcg	tggggagcaa	780
	acaggattag	ataccctggg	agtcaccgcc	gtaaacgatg	agtgtctaag	gttagagggg	840
	ttccgcccct	tagtgctgaa	gttaacgcat	taagcactcc	gcctggggag	tacggccgca	900
	aggctgaaac	tcaaaaggaat	tgacgggggc	ccgcacaagc	ggtgaggcat	gtggtttaat	960
	togaagcaac	gcgaagaacc	ttaccaggct	ttgacatcct	ctgacaaccc	tagagatagg	1020
30	gctctctcct	cgggagcaga	gtgacagggtg	gtgcatgggt	tcgtcgactg	cgtgtcctgc	1080
	gatgttgggt	taagttccgc	aacgagcgca	acccttgatc	ttagttgcca	tcattaaagt	1140
	gggcactcta	aggtgactgc	cgggtgacaaa	ccggagggaag	gtggggatga	cgtcaaatca	1200
	tcatgccctt	tatgactcgg	gtcacacacg	tgctacaatg	gacggtacaa	agagctgcaa	1260
	gacgcgagg	tggagctaat	ctcataaaac	cgttctcagt	tcggattgta	ggctgcaact	1320
35	cgccatcatg	aagctggaat	cgctagtaat	cgcggatcag	catgcccgcg	tgaatacgtt	1380
	ccgcggcctt	gtcacacacg	cccgctcac	cacgagagtt	gttaacaccc	gaagtcgggt	1440
	gggtaacctt	tttgagacca	gccgcctaag	gtgggacaga	tgattggggg	gaagtcgtaa	1500
	caaggtagcc	gtatcgaag	gtgcggctgg	atcacctcct	ttct		1544
40							
	<210> 25						
	<211> 1449						
	<212> DNA						
	<213> <i>Enterococcus faecalis</i>						
45							
	<400> 25						
	cgaacgctgg	cygcgtgcct	aatacatgca	agtcgaacgc	ttctttctcc	cagagtgcct	60
	gcactcaatt	ggaaagagga	gtggcgggac	ggtagtaaac	acgtgggtaa	cctaccatcc	120
	agagggggat	aacacttgga	aacaggtgct	aataccgcgt	aacagtttat	gccgcattgc	180
50	ataagtagta	aaggcgcttt	cgggtgtcgc	tgatggatgg	accgcgggtg	cattagctag	240
	ttggtgaggt	aacggctcac	caaggccacg	atgcataagc	gacctgagag	gtgatcgcc	300
	cacactggga	ctgagacacg	ccccagactc	ctacgggagg	cagcagtagg	gaattcttcgc	360
	caatgagcga	aagtctgacc	gagcaacgcc	gcgtgagtag	agaaggtttt	cggaatcgtaa	420
	aaactctgtg	ttagagaaga	acaaggacgt	tagtaactga	acgtcccctg	acgtatctta	480
55	accagaaaag	cacggctaac	tacgtgccag	cagccgcggt	aatacgtagg	tggcaagcgt	540
	tgctccgatt	tatggggcgt	aaagcgagcg	caggcggttt	cttaagtctg	atgtgaaagc	600

ccccggtctca accggggagg gtcattggaa actggggagac ttgagtgacag aagaggagag 660
 tggaaattcca tgtgtagcgg tgaatgcgt agatataatgg aggaacacca gttggcgaagg 720
 cggctctctgt gctctgaact gacgcgtgagg ctgcaaaagcg tggggagacaa acaggattag 780
 ataccttggt atccacacgc gtaaacgatg agtgctaagt gtggagggt ttccgcccc 840
 5 cagtgcgtgca gcaaacgcgt taagcactcc gcctggggag taccgaccga aggttgaac 900
 tcaaggaaat tgacgggggc ccgcacaagc ggtggagcat gtggtttaat tcgaagcaac 960
 gcgaagaacc ttaccaggct ttgacatcct ttgaccactc tagagataga gctttccctt 1020
 cggggacaaa gtgacagggt gtgcattggt gtgcgcagct cgtgctgtag gatgtgggt 1080
 10 ttaagtcgcc aacgagcgca acccttattg ttagtgtcca tcatttagtt gggaactcta 1140
 cggagactgc cgggtgacaaa ccggaggaaag gtggggatga cgtaaatca tcactgccct 1200
 gctacactgg gctacacacg tgcataaatg ggaagtacaa cgagtcgcta gaccgcgagg 1260
 tcatgcgaat ctcttaaacg ttctctcagt tcggattgca ggctgcaact ccctcgactg 1320
 aagccggaat cgctagtaat cgcggatcag caccgcgcgg tgaatacgtt cccgggacct 1380
 15 gtacacaccc cccgtcacac caccagaggt ttgaacaccc gaagtcggtg aggttaacct 1440
 ttggagacc 1449

<210> 26
 <211> 1548
 20 <212> DNA
 <213> *Lactococcus lactis*

<400> 26
 25 ttattattgag agttttagtc tggctcagga cgaacgctgg cggcgctgct aatacatgca 60
 agtttagcgc tgaaggttgg tacttgtacc gactggatga gcagcgaagg ggtgagtaac 120
 gcgtggggaa tctgcctttg agcgggggac aacatttgga aacgaatgct aataccgat 180
 aaaaacttta aacacaagtt ttaagtttga aagatgcaat tgcatactc aaagatgatc 240
 ccgcgttgta tttagtagtt ggtgaggtaa aggcacacca aggcgatgat acatagccga 300
 30 cctgagaggg tgatcgggca cattgggact gagacacggc ccaaacctct acgggaggca 360
 gcagtaggga atcttcggca atggacgaaa gtctgaccga gcaacgcgc gtgagtgaag 420
 aaggttttcg gatcgtaaaa ctctgtgtgt agagaagaac gttggtgaga gtggaaagct 480
 catcaagtga cggtaactac ccagaaaggg accgctaact acgtgccagc agccgcggtta 540
 atacgtaggt ccgagcggtt gtccggattt attgggcgta aagcgagcgc aggtggttta 600
 35 ttaagtctgg tgtaaaaggc agtggctcaa ccattgtatg cattggaaac ttgtagactt 660
 gagtgcagga gaggagagtg gaattccatg ttagcggttg aaa tgcgtag atataaggag 720
 gaacacggtt gggcgaaggc gctctctggc ctgtaactga cactgagctt cgaaagcgtg 780
 gggagcaaac aggtattgat accctggtag tccacgcgct aaacgatgag ttagtagatg 840
 agggagctat agttctctgt tatcgagct aacgcaataa gcactccgc ttggggagtag 900
 40 gaccgcgaag ttgaactca aaggaattga cgggggccc cacaagcggt ggagcatgtg 960
 gtttaactgt aagcaacgcg aagaacctta ccaggtcttg acatactcgt gctatctcca 1020
 gagataggaa gtctcttcgg gacacgggat acaggtggtt catggtgtgc gtcagctcgt 1080
 gtctggagat gttgggttaa gtcccgcaac gagcgcaacc cctattgtta gttgcatac 1140
 ttaagtggg cactctaacg agactgcggc tgaataacgg gaggaagggt gggatgact 1200
 45 caaatcatca tgccccttat gacctggggt acacacgtgc tacaattggt ggtacaacga 1260
 gtccgagagc agtgatggtt agctaacttc ttaaaacatc tctcagttcg gattgtaggc 1320
 tgcacactgc taccatgaag tcggaatcgc tagtaatcgc ggatcagcac gcccggtgga 1380
 atacgtctcc gggccttgta cacacgcccc gtccacaccc gggagttggg agtaccgaa 1440
 gttaggtgcc taaacgcaag gagggcgctt cctaaggtaa gaccgatgac tggggtgaag 1500
 50 tctaacaag gttagcggtat cgggaaggtc ggtggatga cctccttt 1548

<210> 27
 <211> 1524
 <212> DNA
 55 <213> *Listeria monocytogenes*

	<400> 27	
	gacctgcaggt cgacaacaga gtttgatcat ggtcaggac gaacgtggc ggcgtgcta 60	
	atacatgcaa gtcgaacgaa cggagggaaga gcttgctctt ccaaagttag tggcggacgg 120	
5	gtgagttaaca gtcggggcaac ctgcctgtaa gttggggata actccgggaa accgggcta 180	
	ataccgaagt atcaagtggt gcgcgatcca cgcttttgaa agatcggttc ggctatcgct 240	
	tacagatggg ctcggcggtgc attagctagt tggtagggta atggcctacc aaggcaacga 300	
	tgcatagccg acctgagagg gtgatcgccc acactgggac tgagacacgg cccagactcc 360	
	tacgggaggg agcagtaggg aatcttccgc aatggacgaa agtctgacgg agcaacggcg 420	
10	cggtgatgaa gaaggttttc ggatcgtaaa gtactgtgt tagagaagaa caaggataag 480	
	agtaactgct tgtcccttga cggatcttaa ccagaaagcc accgctaact acgtgccagc 540	
	agccgcggta atacgtaggt ggcaagcggt gtccggattt attggcgcta aagcgcgcgc 600	
	agcggctctt ttaagtctga tgtgaagcc ccggcttaa ccggggaggg tcattggaaa 660	
	ctggaagact ggaagtgcga agaggagagt ggaattccac gtgtagcggt gaaatcgta 720	
15	gatatgtgga ggaacaccag tggcgaaggc gactctctgg tctgtaactg acgtgaggg 780	
	gcgaaagcgt ggggagcaaa caggattaga taccctggta gtccacggcg taaacgatga 840	
	gtgctaagtg ttaggggggt tccgcccctt agtgcctgac ctaacgcatt aagcactctg 900	
	cctggggagt acgaccgcaa ggttgaaact caaaggaatt gacggggccc cgcacaagcg 960	
	tggagcatgt ggtttaaatt gaagcaacgc gaagaacctt accaggtctt gacactcttt 1020	
	gacactctgt gagacagagc ttccctctcg ggacaagtgt acaggttggt catggttgtc 1080	
20	ctcagctcgt tctgtgagat gttgggttaa gtcccgcac gagcgcaacc ctgatttta 1140	
	gttgccagca tttagtggg cactctaaag tgaactgcgg tgcaagccga tgcgtagctg 1200	
	gatgacgtca aatcatcatg ccccttatga cctgggctac acacgtgcta caatgtagat 1260	
	tacaaagggg cgcgaagccg cggagtgagg ctaatcccat aaaactattc agtcttcgga 1320	
	ttgtagcgtg caactcgctt acatgaagcc ggaatcgcta gtaatcggt atcagcatgc 1380	
25	cagggtgaat agcttcccgg gcctgtgaca caccgccggt cacaccacga gattttgtaa 1440	
	caccggaagt cggtagggta acctttatgg agccagccgc cgaaggtggg acagataatt 1500	
	gggtggaagt cgtaacaagg taaa 1524	
30	<210> 28	
	<211> 1555	
	<212> DNA	
	<213> Staphylococcus aureus	
35	<400> 28	
	ttttatggag agtttgatcc tggctcagga tgaacgtgg cgcgctgctt aatacatgca 60	
	agtcgagcga accgacgaga agcttgcctc tctgatgtta gcggcgagcg ggtgagtaac 120	
	acgtggataaa cctacctata agactgggat aacttcggga aaccggagct aataccggat 180	
	aaatttttga accgcatggt tcaaaagtga aagacggtct tgctgtcact tatagatgga 240	
40	tcgcgctcgc attagctagt tggtaaggta acggtcttacc aaggcaacga tgcgtagcgg 300	
	acctgagagg gtgatcgccc acactggaac tgagacacgg tccagactcc tacgggaggg 360	
	agcagtaggg aatcttccgc aatggcgcaa agcctgacgg agcaacggcg cgtgagtagt 420	
	gaaggtcttc tagctgtaaa actctgttat taggaaagaa atcatgtgta agtaactgtg 480	
	cacatcttga cggtaacctaa tcagaaagcc acggtcaact acgtgccagc agccgcggta 540	
45	atacgtaggt aggaacggtt attccggaatt attggcgcta aagcgcgcgt aggcggtttt 600	
	ttaagtctga tgtgaaagcc cacggctcaa ccgtggaggg tcattggaaa ctggaaaaact 660	
	tgaagtgcaga agagaaaggt ggaattccat gtgtagcggg gaaatgcgca gagatatgga 720	
	ggaacaccag tggcgaaggc gactttctgg tctgtaactg acgctgatgt gcgaaagcgt 780	
	ggggatcaaa caggattaga taccctggtg gtccacggcg taaacgatga gtctaatgtg 840	
50	ttagggggtt tccgcccctt agtgcctgac ctaacgcatt aagcactccg cctggggagt 900	
	acgaccgcga ggttgaaact caaaggaatt gacggggacc cgcaacgctg agtgagcatg 960	
	tggtttaaatt cgaagcaacg cgaagaacct taccaaactc tgacactcct tgacaactct 1020	
	agagatagag ccttcccctt cgggggacaa agtgacaggt ggtgcatggt tgtcctcagc 1080	
	tcgtgtcgtg agatgttggg ttaagtcccg caacgagcgc aacccttaag cttagttgcc 1140	
55	atcattaaat tgggcaactc aagttgactg ccggtgacaa accggaggaa ggtggggagt 1200	
	acgtcaaatc atcatgcccc ttatgatattg ggtcacacac gtgctacaa gtgctacaa 1260	

	aaggcgagcg	aaaccgagcg	gtcaagcaaa	tcccataaag	ttgtttctcag	ttcggtattgt	1320
	agctctgaac	tcgactacat	gaagctggaa	tcgctagtaa	tcgtagatca	gcattgctacg	1380
	gtgaatacgt	tcgccgggat	tgtacacacc	gcccgctaca	ccacgagagt	ttgtaacacc	1440
	cgaagccggg	ggagtaacct	tttaggagct	agccgtcgaa	ggtgggacaa	atgatggggg	1500
5	tgaagtcgta	acaaggtagc	cgtatcggaa	ggtgcggctg	gatcacctcc	ttctct	1555
	<210> 29						
	<211> 1551						
10	<212> DNA						
	<213> Streptococcus mutans						
	<400> 29						
	agagtttgat	cctgggctcag	gacgaacgct	ggcggcgctgc	ctaatacatg	caagtgaggac	60
15	gcaaggaaac	acactgtgct	tgacacccgt	gttttcttga	gtcgcgaacg	ggtgagtaac	120
	gcgtatgtaa	cctgcctatt	agcgggggat	aactattgga	aacgatagct	aataccgcat	180
	aatattaact	attgcatgat	aattgattga	aagatgcaag	cgcataccta	tgatagggac	240
	ctcgcgtgta	tgatctagtt	ggtaaggtaa	gagcttacca	aggcgacgat	acataccgca	300
	ccgtgagggg	atctcggcca	cactgggact	gagacacggc	ccagactcct	acgggagagca	360
20	gcagtaggga	atctcggcca	atggacgaaa	gtctgacgga	gcaacgcgcg	gtgtaggaag	420
	aagggttttcg	ctcgttaaag	ctctgttgta	agtcagaagc	gtgtgtgaga	gtggaaagtt	480
	cacacagtga	cggtagctta	ccagaaaggg	acggctaact	acgtgccacg	agccgcggta	540
	atacgtaggt	cccgagcgtt	gtccggattt	attgggcgta	aagggagcgc	agggcggtcag	600
	gaaagtctcg	agtaaaaggc	tatggctcaa	ccatagtgtg	ctctggaaac	tgtctgactt	660
25	gagtgacagaa	ggggagagtg	gaattccatg	tgtagcgggtg	aaatgcgtag	atataaggag	720
	gaacaccagt	ggcgaaagcg	gctctctgtg	ctgtcactga	cgctgaggct	cgaaagcggtg	780
	ggttagcgaa	aggtattgat	accctggtag	tccacgcgtt	aaacgatgag	tgctaggtgt	840
	tagggcccttt	ccggggccta	gtgccggagc	taacgcaata	agcactccgc	ctggggagta	900
	cgaccgcaag	gttgaaactc	aaaggaattg	acggggggccc	gcacaagcgg	tgaggacatg	960
30	gggttaaatc	agagcaacgc	gaagaacctt	accaggctct	gacatcccca	tgctattctt	1020
	agagatagga	agttactctg	gtacatcgga	gacagggtgt	gcattgggtg	cgtagctctg	1080
	tgtcgtgaga	tgttgggtta	agtcgcccaa	cgagcgcaac	ccttattgtt	agttgccatc	1140
	attaagttgg	gcactctagc	gagactgccg	gtaataaacc	ggaggaaagg	ggggtagtagc	1200
	tcaaatcatc	atgcccccta	tgacctgggc	tacacacgtg	ctacaatggt	cggtacaacg	1260
35	agt tgcagc	cggtgacggc	aagctaactc	ctgaaagccg	atctcaatgt	ggatttgaggg	1320
	ctgcaactcg	ctccatgaa	gtcggaatcg	ctagtaatcg	cggtagcgca	cgccgcggctg	1380
	aatacgttcc	cgggccctgt	acacacgcgc	cgtagcaccg	cgagagtttg	taacaccgca	1440
	agtcggtgag	gtaacctttt	aaggggcaag	ccgcctaagg	tgggatgtag	gattgggggtg	1500
40	aagtcgtaac	aaggtagcgg	tatcggaagg	tgcgctggga	tcacctctct	t	1551
	<210> 30						
	<211> 1515						
	<212> DNA						
45	<213> Streptococcus pneumoniae						
	<400> 30						
	atttgatcct	ggctcaggac	gaacgctggc	ggcgtgccta	atacatgcaa	gtagaacgct	60
	gaaggagggg	cttgctcttc	tggaatgagt	gcgaaagggt	gagtaacgcg	tagtgaacct	120
50	gctcgttagc	gggggataac	tattggaaac	gatagctaact	accgcataag	agtggaatgt	180
	gcatacacatt	tgcttaaaag	gtgcacttgc	atcatacca	gatggacctg	cgctgtatta	240
	ctgagttggt	gggggtaacg	ctcaccgaag	cgacgatata	tagccgacct	gagagggtga	300
	tcggccacac	ggggactgag	acacgkccca	gactcctacg	ggaggcgagca	gtagggaact	360
	ttcgccaatg	gacggaagtc	tgaccgagca	acgcccgcgt	agtgaagaag	gttttccgat	420
55	cgtaaaagtc	tggttgtaaga	gaagaacgag	tgtgagagtg	gaaggtccac	gctgtgacgg	480
	tatcttacca	gaaaggagcg	gctaactacg	tgccagcagc	ggcggttaata	cgtaggtccc	540

	gagcgttgctc	cggatttatt	ggcgtaaa	cgagcgagg	cggtagata	agtctgaagt	600
	taaaggctgt	ggcttaacca	tagtaggctt	tggaactgt	ttaacttgag	tgcaagaggg	660
	gagagtgaa	ttccatgtgt	agcggtgaaa	tgcgtagata	tatggaggaa	caccggctggc	720
	gaaagcgctt	ctctggcttg	taactgacgc	tgaggctcga	aagcgggggg	agcaaacagg	780
5	attagatacc	cttgtagtcc	acgctgtaaa	cgatgagtcg	taggtgttag	accctttccgc	840
	gggtttagtg	cgtagcttaa	cgcattaaag	actccgctcg	gggagtagca	cgcgaagggt	900
	gaaactcaaa	ggaattgacg	ggggcccgca	caagcgggtg	agcatgtggt	ttaatcgaa	960
	gcaacgcgaa	gaaccttacc	aggtcttgac	atccctctga	cgcctctaga	gatagagttt	1020
	tccttcggga	cagaggtgac	aggtggtgca	tggttgctgt	cagctcgtgt	cgtgagatgt	1080
10	tgggttaagt	ccgcgaacga	gcgcaacccc	tattgttagt	tgccatcatt	cagttggggc	1140
	ctctagcag	actgccggta	ataaacccga	ggaaggtggg	gatgacgtca	aatcatcatg	1200
	ccctctatga	cctgggtctac	acaegtgtcta	caatggctcg	tacaacgagt	cgcgaacccg	1260
	tgacggcaag	ctaactctct	aaagccagtc	tcagttcgga	ttgtaggctg	caactcgctt	1320
	acatgaagtc	ggaatcgcta	gtaatcgcg	atcagcacgc	cgcggtgaa	acgttccccg	1380
15	gccttgtaca	caccgccctg	cacaccaaga	gagtttgtaa	cacccgaa	cggtaggga	1440
	accgtaagga	gccagccgcc	taaggtggga	tagatgattg	gggtgaagtc	gtacaacagt	1500
	cagccgtttg	ggaga					1515
20	<210> 31						
	<211> 1335						
	<212> DNA						
	<213> Streptococcus pyogenes						
25	<400> 31						
	gaacgggtga	gtaacgcgta	ggtaacctac	ctcatagcgg	gggataacta	ttggaaacga	60
	tagctaatac	cgcataagag	agactaacgc	atgttagtaa	tttaaaaggg	gcaattgtct	120
	cactatagaga	tggacctcg	ttgtattagc	tagttggtga	ggtaaaagct	caccaaggcg	180
	acgatacata	gccgacctga	gaggggtgatc	ggccacactg	ggactgagac	acggcccaga	240
30	ctccacaggg	aggcagcagt	agggaaatctt	cggaatggg	ggcaaccctg	accgagcaac	300
	gccgcgtgag	tgaagaaggt	tttcggatcg	taaaactctg	ttgttagaga	agaatgatgg	360
	tgggagtggga	aaatccacca	agtgaacgga	actaacccga	aagggagcgc	taactacgtg	420
	ccagcagccg	cggttaatac	taggtcccgga	gcgttgctcg	gatttattgg	gcgtaaagcg	480
	agcgagggcg	gttttttaag	tctgaagtta	aaggcattgg	ctcaaccaat	gtacgctttg	540
35	gaaactggag	aacttgagtg	cagaagggga	gagtggaatt	ccatgtgtag	cgggtgaaatg	600
	ctgagatata	tggaggaaaca	ccggtggcgga	aagcggtctt	ctggtctgta	actgacgctg	660
	aggctcgaaa	cggtggggag	caaacaggat	tagataccct	ggtagtccac	gccgtaaacg	720
	atgagtgcta	ggtgttagcg	ctttccggg	gcttagtgcc	ggagctaaac	cattaaacac	780
	tcgcctcggg	gagtagcacc	gcaaggttga	aactcaaggg	aattgacggg	ggcccgcaca	840
40	agcggtggag	catgtggttt	aattcgaaag	aacgggaaga	acctaccag	gtcttgacat	900
	cccgatgcc	gctctagaga	tagagtttta	cttcggtaca	tcggtgacag	gtgggtgatg	960
	gttgtgtgca	ctctgtgtcg	tgagatgttg	ggtaagttcc	cgcaacgagc	gcaacctcca	1020
	ttgttagttg	ccatcattaa	gttgggcact	ctagcgagac	tgccggtaat	aaacccgagg	1080
	aaggtggggga	tgacgtcaaa	tcactcatgcc	ccttatgacc	tgggctcacac	acgtgtctaca	1140
45	atggttggtga	caaocagtcg	caagccgggtg	acggcaagct	aactctttaa	agccaattctc	1200
	agttcgagatt	gttaggttgca	actcgctcac	atgaagtccg	aatcgctagt	aatcgcgagt	1260
	cagcacgcgc	cgggtgaatac	gttcccgggc	cttgtagaca	cgcgccgtca	caccacagga	1320
	gtttgttaaca	cccgga					1335
50	<210> 32						
	<211> 1465						
	<212> DNA						
	<213> Mycobacterium avium						
55	<220>						

<221> modified_base
 <222> (298) .. (881)
 <223> N = A, C, G or T/U

5 <400> 32
 ggcgcgctgc ttaacacatg caagtcgaac ggaagggcct ctccggaggt actcagatgg 60
 cgaacgggtg agtaaacagt gggcaatcta cctcgcactt cgggataaag ctggggaact 120
 gggcttaata ccggatagga cctcaagacg catgtcttct ggtggaagc ttttcggtg 180
 tgggatgggc ccgcggccta tcagcttggt ggtgggtgta cgccctacca aggcgacgac 240
 10 gggtagccgg cctgagaggg tgcctggcca cactgggact gagatacgg ccagactnct 300
 acgggaggca cagatgggga atattgcaca atgggcgcaa gcctgatgca gcgacggcgc 360
 gtgggggatg acggccttcg ggttgtaaac ctctttcacc atcgacgaag gtccgggttt 420
 tctcggattg accgtaggtg gagaagaagc accggccaac tacgtgccag cagccggcgt 480
 aatacgtagg gtgcgagcgt tgcctgggaat tactgggcgt aaagagctcg taggtggttt 540
 15 gtgcgcttgt tcgtgaaatc tcacggctta actgtgagcg tgcgngcgat accggcgagc 600
 tagagtactg caggggagac tggaaattcct ggtgtagcgg tggaaatgcgc agatatcagg 660
 aggaacacccg gtggcgaaag cgggtctctg ggcagtaact gacgctgagg agcgaagcgc 720
 tggggagagca acagattag ataccctgggt agtccacgnc gtaaacgggt ggtactaggt 780
 gtgggttttc tctctggga tccgtgcggt agctaacgca ttaagtaccc cgcctgggga 840
 20 gtacgcnccg aaggctaaaa ctcaaaaggaa ttgacggggg nccgcacaa cgccggagca 900
 tctgattaaa tctgatgcaa ccgcaagaac ctacactggg ttgacatgc acaggacgcg 960
 tctagatgaa ggcgttcctt tctggcctgt gtgcaggtgg tgcattggct tcgtcagctc 1020
 gtgtcgtgag atgttgggtt aagtcgccga acgacgcgca cccttgcttc atgttgccag 1080
 25 cgggtaatgc cggggactcg tgaagactg ccggggccta ctcggggaaa ggtggggatg 1140
 acgtcaagtc atcatgcccc ttatgtccag ggcttcacac atgctacaat ccgcggtaca 1200
 aagggtctgc atccgctaag gtaagcgaa tcttttaaa gccggttcta gttccggattg 1260
 gggctctgca atcgaccaca tgaagtcgga gtgcgtagta atcgacagt acacacgctg 1320
 cgttgaaatc gttccggggc cttgtacaca ccgcccgtca cgtcatgaaa ctgggtaaca 1380
 cccgaagcca gtggcctaac ccttttggga gggagctgtc gaaggtggga tcggcgattg 1440
 30 ggacgaagtc gtaacaagggt agccg 1455

<210> 33
 <211> 1536
 35 <212> DNA
 <213> Mycobacterium tuberculosis

<400> 33
 40 tttgtttgga gagtttgatc ctggctcagg acgaacgctg gcggcgtgct taacacatgc 60
 aagtcgaagc gaaaggtctc ttccgagata ctgcagtggt gaacgggtga gtaacacgtg 120
 ggtgatctgc cctgcacttc gggataaagg tgggaaactg ggtctaatac cggataggac 180
 cacgggatgc atgtcttggt ttggaagaagc ctttagcggt gtgggatgag ccgcggcct 240
 atcagcttgt tgggtgggtg acggcctacc aaggcgacga cttgtagcgg gcctgagagg 300
 gtgtccggcc acactgggac tgagatacgg ccagactccc tactgggggg agcagtgagg 360
 45 aatattgcac aatgggcgca agcctgatgc agcgacgcgg cgtgggggag cagcgctctc 420
 ggggtgtaaa cctctttcac catcgacgaa ggtccgggtt ctctcggatt gacggtaggt 480
 ggagaagaag cacccggcaa ctacgtgcca gcagccgcg taatacgtat ggtgcagcgg 540
 ttgtccggaa ttaactgggcg taaagagctc gtagggtggt tgcgcgcttg ttcgtgaaat 600
 ctacggcttc aactgtgagc gtgcgggcga tactgggcga ctagatgact gcaggggaga 660
 50 ggtgaattcc tgggtgagcg gtggaatgag cagatatac gaggaacacc ggtggcgaag 720
 cggggtctct gggcagtaac tgacgtgag gacggaagc gtggggagcg aacaggatta 780
 gataccctgc tagtccacgc cgtaaacggt ggttactagg tgtgggtttc ctctccttgg 840
 atccgctcgg taagtaacgc attaaagtacc ccgcctgggg agtacggccc agagctaaa 900
 actcaagga attgacgggg gcccgacaaa gcggcgagc atgtgatta attcgtatga 960
 55 accgcaagaa ccttaactcg gtttgacatg cacaggacgc gcttaagatg agcgattccc 1020
 ttgtggcctg tgtgcagggt gtgcattgggt gtgcctcagc cgtgtcgtga gatgttgggt 1080

	taagtcgccg	aacgagcgca	acccttgtct	catgttgcca	gcaagtaatg	gtggggactc	1140
	gtgagagact	gcgcgggtca	actcggagga	aggtggggat	gaagtcgaat	catcatgcc	1200
	cttatgtcca	gggcttcaca	catgctacaa	tggcgggtac	aaagggctgc	gatgccgcga	1260
	ggtaagcgca	atccttaaaa	gcgggtctca	gttcggatcg	gggtctcgaa	ctcgaccccg	1320
5	tgaagtcgga	gtcgcctagta	atcgcagatc	agcaacgcgt	cggtgaatac	gttcccgggc	1380
	cttgtacaca	cgcgccgtca	cgtcatgaaa	gtcggtaaca	ccggaagcca	gtggcctaac	1440
	cttcgggagg	gagctgtcga	aggtgggatc	ggcgattggg	acgaagtcgt	aacaaggtag	1500
	ccgtaccgga	aggtgcggt	ggatcacctc	ctttct			1536
10	<210>	34					
	<211>	1536					
	<212>	DNA					
	<213>	<i>Escherichia coli</i>					
15	<400>	34					
	ttgtttgga	gagtttgatc	ctggctcagg	acgaacgcgt	gcggcgctgt	taacacatgc	60
	aagtgcgaacg	gaaaggtctc	tccggagata	ctcgagtgcc	gaacgggtga	gtaaacactg	120
	gggtgctctgc	ctcgcacttc	gggataagcc	tgggaaactc	ggctctaatac	cggataggac	180
20	cacgggatgc	atgtcttgtg	gtggaaagcg	ctttacgcgt	gtgggatgag	cccgcgccct	240
	atagctctgt	tgggtgggtg	acggcctacc	aaggcgacga	cgggtagccg	gcctgagagg	300
	gtgtccggcg	acactgggac	tgaatcacgg	ccgagactcc	tacggggagg	agcagtgagg	360
	aatctgcac	aatgggcgca	agcctgatgc	agcgacgcgc	cgtgggggat	gacggccttc	420
	gggttgtaaa	cctctttcac	catcgacgaa	ggtccgggtt	ctctcggtat	gacggtagg	480
25	ggagaagaag	cacggcccaa	ctacgtgcca	gcagccgcgg	taatacgtag	ggtgcgagcg	540
	ttgtccggaa	tactggggcg	taaaagatcc	gtaggtgggt	tgtcgcgttg	ttcgtgaaat	600
	ctcacggctt	aactgtgagc	gtgcggggcg	tacgggcaga	ctagagtact	gcagggggaga	660
	ctggaaattcc	tgggtgtagcg	gtggaatgcg	cagatatcac	gaggaacacc	ggtggcggaag	720
	gcgggtctct	gggcagtaac	tgcagctgag	gagcgaaagc	gtggggagcg	aacaggatta	780
30	gataccctgg	tagtccacgc	cgtaaacggt	gggtactagg	tgtgggtttc	cttcttggg	840
	atccgtgccg	tagctaacgc	attaaagtacc	ccgcctgggg	agtcacggcg	caaggctaaa	900
	actcaaaagg	attgacgggg	gcccgacaaa	gcggcggaag	atgtggatta	attcgatgaa	960
	acgcgaagaa	ccttacctgg	gtttgacatg	cacaggacgc	gtctagagat	agcggtccc	1020
	ttgtggcctg	tgtgcaggtg	gtgcatggct	gtcgtcagct	cgtgtcgtga	gatgtgggt	1080
35	taagtccgcg	aacgagcgca	acccttgtct	catgttgcca	gcaagtaatg	gtggggactc	1140
	gtgagagact	gcgcgggtca	actcggagga	aggtggggat	gaagtcgaat	catcatgcc	1200
	cttatgtcca	gggcttcaca	catgctacaa	tggcgggtac	aaagggctgc	gatgccgcga	1260
	ggtaagcgca	atccttaaaa	gcgggtctca	gttcggatcg	gggtctcgaa	ctcgaccccg	1320
	tgaagtcgga	gtcgcctagta	atcgcagatc	agcaacgcgt	cggtgaatac	gttcccgggc	1380
40	cttgtacaca	cgcgccgtca	cgtcatgaaa	gtcggtaaca	ccggaagcca	gtggcctaac	1440
	cttcgggagg	gagctgtcga	aggtgggatc	ggcgattggg	acgaagtcgt	aacaaggtag	1500
	ccgtaccgga	aggtgcggt	ggatcacctc	ctttct			1536
45	<210>	35					
	<211>	1534					
	<212>	DNA					
	<213>	<i>Klebsiella pneumoniae</i>					
50	<220>						
	<221>	modified base					
	<222>	(11) .. (12)					
	<223>	N = A, C, G or T/U					
55	<400>	35					
	agagtttgat	nntggtctag	attgaacgct	ggcgccaggc	ctaacacatg	caagtcgagc	60

5 ggtagcacag agagcttgct ctccgggtgac gagcggcgga cgggtgagta atgtctggga 120
 aactgcctga tggaggggga taactactgg aaacggtagc taataccgca taacgtcgca 180
 agaccaaaagt gggggacctt cgggcctcat gccatcagat gtgccagat gggattagct 240
 agtaggtggg gtaaacggctc acctaggcga cgtaccctag ctggctctgag aggtagacca 300
 10 gccacacttg gcaatgagaca cgtccagacg tctacgggga ggacagcagt gggaatattg 360
 cacaaatgggg aacagcctga tgcagccatg ccgcgtgtgt gaagaaggcc ttccgggttgt 420
 aaagcacttt cagcggggag gaaggcgatg aggttaataa cctcatcgat tgacgtttac 480
 ctgcagaaga agcaccggct aactccgtgc cagcagccgc ggtaatacag aggggtcaag 540
 cgttaatcgg aattactggg cgtaaagcgc acgcaggcgg tctgtcaagt cggatgtgaa 600
 15 attcccgccc ctggacaaag aactcgattc gaaactggca ggctagagtc ttgtagagagg 660
 gggtagaatt ccaggtgtag cggtgaaatg cgtagagatc tggaggaata ccggtgcgca 720
 aggcggccccc ctggacaaag actgacgctc aggtgcgaaa cgtgggggag caaacaggat 780
 tagatacctt ggtagtcac gccgtaaacg atgtcgattt ggaggtttgt ccttgaggcg 840
 gtggcttcgg gagctaacgc gttaaatcga ccgcctgggg atgtacggcg caaggttaaa 900
 20 actcaaatga attgacacgc gccgcacaa cgggtggagc atgtggttta attcgatgca 960
 acgcgaagaa ctttacctgg tcttgacatc cacagaactt tccagagatg gattggtgcc 1020
 ttccggaaact gttgacagag tctgtcatgg ctgctgttag atgtggttga gaaatgttgg 1080
 gtttaagtcgc gcaacgagcg caacctttat cctttgttgc cagcggttag gccgggaact 1140
 caaaggagac tgcagctgat aaactggagg aaggtgggga tgagctcaag tcactatggc 1200
 25 ccttacgacc agggctacac acgtgttaca atggcatata caaagagaag gcacctcgcg 1260
 agagcaagcg gacctcataa agtatgtctg agtcggagtt ggaagtctga actcgatccc 1320
 atgaagtcgg aatcgttagt aatcgttagt cagaatgcta cgggtgaata gtctccgggc 1380
 cttgtacaca ccgcccgcca caccatggga gtgggttgca aaagaagtga gatcgttaac 1440
 cttcgggagg gcgcttacc ctttgtgatt catgactggg gtgaagtcgt aacaaggtaa 1500
 25 ccgtagggga acctcgcggt ggaacacctt cttt 1534

<210> 36
 <211> 1485
 30 <212> DNA
 <213> ACTINOBACILLUS ACTIN

<220>
 <221> modified_base
 35 <222> (208) ..(1476)
 <223> N = A, C, G or T/U

<400> 36
 40 attgaagagt ttgatcatgg ctacagattga acgtggcgg caggcttaac acatgcaagt 60
 cggacggtag caggagaaag cttgctttct tctgacgag tggcggacgg gtgagtaattg 120
 cttgggaatc tgtcttatgg agggggataa cgacgggaaa ctctgcgtaa taccgcgtag 180
 agtcgggaga cgaaagtgcg ggaacttntg ccgcgatgcc atgagatgag cccaagtgtg 240
 attagtagt tgggtgggga aaggcctacc aagccgacga tgcgtactgt gtctgagagg 300
 atggccagcc acaccgggac tgagacacgg ccncaactcc tacgggagcg cagcagtggg 360
 45 aatatgtgcg aatgggggca accctgacgc agccatgccg cgtgaatgaa gaaggccttc 420
 ggggtgtgaa gttctttcgg tattgaggaa ggttggtgtg ttaatagcat gccaaattga 480
 cgtttaaatc agaagaagca ccgcctaact ccgtgccagc agcccggtta tacggggggg 540
 tgcgagcggtt aactcggaata actgggcgta aagggcacgt agccggagct ttaagttagg 600
 50 tgtgaaatcc ccgggcttaa cctgggnatt cgatttcaat ctgggggtct gtagtacttt 660
 ngggagggnt agaattccac gtgtagcgtt gaaatgcgta gagatgtgga ggaataccga 720
 aggcgaaggg agccccttgg ggaatgactg acgctgatgt gcgaaagcgt ggggagcaaa 780
 caggatgata taacctggta gtccacgctg taacagggtg cgatttgggg attgggggtt 840
 agccctgggt ccggaagcta acgtgataaa tcgacgcctc ggggagtagc gccgcaaggt 900
 55 taaaactcaa atgaattgac gggggccccc acaagcgggt gagcatgtgg ttaattcga 960
 tgcaaccgca agaaccttac ctactcttga catccgaaga agaaactcga gatgggtttg 1020
 tgccttaggg agctttgaga cagggtgtgc atggcngtcg tcagctcgtg ttgtgaaatg 1080

ttgggttaag tcccgcaacg agcgcaaccc ttatcctttg tggccagcga cgtggtcggg 1140
 aactcaaaag agactgcggg tgataaaccc gaggaagggt gggatgacgt caagtcatca 1200
 tggcccttac tagtaggggt acacacgtgc tacaatggcg tatacagaggt gtaaccaacc 1260
 agcgatgggg agtgaatctc agaaagtgcg tctaagttcg gattggagtc tgcaactcga 1320
 5 ctccatgaag tcggaatcgc tagtaatcgc gaatcagaat gttgcgggtg atacgttccc 1380
 ggcgcttgta cacaccgccc gtcacaccat gggagtgggt tgtaccagaa gtggtatagct 1440
 gaaccgagag ggtggcgctt accacgggtat gattcangac tgggg 1485

10 <210> 37
 <211> 1487
 <212> DNA
 <213> Haemophilus influenzae

15 <220>
 <221> modified_base
 <222> (1)..(1387)
 <223> N = A, C, G or T/U

20 <400> 37
 naattgaaga gtttgatcat ggctcagatt gaacgctggc ggcaggctta acacatgcaa 60
 tgcgaacgggt agcaggagaa agcttgcctt ctgtctgacg agtggcggac gggtagtaaa 120
 tgcctgggaa tctggcttat ggagggggat aacgacggga aactgtcgct aataccgcgt 180
 attatcgga gatgaagtgc cgggaactgag aggcgcgatg ccatagaggt agcccaagtgt 240
 25 ggaattagga ttgtgtgggg taaatgccta ccaagcctgc gatctctagc tggctctgaga 300
 ggaatgaccag ccacactgga actgagacac ggtccagact cctacgggag gcagcaggtg 360
 ggaattatgc gcnatggggg gaacctgac gcagccatgc cgcgtgaatg aagaaggcct 420
 tccggttgta aagtctcttc ggtattgagg aagggtgatg tgttaatagc acatcaaat 480
 gacgttaaat acagaagaag caccggctaa ctccgtgccca gcagccggcg taatacggag 540
 30 ngtgcgagcg ttaatcgaa taactgggag taaagggcac gcaggcggtt atttaagtga 600
 ggtgtgaaag ccccgggctt aacctgggna ttgcatttca gactgggtaa ctagagtaact 660
 ttaggggggg gtgaatttcc acgtgtagcg gtgaatgcg tagagatgtg gaggaatacc 720
 gaaggcgaag gcagccctct gggaatgtac tgacgctcat gtgcgaaagc gtggggagca 780
 aacaggatta gataccctgg tagtccacgc tgtaaacgct gtcgatttgg ggggttgggt 840
 35 ttaactctcg caccctgacg taactgtgata aatcgacgcg ctggggagta cgcccgcaag 900
 gttaaaactc aaatgaattg acggggggccn gcacaagcgg tggagcatgt ggtttaattc 960
 gatgcaacgc gaagaacctt acctactctt gacatcctaa gaagagctca gagatgagct 1020
 tgtgcttcg ggaacttaga gacaggtgct gcatggctgt cgtcagctgt tgtgtgtaaa 1080
 tgttgggtta agtcccgcaa cgagcgcaac ccttatcctt tgttgcacag gacttggctg 1140
 40 ggaactcaaa ggagactgcc agtgataaac tggaggaaag tggggatgac gtcaagtcat 1200
 catggccctt acgagtaggc ctacacacgt gctacaatgg cgtatacaga gggaagcgaa 1260
 gctgcgaggt ggagcgaatc tcataaagta cgtctaagtc cggattggag tctgcaactc 1320
 gactccatga agctcggaatc gctagtaatc gcgaatcaga atgtcgcggt gaatacgttc 1380
 ccgggcnctg tacacaccgc ccgtcacacc atgggagtggt gttgtaccag aagtagatag 1440
 45 cttaacccctt tggagggcgt ttaccacggt atgattcatg actgggg 1487

<210> 38
 <211> 1532
 50 <212> DNA
 <213> Bordetella bronchiseptica

<400> 38
 tgaactgaag agttttagtcc tggctcagat tgaacgctgg cgggatgctt tacacatgca 60
 55 agctcgagcgt cagcagcggc ttccgctctg tggcgagtg cgaacgggtg agtaagtgt 120
 cggaaactgc ccagtagcgg gggataacta cgcgaaagcg tggctaatac cgcatacgcc 180

	ctacgsgggga	aagcggggga	ccttcggggc	tcgcactatt	ggagcggcgg	atatcggaatt	240
	agctagttgg	tggggtaaac	gcctaccaag	gcgacgattc	gtagctgggt	tgagaggagc	300
	accagccaca	ctggggactga	gacacggccc	agactcctac	gggaggcagc	agtcgggaat	360
5	ttgggcaaat	ggggggcaacc	ctgattccagc	catcccgctg	gtgcgatgaa	ggccttcggg	420
	ttgttaagca	cttttggcag	gaaagaaacg	gcacggcgta	atatcctgtg	caactgcagc	480
	tactgcaga	ataacacacg	gctaactacg	tgccagcagc	cgcggttaata	ctcagggtgc	540
	aagcgttaat	cggaattact	gggcgttaag	cgtgcgcagg	cggttcggaa	agaaagatgt	600
	gaaatcccg	ggcttaacct	tggaactgca	tttttaacta	ccggcgctaga	gtgtgtcaga	660
	gggaggtgga	atccgcgtg	tagcagtgaa	atgcgtagat	atcgaggaga	acaccgatgt	720
10	cgaaggcagc	ctccctggat	aacactgacg	ctcatgacg	aaagcgtggg	gagcaaacag	780
	gattagatgc	cctggtatgc	cacgccttaa	acgatgtcaa	ctagctgtgt	gggccttcgg	840
	gccttgttag	cgacgtcaac	gcgtgaagtt	gaccgcctgg	ggagctacgt	cgcaagatta	900
	aaactcaaac	gaattgacgg	ggaacccgac	aagcgtggga	tgatgtggat	taattcgtat	960
	caacgcgaaa	aaccttacct	acccttgaca	tgtctggaa	cccgaagaga	tttggggagt	1020
15	ctcgcgaag	aaccggaaac	cagggtgctgc	atggctgtgc	tcagctcgtg	tcgtgagatg	1080
	ttggggtaag	tccgcgaacg	agcgcaaccc	ttgtcattag	ttgcctcgaa	agggcactct	1140
	aagtggatgc	ccgggtacaa	accggaggaa	gggtgggagt	acgtcaagtc	ctcatggccc	1200
	ttatgggtag	ggcttcacac	gtcatatacat	ggctgggaca	gagggtcgcc	acacccgcag	1260
	ggggagccaa	tcccgaaaac	ccgactgtag	tccgactcgc	agtcctgaac	tcagctcggt	1320
20	gaagtcggaa	tcctagtaga	tcgcggatca	gcattgtcgc	gtgaatacgt	tcccggtctt	1380
	tgtaacaccc	cccgctcaca	ccatgggagt	gggttttacc	agaagtagtt	agcctaaccg	1440
	caaggggggc	gattaccacg	gtaggattca	tgactggggg	gaagtcgtaa	caaggtagcc	1500
	gtatcggaag	gtgcggctgg	atcacctcct	tt			1532
25	<210> 39						
	<211> 1485						
	<212> DNA						
	<213> Bordetella parapertussis						
30	<400> 39						
	attgaacgct	ggcgggatgc	tttacacatg	caagtcggac	ggcagcagcg	gcttcggcct	60
	gggtggcag	ggcgaaacgg	tgagtaattg	atcggaaacg	gcccgatagc	gggggataac	120
	tacgcgaaa	cgtggctaat	acgcatacgc	ccctacgggg	gaaagcgggg	gactttcggg	180
	ccctgcacta	tttgagcggc	cgatatcgga	ttagctagtt	gggtgggtaa	cggcctacca	240
	aggcgacagt	ctgtgactgg	tttgagagga	cgacagacga	cactgggact	gagacacggc	300
	ccagactcct	acgggaggca	gcagtgggga	attttggaca	atggggggcaa	ccctgatcca	360
	gcactccgcg	gtgtgcgatg	aaggccttcg	gggtgtaaa	cacttttggc	agggaaagaa	420
	cgccacggcg	taatatccctg	tgcaactgac	ggtaactgca	gaataagcac	cggtctaact	480
40	cgtgcgcagc	gcgcgggtaa	tacgtagggt	gcaagcgtta	atcggaatta	ctgggcgtaa	540
	agcgtgcgca	ggcggttcgg	aaagaaagat	gtgaaatccc	aggggttaac	cttggaactgt	600
	gaattttaac	taccgggcta	gagtggtgca	gagggaaggt	gaattccgcg	tgtagcagtg	660
	aaatgcgtag	atatgcggag	gaacacgcag	ggcgaaagg	gcctcctggg	ataacactga	720
	cgctcatgca	cgaagccggt	gggagcaaac	aggattagat	accctggtag	tccacgcctc	780
45	aaacgatgtc	aactagctgt	tggggccttc	gggccttggt	agcgacagcta	acgcgtgaag	840
	ttgaccgcct	ggggagtagc	gtcgcgaagt	taaaactcaa	aggaattgac	gggggacccg	900
	acaagcggtg	gtgatgtgg	atttaattcga	tgcaacgcga	aaaaccttac	ctacccttga	960
	catgtctgga	atcccggaaga	gatttgggag	tgctcgcaag	agaacccgaa	cacaggtgct	1020
	gcatggctgt	ctccagctcg	tgctgtgaga	tgttgggtta	agtcccgcaa	cgagcgcacac	1080
50	ccttgtcatt	agtgctcacg	aaagggcact	ctaattgagac	tgccgggtac	aaaccggagg	1140
	aaagtgggga	tgacgtcaag	tcctcatggc	catttgggtg	agggcttcaac	acgtcataca	1200
	atggtcgggg	cagaggttcg	ccaaacccgcg	agggggagcc	aatcccgaaa	accgcagctgt	1260
	agtcggagat	gcagctcgca	actcgactcg	gtgaagtcgg	aatcgctagt	aatcgcgagat	1320
	cagcatgtcg	cggtgaaatc	gttcccgggt	cttgatacaca	ccgcccgtca	caccatggga	1380
55	cgaggtttta	ccagaagtag	ttagcctaac	cgcaaggggg	ggggcgattac	cacggtagga	1440
	ttcatgactg	gggtgaagtc	gtacaacaggt	agccgtatcg	gaagg		1485

<210> 40
 <211> 1464
 5 <212> DNA
 <213> *Bordetella pertussis*

 <220>
 <221> modified_base
 10 <222> (87) ..(1391)
 <223> N = A, C, G or T/U

 <400> 40
 15 aactgaagag ttgtatcctg gctcagattg aaocgtggcg ggatgcttta cacatgcaag 60
 tcggacggca gcacgggctt cggcctnctg gcgagtgccg aacgggtgag taatgtatcg 120
 gaacgtgccc agtagcgggg gataactacg cgaagacgta gctaataccg catacgcctc 180
 acgggggaaa cggggggacc ttccgggctc gcactattgg agcggccgat atcgggattag 240
 ctngttgggt gggtaacggc ctaccaaggc gacgatccgt agctgggttg agaggacagc 300
 cagccacact gggactcgaga cagggcccg nctcctacgg gaggcagcag tggggaaattt 360
 20 tggacaatcg gggcaaccct gatccagcca tcccgctgt gcgatgaagg ccttcgggtt 420
 gtaaacgact ttggcgagga aagaacggcg acgggcta atcctgtgca actgacggta 480
 cctgcagaat aagcacggcg taactacgtg ccagcagccg cggtaatacg tagggtgcaa 540
 gcgttaatcg gaattactgg gcgtaaaagg tgcgcaggcg gtccggaaaag aaagatgtga 600
 aatccccagg cttaaccttg gaactgcatt ttaactacc gggctagagt gtgtcagagg 660
 25 gaggtggaat tccgcgtgta gcagtgaat gcgtagatat gcggaggaac accgatggcg 720
 aaggcagcct cctgggataa cactgacgct catgcacgaa agtgtgggga gcaaacagga 780
 ttgatatacc tggtagtcca cgccttaaac gatgtcaact agctgttggg gccttcgggc 840
 ctctgtagcg cagctaacgc gtgaagtga cgcctgggg agtacggtcg caagattaaa 900
 actcaaaagg attgacgggg accgcacaaa gcgggtggatg atgtggatta attcgatgca 960
 30 acgcgaaaaa ccttaacctac ccttgacatg tctggaatcc cgaagagatt tgggagtgtc 1020
 ccgaagagaa cgggaacaca ggtgctgcat ggcctgcgtc agctcgtgtc gtgagatgtt 1080
 ggggttaagt ccgcaacgag cgcaaccctt gtcattagtt gctacgaaa ggcaactcaa 1140
 tgagactgcc ggtgacaaac cggaggaagg tggggatgac gtgaagtccat catggccctt 1200
 atgggttaggg cttcacacgt catacaatgg tcgggacaga ggggttgncaa ccgcgaggg 1260
 35 ggagccaatc ccagaaaccc ggtcgtngtc cggatcgcat tctgcaactc gactgcgtga 1320
 agtcggaaat gctagtaatc cgggatcagc atgtgcgggt gaatacgttc gactgctgtg 1380
 tacacaccgc nctgcacacc atgggagtggt gttttaccag aagtagttag cctaaccgca 1440
 agggggcgca taccacgggt agga 1464

 40 <210> 41
 <211> 1535
 <212> DNA
 <213> *Burkholderia cepacia*

 45 <400> 41
 taaactgaag agtttgcctg tggctcagat tgaacgtggy cggcatgctt aacacatgca 60
 atgcgaacgg cagcacgggt gcttgacact ggtggcgagt ggcgaacggg tgagtaatac 120
 50 atgcgaacat gtcctgtagt gggggatagc ccggcgaaaag ccggattaat accgcatacg 180
 atctacggat gaaagcgggg gaccttcggg cctcgcgcta taggggtgac gatggtgtat 240
 tagctagtgt gtggggtaaa ggcctaccaa ggcacgacat agtagctggt ctgagaggac 300
 gaccagccac actgggagtg agacacggcc cagactccta cgggagcgag cagtggggaa 360
 ttttgcacaa tggggcgaag cctgatccag caatccggcg tgtgtgaaga agcccttcgg 420
 gttgtaaagc actttgttcc ggaagaataa ccttgctctc aatacagctg ggggatgacg 480
 55 gtaccgggaag aataagcacc ggcataactc gtgcagcgag ccgcggtaat acgtagggtg 540
 caagcgtaa tcggaattac tgggcgtaaa gcgtgcgcag gcgggttctt aagaccgatg 600

	tgaatcccc	gggtccaacc	tgggaactgc	attgggtgact	ggcaggctag	agtatggcag	660
	aggggggtag	aattccacgt	gtagcagtaga	aatgcgtaga	gatgtggagg	aataccgtag	720
	gcgaaggcag	ccccctgggc	caatactgac	gctcatgcac	gaaagcgtgg	ggagcaaac	780
	ggattagata	ccctggtagt	ccacgcccta	aacgatgtca	actagtgtt	ggggattcat	840
5	ttcttagta	acgtagctaa	cgcgtgaagt	tgaccgccctg	gggagtagcg	tgcgaagatt	900
	aaaactcaaa	ggaattgacg	gggaccgcga	caagcggctg	atgatgtgga	ttaattcgat	960
	gcaacgcgaa	aaaccttacc	tacccttgac	atggctcgaa	tcctgctgag	aggtgggagt	1020
	gctcgaaaga	gaaccggcgc	acaggtgctg	catggctgct	gtcagctcgt	gtcgtgagat	1080
	gttgggttaa	gtcccgcaac	gagcgcaacc	cttgctctta	gttgctacgc	aagagcactc	1140
10	taaggagact	gccggtgaca	aaccggagga	aggtggggat	gacgtcaagt	ctctatggcc	1200
	cttatgggta	gggtctcaca	cgctacataa	tggtcggaac	agaggggttc	caaccgccga	1260
	ggggggagcta	atccccagaa	acccatcgta	gtccggattg	cactctgcaa	ctcgagtgca	1320
	tgaagctgga	atcgctagta	atcgcggtac	agcatgcgcg	ggtgaatacg	ttcccgggtc	1380
	ttgtacacac	cgcccgctac	accatgggag	tgggttttacc	cagaagtggc	tagcttaacc	1440
15	gcaaggagga	cggtcaccac	ggtaggattc	atgactgggg	tgaagtcgta	acaaggtagt	1500
	cgatcgcgaa	ggtcgcgctg	gatacactcc	ttctct			1535
	<210> 42						
20	<211> 1488						
	<212> DNA						
	<213> Burkholderia mallei						
	<400> 42						
25	agattgaacg	ctggcggcat	gccttacaca	tgcaagtoga	acgcgagcac	ggggtctcggc	60
	ctgggtggcg	gtggtagaac	ggtgagtaat	acatcggaac	atgtcctgta	gtgggggata	120
	gcccggcgaa	agccggatta	ataccgcata	cgatctgagg	atgaaagcgg	gggaccttgc	180
	ggcctcgccg	tataggggtg	gccgatggct	gattagctag	ttgggtgggtg	aaaggcctac	240
	caagcgacg	atcagtagct	ggtctgagag	gacgaccagc	cacactggga	ctgagacacg	300
30	gcccagactc	ctacgggagg	cagcagtggt	gaattttgga	caatgggcgc	aagcctgac	360
	cagcaatgcc	gcgtgtgtga	agaaggcctt	cgggttgtaa	agcacttttg	tccgggaaga	420
	aatcattctg	gctaataacc	ggaagtggat	acggtaaccg	aagaataagc	accggctaac	480
	tacgtgccag	cagccgcggt	aatactgtag	gtcgacgcgt	taattggaat	tactggcgct	540
	aaagcgtgcg	caggcggttt	gctaagaccg	atgtgaaatc	cccgggctca	acctgggaac	600
35	tgcatctggt	actggcaggc	tagagtagtg	cagagggggg	tagaattcca	cgtagtagca	660
	tgaatgcgtg	agagatgtgg	aggaataacc	atggcgaaag	cagccccctg	ggccaatact	720
	gacgtccatg	cagaaagcgc	tggggagcaa	acaggattag	ataccttggt	agtcacgcgc	780
	ctaaacgatg	tcaactagtt	gttggggatt	catcttccat	gtaacgtagc	taacgcgtga	840
	agttgacgcg	ctggggagta	cggtcgcaag	attaaaaact	aaaggaatgt	acggggaccg	900
40	gcacaagcgg	tggatgatgt	ggattaattc	gatgcacgcg	gaaaaacctt	acctaccttc	960
	gacatggtcg	gaagcccgat	gagagttggg	cgtagctcgaa	agagaaaccg	cgcacagggt	1020
	ctcctatggct	ttggtcaact	cgtagctgta	gatgtttgggt	taagtccccg	aacgagcgca	1080
	acctctgtcc	ctagttgcta	cgcaagagca	ctctaaggag	actgcgggtg	acaaaccgga	1140
	gggaagtggtg	gatgagctca	agtcctcatg	gcccttatgg	gtaggggttc	acacgtcata	1200
45	caatggtcgg	acagaggggt	cgccaaccgc	cgagggggag	cgaatcccg	aaaaccgcat	1260
	gtagtcgcca	gtgcactctg	caactcgagt	gcatgaagct	ggaatcgcta	gtaatcgcggt	1320
	atcagcagtc	cgcggtgaat	acgttccggc	gtcttgtaca	caccgccggt	cacaccatgg	1380
	gagtggtgtt	taccagaagt	ggctagtcta	accgcaagga	ggacggctac	cacggtagga	1440
	ttcatgactg	gggtgaagtc	gtaaccaagg	agccgtatcg	gaaggctgc		1488
50	<210> 43						
	<211> 1610						
	<212> DNA						
55	<213> Burkholderia pseudomallei						

	ctcatggccc	ttagtaccag	ggcttcacac	gtcatacaat	ggctcggtaca	gagggtagcc	1260
	aagccgcgag	gcggagccaa	tctcacaaaa	ccgatccgtag	tccggattgc	actctgcaac	1320
	tccagtgcat	gaagtcgga	tcgctagtaa	tcgcaggcca	gcatactcgc	gtgaatacgt	1380
	tcccgggtct	tgtacacacc	gcccggtaca	ccatgggaat	gggggatacc	agaagtaggt	1440
5	agggtaaccg	caaggagtc	gcttaccacg	gtatgcttca	tgactggggt	gaagtcgtaa	1500
	caaggtagcc	gtagggaac	ctgcggctcg	atcacctcct	ttct		1544
	<210> 45						
10	<211> 1544						
	<212> DNA						
	<213> <i>Neisseria meningitidis</i>						
	<400> 45						
15	tgaacataag	agtttgatcc	tggtccagat	tgaacgcctg	cgccatgctt	tacacatgca	60
	agtcggacgg	cagcacagag	aagcttgctt	ctcgggtggc	gagtgggcaa	cgggtgagta	120
	acatactcga	acgtaccgag	tagtggggga	taactgatcg	aaagatccag	taataccgca	180
	tcagctctga	gagagaaagc	aggggacctt	cgggccttgc	gctattcgag	cggccgatat	240
	ctgattagct	agtggtggg	gtaaaaggct	accaaggcga	cgatcagtag	cggctctgag	300
20	aggatgatcc	gccacactgg	gactagagca	cggcccgagc	tcctacggga	ggcagcagtc	360
	gggaattttg	gcaaatgggc	gcaagcctga	tcacgccatg	ccgcgtgtct	gaagaaggcc	420
	ttcgggtgtg	aaagagcttt	tgtcagggaa	gaaaaggctg	ttgcataat	cagcggctga	480
	tgacggatcc	tgaagaataa	gcaccggcta	actacgtgcc	agcagccgcg	gtaatacgta	540
	gggtgcgagc	gttaatcgga	attactgggc	gtaaaaggcg	cgacagcggt	tacttaagca	600
25	ggatgtgaaa	tccccgggct	caaccggga	actgcgttct	gaactgggtg	actcgagtg	660
	gtcagagaaa	ggtagaattc	cacgtgttag	agtgaaatgc	gtagagatgt	ggaggaatac	720
	cgatggcgaa	gcagccctcc	tgggacaaca	ctgacgttca	tgcccgaag	cgtggttagc	780
	aaacaggatt	agataccctg	gtagtccacg	ccctaaccga	tgtcaattag	ctgttgggca	840
	acctgattgc	ttggtagcgt	agctaacgcg	tgaatttgac	cgccctggga	gtacggtcgc	900
30	aaagattaaa	ctcaaaaggaa	ttgacgggga	ccgcacaaag	cgggtggatga	tgtgtgattaa	960
	ttcagtgcaa	cgcgaagaac	cttaactcgt	cttgacatgt	acggaaatcct	cgggagacgg	1020
	aggatgcctt	tcgggagcgc	taacacaggt	gctgcattgc	tgtcgtcagc	tcgtgtcgtg	1080
	agatgttggt	ttaagtcctg	caacgagcgc	aacccttgct	attagttgcc	atcatctcag	1140
	tgggcactct	aatgagactg	ccggtgacaa	gccggaggaa	ggtggggatg	acgtcaagtc	1200
35	ctcatggccc	ttagtaccag	ggcttcacac	gtcatacaat	ggctcggtaca	gagggtagcc	1260
	aaagccgcgag	gcggagccaa	tctcacaaaa	ccgatccgtag	tcggattcct	actctgcaac	1320
	tcagatgcat	gaagtcgga	tcgctagtaa	tcgcaggcca	gcatactcgc	gtgaatacgt	1380
	tcccgggtct	tgtacacacc	gcccggtaca	ccatgggaat	gggggatacc	agaagtaggt	1440
	aggataacca	caaggagtc	gcttaccacg	gtatgcttca	tgactggggt	gaagtcgtaa	1500
40	caaggtagcc	gtagggaac	ctgcggctcg	atcacctcct	ttct		1544
	<210> 46						
	<211> 1537						
45	<212> DNA						
	<213> <i>Pseudomonas aeruginosa</i>						
	<400> 46						
50	gaactgaaga	gtttgatcat	ggctcagatt	gaacgctggc	agcaggggcc	ttcaacacat	60
	gcaagtcgag	cttatgaagg	gagcttgctt	tggatttcagc	ggcggacggg	tgagtaatgc	120
	ctaggaactc	ccctggtagt	gggggataac	gtccggaaac	ggcccgtaac	agccatacag	180
	ttcttagagg	gaaagtcggg	gatcttcgga	cctcacgcta	tcagatgagc	ctaggtcgga	240
	ttagctagtt	gggggggtaa	aggcctacca	agggcagcat	ccgttaactgc	ttcgagagga	300
	tgatcagcca	cactggaaact	gagacacggt	ccagactcct	acgggaggca	gcagtgggga	360
55	atattggaca	atgggcgcga	gcctgatcca	gccatgccgc	gtgtgtgaag	aaggtctctg	420
	gattgtaaag	cactttaagt	tgggagggaag	ggcagtaagt	taatacctgt	ctgtttgagc	480

5 ttaccaacag aataagcacc ggctaacttc gtgccagcag cgcgcggaat acgaagggtg 540
 caagcgtaaa tcggaattac tgggcgtaaa gcgcgcgtaa gtgggtcaagc aagcttgatg 600
 tgaatcccc gggctcaacc tgggaactgc atccaaaagc tactgagcta gaggatcggt 660
 gagggtggtag aatttccgtg ttagcggtaga aatgcgtaga tatagggaagg aacaccagtg 720
 gcgaaggcga ccactcggaac tgtactgaca ctgaggtgctg aaagcggtggg gagcaaacag 780
 gattagataga ccttggtagtc caccgcgttaa acgatgtcga ctagccgttg ggatcccttga 840
 gatcttagtg cgcgcagtaa cgcgataagt cgaccgcctg gggagtagcgg ccgcaagggt 900
 aaaactcaaa tgaattgacg ggggcccgcga caagcggtgg agcatgtggt ttaattcgaa 960
 10 gcaacgcgaa gaaccttacc tggccttgac atgctgagaa ctttccagag atggattgtg 1020
 gcccttcggga acagagacac aggtgctgca tggctgtcgt cagctcgtgt cgtgagatgt 1080
 tgggttaagt cccgtaacga gcgcacacct tgtccttagt tacaccagcc tcgggtggcg 1140
 actctaaagg gactgccgtg gacaaaaccg aggaagggtgg ggtatgacgt aagtaatcat 1200
 ggccttaccg gccagggtga cacacgtgct acaatggctg gtacaaaagg ttgccaaagg 1260
 15 gcgagtgagg gctaattccc taaaaccgat cgtagtcggg atcgagatct gcaactcgac 1320
 tgcgtgaagt cggaatcgct agtaatcgct aatcagaatg tcacggtgaa tacgtccccg 1380
 ggcctgttac acaccgccc tcacaccatg ggaagtgggt gctccagaag tagctagtct 1440
 aaccgcgaag ggagcgggta ccacggagtg attcatgact ggggtgaagt cgtaacaagg 1500
 tagccgtagg ggaacctgct gctggatcac ctcccta 1537

20 <210> 47
 <211> 1467
 <212> DNA
 <213> *Vibrio cholerae*

25 <220>
 <221> modified_base
 <222> (928)..(1464)
 <223> N = A, C, G or T/U

30 <400> 47
 attgaagagt ttgatcctgg ctacagattga acgctggcgg caggcctaac acatgcaagt 60
 cgagcggcag cacagaggaa cttgttccct ggggtggcgg cggcggacgg gtgagtaagt 120
 cctgggaaat tgcccggtag agggggataa ccattggaaa cgaatggcta taccgcataa 180
 35 cctcgcaga gcaaaagcagg ggaacctcgg gccctgacct accggatag cccaggtcgg 240
 attagctagt ttgtgaggta agggctcacc aaggcgacga tccctatgct gcttgagagg 300
 atgatcagcc acactggaac tgagacacgg tccagactcc tacgggaggg agcagtgagg 360
 aatatgtcac aatgggcgca agcctgatgc agccatgccg cgtgtatgaa gaaggccttc 420
 ggggtgtaaa gctacttccag tagggaggaa ggtggtttag ttaatacctt aatcatttga 480
 40 cgttacctac agaagaagca ccggctaact ccgtgccagc agccgcggta atacggagggg 540
 tgcaagcggt aatcggaatt actgggcgta aagcgcagtc aggtggtttg ttaagtca 600
 tgtgaaagcc ctggggtcaa cctaggaatc gcaattgaaa ctgacaagct agagatctgt 660
 agaagggggg agaatttcag gtgtagcggg gaaatgcgta gagatctgaa ggaataccgg 720
 tggcgaaggg ggcctccctgg acagatactg acactcagat gcgaagaggt ggggagcaaa 780
 45 caggattaga agtctgggta gtccacggcg taaacgatgt ctacttgagg gttgtgcctc 840
 agagtctggt ctttcggagc taacgcgtta agtagacggc ctggggagta cgttcgcaag 900
 attaaaaact aatgcaattg acggggggnc gcacaaagcg tggagcatgt ggtttaattc 960
 ganncaacgc gaagaacctt acctactctt gacatccaga gaactctagc gagacgctgg 1020
 agtgcctcg ggaagctctga gacaggtgct gcatggctgt cgtcagctcg tttgtgaaa 1080
 50 tgttgggtta agtcccgcaa cgagcgcaac ccttatcctt gtttgcagc acgtaattgt 1140
 gggaactcca ggaagactgc cgtgtataaa ccggaggaa gctggggaga cgtcaagctca 1200
 tcatggccct tcagagtagg gctacacacg tctacaatg gcgtatacag agggcagcga 1260
 tacgcgagg tggagcgaat ctcaaaaagt acgtcgtagt ccggtatgga cgtcgcaact 1320
 cgactccatg aagtcggaat cgtatgtaac cgcgaatcag aatgttgcgg tgaatacgtt 1380
 55 cccgggctct gtacacacgg cccgtcacac catgggagtg ggtcgcaaaa gaagcangta 1440
 gtttaacctt cgggagagag ctttcccc 1467

<210> 48
 <211> 1485
 5 <212> DNA
 <213> *Yersinia enterocolitica*

 <220>
 <221> modified_base
 10 <222> (1)..(1484)
 <223> N = A, C, G or T/U

 <400> 48
 15 naattgaaga gtttgatcat ggctcagatn gaacgctggc ggcaggccta acacatgcaa 60
 gtcgagcgcc agcgggaagn agtttactac tttcnngggc agcggcggnac gggtagtaaa 120
 tgcctgggaa actgcctgat ggagggggat aactactgga aacggtagct aataccgat 180
 aacgtcttcg gaccaaaagt ggggacctta gggcctcacg ccatcngatg tgcccagatg 240
 ggattagcta gtagggtggg taatggctca cctaggcgac gatccctagc tggctctgaga 300
 20 ggaatagcga ccacactgga actgagacac ggctcagact cctacgggag gcagcagtg 360
 ggaatattgc acaactggcg caagcctgat gcagccatgc cgcgtgtgtg aagaaggcct 420
 tccggttgta aagcactttc agcaggaggg aaggccaata acttaatacg ttggtggatt 480
 gacgttactc gcgaagaag caccggctaa ctccgtgcc aacggccggg taatacggag 540
 ggtgcaagcg ttaactcgaa ttactggcg taaagcgac gcaggcgggt tgtaaatgca 600
 gatgtgaaat cccgcgcctt aacgtgggna cngcatttga aactggcaag ctagaatctt 660
 25 gtagaggggg gtagaattcc aggtgtagcg gtgaaatgcg tagagatctg naggaataacc 720
 ggtggcggaag gcggcccccct ggaacaaagc tgacgctcag gtgcgaagcg gtggggagca 780
 aacagagatta gatacccttg tagtccacgc ttgacatcca cggaaattag cagagatgct 840
 ctgagggcgt ggcttccgga gctaaccgct taagtccagc cccctggggag tacggcgcca 900
 aggttaaaac tcaaatgaat tnnccggggc cngcacaagc ggtggagcat gtggtttaat 960
 30 tcatgcaac gcgaagaacc ttacctactc ttgacatcca cggaaattag cagagatgct 1020
 ttagtgnctt cgggaaccgt gagacagggt ctgcattggt ctgcctcagc cgtgtgtgta 1080
 aatggtgggt taagtcccg aacgagcgca acccttatcc tttgttgcca gcacgtaagt 1140
 gtgggaactc aaaggagact gccggtgata aaccggagga aggtggggat gacgtcaagt 1200
 catcatggcc ctacagagta gggctacaca cgtgctacaa tggcagatac aaagtgaagc 1260
 35 gaactgcgga gagcaagcgg accacataaa gtctgtcgta gtccggattg gactgtgcaa 1320
 ctgactccca tgaagtcgga atcgctagta atcgtagatc agaattgctc ggtgaatcag 1380
 ttcccgggcc ttgtacacac cgcgcgtcac acntggggag tgggttgcaa aagaagtagg 1440
 tagcttaacn ttcgggaggg cgcgtaccac tttgtgattc nngnc 1485

 <210> 49
 <211> 2927
 <212> DNA
 45 <213> *Bacillus subtilis*

 <400> 49
 ggtaagtta gaaagggcgc acgggtgatg ccttgccact agggagccat gaaggacggg 60
 acgaacaccc atctgcttcg gggagctgta agcaagcttt gatccggaga ttcccgaaatg 120
 gggaaaccca ccatctgtaa tggagtggta tccatctatg aattcatagg atatgagaaa 180
 cgagacccgg ggaactgaaa catctaatga cccggagaag agaaagcaaa tgcgattccc 240
 20 tgaatagcgg cgagcaaacg gggatcagcc caaaccaaga ggcctgcctc tgtgtgtgta 300
 ggaactctctg tacggagtta caaagaacg aggtagatga agaggtctcg aaagggcccg 360
 ccatagaggg taacagccct gtagtcaaaa cttcgtctct tcctgagtgt atcctgagta 420
 cggcggaaca cgtgaaattc cgtcggaatc cgggaggacc atctcccaag gctaaatact 480
 55 ccctagtgc cgtagtgtga ccagtaccgt gagggaagg tgaaaagcgc cccggaaggg 540
 gagtgaaga gatctcgaaa cgtgtgcct acaagtagc agagcccggt aacggtgatg 600

5 gcggtgccttt tgtagaatga accggcgagtg tacgatcccc tgcaaggtta agcagaagat 660
 gggagcgcg agcgaaaagcg agtctgaata gggcgcatga gtacgtggtc gtgagaccga 720
 aaccagggtga tctaccatcg tccagggtga agttcaggta acactgaatg gagggccgca 780
 cccacgcacg tgcaaaagtg cggggatgag gtgtgggtag ggggtgaatg ccaatcgaa 840
 ctggagatag ctggttctct cggaaatagc tttagggtcta gccctcaaggt aagagctctg 900
 gaggttagac actgatttga ctaggggccc tcaccgggtt accgaattca gctcaactcc 960
 gaatgccaat gacttatctc tgggagtcag actgcgagtg ataagatccg tagtcgaaag 1020
 ggaaacagcc cagaccgcca gctaaggtcc caaagtatac gtttaagtga aaaggatgtg 1080
 gagttgctta gacaaccagg atgttggctt agaagcagcc accattttaa gagtgcgtaa 1140
 10 tagtcaactg gtccagtgac tctgcgcga aatgtaccg gggctaaacg tatcacgca 1200
 gctgcggact gttcttcgaa cagtgttagg agagcgttct aagggtctgt aagccagacc 1260
 ggaagagctg gtggacggct tagaagttag aatgccggta tgagtgcga aaagaggggt 1320
 gagaatccct ccaccgaatg cctaagggtt cctgaggaa gctcgtccgc tcagggttag 1380
 15 tccggaccta agccgagggc gaaaggcgta ggcgatggac aacagggtga tattctctga 1440
 ccacctcttc accatttgag caatgggggg tcgcaggagg atagggttaag cgcggtattg 1500
 gatattccgg ctcaagcagt taggtcggga aataggcaaa tccgtttccc ataaggctga 1560
 gctgtgagtg cgagcgaaat atagtgcga agttcctgat tccacactgc caagaaaagc 1620
 ctctacgagc gtgagaggtg cccgtaccgc aaacctgcac aggtaggcga ggagagaatt 1680
 20 cttaaggtgag ctgagagaact ctctgttaagg aactcggcaa aatgaccocg taactctcgcc 1740
 agaagggttg ctctgttagg gtgcaagccc gagagagccg cagtgaatag gccacggcga 1800
 ctgttttagca aaaaacacagg tctctgcgaa gccgttaagg gaagtataag gctgcagccc 1860
 tgcggcggtg tggaaaggtta agaggagcgc tttagcgttaag cgaaagtgcc aattgaaagc 1920
 ccagtaaacg cggcccgtaa ctataacggt cctaaggttag gtaactcctc tctcgggtta 1980
 25 gttccgagcc gcacgaaagg cgcaacgcat tgggcgctgt ctcaacgaga gactcgggtga 2040
 aattatagta cctgtgaaga tgcaggttac ccgcgacagg acggaagacc ccggtggagc 2100
 tttactgcag cctgatattg aatgttggtta cagctgtgac aggtatagta ggagccttgg 2160
 aaaccggagc gccagcttcg gtggaggcat cgggtgggta ctaccctggc tgtattgacc 2220
 ttctaacccc ccgcctctat cgggcgggga gacagtgaca ggtgggcat gtgactggg 2280
 30 cggtcgcttc ctaaaaggta acggagggcg ccaaaaggtc cctcagaatg gttggaaatc 2340
 attcgcagag tgtaaaaggca caaggagctc tgactgcgag acctacaagt cgagcaggg 2400
 cgaagtcgg gcttagtgat ccggtgggtc cgcattgaa ggcctatctc tccacatcga cggggaggtt 2460
 aagctacccc ggggataaca ggcttatctc ccccaagagc tccacatcga cggggaggtt 2520
 tggcaccctc atgtcggtc atcgcattct ggggctgtag tcggtcccaa ggttgggtc 2580
 35 gttcggccat taaagcggt cgcgagctgg gttcagaac gctgagaca gttcgtccc 2640
 tatccgtctc gggcgctgga aatttgagag gagctgtcct tagtcagaga ggaccgggat 2700
 ggacgcaccg ctgtgttacc agttgttctg ccaaggcatc cgctgggtcg ctatgtcgg 2760
 acgggataag tgctgaaagc atctaagcat gaagcccccc tcaagatgag atttcccat 2820
 ccgcaaggaa tgaagatccc tgaagatga atgcttgtag aggtctgagg tggaaagtgtg 2880
 40 gcaacacatg gagctgacag atactaatcg atcaggagct taacctat 2927

<210> 50

<211> 2922

<212> DNA

45 <213> *Bacillus anthracis*

<400> 50

50 ggttaagtta gaaagggcgc acggtggatg ccttgacact agggatcgat gaaggacggg 60
 actaaccccg atatgcttcg gggagctgta agtaagcttt ttccgaaatg 120
 ggggaaccaca ccatcgttaa tggatagtta tcttatctg aatacatagat gtaaggaaag 180
 cgagcccaag gaactcgaac atctaagta cctggaggaag tgcgattttcc 240
 tgaagtacgg cgagcgaaac ggaacatagc ccaaaccaag aggcctgctc ctgggggtg 300
 taggacattc tatacggagt tacaaaaggaa gaagcgtagac cgaaaggtcc 360
 55 gtcgtagagg gtaacaaccc cgtagtgcga acttcgttct ctcttgatg tatcctgagt 420
 acggcggaac acgtgaaatt ccgtcggaat ctgggaggac catctcccaa ggctaaatat 480
 tccctagtga tctatagtga accagtagc tgagggaag gtgaaaagca ccccggaagg 540

5 ggagtgaaag agatcctgaa accgtgtgcc tacaaatagt cagagcccggt taacgggtga 600
 tggcgctgacct tttgtagaat gaaccggcga gttacgatcc cgtgcgaggt taagctgaag 660
 agccggagacc gcagcgaaag cgaagctctgaa tagggcgctt agtactggtt cgtagaccgcg 720
 aaaccaggtg gtctaccat gtccagggtg aagttcaggt aacactgaaat ggagggccga 780
 accccagcac gtgtaaaaagt gcggggatga ggtgtgggtg gccggagaaat tccaatcgaa 840
 cctggagata cgtggttctc ccgaaatag ctttagggct agccttaagt taagagtact 900
 tggaggtaga gcactgattg gactagggtt cctcatcgga ttaccgaatt cagtcaaatc 960
 ccgaatgccat atgacttctc cttaggagtc agactcgag tgataagatc cgtagtcaaa 1020
 agggaaacag ccagaccgcg cagctaaagt cccaaagtgt gtattaaagt gaaaaggatg 1080
 tggagttgct tagcaacta ggatgttggc ttagaagcag ccacattta agagtgcgt 1140
 aatagctcac tagtcgagt actctgcgcg gaaaatgtac cggggctaaa tacaccaccg 1200
 aagctcgctga agctaccaa tggatcaggt ggtaggggag cgttctaag acagtgaagt 1260
 cagaccggaa ggactggtgg agtgcttaga agtgagaatg ccggtatgag tagcgaaaga 1320
 cgggtagaaa tcccgctcac gsaatgccta aggtttctcg aggaaggctc gtccgctcag 1380
 15 ggttagctcag gacctaaagc gaggccgaca ggcgtaggcg atggacaaca ggttgatatt 1440
 cctgtaccac ctctttatcg tttgagcaat ggagggagcg agaaggatag aagaagcgtg 1500
 cgattggttg tgcagctcca agcagttagg ctgataagta ggcaaatcog cttactgtga 1560
 aggctgagct gtgatgggga agctccttat ggagcgaagt ctttgattcc ccgctgccaa 1620
 20 gaaaagcttc tagcagata aaaggtgcct gtaccgaca cgcacacagg ccgacacaga 1680
 gagaattccta aggtgtgcga gagaactctg gttaaagaa tcggcaaaat gaccgccgtaa 1740
 ctctcgggga aggggtgctt tcttaacgga aagccgagct gaataggccc gacactgctt 1800
 tttagcaaaaa cacagctctc tgcgaagccg taaggcgaa tatagggggt gacactccgc 1860
 cggtgtcggga aggttaagga gaggggttag cgtaaagcga cgtactgaat gaagccccag 1920
 25 taaacgcggc cgttaactat aacggtccta aggtagcgaa attccttctc gggttaagttc 1980
 cgaccgccga gaaaggtgta acgatttggg cactgtctca accagagact cggtgaaatt 2040
 atagtagctg tgaagatgca ggttaccgcg gacaggacgg aaagaccgcc tggagcttta 2100
 ctgtagctcg atattgaatt ttggtacagt ttgtacagga taggcgggag aggttgaaac 2160
 cggagcgcta gcttcggtgg aggcgctggt gggataccgc cctgactgta ttgaaattct 2220
 30 aacctacggg tcttatcgac ccgggagaca gtgtcaggtg ggcagttga cttggggcggt 2280
 cgctcctcaa agtgtaacgg aggcgcccga aggttccctc agaagtggtt gaaatcattc 2340
 gttagagtga aaggcataag ggaagctgac tgcgagacct acaagctcag cagggaacga 2400
 agtcgggctt agtgatccgg tggttccgca tggaaaggcc atcgctcaac ggataaaagc 2460
 taccocgggg ataacaggct tatctccccc aagagctcac atcgacgggg aggtttggca 2520
 35 cctcgatgct cgttcatcgc atcctggggc tgtagtcggt cccaagggtt gggctgttcg 2580
 cccattaaag caggtacgca gctgggttca gaacgtcgtg agacagttcg gtccctatcc 2640
 gtctgtyggc ttgaaattt gagaggaagct gtcccttagta cgagagggacc ggaggggagc 2700
 caccgcgtgt ttaccagttg tttcgccaag ggcataagct ggtagctatg tgcggaaagg 2760
 ataatgtcgt aaagcatcta agcatgaagc cccctcaag atgagatttc cgtacgcta 2820
 40 agctagtaga atccctgaaa gatgatcagg ttgtagagtt cgaggttgaaa gcatggtgac 2880
 atgtggagct gacgaatact aatagatcga ggactaacc at 2922

<210> 51

<211> 2912

45 <212> DNA

<213> Enterococcus faecalis

<400> 51

50 ggttaaagtga ataagggcgc acggtggatg ccttggcact agggagccgat gaaggacggg 60
 actaacaccgc atatgctttg gggagctgta agtaagctat gatccagaga ttccgaatg 120
 ggggaaccaca atactcttta taggatatta cttttcagtg aatacatagc ttagtagag 180
 tagacgcga caactgaaac atcttagtac ctgcaggaa agaaagaaaa ttgatttccc 240
 tgaagtacgc ggaagcgaac gggaaagacc caaaccacaa agcttgcgtt ttcgggtgtc 300
 aggaactccaa ttggttagtc tgttagtata gttgaagatt ttggaaattt ccgtcaaa 360
 55 gggtagaaag ccgttagacg aaatgtcaac aacacctagg aggatcctga ctacgcggga 420
 acacgagaaa ttccgtcgga atccgcgggg accatccgcg aaggctaaat actccctagt 480

	gaccgatagt	gaaccagatc	cgtaggggaa	aggtgaaaag	caccccgga	ggggagtgaa	540
	atagatccctg	aaaccgtgtg	cctacaacaa	gtcaaaagctc	gttaatgagt	gtggcggtgc	600
	ctttttgtaga	atgaaccggc	gagttacgat	tgcatcgag	gttaagtcca	agagacggag	660
	ccgcagcgaa	agcgagtcgt	aataggcgca	atgagtatgt	cgctcgtagc	ccgaaccat	720
5	gtgatctacc	catgtccagg	ttgaaggtgc	ggtaaaacgc	actggaggac	cgaaccaccg	780
	tacgttgaaa	agcgcgggga	tgaggtgtgg	gtagcggaga	aattccaaac	gaactctggag	840
	atagctggtt	ctctccgaaa	tagcttttagg	gctagcctcg	gaattgagaa	tgatggaggt	900
	agagcactgt	ttggactagg	ggcccatctc	gggttaccga	attcagataa	actccgaatg	960
	ccattctatt	atatccggga	gtcagactgc	gagtgataag	atccgtatgc	gaaagggaaa	1020
10	cagcccgagc	caccagctaa	gggtcccaaa	tatatgttaa	gtggaaaagg	atgtgtgggtt	1080
	gcacagacaa	ctaggatggt	ggcttagaag	cagccaccat	ttaaaagagt	cgtaatatgt	1140
	cactagtcga	gtgaccctgc	gccgaaaatg	taccggggct	aaacatatta	ccgaagctgt	1200
	ggactacacc	atagggtgta	gtggtaggag	agcgttctaa	gggcgttgaa	ggtctgcgt	1260
	gaggacgggt	ggagcgctta	gaagtggaga	tgccggtagt	agtgcgaaa	gacaggtgag	1320
15	aatccctgtcc	accgtatgac	taaggtttcc	tggggaaggc	tcgtccgccc	agggttagtc	1380
	gggacctaag	ccgagggcca	taggcgttag	cgatggacaa	caggttgata	ttcctgtacc	1440
	agtttctttt	gtttgagcaa	tggagggacg	cagtaggcta	aggaatgcat	gcgattggaa	1500
	gtgcabgtcc	aagcaatgag	tcttgagtag	agttaaatgc	tttactcttt	aaggacaagt	1560
	tgtgacgggg	agcgaataaa	tagtagcgaa	gttctctgat	tcacactgcc	aagaaaagct	1620
20	tctagtgaag	aaacaaactc	ccgtaccgta	aaccgacaca	ggtagtcgag	gagagatacc	1680
	taaggttgagc	gcgcgaactc	tcgttaagaa	actcggcaaa	atgaccctgc	aactctggga	1740
	gaaggggtgc	tgactctcgt	cagccgcagt	gaataggccc	aagcgactgt	ttatcaaaaa	1800
	cacaggtctc	tgcaaaaatc	taagatgaag	tataggggct	gacgctctcc	cggtgtcgga	1860
	aggttaagag	gatgggttag	cttcggcgaa	gctcagaatt	gaagccccag	taaacggcgg	1920
25	cgtaactcat	aacgggtcta	aggtagcgaa	attcctgtgc	gggttaagttc	cgaccgcgac	1980
	gaaaggcgta	acgatttggt	cactgtctca	acgagagact	cggtgaaatt	ttagtacctg	2040
	tgaagatgca	ggttaccgcg	gacaggcagg	aaagacccca	tggagcttta	ctgtagtttg	2100
	atattgtagtg	ttgtaccac	atgtacagga	taggtaggag	ccgatgagac	cgccagctca	2160
	gtttcggagg	agcgctggtg	gggatactac	ccttgtgtta	tgaacctctc	aaccgcacc	2220
30	actaatcgtg	gtgggagaca	gtgtcagatg	ggcagtttga	ctggggcggt	cgctcctaa	2280
	aaggtaacgg	agggcccca	aggttccctc	agaatggttg	gaaatcattc	gaagagtgt	2340
	aaggcagaag	ggagcttgac	tgcgagacct	acaagtcgag	caggagcgaa	agtcgggctt	2400
	agtcatccgg	tggttccgca	tggaaaggcc	atcgctcaac	ggtaaaagct	accctgggga	2460
	taacagcctt	atctccccca	agagtccaca	tcgacgggga	ggtttgccac	ctcgatgtcg	2520
35	cgctcgtcga	tcctggggct	gtagtcggtc	ccaaggggtg	ggctgttcgc	ccattaaaag	2580
	ggcacgagcg	ctgggtttcag	aacgtcgtga	gacagtttcg	tcctcatctg	ctcgccggctg	2640
	tggaaaatttg	atggagagctg	tccttagtac	gagaggaccg	ggatggactt	accctgtggt	2700
	taccagattgt	tgcccaagg	gcattctctg	gtagctatgt	aggggaaggga	taaacctcga	2760
	aagcatcttaa	gtgtgaagcc	cacctcaaga	tgaagtattc	catttcttta	agaaagttaag	2820
40	acccctgaga	gatgatcagg	tagatagggt	tgaaagtgga	ggctagtgtat	agttggagcg	2880
	gaccaatact	atacgttcga	ggacttaacc	aa			2912

<210> 52

<211> 2898

<212> DNA

<213> *Lactococcus lactis*

<400> 52

50	ggcaaaagta	ataaaggcgc	acgggtggatg	ccttgccact	aagagccgat	gaaggacgtg	60
	actaacgacg	atatcttagg	gggagcagta	agtacgactt	gatccctagg	ctcccgaaatg	120
	ggaaaaccaca	cgctgactata	gcagttattc	atgagtgaa	acatagctca	tgtaaaagta	180
	acgcagagaa	ctgaaaatc	taagtacctg	caggaaagaa	aagtaaaaaa	gattctcgtaa	240
	gtagcggcga	gcgaacgcga	agaaggcgaa	accaagaagc	ttgcttctgt	gggttgtagg	300
	actgcaacgt	ggacttaagc	attatagctg	aataacctgg	gaaggttaag	caaaaggggt	360
55	aataatcccg	tgacgaaat	agcgcttata	cctagcagta	tcctgagtag	ggctggacac	420

	gcgaaatcca gtttgaatcc gggaggacca tctcccaacc ctaaaactac cttagtacc 480
	gatagtgaac cagtaccgtg agggaaagggt gaaaagaacc cgagagggga gtgaaatagc 540
	acctgaaacc cgtgtgctac aagaagtctg agcccgctaa tgggtgagag cgtgcctttt 600
5	gtagaatgaa ccggcgagtt acgtttatgat gcgaggttaa gtgaaagaga cggagccgta 660
	gggaaccaga cgtctgaatag ggcgacttag tatcatgatg tagaccgcaa acctagtacg 720
	ctatccatga gcaggggtgaa ggtgtggttaa gacgcactgg aggcccgaa caggacagct 780
	tgaaaagtgt ttggatgact tgtggatagc ggagaaatcc caaacgaact gggagatagc 840
	tggtctcttc cgaaatagct ttagggttag cgtcgaaatg taagtgtatt ggaggtagag 900
	cactgtttgg ttgagggggtc cgtctaggat taccatcttc agataaactc cgaatcgtaa 960
10	tacacatgtt cggcagtcag actgcgagtg ctaagatccg tagtcgaaag ggaaacagcc 1020
	cagaccaaca gctaaaggtcc caaaatatat gttaagtggg aaaggatgtg ggggtcgaca 1080
	gacaactagg atgttagctc agaagcagct atcattcaaa gagtgcgtaa tagctcata 1140
	gtcgagtgac cctgcccga aaatgtaccg gggctaaaaa tattaccgaa gctttggatt 1200
15	gatattttat caatggtagg agagcgttct taaccgcgat gaaggatata cgtgaggagt 1260
	gctggagcgt taagaagtga gaatgccggt atgagttagc caagataagt gagaattcta 1320
	tccaccgtaa gactaagggt tccaggggaa ggctcgtccg cctcgggtta gtcgggacct 1380
	aaaggcgagg cgaaaggcgt agtcgatgga caactggttg atattccagt actagatatg 1440
	atcgtgatgg agggagcgag taggctaaga gatgccagtt aatggattct ggtctcaaga 1500
20	gtgaggtgtg agatgtgtca aatgcatttc tcttttaact tgagctgtga tggggaaaga 1560
	actacgttgt cgaactctct gatgtcacac tgccaagaaa agctcttagc gttaaagcat 1620
	atctaccgct agccgaaacc gacacagggt gtcgaggcga gtacgctcag gtgactcgaga 1680
	gaactctcgt taaggaaact ggcaaaatag ccccgtaact tcggggagaa ggggtcggtg 1740
	gtaaaagcga ccgcgcagtga ataggcccaa gcaactgttt atcaaaaaca cagctctctg 1800
25	ctaacccgca aggtgatgta taggggggtga cgctgcgccg gtgctggaaag gctaaagaga 1860
	gtgcttagac gtaagtcgaa ggtatgaatt gaagcccgag taaacggcgg cgtactaat 1920
	aacggtccta aggtagcgaa attccttgtc gggtaagttc cgagccgcac gaaagcgta 1980
	atgattttgg cactgtctca acgagagact cggtgaaatt ttagtacctg tgaagatga 2040
	ggttaccgcg gacaggaagg aaagacccca tggagcttta ctgtagttg atattgagta 2100
30	cctgtaaatc atgtacagga taggtaggag ccattgaaat agggacgcta gttcttattg 2160
	aggcgttgtt gggatactac ccttgactta tggttactct aaccgcgtgg cataatcgcc 2220
	caggagagca gtgtctgacg gacagtttga ctggggcggt cgctctcaaa gagtacagg 2280
	ggcgctcaaa ggttggtcga gattggttgg aaatcaatcg tagagttaa aggtaaaagc 2340
	cagcttgact gcgagagcta caactcgagc aggtaggaaa ctaggactta gtgactcgg 2400
35	ggtaaccgat ggaaggccca tcgctcaacg gataaaagct accctgggga taacaggctt 2460
	atctccccca agagttcaca tcgacgggga ggtttggcac ctcgatgtcg gctcgtcgca 2520
	tctgtggggt gtagtcggtc ccaagggttg ggcgtgttcg cattaaacgc gcacgcagcg 2580
	tggggttcaga cctctgttag acagttcggt cctatccgt cgcgggcgta ggttaattga 2640
	gaggaactgt ccttagctacg agaggacgg gatggactta ccgctgggtg accagttgtt 2700
40	cgcgacgagc cacggctgga tagctatgta gggaaaggat aagcgtgtaa agcatctaa 2760
	tcgcaagccc acctcaagat gagattacc attcgtaaga attaagagcc cagagagatg 2820
	atctggtaga taggctggaa gtggaagagt tgcgagactt ggagcggacc agtactaat 2880
	gctcgaggac tttaacaa 2898
45	<210> 53
	<211> 2932
	<212> DNA
	<213> <i>Listeria monocytogenes</i>
50	<400> 53
	ggtttaagtt gaaaggcgcc acgggtggatg ccttgccact agggagccga gaaggacggg 60
	actaacaccc atatgctttg gggagctgta cgtaagcggt gatccagaga ttccggaagt 120
	gggggaaccca ctactctttag tcggaataga tctttacgtg aatacatagc gtgaggaagg 180
	cagaccacgg gaaactgaaac atctaatgat ctggaggaag agaaagaaaa atcgatttcc 240
55	tgagttagcg cgagcgaaac ggaagagacc caaccaaga agcttgcttc ttggggttgt 300
	aggacacctc atacggagtt acaaaagaaa gttataaatg aagcggtctg gaaaggcccg 360

	ccaaagacg	taacagccc	gtagttgaaa	tggctttccc	tccagagtg	atctcgagta	420
	cgccgggaaca	cgtgaaattc	cgtcgggaac	cgccgggaac	atctcccaag	gctaaatact	480
	ccctagtgac	cgatagtgaa	ccagtagcgt	gagggaaaag	tgaaaagcac	cccggaaggg	540
5	gagtgaaca	gttctcgaaa	ccgtgtgcct	acaagtagtt	agagcccggt	aatgggtgat	600
	agcgtgcctt	ttgtagaatg	aaccggcgag	ttacgatttg	ttgcaagagtt	aagcggaaaa	660
	agcggagagc	tcagaaaagc	gagtcctaat	agggcgcata	agtaacaggt	ccagagcggt	720
	aaaccaggtg	atctaccat	gtccagagtg	aaggtaaggt	aatacttact	ggaggtccga	780
	accacgacac	gttgaaaagt	gcggggatga	gggtggtgta	gcggagaaat	tccaatcgaa	840
	cttgagata	gctggttctc	tccgaaatag	ctttagggtc	agcctcgagg	taaagagta	900
10	tggaggtaga	gactggtttg	gactaggggc	ccttctcggg	ttaccgaatt	cagataaagt	960
	ccgaatgcc	tgtacttata	ctcgggagtc	agactcgagc	tgataagatc	cgtagtcgaa	1020
	agggaaacag	ccagaccac	cagttaaagt	ccccaatat	atgttaagtg	gaaaaggtatg	1080
	tgggtgtgct	tagacaacca	ggatgtttgc	ttagaagcag	ccaccattga	aagagtcggt	1140
	aatagctcac	tggtcgagtg	accccgcgcc	gaaaatgtac	cggggtctaa	catattaccg	1200
15	aaactgtgga	tgaacctctt	tagaggttcg	ggtaggaga	gcgttctaac	ggcgggtgaag	1260
	tacagaccga	aggactgggt	gagcgcttag	aagtgagaat	gccggtagta	gtagcgaaag	1320
	aagggtgaga	atcccttcca	ccgaatatct	aaggtttcct	gaggaaggct	cgtccgctca	1380
	gggttagtcg	ggacctaagc	cgagggcgat	aggcgtagcg	gatggacaac	aggttagagat	1440
20	tctctgacca	gtgcctaatt	gtcgaagtgt	tgagaagtgt	gcaaatccgc	ttctcacgaa	1500
	gcatgagctg	tgatggggaa	ggaaattaag	tacggaaagt	cctgatttca	cgcgtgtcaag	1560
	aaaagcctct	aggaagagta	gtactgcccc	taccgcaaac	cgacacaggt	agatgagagg	1620
	agaaatctcaa	ggtagcgag	agaaactctg	ttaaaggaa	cgcaaaaatg	accccgctac	1680
	ttcgggagaa	gggtgtctct	attagggtgc	aagcccgaga	gagcccgagt	gaatagggccc	1740
25	agggcgactg	ttagcaaaaa	cacaggtctc	tgcaaaaccg	taagggtgacg	tataggggct	1800
	gcagcctgcc	cggtgtcgga	aggttaagag	gagtgcttag	cttcggcgaa	ggtagcaatt	1860
	gaagcccgag	taaaaggcgg	ccgtaactat	aacggtctca	aggtagcgca	attcctgtct	1920
	gggttaagtt	cgacccgcac	gaaaggcgca	acgatctggg	cactgtctca	acgagagact	1980
	cggtgaaatt	atagtaacct	tgaagatgca	gggtaccgcg	gacaggacgg	aaagaccgcg	2040
30	ttgagcttta	ctgcaacctg	atatggaatg	tttgtaccgc	ctgtacagga	taggttaggag	2100
	ccgaagagac	gtgtgcgcta	gcatacgagg	aggcaatggt	gggatactac	cctggctgta	2160
	tgaccattct	aacccgcac	gcttagcgcg	tggggagaca	gtgtcaggtg	ggcagtttga	2220
	ctggggcggt	cgctccttaa	agagtaacgg	aggcgcccaa	aggttccctc	agaatggatg	2280
	gaaatcattc	gcagagtgta	aaggcacaag	ggagcttgac	tgcgagactg	acaagtgcag	2340
35	caggagacgaa	atcggggctt	agtgatccgg	tggttccgca	tggaaaggcc	atcgctcaac	2400
	ggataaaagc	taccccgggg	ataacaggct	tatctccccc	agaagtcacc	atcgagccgg	2460
	aggtttggca	ctcgatgtc	ggctcgtcgc	atcctggggc	tgtagtcggt	cccaagggtt	2520
	gggtcgttgc	cccataaag	cggcacgcga	gctgggttca	gaacgtctgc	agacagtcgc	2580
	gtccctatct	gtcgcggggc	caggaaattt	gagaggagct	gtccttagta	cgagaggacc	2640
40	gggatggaca	caccgctgg	gtaccagttg	ttccgcgagg	agcatcgctg	ggtagctatg	2700
	gtggcgaggg	ataaacgctg	aaagcatctc	agcgtgaagc	ccccctcaag	atgagatttc	2760
	ccattttctc	ggaaatgaag	atccctgaaa	gatgatcgag	tagataggtt	tggagtgaaa	2820
	gtgtagcgat	acatggagcg	gacaaatact	aatcgatcga	ggacttaacc	aa	2880
45	<210>	54					2932
	<211>	2923					
	<212>	DNA					
	<213>	Staphylococcus aureus					
50	<400>	54					
	gattaaggtta	ttaaggcgcc	acgggtggatg	ccttggcact	agaagccgat	gaaggacgtt	60
	actaaacgac	atatgctttg	gggagctgta	agtaagcttt	gatccagaga	tttccgaatg	120
	gggaaaccca	catgagtgta	tgctatgtta	tcgatattgt	aatacatagc	atatacagaag	180
55	gcacacccgg	agaaactgaaa	catcttagta	cccgaggaaa	gagaaagaaa	attcgatctc	240
	cttagtagcg	gcgagcgaaa	cgggaagagc	ccaaaccaac	aagcttgctt	gttgggggtg	300

	taggcacactc	tatacggagt	tacaaaggac	gacattagac	gaatcatctg	gaaagatgaa	360
	tcaaagaagg	taataatcct	gtatgcgaaa	atgtgtgtct	tcttgagtg	atcctcagta	420
	cgcagtagca	cgtgaaatcc	cgtcggaatc	tggggaggacc	atctcctaag	gctaaataact	480
	ctctagtgac	cgtagtgtgaa	ccagtagcgt	gaggggaaagg	tgaaaagcac	cccggaagg	540
5	gagtgaaata	gaacctgaaa	ccgtgtgctt	acaagtagtc	agagcccgtt	aatgggtgat	600
	ggcgtccctt	tgttagaatg	aacgcgcgag	ttacgatttg	atgcgaagtg	agccagtaaa	660
	tgtggagccg	tagcgaaagc	gagtcctgaat	agggcggtta	gtatttggct	gtagaccgca	720
	aaccagggtg	tctacccttg	gtcaggttga	agttcaggtg	acactgaatg	gaggaccgaa	780
	ccgacttacg	tgtgaaaagt	agcggatgaa	ctgaggggtg	cgagagaatt	ccaatcgaa	840
10	ctggagatag	ctggttctct	ccgaaatagc	tttagggcta	gcctcaagtg	atgattattg	900
	gaggtagagc	actggttgga	cgagggggcc	ctctcgggtt	accgaaattc	gacaaactcc	960
	gaatgccaat	taatttaact	tgggagtcag	aacatgggtg	ataaggtccg	tgttcgaaa	1020
	ggaaacagcc	cagaccacca	gctaaggtcc	caaataatat	gttaagtggg	aaaggatgtg	1080
	gcgttgccca	gacaactagg	atgttggctt	agaagcagcc	atcatttaaa	gagtgcgtaa	1140
15	tagctcacta	gtcgagtgac	actgcgcgca	aaatgtacog	gggctaaca	tattaccgaa	1200
	gctgtggatt	gtcctttgga	caatggttag	agagcgttct	aaggggcttg	aagcatgatc	1260
	gtaagcgacat	gtggagcgct	tagaagttag	aatgcgggtg	tgagttagcg	aagacggggtg	1320
	agaatccccg	ccaccgattg	actaagggtt	ccagaggaag	gctcgtccgc	cttgggttag	1380
20	tcgggttccta	agctgaggcc	gacaggcgta	ggcgatggat	aacaggttga	tattcctgta	1440
	ccacctataa	ctgttttaat	cgatgggggg	acgcagtagg	ataggcggaag	cgtgcgattg	1500
	gattgcagctc	ctgaagcagta	aggctgagta	ttaggcaaat	ccggtactcg	ccagagctga	1560
	gctgtgattg	ggagaagaca	ttgtctcttc	gagtcgttga	tttcacactg	ccgagaaaa	1620
	cctctagata	gaaataaggt	gcccgtaacc	caaacgcgca	caggtagtca	agatgtagatt	1680
	tctaaggtga	gcgagcgaa	tctcgttaa	gaactcggca	aaatgacccc	gtactctcgg	1740
25	gagaaggggg	gctctttagg	gttaaaccgcc	agaagagccg	cagtgaaatg	gcccaagcga	1800
	ctgtttatca	aaaacacagg	tctctgctaa	accgtaaagt	gatgtatagg	ggctgacgcc	1860
	tgcccgggtg	tgggaaggta	agaggagtg	ttagctttcg	cgaagctatc	aatcgaaagg	1920
	ccagtaaacg	gcggccgtaa	ctataacggt	ccctaagtg	cgaaaatctc	tgtcgggtaa	1980
30	gttcgcgacc	gcacgaaagg	cgtaacgatt	tgggcactgt	ctcaacgaga	gactcggtag	2040
	aatcatagta	cctgtgaaga	tgcaggttac	ccgcgacagg	acggaaaagc	ccctcggagc	2100
	tttactgtag	cctgatattg	aaattcggca	cagcttgtac	aggataggtg	ggagcctttg	2160
	aaacgctgag	gctagcttac	gtggaggcgc	tggtgggata	ctaccctagc	tgtgttggtc	2220
	ttctaacccg	caccacttat	cgtggtgagg	gacagtgcca	ggcgggcagt	ttgactgggg	2280
35	cggtcgccct	ctaaaaagta	acggaggcgc	tcaaaagttc	cctcagaagt	gttggaaatc	2340
	attcatagag	tgtaaaaggca	taaggagagc	tgactgcgag	acctacaagt	cgagcaggtg	2400
	cgaagacgag	acttagtgat	ccggtgggtc	cgactggaag	ggccatgact	caacggataa	2460
	aagctaccgc	gggtgatca	ggcttatctc	ccccaaagtg	tcacatcgag	ggggaggttt	2520
	ggcaactcga	tgtcgctca	tcgcactcgt	gggctgtagt	cggtcacca	ggttggggctg	2580
	ttcgcgccatt	aaagcggtag	gcgagctggg	ttcagaacct	cgtgagacag	ttcggctccct	2640
40	atccgtcgtg	ggcgtaggaa	atttgagagg	agctcgttgt	agtaacgag	gaccggagtg	2700
	gacatacctc	gtgtgtacca	gttctcgtgc	caacggcata	gctgggtagc	tatgtgtgga	2760
	cgggataaag	gctgaaagca	tctaagcatg	aagcccccct	caagatgaga	tttcccaact	2820
	tcgggtataa	gatccctcaa	agatgatgag	gttaataggt	cagagtgga	agcatggtga	2880
45	catgtggagc	tgacgaatac	taatcgatcg	aagacttaat	caa		2923

<210> 55

<211> 2900

<212> DNA

50 <213> *Streptococcus mutans*

<400> 55

	gtaaggttaa	taaggcgcca	cggtggatgc	ctaggcacta	ggagccgatg	aaggacgtga	60
	cgaacgacga	cagcttttgg	ggagctgtaa	gtaagccttg	atccagagat	atccgagatg	120
55	gggaacccaa	caggttaatg	ctgttatcca	taactgttaa	gggtatgaga	aggaaagcgc	180
	agtgaactga	aacatctcag	tagctgcagg	aagagaana	gagcggatg	gcttcagtag	240

	cgccgagcga	agagggcagga	gggcaaacca	gagtgtttac	actctggggg	tgtaggactg	300
	cgataaagca	gccaaaggaa	tagaagaaga	ctctgggaag	agtcgccaga	gagagtga	360
	gcctctgatt	ggaattccac	ttgatgccaa	gcaggatcct	gagtagccgc	ggacacagag	420
	aatcccgctg	taactctggga	ggcccatctc	ccaaacctaa	atactcccta	gtgaccgata	480
5	tgaaaccagt	accgtgaggg	aaaggtgaaa	agtaaccocg	aaggggagtg	aaagagaacc	540
	tgaaacccgt	gctctacaag	aagttcagagc	ccgttaabtg	gtgagagcgt	gccctttgtg	600
	gaatgaaccg	gcgagttacg	tttacctgcg	aggttaagtt	gaagagacgg	agccgtaggg	660
	aaaccgagtc	tgaaaagggc	ggttaaagtac	gtagatgtag	accggaacc	aagtgaacct	720
	cccatgagca	ggttgaaggt	gcggtaaaaa	gcactggagg	accgaaccag	gacacgttga	780
10	gtttgatttg	gatgacttgt	gggtagcggg	gaaattccaa	acgaacttgg	agatagctgg	840
	ttctctccga	aatagcttta	gggttagcgt	cggtcgccag	actcttgagg	gtagagcact	900
	gtttgatttg	gggtccatc	ccggattacc	aatctcaagat	aaactccgaa	tgccaacag	960
	ttaaagaccg	cagtcagact	gcgagtgcta	agatccgtag	tcgaaaggga	aaacagccag	1020
	accaccagct	aaggtcccca	aataattgtt	aagtggaaaa	ggatgtgggg	ttgcacagac	1080
15	aactaggatg	gatgcttaga	agcagctatt	cattcaagaa	gtgcgtaata	gctcactagt	1140
	ccagtgcacc	tgccgccaaa	atgtaccggg	gctgaaacaa	tttaccgag	ctgtggatcc	1200
	cttaggggat	ggtagagagag	cgttctatgt	gcgcagaagg	tgtaccgcaa	ggagccgctg	1260
	agtgcataga	agtgagaaat	ccggtatgag	tagcgtaaga	caggtgagaa	tcctgtccac	1320
	ctgaagacta	aggattccag	gggaaggctc	gtccgcctcg	ggtttagtcg	gacctaaagg	1380
20	gagaccgata	gggtgatccg	atgggcaaca	ggttgatatt	cctgtactag	agttattgag	1440
	gaagagagga	cgacgacggc	taactagagc	gtgcgatttg	aagagcacgt	ccaagcagtg	1500
	aggtgaggac	tgagtcacaa	gcttagttct	gcgccaccac	gctgtgacgg	ggagcgcaag	1560
	ttagtacgca	agctagtga	gtcactctgc	caagaaaagc	ttctagcgtt	aatgaatact	1620
	ctaccgcgtac	cgcaaaccca	cacaggtagt	cgagcgagct	agcctcaggt	gatcgagcga	1680
25	actctcgcta	aggaactcgg	caaaatggcc	ccgtaacttc	gggagagggg	gcgctggcga	1740
	taagtccagc	cgagtgaaaa	ggcccaagca	actgtttatc	aaaaacacag	ctctctcgca	1800
	aatcgtaaga	tgaagtatag	ggggtgacgc	ctgcccggtg	ctggaaagtt	taagagagcg	1860
	cttagacgtt	tgtcgaaagt	gtgaattgaa	gccccagtaa	acggcgccgc	taactataac	1920
	ggctctaagg	tagcgaatc	ccttgtcggg	taagttccga	cccgcacgaa	aggcgaatg	1980
30	atttgggcac	tgtctcaacg	agagactcgg	tgaattttaa	gtacctgtga	agatgcaggt	2040
	taccgcgcac	aggacggaaa	gaccccatgg	agctttactg	cagtttgata	ttgcgtatct	2100
	gttacacatg	tacaggatag	gtaggagcca	aggaagagtg	aacgctagtt	tacttggagg	2160
	cggtgttggtg	atactaccct	tgtgtgatgg	ctactctaac	ccggtaggtt	gatcatctac	2220
35	ggagacagtg	tctgacgggc	agtttgactg	gggcgggtcg	ctcctaagcg	gtaacggagg	2280
	gcgccaaagg	tctccctcaga	ctgggtggaa	atcagtcgta	gagtgtaagg	gtataaggga	2340
	gcttgaactg	gagacagaca	agtcgagcag	ggacgaaagt	cggtgttagt	gtacccgttg	2400
	tacogtatgg	aagggccatc	gctcaacgga	taaaagctac	cctgggggata	acagcgctat	2460
	ctcccccaag	agttcacatc	gacggggagg	tttggcacct	cgatgtccgc	ctgcctcact	2520
	ctggggcggt	agtcggtccc	aagggttggtg	ctgttcgccc	attaaagcgg	cacgcagctg	2580
40	gggttcagaa	cgctcgtaga	cagttcggtc	cctatccgtc	gcggcggaag	gaattttgag	2640
	tgcatctgct	cctagtcaga	gaggaccaga	gtggacttac	cgctgggtga	ccagttgttc	2700
	ggccaagagc	agtcgtgggt	agctaagtga	ggaggggata	aacgctgaaa	gcattcaggt	2760
	gtgaagcccc	cctcaagatg	agatttccca	taacgttcag	ttagtaagag	ccctgaaaga	2820
	agaaacggta	gataggttgg	gagtggaagc	gttgtgagac	gtgaagcgga	ccaatactaa	2880
45	tcgctcgagg	acttatccaa					2900

<210> 56

<211> 2902

50 <212> DNA

<213> Streptococcus pneumoniae

<400> 56

55 ggttaagtta ataagggcgc acgggtggatg ccttgccact agggagccga gaaggaagctg 60
 aaaaacagca atatgccttg gtagctgtga ctttaagcgt gatccagga ttccgaagt 120
 ggggaaccca acaggttaata cctgttaccac acatctgtta aggatgtgag gaggaaagacg 180

	cagtgaactg	aaacatctaa	gtagctgcag	gaagagaaag	caaaagcgat	tcctcttagta	240
	gcggcgagcg	aaacggcaga	agggcaaac	gaagagtta	ctcttcgggg	ttgtaggact	300
	gcaatgtgga	ctcaaaagatt	atagaagaat	gatttgggaa	gatcagccaa	agagagtaaat	360
	agcctgctat	ctaaatagat	ctttgtactt	agcagtatcc	tgagtacggc	gggacacgtg	420
5	aaatcccgctc	ggaaatctggg	aggacatct	ccaaccccta	aatactcccc	agtgaaccgat	480
	agtgaaacac	taccgtgagg	gaaaggtgaa	aagcaccgcc	ggaggggagc	gaaatagaac	540
	ctgaaaccgt	gtgectacaa	caagttcgag	ccogttaatg	ggtgagagcg	tcctctttgt	600
	agaatgaacc	ggcgagttac	gttatgatgc	gaggttaaag	tgaaagagacg	gagccgtagg	660
	gaaaccagagt	ctgaataggg	gcctcttagta	tcattgacgta	gaccggaac	catgtgacct	720
10	accctagagc	aggttgaagg	tgccgtaaga	cgactggag	gaccgaaacca	gggcaacctg	780
	aaaagtgcct	ggatgacttg	tgggtagcgg	agaaattcca	aacgaacttg	gagatagctg	840
	gttctctccg	aaatagcttt	agggctagcg	tcgacattag	agattcttgg	aggttagaca	900
	ctgtttgggt	gaggggtcca	tcctcgatta	ccaatctcag	ataaactccg	aatgccaagt	960
	aattatggtc	ggcagtcaga	ctgcgagtg	taagatccgt	agtcgaagg	gaaacagccc	1020
15	agaccaccag	ctaaggtccc	aaaataattg	ttaagtggaa	aaggtatggg	gggtgcacag	1080
	acaactagga	ctgttagctta	gaagcagcta	ttcattcaaa	gagtgcgtaa	tagctcata	1140
	ctcgagtgac	tccgcgcgca	aaatgtaccg	gggctaaaac	aatttaccga	atgtctgact	1200
	acctttatag	gtatggttag	agagcgttct	atgtgtgatg	aaggtatacc	gtgaggagtg	1260
	ctggaaacga	tagaagttag	aatgcgcgta	tgagttagca	aagacaggtg	agaactctgt	1320
20	ccaccgtaag	actaagggtt	ccaggggaag	gctcgtccgc	cctggggttag	tcgggaccta	1380
	aggagagacc	gaaaggtgta	tcogattggac	aacaggttga	tattcctctga	ctagagtagt	1440
	tagtgatgga	gggacgcagt	aggcttaact	aagcagacga	ttggaagagt	ctgtctaaag	1500
	agtgaggtgt	gaattgagtc	aaatgcttaa	ttctataaca	ttgagctgtg	attggggagcg	1560
	aagtttagta	gogaagttag	tgaogtcaca	ctgccaaaga	aagcttctag	cgtttaaaca	1620
25	tactctacc	gtaccgcgca	ccgacacagg	tagtcgaggg	gagtagcctc	aggtgagcga	1680
	gagaactctc	gttaaaggaa	tcggcgaat	gaccccgtaa	cttcgggaga	aggggtgctg	1740
	acttaaaagt	agccgcagtg	aataggccca	agcaactgtt	tatcaaaaac	acagctctct	1800
	gctaaatcgt	aagatgatgt	atagggggtg	agccctgccc	gggtctggaa	ggttaagagg	1860
	agtgcttagc	gtaagcgaag	gtatgaattg	aagccccaag	aaacggcgcc	cgtaactata	1920
30	acggctctaa	ggtagcgaaa	ttcctgtctg	ggtaagtcc	gaccgcacg	aaaggcgtaa	1980
	tgatttgggc	actgtctcaa	cgagagactc	ggtagaattt	tagtacctgt	gaagatgcag	2040
	gttaccgcgc	acaggacgga	aagaccccat	ggagctttac	tgacgtttga	tattgagtgt	2100
	ctgtaccaca	tgtagcagat	aggtaggagt	ctaagagatc	gggacggcag	tttcgaagga	2160
35	gacgtctgtt	ggatactacc	cttgtgttat	ggccactcta	accacgatag	gtgatcccta	2220
	tcggagagacg	tgctcagcgg	gcagtttgac	tgggcgcgct	gcctccctaa	aggtaacgga	2280
	ggcgcccaaa	gggtccctca	gaatgggttg	aaatcattcg	cagagtctaa	aggtataagg	2340
	gagcttgact	gcgagagcta	caactcgagc	agggacgaaa	gtcgggctta	gtgatccgtg	2400
	ggctccgtat	ggaaggccca	tcgctcaacg	gataaaaagt	accctgggga	taacacagtt	2460
	atctccccca	agagttcaca	tcgacgggga	ggtttggcac	ctcgatgtcg	gctcgtcgca	2520
40	tcctggggct	tgatgctggc	ccaaggggtg	ggcagcttcg	ccatataaag	ggcaccgcag	2580
	ctggggtcag	aacgtcgtga	gacagttcgg	tcctatcccg	tcgcggcggt	aggaatttgg	2640
	agagagatcg	ctctcagtag	gagaggacca	gagtgagctt	accgctgggt	taccagttgt	2700
	cttgccaaaag	gcactcgtcg	gtagctatgt	agggaaaggga	taaacgctga	aagcatctaa	2760
	gtgtgaaacc	cacctcaaga	tgagatttcc	catgattata	tatcagtaga	agccctgaga	2820
45	gatgatcagg	tagataggtt	agaagtgga	gtgtggcgac	acatgtagcg	gactaatact	2880
	aatagctcga	ggacttatcc	aa				2902

<210> 57
 50 <211> 2901
 <212> DNA
 <213> Streptococcus pyogenes

<400> 57
 55 ggtaagttta ataagggcgc acggtggatg ccttggcact agaagccgaa gaaggagctg 60
 actaacgacg aaatgcttgg gggagctgta agtaagcgct gatccagaga tgtccgaatg 120

	ggggaacccg	gcactgtaag	catgtcatcc	atgactgtta	aggtcatgag	aagggaagacg	180
	cagtgaactg	aaacatctaa	gtagctgcag	gaagagaaga	caaacgcgat	tgcccttagta	240
	gcggcgagcg	aaacgcgcag	agggcacaac	gaggagttta	ctcctcgggg	ttgttaggact	300
	gcgaagtggg	actataaagt	aataagaaga	ttacctggga	aggtaaagcca	aagagagataa	360
5	cgacctcgta	tttaaaattg	acttttagccc	tagcagatgc	ctgagtcagg	cgagacacgc	420
	gaactctcgt	ctgaactcgg	gaggaccatc	tcaccaacct	aaataactctc	tagtgatcgca	480
	tagtgaacca	gtaccgtgag	ggaaaggtga	aaagcacccc	gggaggggag	tgaataagaa	540
	cttgaacccg	tggtcctaca	acaagttcga	gcccgttaat	gggtgagagc	gtgccttttg	600
	tagaatgaac	cggcgagtta	cgatatgatg	cgaggtttaag	ttgaagagac	ggagccgtgac	660
10	ggaaacccgag	tcttaataagg	gcgtcatagt	atcatgttgt	agaccgcaaa	ccatgtgacc	720
	taccatgag	cagggtgaag	gtgtggttaa	acgcactgga	ggaccgaacc	agggcacgtt	780
	gaaaagtgct	tggatgactt	gtgggtagcg	gagaaattcc	gaagaaactt	ggagatagct	840
	ggttctctcc	gaaatagctt	tagggctagc	gtcgatgtta	agtcctcttg	aggtagagca	900
15	ctgtttgggt	gaggggtcca	tcoccgatta	ccaactctag	ataaacctcg	aatgccaaag	960
	agataaatc	ggcagtcaga	ctgcgagtc	taagatccgt	agtcgaaagg	gaaacagccc	1020
	agaccacag	ctaaggctcc	aaaataactg	ttaagtgga	aaggatgtgg	ggttgacag	1080
	acaactagg	tgtagcttta	gaagcagcta	ttcattcaaa	gagtgcgtaa	gagtgactta	1140
	ctcgagtga	cctgcgcga	aaatgtaccg	gggctaaaac	agtttaccga	agctgtggat	1200
20	gacacaaaag	gtgtcatggt	ggagagcggt	ctatgtgtga	agaaggtgta	ccgtgaggag	1260
	cgctgggaacg	catagaagtg	agaatgcggg	tatgagtgc	gaaagacagg	tgaagaatcct	1320
	gtccacggta	agactaaggt	ttccaggggg	aggctcgtcc	gccctgggtg	agtcgggacc	1380
	taaggagaga	ccgaaaagtg	tatccgatgg	ccaacaggtt	gatattcctg	tactagagta	1440
	tatagtgtag	gagggacgca	gtaggctaac	taaacccggg	gattggaaga	gtccggctaa	1500
25	cgagtggagt	tgaagatgag	tcaaatgctt	atctttataa	catttgagctg	tgatggggag	1560
	cgaaattttag	tagcgaagtt	agtgaatgca	cactgccaa	aaaagcttct	agcgtttaat	1620
	gataactctac	ccgttaacgca	aaocgacaca	ggtagtgcag	gcgagtggcc	tcagggtgatc	1680
	gagagaactc	tgcttaagga	actcggcaaa	atgaccocgt	aacttcggga	gaagggtgtg	1740
	tgacttaggt	cagcccgagt	gaataggccc	aagcaactgt	ttatcaaaaa	cacagctctc	1800
30	tgctaaatcg	taagatgatg	tatagggggt	gacgcctgcc	cggtgctgga	aggttaagag	1860
	gaggggttag	cgcaagcgaa	gatctgaatt	gaagcccgag	taaacgcggg	ccgtaaactat	1920
	aacggctcta	aggttagcgaa	attccttgtc	gggtgaattc	cgaccgcgac	gaaaggcgta	1980
	atgatttggg	cactgtctca	acgagagact	cggtgaaatt	ttagtacctg	tgaagatgca	2040
	ggttaccgcg	gacaggacgg	aaagacccca	tggagcttta	ctgcagtttg	atatagagta	2100
35	ctctgaccac	atgtacagga	taggttaggag	ccattgactt	cgggacgcca	gtttcgaaatg	2160
	aggcgttgtt	gggatactac	ctttgtgtta	tggtactctt	aaccagagta	ggttatccct	2220
	atcgagagca	gtgtctgacg	ggcagtttga	ctggggcgct	cgctccttaa	aggttaacgg	2280
	aggcccccac	aggttccctc	agatttggtg	gaaatcaatc	gcagagtgtta	aaggtataag	2340
	ggagctgtgac	tgctgagagct	acaactcgag	cagggaagca	agtcgggctt	aggtatcggg	2400
40	tggtaccgaa	tgaagggccc	atcgctcaac	ggataaaaag	taccctgggg	ataacaggct	2460
	tactctcccc	aggaattcac	atcgacgggg	aggtttggca	ccctgatctg	ggctcgtcgc	2520
	atcctggggc	tgtagtcggt	cccaagggtt	gggtgtgtcg	cccatataag	cggtcagcgca	2580
	gctgggttca	gaacctcggt	agacagttcg	gtccctatcc	gtccggtggt	tgagaaattt	2640
	gagaggatct	gctcctagta	cgagaggacc	agagtggact	taccgctggt	gtaccagttg	2700
45	tctgtccaaa	ggcatcgctg	ggtagctatg	ttaggaaggg	ataagcctg	aaagcatcta	2760
	agtcgcaagc	ccccctcaag	atgagatttc	ccagtatttt	atatcagtaa	gagccctgag	2820
	agatgatcag	gtagataggt	taggagtgtta	agtttagcga	tacatgtgac	ggactaatac	2880
	taatagctcg	aggacttacc	c				2901
50	<210>	58					
	<211>	3107					
	<212>	DNA					
	<213>	Mycobacterium avium					
55	<400>	58					
	tggtgtgaag	taaggtttta	agggcgcatg	gtggatgctt	tggtcatcgag	agccgatgaa	760

	ggacgtggga	ggctgcgata	tgcctcgggg	agctgtcaac	cgagcattga	tccgaggatt	120
	tcggaatggg	ggaaccacagc	acgagtgatg	tcgtgttacc	cgatctgaa	tatataggt	180
	gcgggaggta	acgcggggaa	gtgaaacatc	tcagtagccg	taggagaaga	aaacaattgt	240
	gattccgtca	atgtgtggcg	gcgaaccgga	acaggctaaa	ccgcatgcat	ggacaaccgg	300
5	gtaggggttg	tgtgtgcggg	gttgtgggat	tgtatgtct	cagctctacc	tggtcgaggg	360
	gtatgcagaa	agtgatcggtg	ttagcggaa	tgccctggga	ggcccgccg	tagacccgtga	420
	gagcccgcta	cgcgaaaacc	cgccacctgc	cttatataca	cacccgagta	gcagcgggcc	480
	cgtggaatct	gctgtgaatc	tgccgggacc	accggtaag	cctaataact	tctcgatgac	540
	cgatagcggg	ttagtaccgt	gagggaaatgg	tgaaaagtac	cccgggaggg	agtgaataag	600
10	tacctgaacc	cgtgtgccta	caatccgtca	gagcctcctc	gtggggatg	gcgcgtcctt	660
	tgaagaatg	agcctgcgag	tcaggggacac	gtccgagagt	taaccctgtc	ggggtagcgc	720
	cagcgaaagc	gagtcctgaat	agggcgcatc	ccctttgggg	tgtagtggcg	tgtctgggac	780
	ccgaagcgga	gtgatctacc	catggccagg	gtgaagcgcg	ggtaagacgc	cgtggaggcc	840
	cgaaccact	taggttgaag	actgagggga	tgagctgtgg	gtaggggtga	aaggccaact	900
15	aaactccgtg	atagctgggt	ctccccgaaa	tgcatttagg	tgcagcgttg	gtcggttacc	960
	cacggaggtg	atagctactg	atggccgatg	ggccctacta	ggttactgac	gtcagccaaa	1020
	ctccgaatg	cgtggtgtaa	aagcgtggca	gtgagacggc	gggggataag	ctccgtcagt	1080
	cgaagaggaa	cagaccggca	tcgccggcta	agggccctaa	gcgtgtgtcta	agtgggaaag	1140
	gatgtgtagt	cgacagagaca	accaggaggt	tggtcttagaa	gcagccatcc	tggaaagagt	1200
20	gcgtaatagc	tcaactgggtca	agtgattatg	cgccgataat	gtagcggggg	tcaagcacac	1260
	cgccgagagc	cgccgacatt	catctttaag	gtggatgtgg	gtagggggag	gtccccatt	1320
	cgcaagaagt	cgtggtgacc	ggtggtggag	ggtggggagg	tgagaatgca	ggcatgagta	1380
	gcgataaagg	aagtgagaac	cttgcccgcc	gtaaagccaa	gggttctctg	ggcagggccag	1440
	tcgcccgagg	gtgagtcggg	acctaaaggcg	agggcgacag	ggtagtcgat	ggaacacggg	1500
25	ttgatattcc	cgtaccctgt	tatgggcgtc	cctgatgaat	cagcggtaact	aaccaccaa	1560
	aaaccgatcg	accattcccc	ttcgggggcg	tgccgatctg	gggctcgctg	ggaaccttgc	1620
	tggttagtagt	caagcaatgg	ggtgaagcag	gaaggcgagc	gtaccagtcg	gtggttaatac	1680
	tggggcaagc	ccgtagagag	cgataggcaa	atccctgcct	cactaatcct	gaggggtgat	1740
	gcatagcggg	ttgaggcgaa	ttcggtgatc	ctctgctgcc	aagaaaagcc	cttagcgagc	1800
30	acatacacgg	ccgtaccccc	aaaccaaacc	aggtggctag	gtagagaata	ccaaggcgta	1860
	cgagataact	atggttaagg	aactcggcaa	aatgcccccg	taacttcggg	agaagggggg	1920
	ccggaatacc	gtgaacaccc	ttgcggtggg	agcgggattc	ggccgcagaa	accagtgggt	1980
	agcgactggt	tactaaaaac	acaggtccgt	gcgaagtgcg	aagacgatgt	atacggactg	2040
	acgcctgcct	gggtctggaa	ggttaagagg	accggttaac	cgtaagggtg	gaagcggaga	2100
35	atttaagccc	cagtaaacgg	cggttggtaac	tataaccatc	ctaaggtagc	gaatctctct	2160
	gtcgggtggt	ttccgacctg	cacgaatggc	gtaacgactg	cccaactgtc	tacacatagc	2220
	actcggcgaa	atgtcactac	gagtaaaagt	gctcgttacg	cgccggcagg	cgaaaagacc	2280
	ccgggacctt	cactacaact	tggtattggt	gttcggtacg	gtttgtgtag	gatagggtgg	2340
	agactttgaa	ccacagacgc	cagtttgtgt	ggagtcgttg	ttgaataacc	actctgatcg	2400
40	tatttgagca	cctaactcga	acccttatcg	ggttccaggc	cagtcgctgg	cggttagttt	2460
	aactggggcg	gttgctcctc	aaaatgtaac	ggaggcgccc	aaaggttccc	tcaacctgga	2520
	cgcccaatcag	gtggcgagtg	taagtgcaca	agggagcttg	actcgagacg	tacaagttca	2580
	agcaggggacg	aaagtgggga	ctagtgatcc	ggcaccgccg	agtggaaggg	gtgtcactca	2640
	acgggataaaa	ggatccccgg	ggaataacggg	ctgatctccc	ccaagagtcg	atatcgacgg	2700
45	gatgggtttg	cgactcgatg	tcggctcgct	gcatactggg	gctggagagc	gtcccaacgg	2760
	ttgggctggt	cgcccatata	agcggaacgc	gagctgggtt	tagaacgtcg	tgagacagtt	2820
	cggtctctat	cgcccgccgc	cgtcagaaac	ttgaggaaac	ctgtccctac	tacgagagga	2880
	ccgggacggg	cgaacctctg	gtataccagt	tgtcccaccca	ggggcaccgc	tggtatggca	2940
	cgttcgggaca	ggataaacgc	tgaaagcatc	taagcgggaa	acctctctca	agatcaggtt	3000
50	tctcaccctt	ttagagggat	aaggccccc	gcagaccacg	ggatgtatag	gccagacctg	3060
	gaagctcagt	aatgagtgca	gggaactggc	actaactggc	cgaaaagc		3107

55 <210> 59
 <211> 3138
 <212> DNA

<213> Mycobacterium tuberculosis

<400> 59

	ttgtaagtgt	ctaagggcgc	atggtggatg	ccttggcatc	gagagccgat	gaaggacgtg	60
	ggaggtctcg	atdgcctcgc	gggagctgtc	aaccgagcgt	ggatccgagg	atttccgaat	120
5	ggggaaaccc	atgcacgagtg	atgtcgtgct	accgcacatc	gaatatatag	ggtcggggag	180
	ggaacgcggg	gaagtgaaac	atctcagtag	ccgtagaggg	agaaaaaat	tgtgattccg	240
	caagtgtggt	cgagcgaacg	cggaaacagg	taaacccgac	gcattgggtta	ccgggtaggg	300
	gtttgtgtgt	cggggttgtg	ggaggatatg	tctcagcgct	accgcgctga	gaggcagcta	360
10	gaaagtgtcg	tgggttagcgg	aagtggcctg	ggatgggtctg	ccgtagacgg	tgagagcccg	420
	gtacgcgaaa	accgcgcacc	tgcctagtag	caattcccgca	gtagcagcgg	gcccgtagaa	480
	tcgcgtctga	atccgcgggg	accaccgggt	aagcctaaat	actcctcgat	gaccgatagc	540
	ggattagtac	cgtgaggaaa	tgggtgaaaag	taccocggga	ggggagtga	agagtacctg	600
	aaaccgtgtg	cctacaatcc	gtcagagcct	ccttttccct	tccggaggag	ggtggtgagt	660
15	cgctgacctt	tgaagaatga	gcctgcgagt	cagggacatg	tcgcaagggt	aacccggtgt	720
	gggtagccgc	agcgaagcgc	agtcgaata	ggggacacca	cacgcgcata	cgcggtgtgt	780
	aatagtggcg	tgttctggac	cgaagcggga	gtgatctacc	catggccagg	gtgaagcgcg	840
	ggtaagacgc	cgtggaggcc	cgaaccacat	taggttgaag	actgagggga	tgagctgtgtg	900
	gtagggggtga	aaggccaatc	aaactccgtg	atagctgggt	ctccccgaaa	tgcatttagg	960
20	tgcactcttg	cgtgggttcac	cgcggagggt	gagctactgg	atggccgcat	ggccctacta	1020
	gggttagctag	gtcagccaac	ctccgaatgc	cgtgggttaa	agcgtggcag	tgagacggcg	1080
	ggggataagc	tcggtacgtc	gaaagggaaa	cagcccgagat	cgccgggtaa	ggcccccaag	1140
	cgtgtctcaa	gtgggaagg	atgtgcagtc	gcaaaagaca	caaggaggtg	ggctctagaag	1200
	cagccacccct	tgaagagtg	cgtaatagtc	cactgggtcaa	gtgattgtgc	gccgataatg	1260
25	tagcggggct	caagcacacc	gccgaagccg	cggcacatcc	accttgggtg	gggtgtgggtg	1320
	aggggagcgt	ccctcattca	gcgaagccac	cgggtgaccg	gtgggtggag	gtggggaggt	1380
	gagatgcag	cgatgagtgc	gcacaaggca	atgagaaaac	tgcccccgcc	aaagaccaag	1440
	ggttctctgg	ccaggccag	ccgccacagg	tgagtccgga	cctaaggcga	ggccgacagg	1500
	cgtagtcgat	ggacaacggg	tgtatattcc	cgtaccgtgt	tgtggggccc	cgtgacgaat	1560
30	cagcggtag	aaccacccaa	aaccggatcg	atcactcccc	tcgggggtgt	tggagtctctg	1620
	gggctcgtgt	ggaacttcgc	tggtagtagt	caagcgaaag	ggtgacgcag	gaaggtagcc	1680
	gtaccagtca	gtggtaacac	tggggcaagc	cggtaggagg	agcgataggc	aaatccgtcg	1740
	ctcactaatc	ctgagaggtg	acgcataagc	ggttgaggcg	aattcgtgtga	tcctctgctg	1800
35	ccaagaaaag	cctctagcga	gcacacacac	ggcccgtagc	ccaaaccgac	acaggtgggtc	1860
	aggttagtcga	taccaaggcg	tacgagataa	ctatggttaa	ggaaactcggc	aaaactcgccc	1920
	cgtaactcgc	ggagagaagg	gaccggaata	tggtgaacac	ccttgcggtg	ggagccagct	1980
	ccggctcgag	ataaccagtga	ggagcgactg	tttactaaaa	acacagggtcc	gtgcgaagtc	2040
	cgaaagcagt	gtatccggac	tgcgcctcgc	ccggtgctgg	agggttaaga	agggccggtta	2100
	accgcgaagg	gtgaagcggg	gaatttaagc	cccagtaaac	ggcgggtgta	actataacca	2160
40	tctctaaagta	gcgaatttcc	ttgtcgggta	agttccgacc	tgcaaggaatg	gcgtaacgac	2220
	ttctcaactg	tctcaaccat	agactcggcg	aaattgcact	acgagtaaa	atgctcgtta	2280
	cgcgcggcag	gcgaaaaaga	ccccgggacc	tctactacaa	cttgtatttg	atgcttcggtta	2340
	cgggtttgtgt	ccactctgat	cgtattgggc	aaacctcgac	gccagttggg	gcggagtctgt	2400
	tgttgaataa	tgcggggtag	tttaactcgg	gcggttgctc	ctaataatgt	tcggggttag	2460
45	ggacaggtgc	ccctcaacct	ggacggcaat	caggtggcga	gtgtaaatgc	acaaaggagc	2520
	ttgactcgca	gacttacaag	tcaagcaggg	acgaaagtgc	ggattagtga	tcggccaccc	2580
	ccgagtgga	ggggtgtcgc	tcaacggata	aaaggtaccc	cggggataac	aggtcgatct	2640
	tcccaagag	tccatatcga	cgggtaggtt	tgccacctgc	atgtcggctc	gtgcctacct	2700
50	ggggctggag	caggtcccaa	gggttgggct	gttcgcccat	taaaagcgca	cgcgagctgt	2760
	gtttagaacg	ctgtgagaca	gttcggtctc	tactccgcgc	gcgcgtcaga	aacttgagga	2820
	aaactgtccc	tagtcagcga	ggacccggac	ggacgaacct	ctgggtcacc	agttgtccc	2880
	ccaggggcac	cgtcggtatg	ccacgttcgg	tcaggataac	gcgtgaaag	acttaagcgc	2940
	gaaaccttct	ccaagatcag	gtttctcacc	cacttgggtg	gataaggccc	ccccgagac	3000
55	acgggttcaa	ttaggtcacac	ctggaagctc	agttaatgggt	gtagggaact	ggtgctaacc	3060
	ggccgaaaac	ttacaaca					3120
							3180

	aatgaacgct	gaggcttaac	ctt			2903	
	<210>	61					
5	<211>	2903					
	<212>	DNA					
	<213>	Klebsiella pneumoniae					
	<400>	61					
10	ggttaagcga	ctaagcgctac	acggctggatg	ccctggcagt	cagaggcgat	gaaggacgtg	60
	ctaactctgcg	aaaagcgctcg	gtaaggtgat	atgaaccggt	ataaccggcg	atgtccgaat	120
	ggggaaaccc	agtgaacttc	gttgcaactat	cgttaactga	atacatagg	taacgaggcg	180
	aaccggggga	actgaaacat	ctaagtaacc	cgaggaaaag	aatcaaccg	agattcccc	240
	agtagcggcg	agcgaaacggg	gagcagcgcca	gagctctgaat	cagccttggt	gttagtggaa	300
15	cggtctggaa	agtcggacgg	tacagggtga	tagtcccgta	caccaaaatg	cacaggctgt	360
	gaactcgaa	agtagggcgg	gacacgtggt	atcctgtctg	aatatggggg	gaccatcttc	420
	caaggctaaa	tactcctgac	tgaccgatag	tgaaccagta	ccgtgaggga	aaggcgaaaa	480
	gaaccccggt	gaggggagtg	aaaaagaacc	tgaaacccgt	tacgtacaag	cagtgggagc	540
	acccttcgggt	gtgactgcgt	acccttttga	taatgggtca	cgcaactata	tctcttagca	600
20	aggttaacgc	tataggggag	ccgcagggaa	accgagctct	aactggggcg	taagtgcag	660
	ggatatagacc	cgaaaccccg	tgatctagcc	atgggcagggt	tgaaggttgg	gtaacacata	720
	ctggagagacc	gaaccgacta	atgttgaaaa	attagcggat	gacttgtggc	tgggggtgaa	780
	agggcaatcac	aaccgggaga	tagctggttc	tccccgaaag	ctatttaggt	agcgcctcgt	840
	gaactcatct	tacggggtag	agcactgttt	cggttagggg	gtcatcccca	cttaccaaac	900
25	cgatcgaaac	tacgaatacc	gaagaatggt	atcacgggag	acacacggcg	gggtctaacg	960
	tccgtcgtga	agagggaacc	aaccagagcc	gccagctaag	gtcccaaatg	catggttaag	1020
	tgggaaacga	tgtgggaagg	cacagacagc	caggatgttg	gottagaagc	agccatcaat	1080
	taagaagaagc	gtaaatagctc	actggtcgag	tccggctcgc	cggaagatgt	aaccgggcta	1140
	aacctatgcac	cgaagctcgc	gcagcgacac	tatgttgttg	tgggttaggg	agcgtctcgt	1200
30	aagcttcgca	aggtgtgctg	tgaggcatgc	tggaggatc	agaagtgcga	atgctgacat	1260
	aagtaacgat	aaagcgggtg	aaaagcccg	tcgccggaag	accgaagggt	cctgtcccaac	1320
	gttaatcggg	gcagggtgag	tcgaccccta	aggcgaggcc	gaaaggcgta	gtcgatggga	1380
	aaacaggttaa	tattcctgta	cttggtgtta	ctgcgaaggg	gggacggaga	aggtctatgt	1440
	agccggggca	cggttgtccc	gggttaagca	tgtaggctgg	ttgtccaggc	aaatccggat	1500
35	aatcaaggct	gaggttgtgat	gacgaggcac	tacggtcgtg	aagtaacaaa	tgcctcgtct	1560
	ccaggaaaag	ctcttaagca	tacagtaaca	tcaaatcgta	ccccaaacgc	acacaggtgg	1620
	tcaggttagag	aataccaagg	cgccttgatg	aactcgggtg	aaggaaactag	gcaaaaatgg	1680
	cgcgttaact	cggtaggaag	cacgctggtg	tgtaggtgaa	gccctcgccg	ggtagagctg	1740
	agaccagtgc	aagataccag	ctggctgcga	ctgtttatta	aaaacacagc	actgtgcgaa	1800
40	cacgaaatgc	gacgtatacg	gtgtgacgcc	tggccgggtg	cggaagggtta	attgatgggg	1860
	ttatccgttaa	ggagaaagtc	ttgatcgaag	ccccggtaaa	cgccggcgct	aactataacg	1920
	gtcctaagggt	agcgaataatc	cttgtcgggt	aagttccgac	ctgcacgaat	ggcgttaatga	1980
	tggccaggct	gtctccaccc	gagactcagt	gaaattgaac	tcgctgtgaa	gatgcagtg	2040
	accgcggca	agaeggaaag	accccgtaga	cctttactat	agcttgacac	tgaaacttga	2100
45	gccttgatgt	gtaggatagg	tggaggcgtt	tgaagcgctg	acgcgcactg	cgtctggagc	2160
	aaacttgaaa	taccacccctt	taatgtttga	tgttctaacc	ttggcccttc	accgggggtg	2220
	cggacagtg	ctggtgggta	gtttgactgg	ggcggtctcc	tcccaagagc	taacggagga	2280
	gcacgaaggt	tagctaatcc	tggtcggaca	tcaggagggt	agtgcaatgg	cataagctag	2340
	cttgactcgc	agcgtgacgg	cgcagcaggg	tcgcaaaagc	gggtcatagtg	attccggtgtg	2400
50	cttgaatgga	agggccatcg	ctcaacggat	aaaaggtagt	ccggggataa	caggctcata	2460
	cgcgccaaag	gttctaatcg	acggcggtgt	ttggcacctc	gatgtcgctc	catcacatcc	2520
	tggggctgaa	gtaggtccca	agggtatggc	tgttcgccat	ttaaagtgtg	acgcgagctg	2580
	gggtttagaac	gtcgtgagac	agttccgtcc	ctatctgccg	tgggcgctgtg	agaaatgagg	2640
	gggggtgcctc	ctagtacag	aggaccggag	tgggaogcatc	actggtgttc	gggttgtcat	2700
55	gcaatgcgtc	gtcccggtta	gctaataatgc	gaagagataa	gtcgtcaagca	catctaaaga	2760
	cgaaccttgc	cccgagatga	gttctccctg	agactttaag	tctcctgaag	gaacgttgaa	2820

gacgacgacg ttgatagccc ggggtgtgttaa gcgcagcgat gcgttgagct aacoggtact 2880
aatgaaccgt gaggcttaac ctt 2903

5 <210> 62
<211> 2897
<212> DNA
<213> Haemophilus influenzae

10 <400> 62
gtatagttaa gtgactaagc gtacaagggtg gatgccttgg caatcagagg cgaagaagga 60
cgtgtctaact tgcgaaaagc ttggaatgagt cgataaaggc cgtttaatcc aagataatccg 120
aatgggggaaa cccagtagat gaagaatctta ctatcaacaa gtgaattcat agcttgtgtga 180
ggcaaacccgg gagaaactgaa acatctaagt accccgagga aaagaaatca accgagattt 240
15 cgtcagtagc ggcgagcgaa agcgaagagag ccagtaagtg atagcaaat atgtgaggaga 300
atgtgttggg aagcacaatc aaagagggtg ataatcccg atctaaaaac catattgttg 360
tactaagcta acgaaagta gggcgggaca cgtgatatcc cgttgaaga agggggggccc 420
atctctcaag gcttaataact cctgatctgac cgaatgtgaa ccagtactgt gaagggaaagg 480
cgaaaagaac cgggtgtagg ggaagtgaat agaacctgaa accttgcacg accgactagt 540
20 gggagcgagg gcaaccttgt gactgcgtac cttttgtata atgggtcagc gacttatatt 600
ttgtagcgag tttaaccgaa taggggagcc gaagggaac cagagtctta ctgttggctg 660
agtgctcaag tatagaccg aaacccgggtg atctagccat gggcaggttg aaggttgggt 720
aacactaaact ggagaccgga accgactaat gttgaaaaat tagcggatga cttgtggctg 780
ggggtgaaag gccaatcaaa ccggagagata gctggtttcc cccgaaatct atttaggtag 840
25 agccttgag tgacacactt ggggttagag cactgtttcg cctagggggg catcccggct 900
taccaccccg atgcaaaact cgaatccaa agagtatac tcaggagaca cagggcggtg 960
gctaacgctc gtctgtgaga gggaaacaac ccagaccgc agctaagctc cccaagtcta 1020
tattaaagtg gaaacgaagt gggaaaggct agacagctag gatgttggct tagaagcagc 1080
catcatttaa agaaagcgta atagctcact agtcagatcg gctcggcggg aagatgtaac 1140
30 ggggtgtaaa tatagcaccg aagctgcggc atcagaattt attctgttgg gtacggggagc 1200
gtgtgttaag cgaagaaggg ttcatcgaga ggtggggctg acgtatcaca agtgcgaatg 1260
ctgacataag taacgataaa accgggtgaaa aaccggttcg ccggaagacc aagggttcct 1320
gtccaacggt aatcggggca ggggtgagtcg gctcctaagg cgaagctgaa aagcgtatgc 1380
gatgggaaac aggtttaatat tctgtactt ggtaaagctg cgatgtgggg accgagtagg 1440
35 ttaggttatc cctactgttg atatgtgcgt ttaagttggt aggtgggaaag tttaggcmaa 1500
tcggactct gtaaacacag agagatgat acgaggctct acgaggctct acgaggtagt 1560
ccacagcttc caggaaaagc cactaagcga aaggctttac taaaccgtac tgaaaaccga 1620
cacaggtgtt caggtagaga atactcagg gcttgagaga actcgggtga aggaactaggt 1680
caaaatagca ccgttaacttc gggagaagggt gcgcggcgct agatgtgaag ggctagcccc 1740
40 tgaaggttga accggtcgaa gataccagct ggctgcaact gttattttaa aacacagcac 1800
tctgcaaaac cgaaagtggg cgtatagggt gtgatgcctg cccggtgcgt gaaggttaat 1860
tgatgtatgc atcgaaaag agaacctgta tcgaagcccc agtaaacgccc ggcgctaact 1920
ataacggtrc taaggttagcg aaattccttg tcgggtaagt tccgacctgc acgaatggca 1980
taatgatggc caggctgtct ccaccggaga ctcagtgaaa ctcagtgaaa tgaatatcgc 2040
45 cgggttacc cggctagac ggaagaagcc cgtgaacctt tactatagct tgacactgaa 2100
cattgaattt tgaatgtg ag gataggtggg agcctttgaa gcagtagcgc cagctattgt 2160
ggagcgacc ttgaataacc accctttaac gtttgatgt ttaacgaaga tgacgaaacg 2220
tggctctcga cagtgctctg tgggtagttt gactggggcg gttctctccc aaagcgtata 2280
ggaggaacac taagggttgc taatcacggt cggacatcgt gaggttagtg caatgctata 2340
50 agcagctta actcgagac agacaagctg agcaggtacg aaagttagtc atagtatctc 2400
ggtggttctg aatggaaagg ccatcgctca accgataaaa ggtactccg ggaataacagg 2460
ctgatctcgc ccaagagtct atatcgacgg cgggtgttgg cactctgat tcggctctatc 2520
acatcctggg gctgaagtag gtcccaagggt tctggctgtg cgcattttaa agtggtagcg 2580
gagctggggt tagaactcg tgagacaggt cggctccat ctgcggttgg cgtagatga 2640
55 ttgattgggg gctatcctag tacgagagga cggtagtgga cgcatacgt ggttccggt 2700
tgtgtcgcca gacgcattgc cgggtagcta aatgcggaag agataagtcg tgaagcatc 2760

taagcacgaa	acttgccaag	agatgagtc	tccttgactt	taagtcatga	aggggtgttg	2820
tagactacga	cgtagatagg	ttgggtgtgt	aagtgatgtg	agtcatgtag	ctaaccaata	2880
ctaattgcc	gagaggc					2897

5

<210> 63
 <211> 2865
 <212> DNA
 <213> *Bordetella bronchiseptica*

10

<220>
 <221> modified_base
 <222> (622)
 <223> N = A, C, G or T/U

15

<400> 63
 gatcaagcga ctaagtgcac atggtgggatg ccttggcgat cacaggcgga tgaaggacgt 60
 agtagcctgc gaaaagctgc ggggagctgg caaacaagca ttgatccgca gatatccgaa 120
 tggggaacc caccgcaagc ggtatccctg gctgaatacc taggcagatc gaggcgcaac 180
 gggtagaactg aaacatctca gtatctcgag gaaaagaaat caaccgagat tccgaaagtat 240
 gtggcgagcgg aaatcgggaag agcctttacg atttagcatt tgcatagatc gaacggaatg 300
 gaaagtccgg ccgtagcagg tgatagccct gtacagcaat gcagagtgtg gaactaggcg 360
 taagagaagt agggcgggac acgtgaaatc ctgtctgaag atggggggac catccctcaa 420
 ggctaaatc ctgtgatcga ccgatagtg accagtagcg tgaggaaaag cgaaaagaac 480
 cccggaagga gtgaaataga tctgaaacc gtatgcatac aacagtcgga ccctctttaa 540
 ggggtgacgg cgtacctttt gtataatggg tcacgcagctt acattcagtg gcagcttaac 600
 cgaatcgaga aggcgtcaga anagcagtc ccgaatggcg ttccagtcgc tgggtgtaga 660
 cccgaaacca gatgatctac ccatggccag gttgaaggca cggtaaacgc tgctgaggga 720
 ccgaaccacac tagtggtgaa aaactagggg atgagctgtg gatagggtg aaaggctaaa 780
 caaatctgga aatagctggt tctctccgaa aactatttag gtatgcctc aagtattact 840
 gcagggggta gcgactggt atggctaggg ggtcatggcg acttaccaaa catggcgaaa 900
 ctccgaatac gtgcaagatc agcttgggag acagacgacc ggggtgtaac gtccggactc 960
 aagaggggaaa caaccagac cgccagctaa ggtcccgat tatcgctaag tgggaaaacg 1020
 agtgggaagc catagacagt caggaggttg gcttagaagc agccaccctt taaagaaagc 1080
 gtaatagctc ctgatcgag tctgtcctgc cgggaagatg aacggctaag cgataaacc 1140
 aagctgcggg tgtgcacttt tagtcgacgc gttaggaagc gttctctgaag gctcgaaagg 1200
 tggctgtgtaa aggtctctgg aggtatcaga agtcgcaatg ctgacatgag tagccataaa 1260
 gggggtgaaa agccctctgc ccgtaaagtc aaggtttcct gcgcaacgtb gacgcgca 1320
 gggtagctcg gccctaaagg cgaggcagag atcgtagct gatgggaagc tgggttaaat 1380
 tccagcaccg tctgacagtg cgatgggggg acggatcgcg gaaggtcaac aggggtgtgg 1440
 acgtccctgt tctgtcattg aagatggcgc ttaggcaaat ccggggcgca gaatacaagg 1500
 tgtggcaagc gcgagcaagt ctccgcaagt gatggaaagt ggttccaaga aaagcctcta 1560
 agcttcagct gtacagagacc gtaccgcaaa ccgacaagg tgggacggga tgaattatcc 1620
 aagggcctgt agagaactca ggagaaggaa ctggcaaat tgatacccta actcgggag 1680
 aagggtatac ctggtagtgt gaagcctgcg cgtcgagcat gaaggggcg cagagaatcg 1740
 gtggctcgca ctgtttatta aaaaacagc actctgcaaa gacgaagtc gacgtatagg 1800
 gtgtagcgcc tgcctgggtgc cggaaaggtt agtgatgggg gcaaaactct tgatcgaaagc 1860
 ccgggtcaaac gggggccgta actataacgg tcttaaggta gcgaaattcc ttgtcgggtt 1920
 agtctcgacc tgcacgaatg gcgtaaacgat ggccacatgt gacggaagga ccccatgaac 1980
 aagttgaaat gtttgtgatg atgcaatcta cccgcggcta gacggaagga ccccatgaac 2040
 cttactgtga gctttgcatt ggactgtgaa ccggcctgtg taggaatagg gggagggcga 2100
 gaactcagct cgccagattc gagggagcca tcttgaatat accaccctgg ttgtgtfctg 2160
 gttctaacct tggctcggtta tccggatcgg ggacagtga tggtaggacg ttgtactggg 2220
 gcgggtctctt cccaagcgtt aacggaggag ttcgaaagta cgctaggatg ggtcggaagt 2280
 cgtgctgata gtgcaatggc ataagcgtgc ttgactgtga gactcagat gaacaggtgc 2340
 gaacgggaca tagtgatcgg gtggttctga tggaaaggcc atcgctcaac ggataaagg 2400

	actctgggat	aacaggctga	taccgccc	gagttcatat	cgaaggcggt	gtttggcacc	2460
	tcgatgtcgg	ctcatctcat	cctggggctg	tagccggctc	aagggtatgc	gttccgcat	2520
	ttaaagaggt	acgtgagctg	gggttagaaa	cgctcgtaga	cagtttgctc	cctatctgcc	2580
	gtggcgcttg	gatacttgaa	caggagcctg	ctcctagtac	gagaggacgc	gagtggaagt	2640
5	acctctgggt	taccggtgtg	catgccaatg	gcattgcggc	gtagcttaag	acgggaagga	2700
	taaccgctga	aggcatctaa	gcgggaaact	cgctcgaaga	ttaggtatcc	ccgggtacag	2760
	atccccctga	agggtcgctt	gagaccagga	cggtgatagg	tcgggtgtgg	aagcgagta	2820
	atcggttaag	ctaaccgata	ctaattgccc	gtgaggtta	atctct		2865
10	<210> 64						
	<211> 2865						
	<212> DNA						
	<213> Bordetella parapertussis						
15	<220>						
	<221> modified_base						
	<222> (624)						
	<223> N = A, C, G or T/U						
20	<400> 64						
	gatcaagcga	ctaagtgc	atggtggatg	ccttggcgat	cacaggcgat	gaaggacgta	60
	gtagcctcgc	aaaagctcgc	gggagctggc	aaacaagcat	tgatccgcag	atatccgaat	120
	ggggaaaccc	acggcgaacg	gtatccctcg	ctgaatacat	aggccagctg	aggcgaacgc	180
25	gggtaactga	aacatctcag	tagctcgagg	aaaagaatc	aaccgagatt	ccgaaagtag	240
	tgccgagcga	aatcggaaga	gcctttacga	tttagcat	ttgtcatagtc	aaacggaatgc	300
	aaagtccggc	cgtagcaggt	gatagccctg	tagacgaaat	gcagagtgtg	gaactaggcg	360
	taagagaagt	agggcgggac	acgtgaaatc	ctgtctgaag	atggggggac	catcctccaa	420
	ggctaataac	tcgtgatcga	ccgatagtga	accagtagcg	tgaggaaagg	cgaaaagaac	480
30	cccggaaagg	gtgaaataga	tcctgaaacc	gtatgcatac	aaacagctcg	agctctctta	540
	tggggtgacg	gcgtacacct	tgtataatgg	gtcagcgact	tacattcagt	ggcgagctta	600
	accgaatagg	gaaggcgctc	gaanagcagt	ccgaataggg	cgctccagtc	ctggggttag	660
	accgaaaccc	agatgatcta	cccatggcca	gggtgaaggc	acggtaaacac	gtcgtgggag	720
	accgaaccca	ctagtgttga	aaaactaggg	gatgagctgt	ggataggggg	gaaaggctaa	780
35	acaaatctcg	aaatagctcg	ttctctccga	aaactattta	ggtagtgctc	caagtatatt	840
	tgacgggggt	agagcactgt	tatggctagg	gggtcatggc	gacttaccac	accatggcaa	900
	actccgaata	cctgcaagta	cagcttggga	gacagacgac	cggtgtgtaa	cgctccgact	960
	caagagggaa	acaaccacga	ccgcccagta	aggtccccga	ttatcgctaa	gcgataaac	1020
	aagtgggaag	gcatagacag	tcaggaggtt	ggcttagaag	cagccaccc	ttaaagaaga	1080
40	cgtaaatagc	cgatgatcga	gtcgtccctg	gcggaaagtg	taacgggttaa	gcgataaac	1140
	gaagctcgga	gtgtgcactt	ttagtgcagc	ggtaggagag	cggtctgtaa	gcctgcgaga	1200
	gtggcttgct	aaggctgctg	gaggtatcag	aagtgcgaat	gctgacatga	gtagcgataa	1260
	aggggttgaa	aagccccctc	gccgtaatgc	caaggtttcc	tgccgaacgt	tcactcggtc	1320
	aggggtgagtc	ggccccctaa	gcgaggcaga	gatgcgttag	tgatgggaag	ctgggttaata	1380
45	ttccagcacc	ctcgatcacg	gcgatggggg	gacggatcgc	ggaaagctat	gggggtgtg	1440
	gagctccctg	ttgctgcatt	gaagatggcg	cttaggcata	tcggggcgcg	agaaatcaag	1500
	gtgtggcacg	gtgtgcgaag	ctcgcgaag	tgattggaag	tggttccaa	aaaagcctct	1560
	aagctctcagc	tgtagcagac	cgtaccgcaa	accgacacag	gtggggcggg	atgaatatcc	1620
	caaggcgctct	gagagaactc	aggagaagga	actcggcaca	ttgataccgt	ctgactcgga	1680
50	gaaggtatcc	cctggttagt	tgaagcctgc	gcgctgagca	tgaaggggct	gcagagaactc	1740
	gggtgtcgcg	actgtttatt	aaaaacacag	cactctgcga	agacgaaggt	cgagctatag	1800
	ggctgtgacg	ctgcccggtg	ccggaaggtt	aagtgtatgg	gtgcaagctc	ttgatcgga	1860
	cccgggtaaa	cgccggccgt	aactataacg	gtctcaaggt	agcgaaatct	ctgtcggtgt	1920
	aagttccgac	ctgcacgaat	ggcgtaacga	tgccacacac	gtctctctct	gagactcagc	1980
55	gaagttgaa	ttgtttgtag	gatgcaatct	accgcggctg	agacgggaag	accccatgaa	2040
	ctttactgtg	agctttgcat	tggactgtga	accggcctgt	gtaggatagg	tgaggaggcg	2100

	agaactcgag	tcgccagatt	cgagggagcc	atccttgaaa	taccaccctg	gtttgtttgc	2160
	gggtctaac	ttggctcggt	atccggatcg	gggacagtg	atggtaggca	gtttgactgg	2220
	ggcggtctcc	tccecaagcg	taacggagga	gttcgaaggt	acgctaggtg	cggtcggaata	2280
	tcgtcgtgat	tggtcaatgg	cataagcgtg	cttgactgtg	agactgacag	tcgaacaggt	2340
5	gcgaaccgga	catagtgatc	cggtgggttct	gatggaaagg	ccatcgctca	acggataaag	2400
	gtactctggg	ataacaggct	gataccgccc	aagagttcat	atcgacggcg	gtgtttggca	2460
	cctcgatgtc	ggctcatctc	atcctggggc	tgtagccggg	ccaagggtat	gctgttcgac	2520
	atttaaagag	gtacgtgagc	tgggtttaga	aacgtcgtga	gacagtttgg	tcctatctcg	2580
	cgctgggctg	tggatacttg	aacaggagcc	tgctcctagt	accagaggac	cgagtgagac	2640
10	gtactcctgg	tgtaccgggt	gtcatgccaa	tggcattgcc	gggtagctaa	gtacggaaag	2700
	gataaccgct	gaaggcatct	aagcggaaac	tcgtctgaag	attaggtatc	ccgggactag	2760
	atccccctga	agggctgctc	gagaccagga	cgtgatagtg	tcgggtgtgg	aagcgcagta	2820
	atgcgttaag	ctaaccgata	ctaattgtccc	gtgaggtctg	atccct		2865
15	<210> 65						
	<211> 2864						
	<212> DNA						
	<213> Bordetella pertussis						
20	<220>						
	<221> modified_base						
	<222> (624)						
	<223> N = A, C, G or T/U						
25	<400> 65						
	gatcaagcga	ctaagtgcac	atgggtgatg	ccttggcgat	cacaggcgat	gaaggacgta	60
	gtagcctcgc	aaaagctcgc	gggagctggc	aaacaagcat	tgatccgcag	atatccgaat	120
	ggggaaaccc	acggcaagcg	gtatccctgg	ctgaatacat	agggccagtgg	agggcaaacg	180
30	gggtgaactga	aacatctcag	tagctcgagg	aaaagaaatc	aaccgagatt	ccgaaagtat	240
	tggcgagcga	aatcggaaag	gcctttacga	tttagcattt	tgcatagtgc	aacggaaatg	300
	aaagtccggc	cgtagcaggt	gatagcctcg	tagacgaaat	gcagagtgtg	gaactaggcg	360
	taagagaagt	agggcgggac	acgtgaaatc	ctgtctgaag	atggggggac	catcctccaa	420
	ggctaaatac	ctgtgatcga	ccgatagtga	accagtacgc	tgaggaaagg	cgaaagaac	480
35	cccgaagga	gtgaaataga	tcttgaaccc	gtatgcatac	aaacagtctg	agcctcttta	540
	tggggtgacg	cgctaccttt	tgtataatgg	gtcagcgact	tacattcagt	ggcgagctta	600
	accgaatagg	gaaggcgtca	gaanagcagt	ccgaataggg	cgtccagtgc	ctgggtgtag	660
	accgaaaccc	agatgatcta	cccatggcca	ggttgaaggc	acggtaacac	ctgctggagg	720
	accgaaccga	ctagtgttga	aaaactaggg	gatgagctgt	ggataggggg	gaaggcctaa	780
40	acaaatctgg	aaatagctgg	ttctctccga	aaactattta	ggtagtgcc	caagttat	840
	tgacgggggt	agagcactgt	tatggctagg	gggtcatggc	gaactaccac	accatggcaa	900
	actccgaata	cctgcgaagta	cagcttggga	gacagacgac	cgggtgtctaa	cgtccgagct	960
	caagagggaa	acaacccaga	cgcacagcta	aggtcccgaa	ttaatcgctaa	gtgggaaacg	1020
	aagtgggaag	gcatagacag	tcaggaggtt	ggcttagaag	cagccaccct	ttaaagaagag	1080
45	cgtaatagct	cactgatcga	gtcgtcctgc	gcggaagatg	taacggctaa	gcgataaac	1140
	gaagctcgcg	gtgtgcactt	ttagtgcagc	ggtaggagag	cgttctgtaa	gcctgcgaag	1200
	gtggcttgta	aggtgcgtcg	gaggtatcag	aagtgcgaat	gtgcacatga	gtagcagata	1260
	agggggtgaa	aagccccctc	gcgtaagtc	caaggtttcc	tgccgaacgt	tcactcgccg	1320
	agggctgagtc	ggggctctaa	gcgagggcga	gatgcgtagc	tgatgggaag	ctgggttaata	1380
50	ttccagacac	ctgtacagtc	gcgatggggg	ccggatcgcc	ggaaaggtcat	caggggtgtt	1440
	gagctccctg	tgtctgcatt	gaagatggcg	tattaggcaaa	tcggggcaaa	agaaatcaag	1500
	gtgtggcacg	agcgacgaag	tctcgcgaag	tgtattggaag	tggttccaa	aaagaccctc	1560
	aaagcttcagc	tgtagcgagac	cgtaccgcga	accgacacag	gtgggacggg	atgaatatatt	1620
	caaggcgctt	gagagaactc	aggagaagga	actcggcaaa	ttgataacgt	aactctggga	1680
55	gaaggtatac	cctgttagtg	tgaagcctgc	gcgctgagac	tgaaggggtg	gcagagaatc	1740
	gggtgctcgc	atcgtgttat	aaaaacacag	cactctgcaa	agacgaaagt	cgacgtatag	1800

	gggtgtgacgc	ctgcccggtg	ccggaaggtt	aagtgtatggg	gtgcaagctc	ttgatcgaag	1860
	ccccggtaaa	cggcgccgct	aactataacg	gtcctaaggt	agcgaatttc	cttgtcgggt	1920
	aagttccgac	ctgcacgaat	ggcgtaacga	tggccacact	gtctcctcct	gagactcagc	1980
5	gaagtgtgaag	gtttttgtgat	gatgcaatct	accgcggctg	agacggaaa	gacctatgaa	2040
	ctctttactgt	agctttgcat	tggactgtga	accgcgcctg	gtaggtatag	tgggagcgcg	2100
	agaactcagc	tgcaccagatt	cgagggagcc	atccttgaaa	taccaccctg	gtttgtttgc	2160
	ggttctaacc	ttggtccggt	atccggatcg	gggacagtgc	atggtatggca	gtttgactcg	2220
	ggcggtctcc	tcccaaacgc	taacggagga	gttcgaaggt	acgctaggta	cggtcggaaa	2280
	tcgtgctgat	agtccaatgg	cataagcgtg	cttgactgtg	agactgacag	tcgaacaggt	2340
10	gcgaacggga	catagtgtac	cgggtggtct	gatggaaggg	ccatcgctca	acggataaag	2400
	gtactctcgg	atacaggctc	gatacggccc	aagagtctat	atcgacggcg	gtgtttggca	2460
	cctcgatgct	ggctcatctc	atcctggggc	tgtagccggg	ccaagggtat	cgctgtcgcc	2520
	atttaagaag	gtacgtgagc	tgggtttaaa	acgtcgtgag	acagtttggt	ccctatctgc	2580
	cgtggcggtt	ggatacttga	acaggagcct	gtcctctagt	cgagaggacc	ggaggtggac	2640
15	tacctctggg	gtaccgggtg	tcatgccaat	ggcattgcgg	ggtagctaa	tacggaagag	2700
	ataacgcgtg	aaggcatcta	agcgaaactc	cgctcgaaga	ttaggtatcc	cgggactaga	2760
	tccccctgaa	gggtcgttcg	agaccaggac	gttgataggt	cgggtgtgga	agcgacgata	2820
	tgcgttaagc	taaccgatac	taattgcccg	tgaggtctga	tccct		2884
20	<210> 66						
	<211> 2878						
	<212> DNA						
	<213> Burkholderia cepacia						
25	<400> 66						
	gggtcaagcga	acaagtgcac	gtgggtgatg	ccttgggcat	cacaggcgat	gaaggacgcg	60
	gtagcctcgc	aaaagctacg	gggagctggc	aaacaagctt	tgatccgtat	atgtccgaat	120
30	ggggaaaccc	actccttttg	gagtatccat	ggctgaatca	ataggccatg	cgaaggaaacg	180
	cgggtgaactg	aaacatctaa	gtaacccgag	gaaaagaaat	caaccggagt	tcccaaaagta	240
	gtggcgagcg	aaatgggatg	agccttgcaac	tctttatttg	tattgtttagc	cgaacgcctct	300
	ggaaagtgcg	gccatagcag	gtgatagccc	tgtaggcgaa	aacagtatga	aagaactagg	360
	tgtgcgacaa	gtagggcggg	acacgtgaaa	tctgtctcga	agatgggggg	accatcctctc	420
35	aaggctaaat	actcgtgatc	gaccgatagt	gaaccagtac	cgtaggggaa	agggcgaagag	480
	aaacccggga	ggggagtgaa	atagatcctg	aaacccgatg	catcaaaaca	ctcgaggacct	540
	cgtaagggggt	gacggcgctac	cttttgtata	atgggtcagc	gacttacgtt	cagtagcaag	600
	cttaaccgtga	tagggcaggc	gtaggaagaag	agtcggaata	gggcgttcag	ttgctgggcg	660
	tagaacgcga	accaggtgat	ctatccatgg	ccaggatgaa	ggtagcggtaa	cacgtactgg	720
40	aggtccgaac	ccactaacgt	tgaaaaagta	ggggatgagc	tgtggatagg	ggtagaaggcg	780
	taaaacaacc	tggaaatagc	tggttctctc	cgaaaactat	ttaggttagt	cctcgtgtct	840
	caccttcggg	ggtagagcac	tgtcatgggt	gggggggtcta	ttgcagatta	cccccccatc	900
	gcgaactccg	atacgcgaag	agtgaatcac	cgggagacag	acatcgggtg	ctaacgctcg	960
	gtgtcaagag	ggaaacaacc	cagaccgcga	gggtgggttc	ccaaatatac	ctaagtgga	1020
45	aacgaagtgg	gaaggctaaa	acagtcagga	gggtgggtcta	gaagcagcca	ccctttaaag	1080
	aaagcgtaat	aggtcactga	tcgagtctgc	ctcgcgggaa	gatgtaaagg	ggctaagcta	1140
	tataccgaag	ctcggtgatc	gtgctttgca	cgtaggttag	agagcgttcc	ctgaagcctcg	1200
	gaagggtgct	tgtaaaaggt	gctggaagta	tcgggaagtc	gaatgctcag	atgagtatcg	1260
	ataaaggggg	tgaaaggccc	cctcgccgta	agcccaaggt	ttcctacgca	acgttcacgc	1320
50	cgctaggggt	agtcggcccc	taaggcgagg	cagaaatgg	tagctgatgg	gaagcaggtc	1380
	aatattcctg	caccatttgt	agatgcgatg	gggggacgga	tcgcggaagg	ttgtccgggtg	1440
	gttggaagtc	cgcgtcgctg	cattggagaa	ggcgcttagt	caaatcgggg	cgcagaaatc	1500
	aagggtgtgg	cgcgactctc	ttcgggagcg	aagcaattgg	aagtgtgtcc	aagaaaagcc	1560
	tctaagcttc	agctcaacga	tgaccgtacc	gcaaacggag	acaggtgggg	gagatagcta	1620
	ttctaaggcg	cttgagagaa	ctcgggagaa	ggaactcggc	aaattggatc	cgtaactctg	1680
55	ggataaggta	cgccttgtta	gcttgactgg	ctcgcgcag	gaggttgcaag	gggttgcaag	1740
	aaactgggtg	ctgcgactgt	ttataaaaaa	cacagcactc	tgcaaacacg	aaaggtggag	1800

	tatagggtgt	gacgcctgcc	cggtgccgga	agattaaatg	atggggtgca	agctcttgat	1860
	tgaagtcctg	gtaaacggcg	gccgtaaacta	taacggtcct	aaggtagcga	aattccttgt	1920
	cggtgaagtt	ccgacctgca	cgaatggcgt	aacgatggcc	acactgtctc	ctccccagac	1980
	tcagcgaggt	tgaagtggtt	gtgatgatgc	aatctaccgc	cggctagacg	gaagagccac	2040
5	tgaaaccttt	actgatgctt	tgcatctggc	tttgaaccga	tctgtgtag	atagggtgga	2100
	ggctatgaaa	ccggaacgct	agtctcgggt	gagccgtcct	tgaataacca	ctactgggttg	2160
	tttgaggttc	taacctctgg	ccgtgatccg	ggtcggggac	agtgcatggt	aggcagtttg	2220
	actggggcgg	tctcctccca	aagcgtaacg	gaggagtagc	aaggtacgct	aggtagcggtc	2280
	ggaaatcgtg	ctgatagtgc	aatggcataa	gcgtgcttaa	ctgcgagacc	gacaaagtcca	2340
10	cgaggtgcga	aagcagtgca	tagtgatccg	gtggttctgt	atggaaggcg	catcgactcaa	2400
	cggtataaag	gtactctcgg	gataacaggc	tgataccgcc	caagagtcca	tatcgacggc	2460
	gggtgttggt	actcogatgt	cggtctatct	catctcgggg	ctgtagccgg	tcccaagggtg	2520
	atggctgttc	gccattttaa	gaggtacgtg	agctgggttt	aaaaactcgt	gagacagttt	2580
	ggctccctatc	tgccgtgggc	gttgatattt	tgaagggggc	tgctcctagt	acagagggac	2640
15	cggaagtgag	gaacctctgg	tgtagccggt	gtcacgccc	tggtatcgcc	gggtagctac	2700
	gttcggaaga	gataaacgct	gaaagcatct	aagcgggaaa	ctcgctctaa	gatgagatat	2760
	ccctggggac	tagatcccc	tgaagggtcg	ctcgagacca	ggacgttgat	aggtaggggtg	2820
	tgtaagcgca	gtaatcgctt	cagctaactg	atactaattg	cccgtaaggc	ttgatccct	2878
20	<210> 67						
	<211> 2882						
	<212> DNA						
	<213> Burkholderia mallei						
25	<400> 67						
	ggtaacgcga	acaagtgcac	gtgggtggatg	ccttggecat	cacaggcgat	gaaggacgcg	60
	gtagcctcgc	aaaagctacg	gggagctggc	aaacgagctt	tgatccgtag	atgtccgaat	120
	ggggaaaccc	ggcccttttg	ggtcatccta	gactgaatac	atagggtctag	tgaggcgcaac	180
30	gcggtgaact	gaaacatcta	agtaaccgca	ggaaaagaaa	tcaaccgaga	ttcccaaggt	240
	agtgccgagc	gaaatgggaa	gagcctgtac	tctttatttg	tattgttagc	cgaaacgctct	300
	ggaaagtgcg	gccatagcag	gtgatagccc	tgtagggcga	aacagtatga	aagaactagg	360
	tgtaacgcaa	gtagggcggg	acacgtgaaa	tctgtctcga	agatgggggg	accatcctctc	420
	aaggctaaat	actcgtgac	gaccgatagt	gaaccagtac	cgtagaggaa	aggcgaaaag	480
35	aaccgccgga	ggggagtgaa	atagatcctg	aaaccgcatg	catcaaaaac	ctcgaggcctc	540
	cttcgggggt	gagcggtac	cttttgtata	atgggtcagc	gaactacgtt	cagtacgaag	600
	cttaaccgaa	tagggcaggc	gtagcgaaag	cgagtccgaa	tagggcgctc	agttgtcggg	660
	cgtagaccgc	aaaccagggt	atctatccat	ggccaggatg	aaggtgcggt	aacacgtact	720
	ggaggtccga	accactaaac	gttgaaaagt	taggggatga	gctgtggata	ggggtagaag	780
40	gctaacaaca	cctcgaaaata	gctggttctc	tccgaaaaat	atttaggtag	ggctcgtgtg	840
	ctcacctctg	ggggtagagc	actgtcatcg	ttgggggggtc	tattgcagat	taccccgcga	900
	tagcaaaactc	cgaataccga	agagtgcact	cacggggagc	agacatcggt	gctaactcgt	960
	cggtgtcaag	agggaaacaa	cccagaccgc	cagctaaagg	ccccaaatat	ggctaagtgg	1020
	gaaacgaagt	gggaaggcta	aaacagtcag	gaggttggtg	tagaagcagc	caccctctaa	1080
45	agaaacgcta	atagctcact	gatcgagtcg	tctcgccggt	aagatgtaac	ggggctaaag	1140
	catataaccga	agcttggggt	gcgagctagt	ctcgatggtt	aggagagcgt	tcctgtaagcc	1200
	tgcgaaagtg	cgttgaaaag	cgtgctggag	gtatcggaa	cgtaaatgct	gacatagcta	1260
	gcgataaagg	gggttgaaagg	cccctcgcgc	gtaagcccaa	gggttctctac	gcaacgttca	1320
	tcggcgttagg	gtgagtcggc	ccctaaggcg	aggcagaatt	cgctagctga	tggaagcag	1380
50	ctcaaatattc	ctgcaccgtc	gttagatgcg	atggggggct	ggatcgcgga	aggtgtcccg	1440
	gggtctggaa	ctcgaggtcg	ctgcattgga	gaaggcgctt	aggcaaatcc	gggcgcagga	1500
	ttcaaggggtg	tggcgcgagc	tctctcggga	gcgaagcaat	tggaagtggg	tccaagaaaa	1560
	gcctctaaag	ttcagctctaa	cgatgaccgt	accgcaaacg	gacacaggtg	ggcgaatgga	1620
	gtattctaa	gcgcttgaga	gaactcggga	gaaggaaact	ggcaaatagg	taccgttaact	1680
55	tcgggaataag	gtacgccctg	gtagcttgac	tggtcgtcgc	cagaaggggtg	aagggtgtgc	1740
	aataaactgg	tggtgtcgac	tggttaataa	aaacacagca	ctctgcaaac	acgaaagtgg	1800

	acgtataggg	tgtgacgcct	gcccggtgcc	ggaagattaa	atgatggggg	gcaagctctt	1860
	gattgaagtc	ccggtataacg	gcggccgtaa	ctataacggt	cctaaggtag	cgaaatctct	1920
	tgtcgggttaa	gttccgacct	gcacgaatgg	cgtaacgatg	gccacactgt	ctctcccaga	1980
	gactcagcga	agttgaaagt	tttgtgatga	tgcaatctac	ccgcggctag	accgaaagac	2040
5	ccccgaacc	tttactgtag	ctttgcattg	gactttgaac	cgatctgtgt	aggtaggggt	2100
	ggaggctatg	aaaccggaat	gctagtctcg	gtggagccgt	cttggaaata	ccaccctggt	2160
	ttgtttgagg	ttctaacctt	ggcccgtagt	ccgggtcggg	gacagtgcac	ggtaggcagt	2220
	ttgactgggg	cggctctctc	ccaaagcgta	acggagggat	acgaaggtag	gctaggtacg	2280
	tcgggaaatc	gtgctgatag	tgcaatggca	taagcgtgct	taactcggag	accgacaagt	2340
10	cgagcagggtg	cgaaagcagg	tcatagtgat	ccggttggttc	tgtaggaaag	ggccactcgt	2400
	caacggataa	aaggtactct	ggggataaca	ggctgatacc	gcccaagagt	tcatatcgac	2460
	ggcggtgttt	ggcactctga	tgtcggctca	tctcatctcg	gggctgtagc	cggctcccaag	2520
	ggtagggctg	tgtccgattt	aaagaggtag	gtgagctggg	tttaaaacgt	cgtgagacag	2580
	tttggtccct	atctgcgctg	ggcggtggaa	ggttgaaagg	ggctgtctct	agtagcgagag	2640
15	gaccggagtg	gacgaacctc	tggtgtaccg	gttgtagcgc	cagtcgcact	gccgggtagc	2700
	tatgtctcga	agagataaac	gctgaaagca	tctaagcggg	aaactcgcct	taagatgaga	2760
	cttcccgggg	gaacttgatc	ccttgaaagg	tcggtcgaga	ccaggacgtt	gatagggagg	2820
	gtgtgtaagc	gcagtaatgc	gttcagctaa	ccgatactaa	tgccccgtac	ggctgtatcc	2880
	ta						2882
20							
	<210> 68						
	<211> 2882						
	<212> DNA						
25	<213> Burkholderia pseudomallei						
	<400> 68						
	gggtcaagcga	acaagtgcat	gtggtggatg	ccttggcgat	cacagcgcat	gaaggacgcg	60
	gtagcctcgcg	aaaagctacg	gggagctggc	aaacgagcct	tgatccgtag	atgctccgaat	120
30	ggggaaaccc	ggcccttttg	ggatcatccta	gactgaatac	ataggtctag	tgaaggcgaaac	180
	gcgggtgaact	gaacacatcta	agtaaccgca	ggaaaagaaa	tcaaccgaga	ttcccaaatg	240
	agtggcgagc	gaattgggaa	gagcctgtac	tctttatttg	tattgttagc	cgaacgcctct	300
	ggaaagtgcg	gccatagcag	gtgatagccc	tgtatggcgaa	aacagtatga	aagaactagg	360
	tgtacgcacaa	gtaggggcggg	acacgtgaaa	tctgtctcga	agatgggggg	accatctccc	420
35	aaggcttaaat	actcgtgatc	gaccgatagt	gaaccagtag	cgtgagggaa	agggcgaagaa	480
	aaccocggtag	ggggagtgaa	atagatcctg	aaaccgcgat	catacaaaca	ctcggagcct	540
	cttcgggggtg	gacggcgtag	cttttgtata	atgggtcagc	gacttacgtt	cagttagcaag	600
	cttaaccgaa	tagggcaggc	gtagcgaaag	cgagtcggaa	tagggcgctt	agttgctggg	660
	cgtagaccgc	aaaccagggt	atctatccat	ggccaggatg	aaggtgcggt	aacacgtact	720
40	ggaggtccga	accactaac	gttgaaaagt	taggggatga	gctgtggata	ggggtgaaag	780
	gctaacaacaa	cctggaaata	gctggttctc	tccgaaaact	atttaggtag	tgccctggtg	840
	ctcacctcgc	ggggtagagc	actgtcatgg	ttggggggac	tattgcagat	taccgcccca	900
	tagcaaaactc	cgaataccga	agagtgcaat	cacggggagc	agacatcggt	tgctaaagtc	960
	cgggtgtcaag	agggaaacaa	cccagaccgc	cagctaaagt	ccccaaatat	gggttaagtg	1020
45	ggaagcgaagt	gggaaggcta	aaacagtcag	gaggttggct	tagaagaact	caacctttaa	1080
	agaaagcgta	atagctcaat	gatcgagtcg	tctcgcgcg	aagatgtaac	ggggctaagc	1140
	catataccga	agctgcggat	gcgagctagt	ctcgcatggt	aggagagcgt	ccgttaagct	1200
	tgccgaagtg	cgttgaaaag	cgtgctggag	gtatcggaag	tgccgaatgt	gacatgagta	1260
	cgataaaaag	gggtgaaaag	ccccctgcgc	gtaagcccaa	ggtttccctac	gcaacgttca	1320
50	tcggcgtatg	gtgagtcggc	ccctaaggcg	aggcagaaat	gcgtagctga	tgggaagcga	1380
	cagcagtagc	accaccgctc	gttagatgca	atggggggac	ggatcgagac	aggttgtccg	1440
	gggtgttgaa	gtcccggtcg	ctgcattgga	gaaggcgcct	agggcaatcc	ggggcgagga	1500
	ttcaagggtg	tgccgcgagc	gctctagggc	gcgaagcaat	tggaaagtcg	tccaagaaaa	1560
	gcctctaaag	ttcagctcaa	cgatgaccgt	accgcaaac	gacacaggtg	ggcgagatga	1620
55	gtattctaaag	gcgcttgaga	gaactcggga	gaaggaaact	gcgaataatg	taccgtaaact	1680
	tcgggataag	gtacgcacctg	gtagcttgac	tgccctgcgc	cagaagggtg	aaggggtgac	1740

	aataaactgg	tggtctcgac	tgtttaataa	aaacacagca	ctctgcaaac	acgaaagtgg	1800
	acgtataggg	tgtgacgcct	gcccggtgcc	ggaagattaa	atgatggggt	gcaagctcct	1860
	gat tgaagtc	ccggtaaacg	gcggccgtaa	ctataacggt	cctaaggtag	cgaaatcctt	1920
	tgtcgggttaa	gttcggacct	gcacgaatgg	cgtaacgatg	gcgcacactg	ctctcccgca	1980
5	gactcagcga	agttggaagt	tttgtgatga	tgcaatctac	ccgcggctag	acggaaagac	2040
	cccatgaacc	tttactgtag	ctttgcattg	gactttgaac	cgatctgtgt	aggataggtg	2100
	ggaggctatg	aaaccggaac	gctagtttcg	gtggagccgt	ctttgaaata	ccaccctggg	2160
	ttgtttgagg	ttctaaccct	ggcccggtat	ccgggtcggg	gacagtgcac	ggtaggcagt	2220
	ttgactcggg	cggtctctct	ccaaagcgta	acggaggagt	acgaaagtat	gctaggctacg	2280
10	gtcggaatc	gtgctgatag	tgcaatggca	taagcgtgct	taactcgag	accgacaagt	2340
	cgagcagggt	cgaaagcagg	tcatagtcat	ccggtggttc	tgtatggaa	ggccatcgct	2400
	caacggataa	aaggtactct	gggataaaca	ggctgatacc	gcccaagagt	tcatatcgac	2460
	ggcgggtgtt	ggcacctcga	tgtcggctca	tctcatctcg	gggctgtagc	cggtcccaag	2520
	gggtatggct	tgcgcattt	aaagaggta	gtgagctggg	tttaaaacgt	cgtgagacag	2580
15	tttggctcct	atctgccgtg	ggcgttggaa	ggtcgtcctt	agtcagagag	agtcagagag	2640
	gaccggagtg	gacgaacctc	tggtgtaccg	ggtgtgacgc	cagtcgcac	gccgggtgac	2700
	tatgttcgga	agagataacc	gctgaagaca	tctaagcggg	aaactcgctc	taagatgaga	2760
	cttccccggg	gacttgatcc	ccttgaaggg	tcgttcgaga	ccaggagcgt	gataggtcgg	2820
	gtgtgtaagc	gcagtaatgc	gttcagctaa	ccgatactaa	ttgcccgtac	ggcttgatcc	2880
20	ta						2882

<210> 69

<211> 2890

25 <212> DNA

<213> Neisseria gonorrhoeae

<400> 69

	gggtcaagtga	ataagtgcat	caggcgggatg	ccttggcgat	gataggcgac	gaaggacgtg	60
30	taagcctgcg	aaaagcgcgg	gggagctggc	aataaagcta	tgatcccg	atgtccgaat	120
	ggggaaaccc	actgcattct	gtgcagtatc	ctaagttgaa	tacataggct	tagagaagcg	180
	aaccgcggaga	actgaacct	ctaagtaacc	ggaggaaaag	aaatcaaccg	agattccgca	240
	agttagtgccg	agcgaacgcg	gaggagcctg	tacgtataaa	ctgtcgagat	agaagaacaa	300
	gctggggaagc	tgaacctatg	cggttgacag	tcccgtattc	gaaatctcaa	cagcggtact	360
35	aagcgtacga	aaatagggc	gggacacgtg	aaatcctgtc	tgaatatggg	gggacacatc	420
	tccaagtgta	aatactatc	atcgaccgat	agtgaaacag	taccgtgagc	gaagccgcaa	480
	aagaaacccg	ggagggaagt	gaaacagaa	ctgaaacctg	atgcatacaa	acagtgaggag	540
	cgccctagtg	gtgtgactgc	gtaccttttg	tataatgggt	caacgactta	cattcgtatg	600
	cgagcttaac	cggaataggg	aggcgtaggg	aaaccgagtc	ttaatagggc	gatgaagtgc	660
40	tgggtgtaga	cccgaaacccg	agtgatctat	ccatgggtcag	gttgaaggtg	ccgttaacagg	720
	tactggaggga	ccgaacccac	gcattgttga	aaatgcgggg	atgagctgtg	ggtaggggtg	780
	aaaggctaaa	caaacctcga	gatagctgtg	tctccccgaa	aactattttg	gtagtgcctc	840
	gagcaagaca	ctgatggggg	taaagcactg	ttatggctag	gggggtattg	caactacca	900
	accctatggca	aactcagaat	accatcaagt	gggttccctg	gagacagaca	gcgggtgcta	960
45	acgtccgttg	tcaagaggga	aacaacccag	accgcggctg	aaggctcccaa	atgatagatt	1020
	aagtgggtaaa	cgaagtggga	aggcacagac	agccaggagt	ttggctttag	agcagccatc	1080
	atttaagaaa	agcgttaata	ctcactggtc	gagtcgtcct	gcgcggaaga	tgtaacgggg	1140
	ctcaaatcta	taaccgaagc	tgcggatgcc	gggttaaccg	catggtaggg	gagcgtcttg	1200
	tgcgtgatg	aaggtgcatt	gtaaaagtgtg	ctggagggtat	cagaagtcg	aatgttgaca	1260
50	tgaatagcga	taaaagcggg	gaaaagcccg	ctgcgcgaaa	gccccaggtt	tcctacgcaa	1320
	cgltctacgc	cgtagggtaa	gtccggccct	aaggcgaggg	agaaatagg	cgaaatcggg	1380
	aaacaggtta	atttctctgt	acttgattca	aatgcgatgt	ggggacggag	aaggttaagt	1440
	tggcgaagtg	tgcgaatagc	ttgtttaagc	cggttaggtg	agacttagg	cgactacagg	1500
	ttttctctaac	accgagaagt	gatgacgagt	gtctacggac	acgaaacaa	cgatcacagg	1560
55	cttccaggaa	acgccactaa	gcttcagttt	gaatcgaaac	gtaccacca	cgacacacagg	1620
	tgggtaggat	gagaattctta	aggcgtctga	gagaactcgg	gagaaggaa	tcggcgaatt	1680

	gataccggttaa	cttcggggaga	aggatgcccc	tctaagggtta	aggacttgc	ccgtaagccc	1740
	cgaggggtcg	cagagaatag	gtggctgcga	ctgtttatta	aaaacacagc	actctgccaa	1800
	cacgaagatg	gagctatagg	gtgtgacgcg	tgccccgtgc	cggaagggtta	attgaagatg	1860
	tgcagacatc	ggatcgaaac	cccggtaaac	ggcgcccgta	actataacgg	tccctaaggta	1920
5	cggaattccc	tgtcggggtta	agttccgacc	cgacagcaatg	gcgttaacgt	ggccacacgt	1980
	tctctctccc	agactcacgc	aagttgaagt	ggttgtgaag	atgcaactta	cccgctgcta	2040
	gacggaaaga	ccccgtgaac	ctttactgta	gctttgcatt	ggactttgaa	gtcactttgt	2100
	taggataggt	gggaggcttg	gaagcagaga	cgccagcttc	tgtggagtcg	tccctgaagt	2160
	accacccttg	tgtcttttag	gttctaacc	agaccctgca	tccgggtcgg	ggaccgtgca	2220
10	tcgttaggcag	tttgactggg	gcggtctcct	cccaaagcgt	aacggaggag	ttcgaaggtt	2280
	acctaggctc	ggtcggaaat	cggactgata	gtcgaatggc	aaaaggtagc	ttacttcgca	2340
	gacggacaag	cggcgagggt	gcgaaagcag	gacatagtga	tccggtgtgt	ctgtatggaa	2400
	gggccatcgc	tcaacggata	aaaggtactc	cggggataac	aggctgattc	cgcccaagag	2460
	ttcatatcga	cgggcgaggt	tggcacctcg	atgtcggctc	atcacactct	ggggctgtag	2520
15	tcggtcccaa	gggtatggct	gttcggcatt	taagttggta	cgtgagctgg	gcttataaac	2580
	tcgtgagaca	gttttggtccc	tatctgcagt	ggcgttggaa	gtttgacggg	gctgctccta	2640
	gtacgagagc	acggagtggt	acgaacctct	gggtgaccgg	ttgtaacgcc	agtgtagcag	2700
	ccgggtagct	aagttcgaaa	gagataaagc	ctgaagcgct	ctaagcgcca	aactcgcctg	2760
	aaagttagac	ttcccttcgc	gtttaaccgc	acgaaggggt	cgttcgagac	caggacgtgt	2820
20	atagtggggg	tgtggaagcg	cggttaaccg	tgaagctaac	ccatactaat	tgcccctgag	2880
	gcttgactct						2890
	<210> 70						
25	<211> 2891						
	<212> DNA						
	<213> <i>Neisseria meningitidis</i>						
	<400> 70						
30	gtcaagtga	taagtgcac	agggtggatgc	cttgccgatg	atagggcgag	aaggacgtgt	60
	aagcctgcga	aaagcgcggg	ggagctggca	ataaagcaat	gatccgcgca	tgtccgaatg	120
	gggaaaccca	ctgcattctg	tgcagtatcc	taagttgaat	acatagactt	agagaagcga	180
	accggagaaa	ctgaaccatc	taagtaccgc	gaggaaaaga	aatcaaccga	gattcccgca	240
	gtagtggcga	gcgaacgcgg	aggagcctgt	acgtaataac	tgtcgagata	gaagaacaag	300
	ctgggaagct	tgaccatagt	gggtgacagt	cccgattatgc	aaatctcaac	agcggtacta	360
	agcgtacgaa	aagttagggcg	gggcacgtga	aatctctgtc	gaatatgggg	ggaccattct	420
	ccaaggtcta	atactcatca	tcgaccgata	gtgaaccagt	accgtgaggg	aaaaggcgaa	480
	agacaccccg	gaggggagtg	aaacagaaac	tgaaacctga	tgcatacaaa	cagtgggagc	540
	gccttagtgc	tgtgactcgc	taccttttgt	ataatgggtc	aacgacttac	attcaagtgc	600
40	gagcttaacc	gaatagggga	ggcgtaggga	aaccgagtct	taataggggc	atgagttgct	660
	gggtgtagac	ccgaaaacga	gtgatcttat	catggccagg	ttgaaggtgc	cgtaaacagt	720
	actggaggag	cgaaccacgc	catgttgcaa	aatgcgggga	tgaagctgtg	atagggggtga	780
	aaggctaaac	aaactcggag	atagctgggt	ctccccgaaa	actatttagg	tagtgcctgc	840
	agcaagacac	tgatgggggt	aaagcactgt	tatggctagg	gggttatatg	aacttaccaa	900
45	cccatggcaa	actaagaata	ccatcaagtg	gttccctcgg	agacagagag	cgggtgctaa	960
	cgctcgttgt	caagaggggaa	acaacccgaa	ccgcagacta	agggtcccaa	tgatagatta	1020
	agtgtgtaac	gaagtgggaa	ggcccgagaca	gccaggtagt	ggccttagaa	gcagccatca	1080
	tttaagaana	gcgttaatagc	tcactgtgtc	agtcgtcctg	cgcggaagat	gttaacggggc	1140
	tcaaatctct	aacccaagct	gcggatgccg	gtttacocgc	atggttagggg	agcgttctgt	1200
50	aggctgatag	aggtgcattg	taagttgtgc	tggagggtatc	agaagtgcca	atgttgacat	1260
	gagtgacgat	gaagcggggt	aaaagcccg	ctcgccgaag	cccaaggttt	ctcgccgaac	1320
	gttcatcgcc	tatagggtgag	tcggccctca	aggcgaggca	gaaatgcgta	gtcgatggga	1380
	aacagggttaa	tattctctgta	cttgattcaa	atgcgatgtg	gggacggaga	gtgttagttt	1440
	ggcaagctgt	tggaaatagct	tgtttaagcc	ggttaggtgga	agacttaggc	aaatccgggt	1500
55	cttcttaaca	ccgagaagtg	acgacgagtg	tctaccggaca	cgaagcaacc	gataccacgc	1560
	ttccaggaaa	agccactaag	cttcagtttg	aatcgaaacc	taccgcaaac	cgacacaggt	1620

	gggcaggatg	agaattcttaa	ggcgcttgag	agaactcagg	agaaggaaat	cggcaaatatg	1680
	ataccgtaac	ttcgggagaa	ggatgcccct	ctaagggttaa	ggacttgctc	cgttaagcccc	1740
	ggaggtgtcgc	agagaataagg	tggctcgagac	tgtttatttaa	aaacacagca	ctctgtctaac	1800
	acgaaagtgg	acgtataggg	tgtgacgcct	gcccggtgct	ggaaggttaa	ttgaaagattg	1860
5	gagagcatcgc	gatcgaagcc	ccagtaaacg	gcggccgttaa	ctataacggt	ccctaaggtag	1920
	cgaattctct	tgtcgggtaa	gttccgaccc	gcacgaatgg	cgtaacgcag	gccacactgtg	1980
	ctcctcctga	gaactcagca	agttgaagtg	gttgtaaga	tgcaatctac	ccgctgctag	2040
	acggaagac	cccgtaacc	tttactgtag	ctttgcattg	gactttgaag	tcaacttgtgt	2100
	aggataggtg	ggagccttag	aagcagagac	gccagttctc	gtggagccgt	ccctgaaata	2160
10	ccaccctggg	gtctttgagg	ttctaaacca	gacccgtcat	ccgggtcggg	gaccgtgcat	2220
	ggtaggcagt	ttgactgggg	cggtctcctc	ccaagcgta	acggaggagt	tcgaaagtta	2280
	cctaggtccg	tgcggaaatc	ggactgatag	tgcaattggca	aaaggtagct	taactgcgag	2340
	accgacaagt	cgagcaggtg	cgaaagcagg	acatagtgat	ccggtggctc	tgtatggaag	2400
	ggccatcgct	caacggataa	aaggtactcc	ggggataaca	ggctgattcc	gcccaagagt	2460
15	tcataatcgac	ggcggaagtt	ggcacctcga	tgtcgggtca	tcacatcctg	gggctgtagt	2520
	ccggtcccaag	tttatggctg	ttccgcattt	aaagtggtac	gtgagctggg	tttaaaactg	2580
	cgtagacag	ggttgccct	atctgcagtg	ggcgttgaa	gtttgacggg	ccactccctt	2640
	agtcagagag	gacggagtg	gacgaacctc	tggtgtacgc	gttgtaacgc	caagtgcata	2700
	gcgggttagc	taagttcgga	agagataagc	gttgaaagca	tcataagcgc	aaactcggct	2760
20	gaagatgaga	cttcccttgc	ggtttaaccg	cactaaagcg	tcgttcgaga	ccaggacgct	2820
	gatagggtgg	gtgtggaagc	gcggtaaccg	gtgaagctaa	cccatactaa	ttgctcgta	2880
	ggcttgactc	t					2891
25	<210> 71						
	<211> 2891						
	<212> DNA						
	<213> <i>Pseudomonas aeruginosa</i>						
30	<400> 71						
	ggtcaagtga	agaagcgcat	acgggtggatg	ccttggcagt	cagaggcgat	gaaaagcgtg	60
	gtagcctcg	aaaagcttcg	gggagtcggc	aaacagactt	tgatccggag	atctctgaat	120
	gggggaaccc	acctaggata	acctaggat	cttgactga	atccataggt	gcaagagcg	180
	aaaccagggg	actgaacat	ctaagtaccc	tgaggaaaag	aaatcaacgc	agatccctt	240
35	agtagtgccg	gcgaacggg	gattagccct	taagcttcat	tgattttagc	ggaacgctct	300
	ggaagtggcg	acctaagtgg	gtgatagccc	ctacgcgaa	aggatcttgc	aagtgaactc	360
	gagtagagac	gcgacagaga	aactttgtct	gaacatgggg	ggaccatctc	ccaaggtcta	420
	atactactga	ctgacagata	gtgaaccagt	acogtgaagg	aaagcgcaa	agaacccggc	480
	agaggggagt	gaaatagaac	ctgaaaccgt	atgcgtacaa	gcagtgggag	ctacttgtt	540
40	aggtgaactc	gtaccctttg	tataatgggt	cagcgactta	tattcagtgg	caagcttaac	600
	cgtatagggt	aggcgtagcg	aaagcgagtc	ttaatgaggg	gtttagtcgc	tgggtataga	660
	ccgaaacccg	ggcgctctat	ccatgagcag	gttgaaggtt	aggtaacact	gactggagga	720
	ccgaacccac	ttccgttgaa	aaggtagggg	atgactttgt	gatcgagtg	aaaggtcta	780
	caagctcgga	gatagctggt	tctcctcgaa	agctatttag	gtagcgctc	atgtataact	840
45	ctgggggggt	gagcactggt	tcggctaggg	ggctatcccg	acttaccaaa	ccgatgcaaa	900
	ctccgaatac	ccagaagtgc	cgagcatggg	agacacacgg	cgggtgctaa	cgctccgctg	960
	gaaaagggaa	acaacccaga	ccgccagcta	aggtcccaaa	gttggtgta	gttggtcaac	1020
	gatgtgggaa	ggcttagaca	gctaggagtg	tggttagaa	gcagccaccc	tttaagaaa	1080
	gcgtaaatgc	tcactagtgc	agtcggcctg	ccgggaagat	gtaacggggg	tcaaacacaa	1140
50	cacccaagct	ggcggtgtca	cgtaagtgc	gcggtagagg	agcgttctgt	aagctgtgta	1200
	aggtgagttg	agaaagcttc	tggaggtatc	agaaagtcga	atgctgacat	gagtaacgac	1260
	aatgggtgtg	aaaaaacacc	acgcgcgaag	accaagggtt	cctgcgcaac	gttaactcga	1320
	gcaggggttag	tcggttctca	agggcaggct	gaaaacgta	ctcgatggga	gaactgttaa	1380
	tattcctgta	cttctggtta	ctgcgtagga	gggacggaga	aggtcagtc	agcttggcgt	1440
55	tggtgtccga	agtttaaggt	ggtaggtcga	aatcttaggt	aaatccgggg	tttcaaggcc	1500
	gagagctgat	gacgagtcgt	cttttagatg	acgaagtggt	tgatgccatg	cttccaagaa	1560

	aagcttcttaa	gcttcaggta	accaggaacc	gtaccccaaa	cgcacacagg	tggctcgggta	1620
	gagaatccca	agggcgcttga	gagaactcgg	gtgaaggaaac	taggcaaaaat	ggcaccgttaa	1680
	cttcogggaga	aggtgcgcgcg	gctaggggtga	aggatttact	cogtaagcttc	tggcttggtcg	1740
5	aagatccagc	gcgcctgcga	ctgtttatta	aaaacacagc	actctgcaaa	cacgaaagt	1800
	gcagtatagg	gtgtgacgcgc	tgcccggctgc	cggaaggtta	attgatgggg	ttagcgcgaag	1860
	cgaagctctt	gcgaagaagcc	coggtaaacg	gcggccgttaa	ctataacgggt	cctaaggtag	1920
	cgaatctcct	tgtcgggtga	gttcgcgaact	gcacgaatgg	cgtaacgatg	gcggcgctgt	1980
	ctccaccgga	gactcagtg	aattgaaatc	gctgtgaaga	tgcaagtgtat	ccgcggctag	2040
	acggaagaac	ccogtgaacc	tttactgtag	ctttgcactg	gactttgagc	ctgctttgtt	2100
10	aggaatagtg	ggagcgtttg	aagcgtggac	gccagttcgc	gtggagccat	ccttgaata	2160
	ccaccctggc	atgcttgagg	ttctaactct	ggtccgtaat	coggatcgag	gacagtgtat	2220
	ggtgggcagt	ttagctgggg	cggtctcctc	ctaaagagta	acggaggagt	acgaaggtgc	2280
	gctcagacgc	gtcggaaatc	ggtcgcagag	tataaaggca	aaagcgcgct	tgaactcgag	2340
	acagacagct	cgagcaggta	cgaagtagg	tcttagtgat	ccggtgggtc	tgtatggaag	2400
15	ggccatcgct	acacggataa	aaggtactcc	ggggataaca	ggctgatacc	gcccaagagt	2460
	tcatatcgac	ggcgggtggt	ggcaccctga	tgctcggtca	tcacatcctg	gggctgaagc	2520
	cgttccccag	tgatggctg	ttcgcattt	aaagtggtag	gcgagctggg	tttagaagct	2580
	cgtagagacg	ttcggctcct	atctgccgtg	gacgtttgag	atttgagagg	ggctgcctct	2640
	agtagtcagag	gacgcgagtg	gacgaacctc	tggtgtccgc	gttgtcaecg	cagtgccgatt	2700
20	gccgggtagc	tatgttcgga	aaagataacc	gctgaaagca	tctaagcggg	aaacttgctc	2760
	caagatcgag	tctcaactggg	aactcgattc	cctcgaaagg	cogtgcgaag	ctacagcgtt	2820
	gataggctgg	gtgtgtaagc	gtgttgaggc	gttgagctaa	ccagtactaa	tgtcccgcta	2880
	ggcttgacca	t					2891
25	<210> 72						
	<211> 2886						
	<212> DNA						
	<213> <i>Vibrio cholerae</i>						
30	<400> 72						
	gggttaagtga	ctaagcgtag	acgggtggatg	cctgggcagt	cagaggcgat	gaaggacgta	60
	ctaacttgcg	ataagcgtag	ataaggcgatg	aagagccgtt	tgagtctgcg	atttccgaat	120
	ggggaaacccc	aactgcataa	gcagttactg	ttaactgaat	acatagggtta	acagagcaaa	180
35	ccgggggaaac	tgaaacatct	aagtaccctg	aggagaagaa	atcaaccgag	attccogtga	240
	tagcggcgag	cgaacctgga	ttagccctta	agcaatcggt	gaagtagctg	acaaacgtgt	300
	aaagcttgbc	gacacaggtg	gatagccccc	taaccgacgc	ttcatcgagc	gtgaaatcga	360
	gtagggcgcg	atacgtgata	tctgtctgta	atatgggggg	accatctccc	aaagctaaat	420
	actcctcgact	gaccgatagt	gaaccagtag	cgtgaggaaa	ggcgaaaaga	acccctgtga	480
40	ggggaggtgaa	atagaaacctg	aaaccgtgta	cgtacaagca	gtagagagcac	cttctggttg	540
	tgaactcgta	ccttttgat	aatgggtcag	cgacttata	tcagtggcaa	gggtaaacctg	600
	atagggggagc	cgtagcgaaa	gcgagctcta	actgggcgct	cagttctcgg	atatagacc	660
	gaaaacgggtg	gactagacca	tgggcaggtt	gaaggttgag	taacatcaac	tggaggacog	720
	aaccgactaa	tggtgaaaaa	ttagcggatg	acttggtgct	aggggtgaaa	ggccaatcaa	780
45	actcggagat	agctggttct	ccccgaaagc	tatttagtga	gcgcctcgga	cgaatactac	840
	tgggggtaga	gcactgttaa	ggctaggggg	tcattccgac	ttaccaaccc	tttgcacact	900
	cogaataccca	gttaagtacta	tcggggagac	acacggcggg	tgctaacgtc	cgctgtggag	960
	aggggaaacaa	ccagacccgc	cagctaaagt	cccaaaagtat	tgctaaagtg	gaaacgatgt	1020
	gggaaggctc	agacagctag	gatgttggtc	tagaagcagc	catcatttaa	agaaagctta	1080
50	atagctcact	agtcagatcg	gcctgcgcgg	aagatgtaac	ggggctaagc	aatacaccga	1140
	agctgcggca	atatctttta	gatattgggt	aggggaagct	tctgtaaccc	cttgaaagct	1200
	aatcgtaaag	tttgcggag	gtatcagaag	tgcgaaatgct	gacatgagta	acgacaaagg	1260
	gggtgataaaa	cctcctcgcc	ggaagaccaa	gggttctcgt	ccaaacttaa	tcggggcagg	1320
	gtgagtcgac	ccctaaggtg	agggcgaaag	gcgttaatcga	tggggaaacgg	gttaatatct	1380
55	gcctactctc	gaactttgcg	atggggggac	ggagaagagc	aggtggggca	ggcagcggtt	1440
	gtcctggttc	agactgcgtag	gcttgagagt	taggtaaatc	cggctctctc	taaggctgag	1500

	acacgacgtc	gagctactac	ggtagtgaag	tcattgatgc	catgcttcca	ggaaaagcct	1560
	ctaagcttca	gatatgcagg	aatcgtaccc	caaaccgaca	caggctggtcg	ggtagagaat	1620
	accaagggcg	ttgagagaac	tcgggtgaag	gaactaggca	aaatggtacc	gtaacctcgg	1680
5	gagaaggtac	gcctctgatg	gtgaagtcgc	tcgcggatgg	agctgacgag	agtcgcagat	1740
	accagggtggc	tgcaactggt	tattaaaaac	acagcactgt	gcaaaatcgc	aagatgacgt	1800
	atacgggtgc	acgcctgcgc	ggcgccggaa	gggttaattga	tgggggttagc	gcaagcgaa	1860
	ctcttgatcg	aagccccggt	aaacggcggc	cgttaactata	acggtcctaa	ggtagcgaaa	1920
	tcctctgtcg	ggtaagttcc	gacctgcacg	aatggcgtaa	tgatggccac	gctgtctcca	1980
10	ccccgagctc	agtgaaattg	aaatcgctgt	gaagatgcag	tgtaccgcgc	gctagacgga	2040
	aagaccctgc	gaacctttac	tacagcttgg	cactgaacat	tgaacctaca	tgtgtaggat	2100
	aggtagggagg	ctatgaagac	gtgacgccag	tgcgtttgga	gccgtccttg	aaataccacc	2160
	cttgtatgtg	tgatgttcta	acttagaccc	gttatccggg	ttgaggacag	tgctcggtgg	2220
	gtagtttgac	tggggcggtc	tcttcccaaa	gagtaacgga	ggagcacgaa	ggtagggctaa	2280
	tcacggttgg	acatcgtgag	gttagtgcaa	tggcataagc	ccgcttaact	gcgagaatga	2340
15	cggttcgagc	aggtagcga	gcagggtata	gtgatccggg	ggttctgcat	ggaaaggcca	2400
	tcgctcaacg	tcaaaaagg	actccgggga	taacaggctg	ataccgccca	agagttcata	2460
	tcgagcgccg	tggttggcac	ctcgatgtcg	gctcaacaca	tctggggctg	gaagtcggtc	2520
	ccaaggggat	tgcttctcgc	catttaaagt	ggtagccgag	ctggggttag	aacgtctgta	2580
	gcagcttcgg	ttccctatctg	ccgtgggcgt	tggaaagtgt	aagggggctg	ctctagatgc	2640
20	gagagggaccg	gagtgacga	acctctgggt	tccgggttgt	gtcgcgacag	gcattgcgcc	2700
	gtagcttaagt	tcggaattga	taagcgcgtga	agcactctaa	gcgcgaagcg	agccctcgag	2760
	tgagctctcc	ctgacagttt	aactgtccta	aaggggttgt	cgagactaga	acgttgatag	2820
	gcagggtgtg	taagcgttgt	gaggcgttga	gctaaccctg	actaattgcc	cgtgagggct	2880
25	aacctat						2886
	<210>	73					
	<211>	2906					
	<212>	DNA					
30	<213>	Yersinia enterocolitica					
	<220>						
	<221>	modified_base					
	<222>	(1168)..(1178)					
35	<223>	N = A, C, G or T/U					
	<400>	73					
	ggttaacgca	ccaagcgtac	acgggtggatg	cctaggcagt	cagaggcgat	gaaggacgtg	60
40	ctaactctgc	aaaagcgtcg	gtaagggtgat	atgaaccggt	ataaccgac	atacccgaa	120
	ggggaaaccc	agtgcaattc	gtgcactact	tgcatcgtgga	atacatagcc	atgcaaggcg	180
	aaaccggggga	actgaaacat	ctaagtagcc	cgaggaaaag	aaatcaaccg	agattcccc	240
	agtagcggcg	agcgaaacgg	gaggagccca	gaacctgaat	cagcgtatgt	gttagtgaaa	300
	gctctggaa	agtcgcacgg	tacagggtga	tagtcccgta	cacaaaaatg	catatgttgt	360
45	gagttcgatg	agtagggcgg	gacacgtgac	atcctgtctg	aatatggggg	gaccatcccc	420
	caaggctaaa	tactcctgac	tgaccgatag	tgaaccagta	ccgtgaggga	aaggcgaaaa	480
	gaaccccgcc	gaggggagtg	aaacagaacc	tgaaccgctg	tacgtacaag	cagtgggagc	540
	acctctgctg	tgtagactcg	taccttttgt	ataatgggtc	agcgacttat	atatttgtag	600
	aaggttaacc	gaatagggga	gcgctaggga	aaccgagttc	taactggggc	aatagttgca	660
	aggtagatag	ccgaaacccg	gtgactctagc	catgggcagg	ttgaagggtg	tgtagacata	720
50	actcggaggac	cgaaaccgact	aatgttgaaa	aattagcggg	tgactttgtg	ctggggggtga	780
	aaggccaact	aaaccgggag	atagctgggt	ctccccgaaa	gctattttag	tagccctctg	840
	tgaactcatc	ttcgggggta	gagcactggt	tcggctaggg	ggatcatccc	acttaccaaa	900
	cgaatgcgaaa	ctccgaatac	cgaagaatgt	tatcacggga	gacacacggc	gggtgctaac	960
	gtccgtcgtg	aagagggaaa	caaccagac	cgccagctaa	ggccccaaag	tcatgtgtta	1020
55	gtgggaaacg	atgtgggaag	gcacagacag	ccaggatgtt	ggcttagaag	cagccatcat	1080
	ttaaagaacg	cgtaatatgt	cactggctga	gtcggcctgc	gcggaagaa	tatcaggggc	1140

aaaccatgca ccgaagctgc ggcagcggnn nnnnnnnnnn nnnnnnnngg ggagcggtct 1200
 gtaagccgtt gaaggtgacc tbtgaggggt gctggaggta tcagaagtgc gaatgctgac 1260
 ataagtaacg ataagtcggg tgaaaaaccc gcacgcgcga agaccaaggg ttccgtgcca 1320
 acgttaactg gggcagggtg agtcgacccc taaggcgagg ctgaaaggcg tagtcgatgg 1380
 5 gaaacaggtt aatattcctg tacttgggtg tactgcgaag gggggcgcga gaaggctatg 1440
 ctacgccggc gacggttgtc cgggtttaag catgtaggcg gagtgcacag gtaaatccgg 1500
 ttgcttatca acgctgaggt gtgatgacga gtcactacgg tgatgaagta gttgatgcca 1560
 tgcttccagg aaaagcctct aagcatcagg taacatgaaa tcgtacccca aaccgacaca 1620
 10 ggtggtcagg tagagaatac tcaggcgctt gagagaactc ggggtgaagg actaggcaaa 1680
 atggtgccgt aacttcggga gaaggcacgc tgacacgtag gtgaagcggt ttaccocgtg 1740
 agctgaagtc agtcgaagat accagctggc tgcactgttt tattaataac acagcactgt 1800
 ctaaacacga aagtggacgt atacggtgtg acgcctgccc ggtgctggaa ggttaattga 1860
 tggggtcagg gcaagcgaag ctcttgatcg aagccccggg aaacggcggg cgtaactata 1920
 accgttctaa ggtagcgaaa ttccctgtcg ggttaagtcc gacctgcacg aatggcgtaa 1980
 15 tggatggccg gctgtctcca cccgagactc agtgaattg aactcgctgt gaagatcgag 2040
 tgtaccocgt gcaagacgga aagaccccgt gaacctttac tatagcttga cactgaacat 2100
 tgagccttga tgttaggat aggtgggagg catagaagtg tggacgccag tctgcacgga 2160
 gccaaccttg aaataccacc cttaaatggt tgatgttcta actcggcccc gtaactccgg 2220
 20 ctgaggacag tgtcaggtgg gtgatttgac tggggcggtc tctcccaaaa gagtaacgga 2280
 ggagcagcaa ggttagctaa tcacggctcg acatcgtgag gttagtgcga aggcatgaag 2340
 tagcttcaact ccgagagtga cggctcgagc aggtacgaaa taggttctta gtgatccgt 2400
 ggttctgaat ggaaggccca tcgctcaacg gataaaagg actccgggga taacaggctg 2460
 atacgcccca agagtccata tcgacggcgg tgtttggcac ctcgatgtcg gctcatcaca 2520
 25 tctctgggct gaagtaggtc ccaagggtat ggctgttcgc catttaaagt ggtacgcgag 2580
 ctggttttag aacgtcgtga gacagttcgg tccctatctg ccgtggggcy tggarraytg 2640
 agrggggctg ctctcgtac gagaggaccg gagtggacgm atcaactggtg ttcggggtgt 2700
 ctgcccacat gcaytgcctg gttagctaaat kcggaagaga taasygctga aagcatctaa 2760
 gcrsgaaact tgccycgaga tgagttctcc ctgagactac aagttctctg aaggaaagct 2820
 30 gaagacgacg acgttgatag gcyygggtgt taagcgcgag ttggcggtga gctaaccggt 2880
 actaatgaac cgtgaggctt aacctt 2906

<210> 74
 <211> 23
 35 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 Primer

 <400> 74
 40 gggttgcgct cgttacggga ctt 23

 <210> 75
 <211> 23
 <212> DNA
 50 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 Primer

 <400> 75
 55 gggttgcgct cgttgccgga ctt 23

5 <210> 76
<211> 23
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Description of Artificial Sequence: Synthetic
Primer

<400> 76
tccccactgc tgcctcccgt agg 23

15 <210> 77
<211> 23
<212> DNA
<213> Artificial Sequence

20 <220>
<223> Description of Artificial Sequence: Synthetic
Primer

25 <400> 77
caacatctca cgacacgagc tga 23

30 <210> 78
<211> 23
<212> DNA
<213> Artificial Sequence

35 <220>
<223> Description of Artificial Sequence: Synthetic
Primer

40 <400> 78
tccccactgc tgcctcccgt agg 23

45 <210> 79
<211> 22
<212> DNA
<213> Artificial Sequence

50 <220>
<223> Description of Artificial Sequence: Synthetic
Primer

<400> 79
ttaccgcggc tgctggcacg ga 22

55 <210> 80
<211> 23

<212> DNA
<213> Artificial Sequence

5 <220>
<223> Description of Artificial Sequence: Synthetic
Primer

10 <400> 80
cccgctcaat tcctttgagt ttc 23

<210> 81
<211> 23
<212> DNA
15 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Primer

20 <400> 81
caacatctca cgacacgagc tga 23

25 <210> 82
<211> 23
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Description of Artificial Sequence: Synthetic
Primer

35 <400> 82
tttcaccttt ccttcacggt act 23

40 <210> 83
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Primer

45 <400> 83
ggttcttttc acctttccct cgc 23

50 <210> 84
<211> 23
<212> DNA
<213> Artificial Sequence

55 <220>

<223> Description of Artificial Sequence: Synthetic
Primer

5 <400> 84
tggtttcagg ttctatttca ctc 23

<210> 85
<211> 22
10 <212> DNA
<213> Artificial Sequence

<220>
15 <223> Description of Artificial Sequence: Synthetic
Primer

<400> 85
tttaaccgac aaggaatttc gc 22

20 <210> 86
<211> 23
<212> DNA
<213> Artificial Sequence

25 <220>
<223> Description of Artificial Sequence: Synthetic
Primer

30 <400> 86
ggttcttttc acctttccct cgc 23

<210> 87
35 <211> 15
<212> DNA
<213> Artificial Sequence

<220>
40 <223> Description of Artificial Sequence: Synthetic
Primer

<400> 87
45 taacctggtc gtaac 15

<210> 88
<211> 14
<212> DNA
50 <213> Artificial Sequence

<220>
55 <223> Description of Artificial Sequence: Synthetic
Primer

<400> 88

cccccccccc cccc 14

5 <210> 89
<211> 16
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Description of Artificial Sequence: Synthetic
Primer

15 <400> 89
gcccctaacc tegtgc 16

20 <210> 90
<211> 26
<212> DNA
<213> Artificial Sequence

25 <220>
<223> Description of Artificial Sequence: Synthetic
Primer

30 <400> 90
cgccctagc cgggtcgtac ctccgg 26

35 <210> 91
<211> 26
<212> DNA
<213> Artificial Sequence

40 <220>
<223> Description of Artificial Sequence: Synthetic
Primer

45 <400> 91
cgccctaacc ctggtcgtaa ctccgg 26

50 <210> 92
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Primer

<400> 92
aggcttcgat cccgggatcc gcg 23